



















```

Query Match          2.9%; Score 65.8; DB 9; Length 1883;
Best Local Similarity 62.0%; Pred. No. 0.0003;
Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;

QY 2077 GTCCTCAAGTCTGTCGACACATAATCATTCATCCCAATGATCGCTTGTGCTTTACCACT 2136
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1700 GAGCTCCAGCTCTGCTCTCTCTCTCACTCTCTCCCTTCAGTGTCTGAGAACAGGACT 1759

QY 2137 CTTTCCTTTTATCTTATTAATAAATGTTGGTCTCCACCACTGCTCCCAAAAAA 2196
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1760 TTCTCCACATTTGTTGTAATGCAACATTTTGCATTAAAGGAAATCCACAAAAA 1819

QY 2197 AAAAAA 2242
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1820 AAAAAA 1865

RESULT 1077
ADBI6093
ID ADBI6093 standard; cDNA; 1883 BP.
XX
AC ADBI6093;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #251.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087350-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127821.
XX
PR 04-AUG-1998; 98US-0095301P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786941/74.
DR P-PSDB; ADBI6094.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 2; Fig 501; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

```

```

CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;

```

```

Query Match          2.9%; Score 65.8; DB 9; Length 1883;
Best Local Similarity 62.0%; Pred. No. 0.0003;
Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;

QY 2077 GTCCTCAAGTCTGTCGACACATAATCATTCATCCCAATGATCGCTTGTGCTTTACCACT 2136
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1700 GAGCTCCAGCTCTGCTCTCTCTCTCACTCTCTCCCTTCAGTGTCTGAGAACAGGACT 1759

QY 2137 CTTTCCTTTTATCTTATTAATAAATGTTGGTCTCCACCACTGCTCCCAAAAAA 2196
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1760 TTCTCCACATTTGTTGTAATGCAACATTTTGCATTAAAGGAAATCCACAAAAA 1819

QY 2197 AAAAAA 2242
   ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1820 AAAAAA 1865

```

```

RESULT 1078
ADBI6093
ID ADBI6093 standard; cDNA; 1883 BP.
XX
AC ADBI6093;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #251.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073215-A1.
XX

```

PD 17-APR-2003.  
XX PF 07-MAY-2002; 2002US-00140925.  
XX  
PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019033.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US023952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-644801/61.  
DR P-PSDB; ADA47880.  
XX  
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
PT in gene therapy, detecting the presence of tumor in a mammal, or  
PT modulating the uptake of glucose or free fatty acid by skeletal muscle  
PT cells or adipocyte cells.  
XX  
PS Claim 2; Fig 501; 659pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,







QY 2197 AA 2242  
 DB 1820 AA 1865

## RESULT 1081

ADB30681

ID ADB30681 standard; cDNA; 1883 BP.

XX AC ADB30681;

XX DT 20-NOV-2003 (first entry)

XX DE cDNA encoding human PRO polypeptide #251.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.

XX OS Homo sapiens.

XX XX

XX PN US2003068794-A1.

XX PD 10-APR-2003.

XX PF 15-APR-2002; 2002US-00123155.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019033.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 16-SEP-1998; 98WO-US019177.

XX PR 17-SEP-1998; 98WO-US019330.

XX PR 17-SEP-1998; 98WO-US019437.

XX PR 29-OCT-1998; 98WO-US021141.

XX PR 29-OCT-1998; 98WO-US022991.

XX PR 29-OCT-1998; 98WO-US022992.

XX PR 20-NOV-1998; 98WO-US024855.

XX PR 01-DEC-1998; 98WO-US025108.

XX PR 05-JAN-1999; 99WO-US000106.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 10-MAR-1999; 99WO-US005190.

XX PR 20-APR-1999; 99WO-US008615.

XX PR 14-MAY-1999; 99WO-US010733.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 08-SEP-1999; 99WO-US020594.

XX PR 13-SEP-1999; 99WO-US020944.

XX PR 15-SEP-1999; 99WO-US021090.

XX PR 15-SEP-1999; 99WO-US021547.

XX PR 05-OCT-1999; 99WO-US023089.

XX PR 29-NOV-1999; 99WO-US028214.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 30-NOV-1999; 99WO-US028409.

XX PR 01-DEC-1999; 99WO-US028301.

XX PR 01-DEC-1999; 99WO-US028634.

XX PR 02-DEC-1999; 99WO-US028551.

XX PR 02-DEC-1999; 99WO-US028564.

XX PR 02-DEC-1999; 99WO-US028565.

XX PR 16-DEC-1999; 99WO-US030095.

XX PR 20-DEC-1999; 99WO-US030911.

XX PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00806869.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith JV, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-708391/67.

P-PSDB; ADB30682.

New isolated PRO polypeptides e.g. PRO1801 and PRO1114, useful in the  
 preparation of a medicament for treating a condition responsive to PRO



100

**RESULT 1083**

ADA97189  
ID ADA97189 standard; cDNA: 1883 BP.

AC ADA97189;

DT 20-NOV-2003 (first entry)

Human PRO polynucleotide #251.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;	KW
tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;	KW
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;	KW
liver; microvascular endothelial cell; glucose; FFA;	KW
skeletal muscle cell; adipocyte cell; pericyte cell;	KW
inner ear utricular supporting cell; T-lymphocyte cell;	KW
endothelial cell tube formation; bone disorder; cartilage disorder;	KW
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	KW
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;	KW
immune system cell infiltration.	KW

OS Homo sapiens.

PN US2003082705-A1.

01-MAY-2003.

24-APR-2002; 2002US-00131829.

PR 09-DEC-1999; 99US-0170262P.

PR 19-DEC-2001: 2001US-00028072.

PA (GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PPI  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PPI  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

DR WPI; 2003-755112/71.

**XXXXXXXXXXXX**

PT e.g., tumor or for tissue typing.

PS Claim 2; Fig 501; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte





























PR	05-OCT-1999,	99WO-US023080,
PR	23-NOV-1999,	99WO-US028214,
PR	30-NOV-1999,	99WO-US028313,
PR	30-NOV-1999,	99WO-US028409,
PR	01-DEC-1999,	99WO-US028301,
PR	01-DEC-1999,	99WO-US028634,
PR	02-DEC-1999,	99WO-US028551,
PR	02-DEC-1999,	99WO-US028564,
PR	02-DEC-1999,	99WO-US028565,
PR	16-DEC-1999,	99WO-US030095,
PR	20-DEC-1999,	99WO-US030911,
PR	20-DEC-1999,	99WO-US030999,
PR	22-DEC-1999,	99WO-US030720,
PR	30-DEC-1999,	99WO-US031243,
PR	05-JAN-2000,	99WO-US031274,
PR	05-JAN-2000,	2000WO-US000219,
PR	06-JAN-2000,	2000WO-US000277,
PR	06-JAN-2000,	2000WO-US000376,
PR	11-FEB-2000,	2000WO-US003566,
PR	18-FEB-2000,	2000WO-US004344,
PR	18-FEB-2000,	2000WO-US004342,
PR	23-FEB-2000,	2000WO-US004412,
PR	24-FEB-2000,	2000WO-US004914,
PR	24-FEB-2000,	2000WO-US005004,
PR	01-MAR-2000,	2000WO-US005601,
PR	02-MAR-2000,	2000WO-US005746,
PR	02-MAR-2000,	2000WO-US005841,
PR	10-MAR-2000,	2000WO-US006319,
PR	15-MAR-2000,	2000WO-US006884,
PR	20-MAR-2000,	2000WO-US007377,
PR	21-MAR-2000,	2000WO-US007532,
PR	23-MAR-2000,	2000WO-US008439,
PR	23-AUG-2000,	2000WO-US022031,
PR	17-MAY-2000,	2000WO-US013705,
PR	23-MAY-2000,	2000WO-US014042,
PR	30-MAY-2000,	2000WO-US014941,
PR	02-JUN-2000,	2000WO-US015264,
PR	28-JUN-2000,	2000WO-US020710,
PR	11-AUG-2000,	2000WO-US022031,
PR	23-AUG-2000,	2000WO-US023522,
PR	24-AUG-2000,	2000WO-US023328,
PR	08-NOV-2000,	2000WO-US030952,
PR	10-NOV-2000,	2000WO-US030873,
PR	01-DEC-2000,	2000WO-US032678,
PR	20-DEC-2000,	2000US-U0747259,
PR	20-DEC-2000,	2000US-U0734956,
PR	28-FEB-2001,	2001US-U0796498,
PR	28-FEB-2001,	201WO-US005520,
PR	01-MAR-2001,	2001WO-US006666,
PR	09-MAR-2001,	2001US-U0802706,
PR	14-MAR-2001,	2001US-U0808689,
PR	22-MAR-2001,	2001US-U0816744,
PR	05-APR-2001,	2001US-U0828366,
PR	10-MAY-2001,	2001US-U0854208,
PR	10-MAY-2001,	2001US-U0854280,
PR	18-MAY-2001,	2001US-U0860216,
PR	25-MAY-2001,	2001US-U0874503,
PR	14-JUN-2001,	2001US-U0882636,
PR	19-JUN-2001,	2001US-U0886342,
PR	20-JUN-2001,	2001WO-US019692,
PR	01-JUN-2001,	2001US-U0872035,
PR	21-JUN-2001,	2001US-U0887819,
PR	22-JUN-2001,	2001WO-US020116,
PR	23-JUN-2001,	2001US-U0210666,
PR	09-JUL-2001,	2001WO-US021735,
PR	18-JUL-2001,	2001US-U0908827,
PR	06-AUG-2001,	2001US-U0924419,
PR	09-AUG-2001,	2001US-U0927796,
PR	16-AUG-2001,	2001US-U0931836,
PR	19-DEC-2001,	2001US-U0028072,

















AC ADA61161;  
 XX 20-NOV-2003 (first entry)  
 DT  
 XX Homo sapiens.  
 DE  
 XX Human; secreted and transmembrane protein; PRO; gene; ss;  
 KW Tumour necrosis factor alpha release; TNF-alpha release;  
 KW glucose uptake modulator; FFA uptake modulator;  
 KW cell proliferation stimulator; cell differentiation stimulator;  
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.  
 XX  
 OS Novel.  
 OS human.  
 OS secreted.  
 OS and.  
 OS transmembrane.  
 OS protein.  
 OS PRO1294.  
 OS cDNA.  
 XX  
 PN US2003049817-A1.  
 XX  
 XX 13-MAR-2003.  
 XX  
 PF 10-MAY-2002; 2002US-00142423.  
 XX  
 PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 98WO-US000106.  
 PR 08-MAR-1999; 98WO-US005028.  
 PR 10-MAR-1999; 98WO-US005190.  
 PR 20-APR-1999; 98WO-US008615.  
 PR 14-MAY-1999; 98WO-US010733.  
 PR 02-JUN-1999; 98WO-US012252.  
 PR 01-SEP-1999; 98WO-US020111.  
 PR 08-SEP-1999; 98WO-US020594.  
 PR 13-SEP-1999; 98WO-US020944.  
 PR 15-SEP-1999; 98WO-US021090.  
 PR 15-SEP-1999; 98WO-US021547.  
 PR 05-OCT-1999; 98WO-US023089.  
 PR 29-NOV-1999; 98WO-US028214.  
 PR 30-NOV-1999; 98WO-US028313.  
 PR 30-NOV-1999; 98WO-US028409.  
 PR 01-DEC-1999; 98WO-US028301.  
 PR 01-DEC-1999; 98WO-US028634.  
 PR 02-DEC-1999; 98WO-US028551.  
 PR 02-DEC-1999; 98WO-US028584.  
 PR 16-DEC-1999; 98WO-US028565.  
 PR 16-DEC-1999; 98WO-US030095.  
 PR 20-DEC-1999; 98WO-US030911.  
 PR 20-DEC-1999; 98WO-US030999.  
 PR 22-DEC-1999; 98WO-US030720.  
 PR 30-DEC-1999; 98WO-US031243.  
 PR 30-DEC-1999; 98WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004514.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001US-00886342.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 PR 10-MAR-2009; 2000WO-US006319.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2003-695893/66.  
 DR P-ESDB; ADA61162.  
 XX  
 DR New <sup>secreted</sup> secreted and transmembrane PRO polypeptide and nucleic acid, useful  
 PT for manufacturing a medicament for diagnosing or treating tumor.  
 XX  
 XX Claim 2; Fig 501; 658pp; English.  
 PS  
 XX The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the



	2242
Qy	2197 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
Dd	1820 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
	1865 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 

RESULT 1110

ADA96637  
ID ADA96637 standard; cDNA; 1883 BP.

AC ADA96637:

DT 20-NOV-2003 (first entry)

Human PRO polynucleotide #251.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

OS Homo sapiens.

AX  
PN  
US2003082690-A1

01-MAY-2003

22-APR-2002: 2002IIS-00127837

01-SEP-1998: 98IIS-0098750P.

PR 01-SEP-1999: 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 18-FEB-2000; 2000WO-US004342.

PR 08-NOV-2000; 2000WO-US030952.

01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.  
yy

XX  
PA (GETH ) GENENTECH INC

xx Baker KP, Beresini M, Deforge L, Desnoyers L, Pilvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

DR WPI; 2003-755107/71.

DR P-PSDB; ADA96638.

PRO nucleic acid, useful for preparing a composition for treating e.g., tumor or for tissue typing.

PS Claim 2; Fig 501; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or







```

RESULT 1114
ADB21879
ID   ADB21879 standard; cDNA; 1883 BP.
XX
XX   ADB21879;
XX
XX   20-NOV-2003 (first entry)
XX
XX   Novel human secreted and transmembrane protein PRO1294 cDNA.
XX
XX   Human; secreted and transmembrane protein; PRO; gene; ss;
XX   Tumour necrosis factor alpha release; TNF-alpha release;
XX   Glucose uptake modulator; FFA uptake modulator;
XX   cell proliferation stimulator; cell differentiation stimulator;
XX   cell differentiation inhibitor; cytokine release stimulator; tumour;
XX   lung tumoure; colon tumour; breast tumour; prostate tumour; rectal tumour;
XX   cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX   gene therapy; chromosome identification; chromosome marker.
XX
XX   Homo sapiens.
XX
XX   US2003082765-A1.
XX
XX   01-MAY-2003.
XX
XX   17-MAY-2002; 2002US-00147492.
XX
XX   31-MAR-1997; 97WO-US005230.
XX   12-JUN-1998; 98WO-US012456.
XX   14-JUL-1998; 98WO-US014552.
XX   28-AUG-1998; 98WO-US017888.
XX   10-SEP-1998; 98WO-US018824.
XX   14-SEP-1998; 98WO-US019093.
XX   14-SEP-1998; 98WO-US019094.
XX   14-SEP-1998; 98WO-US019177.
XX   16-SEP-1998; 98WO-US019330.
XX   17-SEP-1998; 98WO-US019437.
XX   07-OCT-1998; 98WO-US021141.
XX   29-OCT-1998; 98WO-US022991.
XX   29-OCT-1998; 98WO-US022992.
XX   20-NOV-1998; 98WO-US024855.
XX   01-DEC-1998; 98WO-US025108.
XX   03-JAN-1999; 99WO-US000106.
XX   08-MAR-1999; 99WO-US005028.
XX   10-MAR-1999; 99WO-US005190.
XX   20-APR-1999; 99WO-US008615.
XX   14-MAY-1999; 99WO-US010733.
XX   02-JUN-1999; 99WO-US012552.
XX   01-SEP-1999; 99WO-US020111.
XX   08-SEP-1999; 99WO-US020594.
XX   13-SEP-1999; 99WO-US020944.

```









(GETH ) GENENTECH INC.

Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;







Qy 2197 AA 2242  
 Db 1820 AA 1865

## RESULT 1123

ADA77106

ID ADA77106 standard; cDNA; 1883 BP.

XX ADA77106;

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #251.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.

XX Homo sapiens.

XX OS US2003059909-A1.

XX 27-MAR-2003.

XX 10-MAY-2002; 2002US-00143032.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 18-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-540684/51.

XX P-PSDB; ADA77107.

XX

XX

XX

XX

XX

XX

XX

XX

XX



PR	07-OCT-1998;	98US-0103328P.	PR	18-FEB-2000; 2000WO-US004342.	PA	(GETH ) GENENTECH INC.	XX	09-JUL-2001; 2001WO-US021735.
PR	07-OCT-1998;	98US-0103395P.	PR	24-FEB-2000; 2000WO-US005004.	XX		XX	
PR	07-OCT-1998;	98US-0103396P.	PR	02-MAR-2000; 2000WO-US005841.	PI	Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;	XX	
PR	07-OCT-1998;	98US-0103401P.	PR	15-MAR-2000; 2000WO-US006884.	PI	Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;	PI	
PR	08-OCT-1998;	98US-0103633P.	PR	17-MAY-2000; 2000WO-US013705.	PI	Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;	PI	
PR	08-OCT-1998;	98US-0103678P.	PR	22-MAY-2000; 2000WO-US014042.	XX	Williams PM, Wood WI;	XX	
PR	08-OCT-1998;	98US-0103679P.	PR	30-MAY-2000; 2000WO-US014941.	PR	WPI; 2003-585292/55.	DR	
PR	08-OCT-1998;	98US-0103711P.	PR	02-JUN-2000; 2000WO-US015264.	PR	P-PSDB; ABO33503.	DR	
PR	14-OCT-1998;	98US-0104257P.	PR	23-AUG-2000; 2000WO-US023522.	PR		XX	
PR	20-OCT-1998;	98US-0104987P.	PR	24-AUG-2000; 2000WO-US023328.	PR		XX	
PR	20-OCT-1998;	98US-0105000P.	PR	08-NOV-2000; 2000WO-US030952.	PR		XX	
PR	20-OCT-1998;	98US-0105002P.	PR	10-NOV-2000; 2000WO-US030873.	PR		XX	
PR	21-OCT-1998;	98US-0105104P.	PR	01-DEC-2000; 2000WO-US032678.	PR		XX	
PR	22-OCT-1998;	98US-0105169P.	PR	28-FEB-2001; 2001WO-US006520.	PR		XX	
PR	22-OCT-1998;	98US-0105266P.	PR	01-MAR-2001; 2001WO-US006666.	PR		XX	
PR	26-OCT-1998;	98US-0105693P.	PR	01-JUN-2001; 2001US-00872035.	PR		XX	
PR	26-OCT-1998;	98US-0105694P.	PR	01-JUN-2001; 2001WO-US017800.	PR		XX	
PR	27-OCT-1998;	98US-0105807P.	PR	14-JUN-2001; 2001US-00882636.	PR		XX	
PR	27-OCT-1998;	98US-0105881P.	PR	20-JUN-2001; 2001WO-US019692.	PR		XX	
PR	27-OCT-1998;	98US-0106022P.	PR	29-JUN-2001; 2001WO-US021066.	PR		XX	
PR	28-OCT-1998;	98US-0106023P.	PR	09-JUL-2001; 2001WO-US021735.	XX		XX	
PR	28-OCT-1998;	98US-0106029P.	XX		XX		XX	
PR	28-OCT-1998;	98US-0106030P.	XX		XX		XX	
PR	28-OCT-1998;	98US-0106032P.	PI	Novel isolated PRO polypeptides e.g. PRO1491 and PRO1571, useful in the	PI		PI	
PR	28-OCT-1998;	98US-0106033P.	PI	preparation of a medicament for treating a condition responsive to PRO	PI		PI	
PR	28-OCT-1998;	98US-0106178P.	PI	polypeptide, and as therapeutic agents e.g. vaccines.	PI		PI	
PR	29-OCT-1998;	98US-0106248P.	XX		XX		XX	
PR	29-OCT-1998;	98US-0106384P.	XX		XX		XX	
PR	29-OCT-1998;	98US-0108500P.	XX		XX		XX	
PR	30-OCT-1998;	98US-0106464P.	XX		XX		XX	
PR	03-NOV-1998;	98US-0106856P.	XX		XX		XX	
PR	03-NOV-1998;	98US-0106902P.	XX		XX		XX	
PR	03-NOV-1998;	98US-0106905P.	XX		XX		XX	
PR	03-NOV-1998;	98US-0106919P.	XX		XX		XX	
PR	03-NOV-1998;	98US-0106932P.	XX		XX		XX	
PR	03-NOV-1998;	98US-0106934P.	XX		XX		XX	
PR	10-NOV-1998;	98US-0107783P.	XX		XX		XX	
PR	17-NOV-1998;	98US-0108775P.	XX		XX		XX	
PR	17-NOV-1998;	98US-0108779P.	XX		XX		XX	
PR	17-NOV-1998;	98US-0108787P.	XX		XX		XX	
PR	17-NOV-1998;	98US-0108788P.	XX		XX		XX	
PR	17-NOV-1998;	98US-0108801P.	XX		XX		XX	
PR	17-NOV-1998;	98US-0108802P.	XX		XX		XX	
PR	17-NOV-1998;	98US-0108806P.	XX		XX		XX	
PR	17-NOV-1998;	98US-0108807P.	XX		XX		XX	
PR	17-NOV-1998;	98US-0108867P.	XX		XX		XX	
PR								

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 XX gene therapy; chromosome identification; chromosome marker.

OS Homo sapiens.

PN US2003073213-A1.

XX 17-APR-2003.

XX 17-APR-2002; 2002US-00124819.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 24-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 01-MAR-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US005841.

PR 10-MAR-2000; 2000WO-US006319.

PR 15-MAR-2000; 2000WO-US006884.

PR 20-MAR-2000; 2000WO-US007377.

PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001US-00874503.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M., Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-743816/70.

P-PSDB; ADA88737.

New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
 in gene therapy, detecting the presence of tumor in a mammal, or  
 modulating the uptake of glucose or free fatty acid by skeletal muscle  
 cells or adipocyte cells.

Claim 2; Fig 501; 659pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and  
 transmembrane) polypeptides (I). (I) is useful for stimulating the  
 release of TNF-alpha from human blood, for modulating the uptake of  
 glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 stimulating the proliferation or differentiation of chondrocyte cells,  
 for stimulating the proliferation of or gene expression in pericyte  
 cells, for stimulating the release of proteoglycans from cartilage, for  
 stimulating the proliferation of inner ear utricular supporting cells,  
 for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 the release of a cytokine from BMC cells, for inhibiting the binding of  
 A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 cells, for stimulating proliferation of endothelial cells, for detecting  
 the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 are useful for isolating genomic and cDNA nucleotide sequences or  
 antisense probes. (i) is also useful as therapeutic agent. PRO is useful  
 in assays to identify other proteins or molecules involved in binding  
 interaction. A polynucleotide (ii) encoding (i) is useful in chromosome



KW	inner ear utricular supporting cell; T-lymphocyte cell;	98US-0084637P
KW	endothelial cell tube formation; bone disorder; cartilage disorder;	98US-0085149P
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	98US-0085323P
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;	98US-0085338P
KW	immune system cell infiltration.	98US-0085339P
XX		98US-0085579P
OS	Homo sapiens.	98US-0085697P
XX		98US-0085704P
FN	US2003022239-A1.	98US-0086414P
XX		98US-0086430P
PD	30-JAN-2003.	98US-0087106P
XX		98US-0088026P
PF	12-APR-2002; 2002US-00121049.	98US-0088730P
XX		98US-0088741P
PR	18-JUN-1997; 97US-0049911P.	98US-0088810P
PR	26-AUG-1997; 97US-0056974P.	98US-0088858P
PR	17-SEP-1997; 97US-0059113P.	98US-008907P
PR	17-SEP-1997; 97US-0059115P.	98US-0090455P
PR	17-SEP-1997; 97US-0059117P.	98US-0090538P
PR	17-SEP-1997; 97US-0059112P.	98US-0090599P
PR	17-SEP-1997; 97US-0059184P.	98US-009077P
PR	18-SEP-1997; 97US-0059263P.	98US-0090947P
PR	19-SEP-1997; 97US-0059352P.	98US-0090949P
PR	19-SEP-1997; 97US-0059588P.	98US-0090429P
PR	24-SEP-1997; 97US-0059836P.	98US-0090445P
PR	17-OCT-1997; 97US-0062250P.	98US-0090538P
PR	17-OCT-1997; 97US-0062285P.	98US-0090863P
PR	17-OCT-1997; 97US-0062287P.	98US-0091360P
PR	17-OCT-1997; 97US-0063755P.	98US-0091519P
PR	24-OCT-1997; 97US-0062814P.	98US-0091982P
PR	24-OCT-1997; 97US-0062816P.	98WO-US014552
PR	24-OCT-1997; 97US-0063045P.	98US-0093339P
PR	24-OCT-1997; 97US-0063082P.	98US-0094651P
PR	24-OCT-1997; 97US-0063127P.	98US-0094651P
PR	27-OCT-1997; 97US-0063327P.	98US-0095285P
PR	27-OCT-1997; 97US-0063329P.	98US-0095301P
PR	28-OCT-1997; 97US-0063350P.	98US-0095302P
PR	28-OCT-1997; 97US-0063550P.	98US-0095325P
PR	29-OCT-1997; 97US-0063561P.	98US-0096143P
PR	29-OCT-1997; 97US-0063704P.	98US-0096146P
PR	29-OCT-1997; 97US-0063733P.	98US-0096329P
PR	29-OCT-1997; 97US-0063735P.	98US-0096768P
PR	29-OCT-1997; 97US-0063738P.	98US-0096773P
PR	03-NOV-1997; 97US-0064248P.	98US-0096791P
PR	07-NOV-1997; 97US-0064809P.	98US-0096891P
PR	12-NOV-1997; 97US-0065186P.	98US-0096895P
PR	17-NOV-1997; 97US-0065846P.	98US-0096960P
PR	21-NOV-1997; 97US-0066364P.	98US-0097141P
PR	24-NOV-1997; 97US-0066453P.	98US-0097218P
PR	24-NOV-1997; 97US-0066511P.	98US-0097951P
PR	24-NOV-1997; 97US-0066770P.	98US-0097986P
PR	11-DEC-1997; 97US-0069212P.	98US-0098010P
PR	11-DEC-1997; 97US-0069218P.	98US-0098033P
PR	11-DEC-1997; 97US-0069234P.	98US-0098033P
PR	16-DEC-1997; 97US-0069694P.	98US-0098525P
PR	23-JAN-1998; 98US-0073202P.	98US-0098525P
PR	04-FEB-1998; 98US-0073612P.	98WO-US017888
PR	09-FEB-1998; 98US-0074086P.	98US-0098525P
PR	09-FEB-1998; 98US-0074092P.	98US-0098750P
PR	12-MAR-1998; 98US-0077791P.	98US-0099536P
PR	09-APR-1998; 98US-0081259P.	98US-0099598P
PR	25-MAR-1998; 98US-0079294P.	98US-0099598P
PR	27-MAR-1998; 98US-0079663P.	98US-0099601P
PR	27-MAR-1998; 98US-0079728P.	98US-0099792P
PR	31-MAR-1998; 98US-0080165P.	98US-0099803P
PR	09-APR-1998; 98US-0081259P.	98US-0099816P
PR	14-APR-1998; 98US-0081695P.	98WO-US018824
PR	15-APR-1998; 98US-0081817P.	98US-0100262P
PR	15-APR-1998; 98US-0081818P.	98US-0100263P
PR	24-APR-1998; 98US-0082959P.	98WO-US019093
PR	28-APR-1998; 98US-0083322P.	98WO-US019094
PR	29-APR-1998; 98US-0083545P.	98WO-US019177
PR	07-MAY-1998; 98US-0084600P.	98US-0100390P
PR	07-MAY-1998; 98US-0084627P.	98US-0100634P
PR		98US-0100634P
PR		98WO-US019330
PR		98US-01





KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003068793-A1.  
 XX  
 PD 10-APR-2003.  
 XX  
 PF 15-APR-2002; 2002US-00123108.  
 XX  
 PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 08-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 10-MAR-2000; 2000WO-US005841.  
 PR 15-MAR-2000; 2000WO-US006319.  
 PR 20-MAR-2000; 2000WO-US006884.  
 PR 21-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808699.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-695925/66.  
 DR P-PSDB; ADA67123.  
 XX  
 DR Novel secreted and transmembrane PRO polypeptides useful for stimulating the  
 PT release of tumor necrosis factor-alpha from human blood and detecting the  
 PT presence of a tumor in a mammal.  
 XX  
 PS Claim 2; Fig 501; 660pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumor necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, the  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a









OS	Homo sapiens.	
XX	US2003087347-A1.	
XX	08-MAY-2003.	
PD		
XX	19-APR-2002; 2002US-00125921.	
XX		
PR	17-AUG-1998; 98US-0096791P.	
PR	02-JUN-1999; 99WO-US012252.	
PR	25-AUG-1999; 99US-00380137.	
PR	30-MAR-2000; 2000WO-US008439.	
PR	01-DEC-2000; 2000WO-US032678.	
PR	19-DEC-2001; 2001US-00028072.	
XX		
XX	(GETH ) GENENTECH INC.	
PA		
XX	Baker KP, Bersesini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
XX		
DR	WPI; 2003-786938/74.	
DR	P-PSDB; ADB38242.	
XX		
PT	New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide	
PT	and for manufacturing a medicament for diagnosing or treating tumor.	
XX		
PS	Claim 2; Fig 501; 637pp; English.	

[illegible]

Db 1820 AA 1865  
RESULT 1136  
ADB66713  
ID ADB66713 standard; cDNA; 1883 BP.  
XX AC ADB66713;  
XX DT 04-DEC-2003 (first entry)  
XX DE Novel human secreted and transmembrane protein PRO1294 cDNA.  
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW lung tumour; colon tumour; cytokine release stimulator; tumour;  
KW cervical tumour; liver tumour; breast tumour; prostate tumour; rectal tumour;  
KW gene therapy; chromosome identification; chromosome marker.  
XX OS Homo sapiens.  
XX PN US2003082689-A1.  
XX PD 01-MAY-2003.  
XX PF 22-APR-2002; 2002US-00127831.  
XX PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022291.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 03-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 03-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 22-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00854280.  
PR 25-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-786905/74.  
DR P-PSDB; ADB66714.  
DR  
XX  
XX New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g. tumor or for tissue typing.  
XX  
XX Claim 2; Fig 501; 637pp; English.  
XX  
XX The invention describes 305 nucleic acids encoding PRO (secreted and

Claim 2; Fig 501; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html)

CC	Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;	
CC	Query Match	2.9%; Score 65.8; DB 9; Length 1883;
CC	Best Local Similarity	62.0%; Pred. No. 0.0003;
CC	Matches 103; Conservative	0; Mismatches 63; Indels 0; Gaps 0;
CC		
CC	2077 GTCTCAAGTCGTGTGACACATATCATTCACATGATCGCCTTGGTTTACCAC	2136
CC		
CC	1700 GAGTGCCAGCTGTGCCTCTCTTCCTCACTCCTCCTTCAGTGTCTCAGGAACAGGACT	1759
CC		
CC	2137 CTTCCTCTTTAFTATTATAAAAAATCTGTGCTGCCACCTGCTCCCAAAAAAAAAA	2196
CC		
CC	1760 TTCTCCATGTTTTTGTTATGGCACATTTTGCATTAAGGAAATCCAAAAA	1819
CC		
CC	2197 AAAAIAA	2242
CC		
CC	1820 AA	1865
CC		
CC		
CC	RESULT 1137	
CC	ADB89793	
CC	ID	ADB89793 standard; cDNA; 1883 BP.
CC	XX	
CC	ADB89793;	
CC	XX	
CC	04-DEC-2003 (first entry)	
CC	DT	
CC	XX	
CC	Human PRO polynucleotide #251.	
CC	DE	
CC	XX	
CC	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;	
CC	KW	

Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;

```
Query Match      2.9%; Score 65.8; DB 10; Length 1883;
Best Local Similarity 62.0%; Pred. No. 0.0003;
Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;
```

Qy	2077	GTCTCAAGTGTGCGACACATAATCATTCATCCATCCATGCGCTTTGCTTTACCACT	2136
1			
2			
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			
61			
62			
63			
64			
65			
66			
67			
68			
69			
70			
71			
72			
73			
74			
75			
76			
77			
78			
79			
80			
81			
82			
83			
84			
85			
86			
87			
88			
89			
90			
91			
92			
93			
94			
95			
96			
97			
98			
99			
100			
101			
102			
103			

2137 CTTTCCTTTATCTTATTAATAAAATGTTGGTCTCCACCACTGNCCTCCAAAAAAA 2196

Db  
1760 TTCTCCACATTGTTTGTGATTGCAACATTTTGCAATAAAAGGAAAATCCACAAAAAAA 1819

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
84

Qy	2197	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2242
Db	1820	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	1865

RESULT 1138

ADB90525  
ID ADB90525 standard; cDNA; 1883 bp.

AC ADB90525;

DT 04-DEC-2003 (first entry)

Human PRO polynucleotide #251.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;  
 cancer; adrenalis; lung; colon; breast; prostate; rectum; kidney; cervix;  
 liver; microvascular endothelial cell; glucose; FFA;  
 skeletal muscle cell; adipocyte cell; pericyte cell;  
 inner ear uricular supporting cell; T-lymphocyte cell;  
 endothelial cell tube formation; bone disorder; cartilage disorder;  
 sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
 immune system cell infiltration.

OS Homo sapiens.

PN US2003082762-A1.

PD 01-MAY-2003.

PF 15-APR-2002; 2002US-00123235.

PR 31-MAR-1997; 97WO-US005230.

PR 14-JUL-1998; 98WO-US014552.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019330.  
PR 16-SEP-1998; 98WO-US019330.

PR 07-OCT-1998; 98WO-US021141.  
PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022992.

PR 01-DEC-1998; 98WO-US025108.

PR 08-MAR-1999; 99WO-US005028.

PR 20-APR-1999; 99WO-US008615.

PR 02-JUN-1999; 99WO-US012252.

PR 08-SEP-1999; 99WO-US020594.

PR 15-SEP-1999; 99WO-US021090.

PR 05-OCT-1999; 99WO-US023089.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028301.

PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028565.

PR 20-DEC-1999; 99WO-US030911.

PR 22-DEC-1999; 99WO-US030720.

PR	30-DEC-1999;	99NW-US031243;
PR	30-DEC-1999;	99NW-US031274;
PR	05-JAN-2000;	2000NW-US000219;
PR	05-JAN-2000;	2000NW-US000277;
PR	06-JAN-2000;	2000NW-US000376;
PR	06-JAN-2000;	2000NW-US000365;
PR	11-FEB-2000;	2000NW-US004341;
PR	11-FEB-2000;	2000NW-US004342;
PR	22-FEB-2000;	2000NW-US004414;
PR	24-FEB-2000;	2000NW-US004415;
PR	24-FEB-2000;	2000NW-US005004;
PR	01-MAR-2000;	2000NW-US005601;
PR	02-MAR-2000;	2000NW-US005746;
PR	02-MAR-2000;	2000NW-US005841;
PR	10-MAR-2000;	2000NW-US006319;
PR	15-MAR-2000;	2000NW-US006888;
PR	20-MAR-2000;	2000NW-US007377;
PR	21-MAR-2000;	2000NW-US007532;
PR	30-MAR-2000;	2000NW-US008439;
PR	17-MAY-2000;	2000NW-US013705;
PR	22-MAY-2000;	2000NW-US014042;
PR	30-MAY-2000;	2000NW-US014941;
PR	02-JUN-2000;	2000NW-US015264;
PR	28-JUL-2000;	2000NW-US020710;
PR	11-AUG-2000;	2000NW-US022031;
PR	23-AUG-2000;	2000NW-US023522;
PR	24-AUG-2000;	2000NW-US023328;
PR	08-NOV-2000;	2000NW-US030952;
PR	10-NOV-2000;	2000NW-US030873;
PR	01-DEC-2000;	2000NW-US032678;
PR	20-DEC-2000;	2000US-00747259;
PR	20-DEC-2000;	2000NW-US034956;
PR	28-FEB-2001;	2001US-00796498;
PR	28-FEB-2001;	2001NW-US006520;
PR	01-MAR-2001;	2001NW-US006666;
PR	09-MAR-2001;	2001US-00802706;
PR	14-MAR-2001;	2001US-00808698;
PR	22-MAR-2001;	2001US-00816744;
PR	05-APR-2001;	2001US-00828366;
PR	10-MAY-2001;	2001US-00854208;
PR	10-MAY-2001;	2001US-00854280;
PR	18-MAY-2001;	2001US-00860216;
PR	25-MAY-2001;	2001US-00866028;
PR	25-MAY-2001;	2001US-00866034;
PR	25-MAY-2001;	2001NW-US017092;
PR	01-JUN-2001;	2001US-00872035;
PR	01-JUN-2001;	2001US-00871780;
PR	05-JUN-2001;	2001US-00874503;
PR	14-JUN-2001;	2001US-00882636;
PR	19-JUN-2001;	2001US-00886342;
PR	20-JUN-2001;	2001US-008913692;
PR	21-JUN-2001;	2001US-00887879;
PR	22-JUN-2001;	2001NW-US020116;
PR	29-JUN-2001;	2001NW-US021066;
PR	09-JUL-2001;	2001NW-US021735;
PR	18-JUL-2001;	2001US-00908827;
PR	06-AUG-2001;	2001US-00924419;
PR	09-AUG-2001;	2001US-00927796;
PR	16-AUG-2001;	2001US-00931836;
PR	19-DEC-2001;	2001US-0028072;

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-743899/70.

P-PSDB; ADB90526.

New secreted and transmembrane PRO polypeptides and nucleic acids, useful in gene therapy, and in the detection and treatment of tumor in a mammal.

XX













XX US2003077718-A1.  
 XX 24-APR-2003.  
 XX 24-APR-2002; 2002US-0011823.  
 PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US0003565.  
 PR 18-FEB-2000; 2000WO-US000431.  
 PR 18-FEB-2000; 2000WO-US000432.  
 PR 22-FEB-2000; 2000WO-US000414.  
 PR 24-FEB-2000; 2000WO-US000491.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 10-MAR-2000; 2000WO-US005841.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US007532.  
 PR 21-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 30-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US014941.  
 PR 28-JUL-2000; 2000WO-US015264.  
 PR 11-AUG-2000; 2000WO-US020710.  
 PR 23-AUG-2000; 2000WO-US022031.  
 PR 24-AUG-2000; 2000WO-US023322.  
 PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US0006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2003-755073/71.  
 DR P-PSDB; ADB35171.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, cervical and/or liver tumors.

XX Claim 2; Fig 501; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating







[illegible]







QY 2197 AA 2242  
DB 1820 AA 1865

## RESULT 1155

ADC60620  
ID ADC60620 standard; cDNA; 1883 BP.

AC ADC60620;

DT 18-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein PRO1294 cDNA.

KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
KW pericyte cell; inner ear utricular supporting cell; adipocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;  
KW immune system cell infiltration; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker; gene; ss.

OS Homo sapiens.

XX US2003087367-A1.

PN 08-MAY-2003.

PD 24-APR-2002; 2002US-00131825.

PP 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019330.

PR 16-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 10-MAR-1999; 2000WO-US006319.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028521.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004514.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 15-MAR-2000; 2000WO-US005841.  
PR 20-MAR-2000; 2000WO-US006884.  
PR 21-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US007532.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 11-AUG-2000; 2000WO-US020311.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001US-00802706.  
PR 09-MAR-2001; 2001US-00806889.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001US-00872035.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001US-00898279.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-801152/75.  
P-PSDB; ADC60621.

New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide



CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC	be used in preparing PRO polypeptides by recombinant techniques and in
CC	generating either transgenic animals or knock-out animals which are
CC	useful in the development and screening of therapeutically useful
CC	reagents. The PRO polypeptides or antibodies are used in preparing a
CC	medicament for treating a condition responsive to the polypeptides or
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation
CC	of human microvascular endothelial cells, for modulating the uptake of
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC	stimulating differentiation of adipocyte cells, for stimulating
CC	proliferation of or gene expression in pericyte cells, for stimulating
CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC	cells, for inducing endothelial cell tube formation and for treating
CC	various bone and/or cartilage disorders such as sports injuries and
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC	from cartilage are useful for treating sports-related joint problems,
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis.
CC	POLYPEPTIDES ARE ALSO USEFUL FOR TREATING VARIOUS MAMMALIAN HAEMOGLOBIN-
CC	ASSOCIATED DISORDERS SUCH AS VARIOUS THALASSEMIAS AND CONDITIONS WHICH
CC	MAY BENEFIT FROM ENHANCED LOCAL IMMUNE SYSTEM CELL INFILTRATION. THIS
CC	SEQUENCE REPRESENTS A HUMAN PRO POLYNUCLEOTIDE OF THE INVENTION. NOTE:
CC	THE SEQUENCE DATA FOR THIS PATENT IS ALSO AVAILABLE IN ELECTRONIC FORMAT
CC	FROM USPTO AT SEQDATA.USPTO.GOV/SEQUENCE.HTML.
CC	
XX	Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;
SQ	
Query Match	2.9%; Score 65.8; DB 10; Length 1883;
Best Local Similarity	62.0%; Pred. No. 0.0003;
Matches 103; Conservative	0; Mismatches 63; Indels 0; Gaps 0;
QY	2077 GTCTTCGAAGTGTGCGTGACACATAATCATTTCCAATCAATGCCTTTTGGCTTTTACCACAT 2136
DB	1700 GAGGTCCAGTGTCTCTCTCTCTCCTCACCTCCCTTCAGTGTCTCTGAGGACACAGGACT 1759
QY	2137 CTITTCCTTTTAUCTTATTAAATAAATGTTGGTCTCCACCACATGNCITCCCAAAAAAAAAAAA 2196
DB	1760 TTCTCCACATTTGTTTTGTATTGCCACATTTTGCAATTAAAAGGAAAAATCCACAAAAAAAAA 1819
QY	2197 AA 2242
DB	1820 AA 1865
RESULT 1158	
ADC54720	
ID	ADC54720 standard; cDNA; 1883 BP.
XX	ADC54720;
XX	
DT	18-DEC-2003 (first entry)
XX	
DE	Novel human secreted and transmembrane protein cDNA Seq ID501.
XX	
KW	human; PRO; membrane bound protein; membrane bound receptor;
KW	cell proliferation; cell migration; cell differentiation;
KW	mitogenic factor; survival factor; cytotoxic factor;
KW	differentiation factor; neuropeptide; hormone; cell receptor;
KW	receptor-ligand interaction; cytosstatic; chondrocyte; tumour; ss; gene.
OS	Homo sapiens.
XX	
PN	US2003087363-A1.
XX	
PD	08-MAY-2003.
XX	
PF	23-APR-2002; 2002US-00128687.
XX	
XX	10-SEP-1998; 98US-0099816P.
PR	01-SEP-1999; 99WO-US020111.
PR	18-OCT-1999; 99US-00403297.
PR	18-FEB-2000; 2000WO-US004342.
PR	01-DEC-2000; 2000WO-US032678.
PR	19-DEC-2001; 2001US-00028072.





[illegible]







SQL	Sequence	1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;
	Query Match	2.9%; Score 65.8; DB 10; Length 1883;
	Best Local Similarity	62.0%; Pred. No. 0.0003;
	Matches 103; Conservative	0; Mismatches 63; Indels 0; Gaps 0;
QY	2077	GTCCTCAAGTGCCTGCGACATCAATCCATCCCATGATCGCCTTTTGCTTTACCACCT 2136
DB	1700	GAGCTCCAGCTGTGCTCTCTCTCTCCCTCACCTCCCTTCAGTGTCTCTGAGAACAGGACT 1759
QY	2137	CTTTCCCTTTTATCTATTATAAATAATGTTGGTCTCCACCACCTGNTCCCAAAAAAAA 2196
DB	1760	TTCCTCCACATGTTTGTGATGCAACATTTGCAATTAAGAAGAAATCCACAATAAAAA 1819
QY	2197	AA 2242
DB	1820	AA 1865
RESULT	l167	
ADDI0155		
ID	ADDI0155 standard; cDNA; 1883 BP.	
XX	XX	
AC	ADDI0155;	
XX	XX	
DT	01-JAN-2004 (first entry)	
XX	XX	
DE	Human PRO polynucleotide #251.	
XX	Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;	
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;	
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;	
KW	liver; microvascular endothelial cell; glucose; FFA;	
KW	skeletal muscle cell; adipocyte cell; pericyte cell;	
KW	inner ear utricular supporting cell; T-lymphocyte cell;	
KW	endothelial cell tube formation; bone disorder; cartilage disorder;	
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;	
KW	immune system cell infiltration.	
XX	Homo sapiens.	
OS	US2003194776-A1.	
PN	16-OCT-2003.	
XX	XX	
PD	29-MAY-2002; 2002US-00157785.	
XX	XX	
PF	05-JUN-2000; 2000US-0209832P.	
XX	PR	
PR	01-DEC-2000; 2000WO-US032678.	
PR	19-DEC-2001; 2001US-00028072.	
XX	(GETH ) GENENTECH INC.	
PA	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	
XX	Pi Gerritson ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
XX	WPI; 2003-852596/79.	
DR	P-PSDB; ADDI0156.	
XX	New secreted and transmembrane PRO nucleic acids and polypeptides, useful	
PT	for detecting a tumor, stimulating the release of proteoglycans from	
PT	cartilage and inhibiting the differentiation of adipocyte cells.	
XX	Claim 2; Fig 501; 637pp; English.	
PS	The invention relates to isolated human PRO polypeptides (secreted and	
CC	transmembrane polypeptides) and the polynucleotides encoding them. The	
CC	invention also relates to an antibody which specifically binds to a PRO	
CC	polypeptide, a method for stimulating the release of tumour necrosis	
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the	
CC	proliferation or differentiation of chondrocyte cells and a method for	













RESULT 1177	
ADD39737	
ID	ADD39737 standard; cDNA; 1883 BP
XX	<sup>1-234</sup>
XX	
AC	ADD39737;
XX	
DT	15-JAN-2004 (first entry)



PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 98WO-US000106.  
 PR 08-MAR-1999; 98WO-US005028.  
 PR 10-MAR-1999; 98WO-US005190.  
 PR 10-MAR-1999; 2000WO-US006319.  
 PR 20-APR-1999; 98WO-US008615.  
 PR 14-MAY-1999; 98WO-US010733.  
 PR 02-JUN-1999; 98WO-US012252.  
 PR 01-SEP-1999; 98WO-US020111.  
 PR 08-SEP-1999; 98WO-US020594.  
 PR 13-SEP-1999; 98WO-US020944.  
 PR 15-SEP-1999; 98WO-US021090.  
 PR 15-SEP-1999; 98WO-US021547.  
 PR 05-OCT-1999; 98WO-US023089.  
 PR 29-NOV-1999; 98WO-US028214.  
 PR 30-NOV-1999; 98WO-US028313.  
 PR 30-NOV-1999; 98WO-US028409.  
 PR 01-DEC-1999; 98WO-US028301.  
 PR 01-DEC-1999; 98WO-US028634.  
 PR 02-DEC-1999; 98WO-US028551.  
 PR 02-DEC-1999; 98WO-US028564.  
 PR 16-DEC-1999; 98WO-US028565.  
 PR 16-DEC-1999; 98WO-US030095.  
 PR 20-DEC-1999; 98WO-US030911.  
 PR 20-DEC-1999; 98WO-US030999.  
 PR 22-DEC-1999; 98WO-US030720.  
 PR 30-DEC-1999; 98WO-US031243.  
 PR 30-DEC-1999; 98WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 11-FEB-2000; 2000WO-US000376.  
 PR 18-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 22-FEB-2000; 2000WO-US004342.  
 PR 24-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 01-MAR-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 15-MAR-2000; 2000WO-US005841.  
 PR 20-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015284.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802796.  
 PR 14-MAR-2001; 2001US-00808689.

PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 FA (GETH ) GENENTECH INC.  
 XX

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX

DR WPI; 2003-852559/79.  
 DR P-PSDB; ADD53196.

XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
 PT PRO4978, useful in chromosome and gene mapping, in generating antisense  
 PT RNA and DNA, and in the treatment of cancer.

XX Claim 2; Fig 501; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems, PRO  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence encodes a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC the USPTO website at seqdata.uspto.gov.





```
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
XX Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KU;
XX Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
XX Williams PM, Wood WI;
XX WPI; 2003-708344/67.
XX P-PSDB; ADD70184.
XX
XX Novel isolated PRO polypeptide useful for tissue typing, modulating
XX biological activity of cell, as molecular weight markers in protein
XX electrophoresis, for treating arthritis, tumor.
XX
XX Claim 2; SEQ ID NO 145; 549pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX
XX Query Match 2.9%; Score 65.8; DB 10; Length 1883;
XX Best Local Similarity 62.0%; Pred. No. 0.0003;
XX Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;
QY 2077 GTCTCAAGTCGTCGACACATAATCATTCATCCATCCATGATCGCTTCTTTACCACT 2136
DB 1700 GAGTCACAGTCGTCCTCTCTCTCCACCTCTCTCCCTGCTGAGGACAGACT 1759
QY 2137 CTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACACTGNTCCCAAAAAA 2196
DB 1760 TTCTCCACATGTTTGTATTGCAACATTTTGCATTAAGGAAATCCACAAAAA 1819
QY 2197 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
DB 1820 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1865
RESULT 1181
ADD38304
ID ADD38304 standard; cDNA; 1883 BP.
XX
XX AC ADD38304;
XX
XX 15-JAN-2004 (first entry)
XX
XX Human cDNA encoding secreted/transmembrane protein PRO1294.
XX
XX Human; ss; gene; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassaemia.
XX
XX Homo sapiens.
XX
XX US2003096955-A1.
XX
XX 22-MAY-2003.
XX
XX 07-DEC-2001; 2001US-00012755.
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
```

```
PR 02-SEP-1998;
PR 02-SEP-1998;
PR 02-SEP-1998;
PR 09-SEP-1998;
PR 09-SEP-1998;
PR 09-SEP-1998;
PR 09-SEP-1998;
PR 09-SEP-1998;
PR 10-SEP-1998;
PR 10-SEP-1998;
PR 10-SEP-1998;
PR 10-SEP-1998;
PR 15-SEP-1998;
PR 15-SEP-1998;
PR 15-SEP-1998;
PR 16-SEP-1998;
PR 16-SEP-1998;
PR 16-SEP-1998;
PR 16-SEP-1998;
PR 17-SEP-1998;
PR 17-SEP-1998;
PR 17-SEP-1998;
PR 17-SEP-1998;
PR 17-SEP-1998;
PR 18-SEP-1998;
PR 18-SEP-1998;
PR 18-SEP-1998;
PR 18-SEP-1998;
PR 22-SEP-1998;
PR 23-SEP-1998;
PR 23-SEP-1998;
PR 23-SEP-1998;
PR 23-SEP-1998;
PR 23-SEP-1998;
PR 24-SEP-1998;
PR 24-SEP-1998;
PR 24-SEP-1998;
PR 29-SEP-1998;
PR 29-SEP-1998;
PR 29-SEP-1998;
PR 29-SEP-1998;
PR 30-SEP-1998;
PR 30-SEP-1998;
PR 30-SEP-1998;
PR 30-SEP-1998;
PR 01-OCT-1998;
PR 01-OCT-1998;
PR 02-OCT-1998;
PR 06-OCT-1998;
PR 06-OCT-1998;
PR 07-OCT-1998;
PR 07-OCT-1998;
PR 07-OCT-1998;
PR 07-OCT-1998;
PR 08-OCT-1998;
PR 08-OCT-1998;
PR 08-OCT-1998;
PR 14-OCT-1998;
PR 20-OCT-1998;
```

```
98US-0098821P.
98US-0098843P.
98US-0098536P.
98US-0098596P.
98US-0098598P.
98US-0098602P.
98US-0098642P.
98US-0098741P.
98US-0098754P.
98US-0098763P.
98US-0098792P.
98US-0098808P.
98US-0098812P.
98US-0098815P.
98US-0098816P.
98US-0100385P.
98US-0100388P.
98US-0100390P.
98US-0100584P.
98US-0100627P.
98US-0100661P.
98US-0100662P.
98US-0100664P.
98US-0100683P.
98US-0100684P.
98US-0100710P.
98US-0100711P.
98US-0100919P.
98US-0100930P.
98US-0100848P.
98US-0100849P.
98US-0101014P.
98US-0101068P.
98US-0101071P.
98US-0101279P.
98US-0101471P.
98US-0101472P.
98US-0101474P.
98US-0101475P.
98US-0101476P.
98US-0101477P.
98US-0101479P.
98US-0101738P.
98US-0101741P.
98US-0101915P.
98US-0101916P.
98US-0102307P.
98US-0102307P.
98US-0102307P.
98US-0102331P.
98US-0102484P.
98US-0102487P.
98US-0102570P.
98US-0102571P.
98US-0102684P.
98US-0102687P.
98US-0102965P.
98US-0103258P.
98US-0103449P.
98US-0103314P.
98US-0103315P.
98US-0103328P.
98US-0103395P.
98US-0103396P.
98US-0103401P.
98US-0103633P.
98US-0103678P.
98US-0103679P.
98US-0103711P.
98US-0104257P.
98US-0104987P.
98US-0105000P.
```



PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 02-SEP-1998; 98US-0099336P.  
PR 02-SEP-1998; 98US-0099596P.  
PR 02-SEP-1998; 98US-0099598P.  
PR 02-SEP-1998; 98US-0099602P.  
PR 02-SEP-1998; 98US-0099642P.  
PR 02-SEP-1998; 98US-0099741P.  
PR 02-SEP-1998; 98US-0099754P.  
PR 02-SEP-1998; 98US-0099763P.  
PR 02-SEP-1998; 98US-0099792P.  
PR 02-SEP-1998; 98US-0099808P.  
PR 02-SEP-1998; 98US-0099812P.  
PR 02-SEP-1998; 98US-0099815P.  
PR 02-SEP-1998; 98US-0099816P.  
PR 02-SEP-1998; 98US-0100385P.  
PR 02-SEP-1998; 98US-0100388P.  
PR 02-SEP-1998; 98US-0100390P.  
PR 02-SEP-1998; 98US-0100584P.  
PR 02-SEP-1998; 98US-0100627P.  
PR 02-SEP-1998; 98US-0100661P.  
PR 02-SEP-1998; 98US-0100662P.  
PR 02-SEP-1998; 98US-0100664P.  
PR 02-SEP-1998; 98US-0100683P.  
PR 02-SEP-1998; 98US-0100684P.  
PR 02-SEP-1998; 98US-0100710P.  
PR 02-SEP-1998; 98US-0100711P.  
PR 02-SEP-1998; 98US-0100919P.  
PR 02-SEP-1998; 98US-0100930P.  
PR 02-SEP-1998; 98US-0100949P.  
PR 02-SEP-1998; 98US-0100849P.  
PR 02-SEP-1998; 98US-0101014P.  
PR 02-SEP-1998; 98US-0101017P.  
PR 02-SEP-1998; 98US-0101279P.  
PR 02-SEP-1998; 98US-0101471P.  
PR 02-SEP-1998; 98US-0101472P.  
PR 02-SEP-1998; 98US-0101474P.  
PR 02-SEP-1998; 98US-0101475P.  
PR 02-SEP-1998; 98US-0101476P.  
PR 02-SEP-1998; 98US-0101477P.  
PR 02-SEP-1998; 98US-0101479P.  
PR 02-SEP-1998; 98US-0101738P.  
PR 02-SEP-1998; 98US-0101741P.  
PR 02-SEP-1998; 98US-0101743P.  
PR 02-SEP-1998; 98US-0101915P.  
PR 02-SEP-1998; 98US-0101916P.  
PR 02-SEP-1998; 98US-0102207P.  
PR 02-SEP-1998; 98US-0102240P.  
PR 02-SEP-1998; 98US-0102307P.  
PR 02-SEP-1998; 98US-0102330P.  
PR 02-SEP-1998; 98US-0102331P.  
PR 02-SEP-1998; 98US-0102484P.  
PR 02-SEP-1998; 98US-0102487P.  
PR 02-SEP-1998; 98US-0102570P.  
PR 02-SEP-1998; 98US-0102571P.  
PR 02-SEP-1998; 98US-0102684P.  
PR 02-SEP-1998; 98US-0102687P.  
PR 02-SEP-1998; 98US-0102965P.  
PR 02-SEP-1998; 98US-0103258P.  
PR 02-SEP-1998; 98US-0103449P.  
PR 02-SEP-1998; 98US-0103314P.  
PR 02-SEP-1998; 98US-0103315P.  
PR 02-SEP-1998; 98US-0103328P.  
PR 02-SEP-1998; 98US-0103395P.  
PR 02-SEP-1998; 98US-0103396P.  
PR 02-SEP-1998; 98US-0103401P.  
PR 02-SEP-1998; 98US-0103633P.  
PR 02-SEP-1998; 98US-0103678P.  
PR 02-SEP-1998; 98US-0103679P.  
PR 02-SEP-1998; 98US-0103711P.  
PR 02-SEP-1998; 98US-0104257P.

PR 20-OCT-1998; 98US-0104987P.  
PR 20-OCT-1998; 98US-0105000P.  
PR 20-OCT-1998; 98US-0105002P.  
PR 20-OCT-1998; 98US-0105104P.  
PR 20-OCT-1998; 98US-0105169P.  
PR 20-OCT-1998; 98US-0105266P.  
PR 20-OCT-1998; 98US-0105693P.  
PR 20-OCT-1998; 98US-0105694P.  
PR 20-OCT-1998; 98US-0105807P.  
PR 20-OCT-1998; 98US-0105881P.  
PR 20-OCT-1998; 98US-0105882P.  
PR 20-OCT-1998; 98US-0106062P.  
PR 20-OCT-1998; 98US-0106032P.  
PR 20-OCT-1998; 98US-0106030P.  
PR 20-OCT-1998; 98US-0106032P.  
PR 20-OCT-1998; 98US-0106033P.  
PR 20-OCT-1998; 98US-0106178P.  
PR 20-OCT-1998; 98US-0106248P.  
PR 20-OCT-1998; 98US-0106384P.  
PR 20-OCT-1998; 98US-0106464P.  
PR 20-OCT-1998; 98US-0106856P.  
PR 20-OCT-1998; 98US-0106902P.  
PR 20-OCT-1998; 98US-0106905P.  
PR 20-OCT-1998; 98US-0106919P.  
PR 20-OCT-1998; 98US-0106932P.  
PR 20-OCT-1998; 98US-0106934P.  
PR 20-OCT-1998; 98US-0107783P.  
PR 20-OCT-1998; 98US-0108779P.  
PR 20-OCT-1998; 98US-0108787P.  
PR 20-OCT-1998; 98US-0108788P.  
PR 20-OCT-1998; 98US-0108801P.  
PR 20-OCT-1998; 98US-0108802P.  
PR 20-OCT-1998; 98US-0108806P.  
PR 20-OCT-1998; 98US-0108807P.  
PR 20-OCT-1998; 98US-0108867P.  
PR 20-OCT-1998; 98US-0108925P.  
PR 20-OCT-1998; 98US-0108848P.  
PR 20-OCT-1998; 98US-0108849P.  
PR 20-OCT-1998; 98US-0108850P.  
PR 20-OCT-1998; 98US-0108851P.  
PR 20-OCT-1998; 98US-0108852P.  
PR 20-OCT-1998; 98US-0108858P.  
PR 20-OCT-1998; 98US-0108904P.  
PR 20-OCT-1998; 98US-0113296P.  
PR 20-OCT-1998; 98US-0114223P.  
PR 20-OCT-1998; 99WO-US000106.  
PR 20-OCT-1998; 99US-0129674P.  
PR 20-OCT-1998; 99US-0141037P.  
PR 20-OCT-1998; 99US-0144758P.  
PR 20-OCT-1998; 99US-0145698P.  
PR 20-OCT-1998; 99WO-US020111.  
PR 20-OCT-1998; 99WO-US021194.  
PR 20-OCT-1998; 99US-0162506P.  
PR 20-OCT-1998; 99WO-US028313.  
PR 20-OCT-1998; 99WO-US028551.  
PR 20-OCT-1998; 99WO-US030095.  
PR 20-OCT-1998; 2000WO-US000219.  
PR 20-OCT-1998; 2000WO-US000376.  
PR 20-OCT-1998; 2000WO-US003565.  
PR 20-OCT-1998; 2000WO-US004342.  
PR 20-OCT-1998; 2000WO-US005004.  
PR 20-OCT-1998; 2000WO-US005841.  
PR 20-OCT-1998; 2000WO-US006884.  
PR 20-OCT-1998; 2000WO-US013705.  
PR 20-OCT-1998; 2000WO-US014042.  
PR 20-OCT-1998; 2000WO-US014941.  
PR 20-OCT-1998; 2000WO-US015264.  
PR 20-OCT-1998; 2000WO-US023522.  
PR 20-OCT-1998; 2000WO-US023328.  
PR 20-OCT-1998; 2000WO-US030952.







[illegible]



PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 18-SEP-1998; 98US-0101071P.  
PR 22-SEP-1998; 98US-0101279P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101474P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101476P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 23-SEP-1998; 98US-0101479P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101741P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101915P.  
PR 24-SEP-1998; 98US-0101916P.  
PR 29-SEP-1998; 98US-0102207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102307P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102333P.  
PR 30-SEP-1998; 98US-0102484P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 01-OCT-1998; 98US-0102571P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 02-OCT-1998; 98US-0102687P.  
PR 06-OCT-1998; 98US-0102965P.  
PR 06-OCT-1998; 98US-0103258P.  
PR 07-OCT-1998; 98US-0103449P.  
PR 07-OCT-1998; 98US-0103314P.  
PR 07-OCT-1998; 98US-0103315P.  
PR 07-OCT-1998; 98US-0103328P.  
PR 07-OCT-1998; 98US-0103329P.  
PR 07-OCT-1998; 98US-0103336P.  
PR 07-OCT-1998; 98US-0103401P.  
PR 08-OCT-1998; 98US-0103633P.  
PR 08-OCT-1998; 98US-0103678P.  
PR 08-OCT-1998; 98US-0103679P.  
PR 14-OCT-1998; 98US-0103711P.  
PR 14-OCT-1998; 98US-0104237P.  
PR 20-OCT-1998; 98US-0104987P.  
PR 20-OCT-1998; 98US-0105000P.  
PR 20-OCT-1998; 98US-0105002P.  
PR 21-OCT-1998; 98US-0105104P.  
PR 22-OCT-1998; 98US-0105169P.  
PR 22-OCT-1998; 98US-0105266P.  
PR 26-OCT-1998; 98US-0105693P.  
PR 26-OCT-1998; 98US-0105694P.  
PR 27-OCT-1998; 98US-0105807P.  
PR 27-OCT-1998; 98US-0105881P.  
PR 27-OCT-1998; 98US-0105882P.  
PR 28-OCT-1998; 98US-0106082P.  
PR 28-OCT-1998; 98US-0106023P.  
PR 28-OCT-1998; 98US-0106029P.  
PR 28-OCT-1998; 98US-0106030P.  
PR 28-OCT-1998; 98US-0106032P.  
PR 28-OCT-1998; 98US-0106033P.  
PR 28-OCT-1998; 98US-0106178P.  
PR 29-OCT-1998; 98US-0106248P.  
PR 29-OCT-1998; 98US-0106384P.  
PR 29-OCT-1998; 98US-0108500P.  
PR 30-OCT-1998; 98US-0108464P.  
PR 03-NOV-1998; 98US-0106856P.  
PR 03-NOV-1998; 98US-0106902P.  
PR 03-NOV-1998; 98US-0106905P.  
PR 03-NOV-1998; 98US-0106919P.  
PR 03-NOV-1998; 98US-0106932P.  
PR 03-NOV-1998; 98US-0106934P.  
PR 10-NOV-1998; 98US-0107783P.  
PR 17-NOV-1998; 98US-0108775P.  
PR 17-NOV-1998; 98US-0108779P.  
PR 17-NOV-1998; 98US-0108787P.  
PR 17-NOV-1998; 98US-0108801P.  
PR 17-NOV-1998; 98US-0108802P.  
PR 17-NOV-1998; 98US-0108806P.  
PR 17-NOV-1998; 98US-0108807P.  
PR 17-NOV-1998; 98US-0108867P.  
PR 17-NOV-1998; 98US-0108925P.  
PR 18-NOV-1998; 98US-0108848P.  
PR 18-NOV-1998; 98US-0108849P.  
PR 18-NOV-1998; 98US-0108850P.  
PR 18-NOV-1998; 98US-0108851P.  
PR 18-NOV-1998; 98US-0108852P.  
PR 18-NOV-1998; 98US-0108858P.  
PR 18-NOV-1998; 98US-0108904P.  
PR 22-DEC-1998; 98US-0113296P.  
PR 30-DEC-1998; 98US-0114223P.  
PR 03-JAN-1999; 99WO-US000106.  
PR 16-APR-1999; 99US-0129674P.  
PR 23-JUN-1999; 99US-0141037P.  
PR 26-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 15-SEP-1999; 99WO-US021194.  
PR 29-OCT-1999; 99US-0162506P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US028551.  
PR 16-DEC-1999; 99WO-US030095.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 04-SEP-2001; 2001US-00946374.  
XX  
XX  
PA (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;  
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;  
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;  
PI Williams PM, Wood WI;  
XX  
XX WPI; 2003-755104/71.  
DR P-PSDB; ADD40215.  
XX  
XX  
PT New isolated PRO polypeptides such as PRO1560, PRO444, PRO1018, PRO1773,  
PT PRO1244, PRO1246, are useful for treating cancerous tumors and cardiac  
PT insufficiency disorders.  
XX  
XX Claim 2; SEQ ID NO 145; 550pp; English.  
PS The invention relates to an isolated PRO polypeptide (secreted or  
CC  
Query Match 2.9%; Score 65.8; DB 10; Length 1883;  
Best Local Similarity 62.0%; Pred. No. 0.0003;  
Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;





000000-0000  
000000-0000  
000000-0000





ID ADE20047 standard; cDNA; 1883 BP.  
XX AC ADE20047;  
XX DT 29-JAN-2004 (first entry)  
XX DE Human cDNA encoding secreted/transmembrane protein PRO1294.  
XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO; tumour;  
KW immune response; cardiac insufficiency disorder; calcium flux;  
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;  
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;  
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;  
KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia.  
XX OS Homo sapiens.  
XX PN US2003092883-A1.  
XX 15-MAY-2003.  
XX PD 10-DEC-2001; 2001US-00013430.  
XX PF 01-SEP-1998; 98US-0098716P.  
XX PR 01-SEP-1998; 98US-0098723P.  
XX PR 01-SEP-1998; 98US-0098749P.  
XX PR 01-SEP-1998; 98US-0098750P.  
XX PR 02-SEP-1998; 98US-0098803P.  
XX PR 02-SEP-1998; 98US-0098821P.  
XX PR 02-SEP-1998; 98US-0098843P.  
XX PR 09-SEP-1998; 98US-0099536P.  
XX PR 09-SEP-1998; 98US-0099596P.  
XX PR 09-SEP-1998; 98US-0099598P.  
XX PR 09-SEP-1998; 98US-0099602P.  
XX PR 09-SEP-1998; 98US-0099642P.  
XX PR 10-SEP-1998; 98US-0099741P.  
XX PR 10-SEP-1998; 98US-0099754P.  
XX PR 10-SEP-1998; 98US-0099763P.  
XX PR 10-SEP-1998; 98US-0099792P.  
XX PR 10-SEP-1998; 98US-0099808P.  
XX PR 10-SEP-1998; 98US-0099812P.  
XX PR 10-SEP-1998; 98US-0099815P.  
XX PR 10-SEP-1998; 98US-0099816P.  
XX PR 15-SEP-1998; 98US-0100385P.  
XX PR 15-SEP-1998; 98US-0100388P.  
XX PR 15-SEP-1998; 98US-0100390P.  
XX PR 16-SEP-1998; 98US-0100584P.  
XX PR 16-SEP-1998; 98US-0100627P.  
XX PR 16-SEP-1998; 98US-0100661P.  
XX PR 16-SEP-1998; 98US-0100662P.  
XX PR 16-SEP-1998; 98US-0100664P.  
XX PR 17-SEP-1998; 98US-0100683P.  
XX PR 17-SEP-1998; 98US-0100684P.  
XX PR 17-SEP-1998; 98US-0100710P.  
XX PR 17-SEP-1998; 98US-0100711P.  
XX PR 17-SEP-1998; 98US-0100919P.  
XX PR 17-SEP-1998; 98US-0100930P.  
XX PR 18-SEP-1998; 98US-0100848P.  
XX PR 18-SEP-1998; 98US-0100849P.  
XX PR 18-SEP-1998; 98US-0101014P.  
XX PR 18-SEP-1998; 98US-0101068P.  
XX PR 18-SEP-1998; 98US-0101071P.  
XX PR 18-SEP-1998; 98US-0101279P.  
XX PR 23-SEP-1998; 98US-0101471P.  
XX PR 23-SEP-1998; 98US-0101472P.  
XX PR 23-SEP-1998; 98US-0101474P.  
XX PR 23-SEP-1998; 98US-0101475P.  
XX PR 23-SEP-1998; 98US-0101476P.  
XX PR 23-SEP-1998; 98US-0101477P.  
XX PR 23-SEP-1998; 98US-0101479P.  
XX PR 24-SEP-1998; 98US-0101738P.  
XX PR 24-SEP-1998; 98US-0101741P.  
XX PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101915P.  
PR 24-SEP-1998; 98US-0101916P.  
PR 29-SEP-1998; 98US-0102207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102307P.  
PR 29-SEP-1998; 98US-0102330P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102484P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 30-SEP-1998; 98US-0102571P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 01-OCT-1998; 98US-0102687P.  
PR 02-OCT-1998; 98US-0102965P.  
PR 06-OCT-1998; 98US-0103258P.  
PR 06-OCT-1998; 98US-0103449P.  
PR 07-OCT-1998; 98US-0103314P.  
PR 07-OCT-1998; 98US-0103315P.  
PR 07-OCT-1998; 98US-0103328P.  
PR 07-OCT-1998; 98US-0103395P.  
PR 07-OCT-1998; 98US-0103396P.  
PR 07-OCT-1998; 98US-0103401P.  
PR 08-OCT-1998; 98US-0103633P.  
PR 08-OCT-1998; 98US-0103678P.  
PR 08-OCT-1998; 98US-0103679P.  
PR 14-OCT-1998; 98US-0103711P.  
PR 14-OCT-1998; 98US-0104257P.  
PR 20-OCT-1998; 98US-0104987P.  
PR 20-OCT-1998; 98US-0105000P.  
PR 20-OCT-1998; 98US-0105002P.  
PR 21-OCT-1998; 98US-0105104P.  
PR 22-OCT-1998; 98US-0105169P.  
PR 22-OCT-1998; 98US-0105266P.  
PR 26-OCT-1998; 98US-0105693P.  
PR 26-OCT-1998; 98US-0105694P.  
PR 27-OCT-1998; 98US-0105807P.  
PR 27-OCT-1998; 98US-0105881P.  
PR 27-OCT-1998; 98US-0105882P.  
PR 27-OCT-1998; 98US-0106062P.  
PR 28-OCT-1998; 98US-0106023P.  
PR 28-OCT-1998; 98US-0106029P.  
PR 28-OCT-1998; 98US-0106030P.  
PR 28-OCT-1998; 98US-0106032P.  
PR 28-OCT-1998; 98US-0106033P.  
PR 28-OCT-1998; 98US-0106178P.  
PR 29-OCT-1998; 98US-0106248P.  
PR 29-OCT-1998; 98US-0106384P.  
PR 29-OCT-1998; 98US-0108500P.  
PR 30-OCT-1998; 98US-0106464P.  
PR 03-NOV-1998; 98US-0106856P.  
PR 03-NOV-1998; 98US-0106902P.  
PR 03-NOV-1998; 98US-0106905P.  
PR 03-NOV-1998; 98US-0106919P.  
PR 03-NOV-1998; 98US-0106932P.  
PR 03-NOV-1998; 98US-0106934P.  
PR 10-NOV-1998; 98US-0107783P.  
PR 17-NOV-1998; 98US-0108775P.  
PR 17-NOV-1998; 98US-0108779P.  
PR 17-NOV-1998; 98US-0108787P.  
PR 17-NOV-1998; 98US-0108788P.  
PR 17-NOV-1998; 98US-0108801P.  
PR 17-NOV-1998; 98US-0108802P.  
PR 17-NOV-1998; 98US-0108806P.  
PR 17-NOV-1998; 98US-0108807P.  
PR 17-NOV-1998; 98US-0108867P.  
PR 17-NOV-1998; 98US-0108925P.  
PR 18-NOV-1998; 98US-0108848P.  
PR 18-NOV-1998; 98US-0108849P.  
PR 18-NOV-1998; 98US-0108850P.  
PR 18-NOV-1998; 98US-0108851P.  
PR 18-NOV-1998; 98US-0108852P.  
PR 18-NOV-1998; 98US-0108858P.  
PR 18-NOV-1998; 98US-0108904P.



[illegible]

[illegible]

RESULT 1196  
ADD79598



KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003199023-A1.

XX 23-OCT-2003.

XX 17-APR-2002; 2002US-00124821.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 10-MAR-1999; 2000WO-US006319.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 02-DEC-1999; 99WO-US028565.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 20-DEC-1999; 99WO-US030999.

XX 22-DEC-1999; 99WO-US030720.

XX 30-DEC-1999; 99WO-US031243.

XX 30-DEC-1999; 99WO-US031274.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000277.

XX 06-JAN-2000; 2000WO-US000376.

XX 11-FEB-2000; 2000WO-US003565.

XX 18-FEB-2000; 2000WO-US004341.

XX 18-FEB-2000; 2000WO-US004342.

XX 22-FEB-2000; 2000WO-US004414.

XX 24-FEB-2000; 2000WO-US004914.

XX 24-FEB-2000; 2000WO-US005004.

XX 01-MAR-2000; 2000WO-US005601.

XX 02-MAR-2000; 2000WO-US005746.

XX 02-MAR-2000; 2000WO-US005841.

XX 15-MAR-2000; 2000WO-US006884.

XX 20-MAR-2000; 2000WO-US007377.

XX 21-MAR-2000; 2000WO-US007532.

XX 30-MAR-2000; 2000WO-US008439.

XX 17-MAY-2000; 2000WO-US013705.

XX 22-MAY-2000; 2000WO-US014042.

XX 30-MAY-2000; 2000WO-US014941.

XX 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001US-00796498.

PR 28-FEB-2001; 2001WO-US006520.

PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.

PR 14-MAR-2001; 2001US-00808689.

PR 22-MAR-2001; 2001US-00816744.

PR 05-APR-2001; 2001US-00828366.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 18-MAY-2001; 2001US-00860216.

PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 14-JUN-2001; 2001US-00882636.

PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.

PR 21-JUN-2001; 2001US-00887879.

PR 22-JUN-2001; 2001WO-US020116.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.

PR 18-JUL-2001; 2001US-00908827.

PR 06-AUG-2001; 2001US-00924419.

PR 09-AUG-2001; 2001US-00927796.

PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.

XX

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI: 2003-900155/82.

P-PSDB; ADE17952.

PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,

PT useful for treating pericyte-associated tumors, diabetes and various bone

XX and/or cartilage disorders, e.g. arthritis.

XX Claim 2; SEQ ID NO 501; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

PR	29-OCT-1998;	98WO-US022991
PR	29-OCT-1998;	98WO-US022992
PR	29-OCT-1998;	98WO-US024855
PR	01-DEC-1998;	98WO-US025108
PR	05-JAN-1999;	99WO-US000106
PR	08-MAR-1999;	99WO-US005028
PR	10-MAR-1999;	99WO-US005190
PR	10-MAR-1999;	2000WO-US006319
PR	20-APR-1999;	99WO-US008615
PR	14-MAY-1999;	99WO-US010733
PR	02-JUN-1999;	99WO-US012252
PR	01-SEP-1999;	99WO-US020111
PR	08-SEP-1999;	99WO-US02094
PR	13-SEP-1999;	99WO-US020944
PR	15-SEP-1999;	99WO-US021090
PR	15-SEP-1999;	99WO-US021547
PR	05-OCT-1999;	99WO-US023089
PR	23-NOV-1999;	99WO-US028214
PR	30-NOV-1999;	99WO-US028313
PR	30-NOV-1999;	99WO-US028314
PR	01-NOV-1999;	99WO-US028409
PR	01-DEC-1999;	99WO-US028301
PR	02-DEC-1999;	99WO-US028634
PR	02-DEC-1999;	99WO-US028551
PR	02-DEC-1999;	99WO-US028564
PR	02-DEC-1999;	99WO-US028565
PR	16-DEC-1999;	99WO-US030095
PR	20-DEC-1999;	99WO-US030911
PR	20-DEC-1999;	99WO-US03099
PR	22-DEC-1999;	99WO-US030720
PR	30-DEC-1999;	99WO-US031243
PR	30-DEC-1999;	99WO-US031274
PR	05-JAN-2000;	2000WO-US000219
PR	05-JAN-2000;	2000WO-US000277
PR	06-JAN-2000;	2000WO-US003076
PR	11-FEB-2000;	2000WO-US003365
PR	18-FEB-2000;	2000WO-US004341
PR	18-FEB-2000;	2000WO-US004342
PR	22-FEB-2000;	2000WO-US004414
PR	24-FEB-2000;	2000WO-US004914
PR	24-FEB-2000;	2000WO-US005004
PR	01-MAR-2000;	2000WO-US005601
PR	02-MAR-2000;	2000WO-US005745
PR	02-MAR-2000;	2000WO-US005841
PR	15-MAR-2000;	2000WO-US006884
PR	20-MAR-2000;	2000WO-US007377
PR	21-MAR-2000;	2000WO-US007532
PR	30-MAR-2000;	2000WO-US008439
PR	17-MAY-2000;	2000WO-US011705
PR	22-MAY-2000;	2000WO-US011402
PR	30-MAY-2000;	2000WO-US014941
PR	02-JUN-2000;	2000WO-US015264
PR	28-JUN-2000;	2000WO-US020710
PR	11-AUG-2000;	2000WO-US022031
PR	23-AUG-2000;	2000WO-US023522
PR	24-AUG-2000;	2000WO-US023328
PR	08-NOV-2000;	2000WO-US030952
PR	10-NOV-2000;	2000WO-US030873
PR	01-DEC-2000;	2000WO-US032678
PR	20-DEC-2000;	2000WO-US074759
PR	20-DEC-2000;	2000WO-US034956
PR	28-FEB-2001;	2001US-US0796498
PR	28-FEB-2001;	2001WO-US005620
PR	01-MAR-2001;	2001WO-US005666
PR	09-MAR-2001;	2001US-US0802706
PR	14-MAR-2001;	2001US-US0808699
PR	22-MAR-2001;	2001US-US0815744
PR	05-APR-2001;	2001US-US0838366
PR	10-MAY-2001;	2001US-US0854208
PR	10-MAY-2001;	2001US-US0854280
PR	15-MAY-2001;	2001US-US0860216
PR	25-MAY-2001;	2001US-US0866028
PR	25-MAY-2001;	2001US-US0866034
PR	25-MAY-2001;	2001WO-US0017092



CC		prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (II) and (III) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.
XX		
SQ		Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;
	Query Match	2.9%; Score 65.8; DB 10; Length 1883;
	Best Local Similarity	62.0%; Pred. No. 0.0003;
	Matches 103; Conservative	0; Mismatches 63; Indels 0; Gaps 0;
QY	2077 GTCTCAAGTCGTCGTGCACATAATCATTTCCAATGCCAATGATCGCCTTGCTTACCACT	2136
Db	1700 GAGTCGCAGCTGTCTCTCTCTCTCACCTCTCTTCACTGCTCTCTGGAGAACAGGACT	1759
QY	2137 CTYTCTTTTTATTCTTAATAAATAATGTTGGTCTCCACCACCTGNCTCCCCAAAAAAA	2196
Db	1760 TTCTCCACATGTTGTTGTTATTCGAACAATTTTGCAATTAAGAAGAAATCCACAAAAAAA	1819
QY	2197 AA 2242	
Db	1820 AA 1865	
RESULT 1201		
ADE34098		
ID	ADE34098 standard; CDNA; 1883 BP.	
XX		
AC	ADE34098;	
XX		
DT	29-JAN-2004 (first entry)	
XX		
DE	Novel human secreted and transmembrane protein PRO1294 CDNA.	
KW	Human; secreted and transmembrane protein; PRO; Gene; ss;	
KW	Tumour necrosis factor alpha release; TNF-alpha release;	
KW	Glucose uptake modulator; FFA uptake modulator;	
KW	cell proliferation stimulator; cell differentiation stimulator;	
KW	cell differentiation inhibitor; cytokine release stimulator; tumour;	
KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;	
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;	
KW	gene therapy; chromosome identification; chromosome marker.	
OS	Homo sapiens.	
XX		
PN	US2003194791-A1.	
XX		
PD	16-OCT-2003.	
PF	11-APR-2002; 2002US-00121046.	
XX		
PR	31-MAR-1997; 97WO-US005230.	
PR	12-JUN-1998; 98WO-US012456.	
PR	14-JUL-1998; 98WO-US014552.	
PR	28-AUG-1998; 98WO-US017888.	
PR	10-SEP-1998; 98WO-US018824.	
PR	14-SEP-1998; 98WO-US019093.	
PR	14-SEP-1998; 98WO-US019094.	
PR	14-SEP-1998; 98WO-US019177.	
PR	16-SEP-1998; 98WO-US019330.	
PR	17-SEP-1998; 98WO-US019437.	
PR	07-OCT-1998; 98WO-US021141.	

[illegible]

















```
Db      1820 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1865
|||||
RESULT 1210
ADE22926
ID ADE22926 standard; cDNA; 1883 BP.
XX AC ADE22926;
XX XX
XX 29-JAN-2004 (first entry)
DE cDNA encoding human PRO polypeptide #251.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003199064-A1.
XX PD 23-OCT-2003.
XX PF 19-APR-2002; 2002US-00125932.
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022391.
PR 29-OCT-1998; 98WO-US022392.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
XX XX
XX XX
XX PI Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX P-PSDB; ADE22927.
XX WPI; 2003-900169/82.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX P-PSDB; ADE22927.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
```



```
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;

Query Match          2.9%; Score 65.8; DB 10; Length 1883;
Best Local Similarity 62.0%; Pred. No. 0.0003;
Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;

QY      2077 GTCTCAAGTCGTCGTGCACATAAATCATTCACATCGCTTGGCTTTTACCACCT 2136
        |||
Db       1700 GAGTCCAGCTGTCTCTCTCTCCTCACCTCCCTTCAGTGCTCTGAGGAACAGACT 1759

QY      2137 CTTTCTCTTTATCTTATTATAAAATGTTGGTCTCCACACACTGNTCCCAAAAAAAA 2196
        |||
Db       1760 TTCTCCACATTTGTTTTGTATTGCAACATTTTGCAATTAAAAAGGAAAAATCCACAAAAAAA 1819

QY      2197 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
        |||
Db       1820 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1865


RESULT 1213
ADE42686
ID      ADE42686 standard; cDNA; 1883 BP.
XX
AC      ADE42686;
XX
DT      29-JAN-2004 (first entry)
XX
XX      Human PRO polynucleotide #251.
XX
KW      Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW      tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW      cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW      liver; microvascular endothelial cell; glucose; FFA;
KW      skeletal muscle cell; adipocyte cell; pericyte cell;
KW      inner ear utricular supporting cell; T-lymphocyte cell;
KW      endothelial cell tube formation; bone disorder; cartilage disorder;
KW      sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW      rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW      immune system cell infiltration.
XX
OS      Homo sapiens.
XX
XX      US2003199032-A1.
XX
PD      23-OCT-2003.
XX
XX      28-MAY-2002; 2002US-00156844.
XX
XX      03-MAR-2000; 2000US-0187202P.
XX
PR      01-DEC-2000; 2000WO-US032678.
XX
PR      19-DEC-2001; 2001US-00028072.
XX
XX      (GETH ) GENENTECH INC.
XX
PI      Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI      Gerritsen WE, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI      Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX      WPI; 2003-900161/82.
DR      P-PSDB; ADE42687.
```



PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030352.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX PA  
 (GETH ) GENENTECH INC.  
 XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-875868/81.  
 DR P-PSDB; ADD80703.  
 DR  
 PT New PRO nucleic acid, useful for manufacturing a medicament for  
 PT diagnosing or treating tumor, for chromosome mapping or for tissue  
 PT typing.  
 XX  
 PS Claim 2; Fig 501; 638pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumor necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence encodes a human PRO polypeptide of the invention. Note: The  
 CC sequence data for this patent is also available in electronic format from  
 CC the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).  
 XX SQ Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;  
 Query Match 2.9%; Score 65.8; DB 10; Length 1883;  
 Best Local Similarity 62.0%; Pred. No. 0.0003;  
 Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;  
 QY 2077 GTCTCAAGTGTCTGTCACACATAATCATTCATCAATGATCGCTTGTTCCTTACCACT 2136  
 DB 1700 GAGGTCAGCTGTGCTCTCTCTCTCACTCTCCCTCAGTGTCTGAGGACAGGACT 1759  
 QY 2137 CTTTCCTTTTATCTTATTAATAAAAAATGTTGTCTCCACCACTGCTCCCAAAAAAAA 2196  
 DB 1760 TTCTCCACATTTGTTGTATTGCAACATTTTGCATTAAAGGAAAAATCCACAAAAAAA 1819  
 QY 2197 AAAAAA AA 2242  
 DB 1820 AAAAAA AA 1865  
 RESULT 1215  
 ADD89730  
 ID ADD89730-standard; cDNA; 1883 BP.  
 XX AC  
 XX ADD89730;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE Human PRO polynucleotide #251.  
 XX  
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX OS Homo sapiens.  
 XX US2003199028-A1.  
 PN 23-OCT-2003.  
 XX  
 PF 22-MAY-2002; 2002US-00153552.  
 XX  
 PR 03-MAR-2000; 2000US-0187202P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.



```
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;
SQ Query Match 2.9%; Score 65.8; DB 10; Length 1883;
Best Local Similarity 62.0%; Pred. No. 0.0003;
Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;

QY 2077 GTCTCAAGTCGTCGACACATAATCATTCATCCATGATCGCTTGTTCACACT 2136
DB 1700 GAGCTCCAGCTCTGTCTCTCTCCCTCACTCCCTTTCAGTCTCGAGAACAGGACT 1759
QY 2137 CTTTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACACTGCTCCCAAAAAA 2196
DB 1760 TTCTCCACATGTTTGTATTCACATTTTGCATTAAGGAAATCCACAAAAA 1819
QY 2197 AAAAAA 2242
DB 1820 AAAAAA 1865

RESULT 1218
ADE04813
ID ADE04813 standard; cDNA; 1883 BP.
XX AC ADE04813;
XX DT 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #251.
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
XX Homo sapiens.
XX OS US2003193034-A1.
XX PN 23-OCT-2003.
XX 28-MAY-2001; 2001US-00156846.
XX PF 03-MAR-2000; 2000US-0187202P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900163/82.
XX P-PSDB; ADE04814.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX Claim 2; Fig 501; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
```



[illegible]

CC	(e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418 polypeptides are useful for treating diabetes in skeletal muscle cells CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for CC treating Berger disease or other nephropathies associated with Schönlein-CC Henoch purpura, coeliac disease, dermatitis, herpetiformis or Crohn's CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1418, CC PRO1410 and PRO1575 are useful in treating thalassaemias. The present CC sequence encodes a PRO protein of the invention.
XX	
SQ	Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;
	Query Match                      2.9%; Score 65.8; DB 10; Length 1883;
	Best Local Similarity    62.0%; Pred. No. 0.0003;
	Matches 103; Conservative    0; Mismatches 63; Indels    0; Gaps    0;
QY	2077 GTCTCAAGTGCCTGACACATAAATCATTCATCCATCCAATGATCGCTTTTGTTACCCT 2136
DB	1700 GAGTCAGCTGTGCTCTCTCCTCACATTTCGATTAAAGGAATCCACAAAAAAA 1759
QY	2137 CTITTCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACGTGCTCCAAAAA 2196
DB	1760 TTCTCCACATTGTTTGTATTGCAACATTTCGATTAAAGGAATCCACAAAAAAA 1819
QY	2197 AAA 2242
DB	1820 AAA 1865
RESULT 1221	
ADG21651	
ID	ADG21651 standard; cDNA; 1883 BP.
XX	
AC	ADG21651;
XX	
DT	26-FEB-2004 (first entry)
XX	
DE	Novel human secreted and transmembrane protein PRO1294 cDNA.
XX	
KW	Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW	rectum; kidney; cervix; liver; microvascular endothelial cell;
KW	glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW	cell differentiation; skeletal muscle cell; adipocyte cell;
KW	pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW	rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW	immune system cell infiltration; chromosome mapping; gene mapping;
KW	gene therapy; chromosome identification; chromosome marker; gene; ss.
OS	Homo sapiens.
QS	
US	US2003207355-A1.
PN	
PD	06-NOV-2003.
XX	
PF	07-MAY-2002; 2002US-00140923.
XX	
PR	03-MAR-2000; 2000US-0187202P.
PR	01-DEC-2000; 2000WO-US032678.
PR	19-DEC-2001; 2001US-00028072.
XX	
PA	(GETH ) GENENTECH INC.
PX	
PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
DR	WPI; 2003-901058/82.
DR	P-PSDB; ADG21652.
PT	New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or











PR	03-NOV-1998;	98US-0106902P.
PR	03-NOV-1998;	98US-0106905P.
PR	03-NOV-1998;	98US-0106919P.
PR	03-NOV-1998;	98US-0106932P.
PR	03-NOV-1998;	98US-0106934P.
PR	03-NOV-1998;	98US-0106938P.
PR	10-NOV-1998;	98US-0107783P.
PR	17-NOV-1998;	98US-0108775P.
PR	17-NOV-1998;	98US-0108779P.
PR	17-NOV-1998;	98US-0108787P.
PR	17-NOV-1998;	98US-0108788P.
PR	17-NOV-1998;	98US-0108801P.
PR	17-NOV-1998;	98US-0108802P.
PR	17-NOV-1998;	98US-0108806P.
PR	17-NOV-1998;	98US-0108807P.
PR	17-NOV-1998;	98US-0108867P.
PR	18-NOV-1998;	98US-0108851P.
PR	18-NOV-1998;	98US-0108852P.
PR	18-NOV-1998;	98US-0108858P.
PR	18-NOV-1998;	98US-0108904P.
PR	20-DEC-1998;	98US-0113296P.
PR	22-DEC-1998;	98US-0114223P.
PR	05-JAN-1999;	99WO-US000106.
PR	15-SEP-1999;	99WO-US020119.
PR	15-SEP-1999;	99WO-US020114.
PR	29-OCT-1999;	99US-0163506P.
PR	30-NOV-1999;	99WO-US028313.
PR	02-DEC-1999;	99WO-US0328551.
PR	16-DEC-1999;	2000WO-US030095.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US000355.
PR	11-FEB-2000;	2000WO-US004342.
PR	02-MAR-2000;	2000WO-US005004.
PR	24-FEB-2000;	2000WO-US005841.
PR	15-MAR-2000;	2000WO-US006884.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-JUN-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	01-JUN-2001;	2001WO-US017800.
PR	20-JUN-2001;	2001WO-US019692.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US023135.
PR	04-SEP-2001;	2001US-00946374.

Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S;  
Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;  
Pan J, Paoni NP, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;  
Williams PM, Wood WI;

P-PSDB; ADH99339.

Novel secreted and transmembrane polypeptide useful identifying agonists or antagonists of polypeptide, as molecular weight markers, and in tissue typing.

XX Claim 2; SEQ ID NO 145; 553pp; English.  
PS The invention relates to an isolated PRO polypeptide (secreted or  
XX  
CC  
Query Match 2.9%; Score 65.8; DB 10; Length 1883;  
Best Local Similarity 62.0%; Pred. No. 0.0003;  
Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;  
QY 2077 GTCTCAAGTCTGTCGACACATAATCATTCATCCATGATCGCTTGTTCACACT 2136  
Db 1700 GAGTCCAGCTCTGCTCTCTCTCCACACTCCCTCCCTTCAGTCTCTGAGAACAGGACT 1759  
QY 2137 CTTCCTTTTATCTTATTAATAAATGTGTCTCCACACTGCTCCCAAAAAA 2196  
Db 1760 TTCTCCACATGTTTGTATGCAACATTTTGCATTAAAGGAAATCCAAAAA 1819  
QY 2197 AAAAAA 2242  
Db 1820 AAAAAA 1865  
RESULT 1229  
ADI64202  
ID ADI64202 standard; cDNA; 1883 BP.  
AC ADI64202;  
XX  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1294 cDNA.  
XX  
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
KW cell differentiation; skeletal muscle cell; adipocyte cell;  
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
KW immune system cell infiltration; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker; gene; ss.  
XX  
OS Homo sapiens.  
XX  
XX US2003207385-A1.  
XX  
XX 06-NOV-2003.  
XX  
XX 29-MAY-2002; 2002US-00157780.  
XX  
XX 05-JUN-2000; 2000US-0209832P.  
XX  
XX 01-DEC-2000; 2000WO-US032678.  
XX  
XX 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-901066/82.  
DR P-PSDB; ADI64203.  
XX  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX  
XX Claim 2; SEQ ID NO 501; 637pp; English.  
PS  
XX The invention relates to isolated human PRO polypeptides (secreted and

transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumour necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
XX cells, for stimulating differentiation of adipocyte cells, for  
XX stimulating proliferation of or gene expression in pericyte cells, for  
XX stimulating the proliferation of inner ear utricular supporting cells or  
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for  
XX treating various bone and/or cartilage disorders such as sports injuries  
XX and arthritis. PRO polypeptides which stimulate the release of  
XX proteoglycans from cartilage are useful for treating sports-related joint  
XX problems, articular cartilage defects, osteoarthritis and rheumatoid  
XX arthritis. PRO polypeptides are also useful for treating various  
XX mammalian haemoglobin-associated disorders such as various thalassaemias  
XX and conditions which may benefit from enhanced local immune system cell  
XX infiltration. This sequence represents a human PRO polynucleotide of the  
XX invention. Note: The sequence data for this patent is also available in  
XX electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX  
SQ Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.8; DB 10; Length 1883;  
Best Local Similarity 62.0%; Pred. No. 0.0003;  
Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;  
QY 2077 GTCTCAAGTCTGTCGACACATAATCATTCATCCATGATCGCTTGTTCACACT 2136  
Db 1700 GAGTCCAGCTCTGCTCTCTCTCCACACTCCCTCCCTTCAGTCTCTGAGAACAGGACT 1759  
QY 2137 CTTCCTTTTATCTTATTAATAAATGTGTCTCCACACTGCTCCCAAAAAA 2196  
Db 1760 TTCTCCACATGTTTGTATGCAACATTTTGCATTAAAGGAAATCCAAAAA 1819  
QY 2197 AAAAAA 2242  
Db 1820 AAAAAA 1865

RESULT 1230

ADI65151

ID ADI65151 standard; cDNA; 1883 BP.

XX  
AC ADI65151;

XX  
DT 22-APR-2004 (first entry)

XX  
DE Novel human secreted and transmembrane protein PRO1294 cDNA.

XX  
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
KW cell differentiation; skeletal muscle cell; adipocyte cell;  
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
KW immune system cell infiltration; chromosome mapping; gene mapping;









DT 23-JUN-2003 (first entry)  
XX cDNA encoding human PRO polypeptide #251.  
XX Human: PRO polypeptide; secreted and transmembrane protein;  
KW anti-PRO antibody; diagnostic assay; gene expression; diabetes;  
KW bone disorder; cartilage disorder; rheumatoid arthritis; obesity;  
KW sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;  
KW hearing loss; conduction disorder; stroke; heart attack; cardiac;  
KW antidiabetic; anorectic; vulnery; antithrombotic; osteopathic;  
KW antirheumatic; auditory; cerebroprotective; angiogenic; gene; ss.  
OS Homo sapiens.  
XX US2003004311-A1.  
XX 02-JAN-2003.  
XX 19-DEC-2001; 2001US-00028072.  
PR 18-JUN-1997; 97US-0049911P.  
PR 26-AUG-1997; 97US-0056974P.  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 19-SEP-1997; 97US-0059352P.  
PR 19-SEP-1997; 97US-0059588P.  
PR 24-SEP-1997; 97US-0059836P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 17-OCT-1997; 97US-0063755P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063082P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063350P.  
PR 28-OCT-1997; 97US-0063561P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063733P.  
PR 29-OCT-1997; 97US-0063733P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.  
PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 11-DEC-1997; 97US-0069212P.  
PR 11-DEC-1997; 97US-0069278P.  
PR 11-DEC-1997; 97US-0069334P.  
PR 16-DEC-1997; 97US-0069694P.  
PR 23-JAN-1998; 98US-0072320P.  
PR 04-FEB-1998; 98US-0073612P.  
PR 09-FEB-1998; 98US-0074086P.  
PR 09-FEB-1998; 98US-0074092P.  
PR 12-MAR-1998; 98US-0077791P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 25-MAR-1998; 98US-0079294P.  
PR 27-MAR-1998; 98US-0079663P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 31-MAR-1998; 98US-0080165P.  
PR 12-JUN-1998; 98US-0080165P.  
PR 14-JUL-1998; 98WO-US012456.  
PR 28-AUG-1998; 98WO-US014552.  
PR 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 20-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 30-DEC-1999; 99WO-US030999.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-352836/33.  
XX P-PSDB; ABU81120.  
XX New isolated PRO polypeptide useful for treating diabetes, rheumatoid  
XX arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or  
XX heart attack.  
XX Claim 2; Fig 501; 643pp; English.  
XX The present invention relates to the isolation of novel human PRO  
XX polypeptides, and the polynucleotide sequences encoding them. The PRO  
XX polypeptides are secreted and transmembrane proteins. The PRO  
XX polypeptides and polynucleotides are useful for preparing a medicament  
XX useful in the treatment of diabetes, bone and/or cartilage disorders  
XX (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,  
XX hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders  
XX (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic  
XX assays for PRO, by detecting its expression in specific cells, tissues or  
XX serum, and for affinity purification of PRO from recombinant cell culture

































CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).  
XX  
SQ Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.8; DB 12; Length 1883;  
Best Local Similarity 62.0%; Pred. No. 0.0003;  
Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;

QY 2077 GTCTCAAGTGTCTGTGACACATATCATTCATCCCAATGATCGCTTTTACCACCT 2136  
DB 1700 GACGTCACAGCTGTGCTCTCTTCTCTCACTCTCCCTTCAGTGTCTGAGGAACAGGACT 1759  
QY 2137 CTTTCCTTTATCTATTATAAATAATGTTGGTCTCCACCACTGCTCCCAAAAAAAA 2196  
DB 1760 TTCTCCACATTTGTTTTGTTATTGCAACATTTTGCATTAAAGAAAAATCCACAAAAAAA 1819  
QY 2197 AAAAAA  
DB 1820 AAAAAA

RESULT 1255  
ADE91243  
ID ADE91243 standard; cDNA; 1883 BP.  
XX  
AC ADE91243;  
XX  
DT 12-FEB-2004 (first entry)  
XX  
DE Human PRO polynucleotide #251.  
XX  
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; PFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
US2003199027-A1.  
XX  
23-OCT-2003.  
XX  
20-MAY-2002; 2002US-00152396.  
XX  
01-MAR-2000; 2000WO-US005601.  
XX  
01-DEC-2000; 2000WO-US032678.  
XX  
19-DEC-2001; 2001US-00028072.  
XX  
(GENTH ) GENENTECH INC.  
XX  
Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;  
XX  
WPI; 2004-059538/06.  
DR P-PSDB; ADE94833.  
XX  
Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX  
Claim 2; Fig 501; 637pp; English.  
XX  
The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or  
antibodies, such as tumours, for stimulating and inhibiting proliferation  
of human microvascular endothelial cells, for modulating the uptake of  
glucose or PFA by skeletal muscle cells or adipocyte cells, for  
stimulating differentiation of adipocyte cells, for stimulating  
proliferation of or gene expression in pericyte cells, for stimulating  
the proliferation of inner ear utricular supporting cells or T-lymphocyte  
cells, for inducing endothelial cell tube formation and for treating  
various bone and/or cartilage disorders such as sports injuries and  
arthritis. PRO polypeptides which stimulate the release of proteoglycans



Db 1760 TTCTCCACATGTTTGTATTGCAACATTTTGCAATTAAGGAAATCCACAAAAA 1819

Qy 2197 AA 2242

Db 1820 AA 1865

RESULT 1256

ADF25829

ID ADF25829 standard; cDNA; 1883 BP.

XX

AC ADF25829;

XX

DT 12-FEB-2004 (first entry)

XX

DE Human cDNA encoding secreted/transmembrane protein PRO1294.

XX

KW Human; ss; gene; secreted protein; transmembrane protein; PRO; tumour;

KW immune response; cardiac insufficiency disorder; calcium flux;

KW umbilical vein endothelial cell; bone disorder; cartilage disorder;

KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;

KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;

KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia.

XX

OS Homo sapiens.

XX

PN US2003199675-A1.

XX

PD 23-OCT-2003.

XX

PF 11-DEC-2001; 2001US-00015389.

XX

01-SEP-1998; 98US-0098716P.

PR 01-SEP-1998; 98US-0098723P.

PR 01-SEP-1998; 98US-0098749P.

PR 01-SEP-1998; 98US-0098750P.

PR 02-SEP-1998; 98US-0098803P.

PR 02-SEP-1998; 98US-0098821P.

PR 02-SEP-1998; 98US-0098843P.

PR 02-SEP-1998; 98US-0099536P.

PR 09-SEP-1998; 98US-0099596P.

PR 09-SEP-1998; 98US-0099598P.

PR 09-SEP-1998; 98US-0099602P.

PR 09-SEP-1998; 98US-0099642P.

PR 09-SEP-1998; 98US-0099741P.

PR 10-SEP-1998; 98US-0099754P.

PR 10-SEP-1998; 98US-0099763P.

PR 10-SEP-1998; 98US-0099792P.

PR 10-SEP-1998; 98US-0099808P.

PR 10-SEP-1998; 98US-0099812P.

PR 10-SEP-1998; 98US-0099815P.

PR 10-SEP-1998; 98US-0099816P.

PR 15-SEP-1998; 98US-0100385P.

PR 15-SEP-1998; 98US-0100388P.

PR 15-SEP-1998; 98US-0100390P.

PR 16-SEP-1998; 98US-0100584P.

PR 16-SEP-1998; 98US-0100627P.

PR 16-SEP-1998; 98US-0100661P.

PR 16-SEP-1998; 98US-0100662P.

PR 16-SEP-1998; 98US-0100664P.

PR 17-SEP-1998; 98US-0100683P.

PR 17-SEP-1998; 98US-0100684P.

PR 17-SEP-1998; 98US-0100710P.

PR 17-SEP-1998; 98US-0100711P.

PR 17-SEP-1998; 98US-0100919P.

PR 17-SEP-1998; 98US-0100930P.

PR 18-SEP-1998; 98US-0100848P.

PR 18-SEP-1998; 98US-0100849P.

PR 18-SEP-1998; 98US-0101014P.

PR 18-SEP-1998; 98US-0101068P.

PR 18-SEP-1998; 98US-0101071P.

PR 22-SEP-1998; 98US-0101279P.

PR 23-SEP-1998; 98US-0101471P.

PR 23-SEP-1998; 98US-0101472P.

PR 23-SEP-1998; 98US-0101474P.

PR 23-SEP-1998; 98US-0101475P.

PR 23-SEP-1998; 98US-0101476P.

PR 23-SEP-1998; 98US-0101477P.

PR 23-SEP-1998; 98US-0101479P.

PR 24-SEP-1998; 98US-0101738P.

PR 24-SEP-1998; 98US-0101741P.

PR 24-SEP-1998; 98US-0101743P.

PR 24-SEP-1998; 98US-0101915P.

PR 24-SEP-1998; 98US-0101916P.

PR 29-SEP-1998; 98US-0102207P.

PR 29-SEP-1998; 98US-0102240P.

PR 29-SEP-1998; 98US-0102307P.

PR 29-SEP-1998; 98US-0102330P.

PR 29-SEP-1998; 98US-0102331P.

PR 30-SEP-1998; 98US-0102484P.

PR 30-SEP-1998; 98US-0102487P.

PR 30-SEP-1998; 98US-0102570P.

PR 30-SEP-1998; 98US-0102571P.

PR 01-OCT-1998; 98US-0103684P.

PR 01-OCT-1998; 98US-0103687P.

PR 02-OCT-1998; 98US-0102965P.

PR 06-OCT-1998; 98US-0103258P.

PR 06-OCT-1998; 98US-0103449P.

PR 07-OCT-1998; 98US-0103314P.

PR 07-OCT-1998; 98US-0103315P.

PR 07-OCT-1998; 98US-0103328P.

PR 07-OCT-1998; 98US-0103395P.

PR 07-OCT-1998; 98US-0103396P.

PR 08-OCT-1998; 98US-0103401P.

PR 08-OCT-1998; 98US-0103633P.

PR 08-OCT-1998; 98US-0103678P.

PR 08-OCT-1998; 98US-0103679P.

PR 14-OCT-1998; 98US-0103711P.

PR 20-OCT-1998; 98US-0104257P.

PR 20-OCT-1998; 98US-0104987P.

PR 20-OCT-1998; 98US-0105000P.

PR 20-OCT-1998; 98US-0105002P.

PR 21-OCT-1998; 98US-0105104P.

PR 22-OCT-1998; 98US-0105169P.

PR 22-OCT-1998; 98US-0105266P.

PR 26-OCT-1998; 98US-0105693P.

PR 26-OCT-1998; 98US-0105694P.

PR 27-OCT-1998; 98US-0105807P.

PR 27-OCT-1998; 98US-0105881P.

PR 27-OCT-1998; 98US-0105882P.

PR 28-OCT-1998; 98US-0106023P.

PR 28-OCT-1998; 98US-0106029P.

PR 28-OCT-1998; 98US-0106030P.

PR 28-OCT-1998; 98US-0106032P.

PR 28-OCT-1998; 98US-0106033P.

PR 29-OCT-1998; 98US-0106178P.

PR 29-OCT-1998; 98US-0106384P.

PR 29-OCT-1998; 98US-0108500P.

PR 30-OCT-1998; 98US-0106464P.

PR 03-NOV-1998; 98US-0106856P.

PR 03-NOV-1998; 98US-0106902P.

PR 03-NOV-1998; 98US-0106905P.

PR 03-NOV-1998; 98US-0106919P.

PR 03-NOV-1998; 98US-0106932P.

PR 03-NOV-1998; 98US-0106934P.

PR 10-NOV-1998; 98US-0107783P.

PR 17-NOV-1998; 98US-0108775P.

PR 17-NOV-1998; 98US-0108779P.

PR 17-NOV-1998; 98US-0108787P.

PR 17-NOV-1998; 98US-0108788P.

PR 17-NOV-1998; 98US-0108801P.

PR 17-NOV-1998; 98US-0108802P.

PR 17-NOV-1998; 98US-0108806P.

PR 17-NOV-1998; 98US-0108807P.





KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.

XX Homo sapiens.

OS US2003199060-A1.

XX 23-OCT-2003.

PF 15-APR-2002; 2002US-00123771.

PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 10-MAR-1999; 2000WO-US006319.  
 PR 14-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854308.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-041358/04.

P-PSDB; ADE93495.

Novel PRO polypeptide useful for treating diabetes, hyper or hypo  
 insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,  
 various coagulation disorders, tumors.

Claim 2; Fig 501; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a





PR 09-SEP-1998; 98US-0099598P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 09-SEP-1998; 98US-0099642P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099792P.  
PR 10-SEP-1998; 98US-0099808P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 10-SEP-1998; 98US-0099815P.  
PR 10-SEP-1998; 98US-0099816P.  
PR 15-SEP-1998; 98US-0100385P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 15-SEP-1998; 98US-0100390P.  
PR 16-SEP-1998; 98US-0100584P.  
PR 16-SEP-1998; 98US-0100627P.  
PR 16-SEP-1998; 98US-0100661P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100710P.  
PR 17-SEP-1998; 98US-0100711P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100848P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 18-SEP-1998; 98US-0101071P.  
PR 22-SEP-1998; 98US-0101279P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101474P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101476P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 23-SEP-1998; 98US-0101479P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101741P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101915P.  
PR 24-SEP-1998; 98US-0101916P.  
PR 29-SEP-1998; 98US-0102207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102307P.  
PR 29-SEP-1998; 98US-0102330P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102484P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 30-SEP-1998; 98US-0102571P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 01-OCT-1998; 98US-0102687P.  
PR 02-OCT-1998; 98US-0102965P.  
PR 06-OCT-1998; 98US-0103258P.  
PR 06-OCT-1998; 98US-0103449P.  
PR 07-OCT-1998; 98US-0103314P.  
PR 07-OCT-1998; 98US-0103315P.  
PR 07-OCT-1998; 98US-0103328P.  
PR 07-OCT-1998; 98US-0103395P.  
PR 07-OCT-1998; 98US-0103396P.  
PR 07-OCT-1998; 98US-0103401P.  
PR 08-OCT-1998; 98US-0103633P.  
PR 08-OCT-1998; 98US-0103678P.  
PR 08-OCT-1998; 98US-0103679P.  
PR 08-OCT-1998; 98US-0103711P.  
PR 14-OCT-1998; 98US-0104257P.  
PR 20-OCT-1998; 98US-0104987P.  
PR 20-OCT-1998; 98US-0105000P.  
PR 20-OCT-1998; 98US-0105002P.  
PR 21-OCT-1998; 98US-0105104P.  
PR 22-OCT-1998; 98US-0105169P.

PR 22-OCT-1998; 98US-0105266P.  
PR 26-OCT-1998; 98US-0105693P.  
PR 26-OCT-1998; 98US-0105694P.  
PR 27-OCT-1998; 98US-0105807P.  
PR 27-OCT-1998; 98US-0105881P.  
PR 27-OCT-1998; 98US-0105882P.  
PR 27-OCT-1998; 98US-0106062P.  
PR 28-OCT-1998; 98US-0106023P.  
PR 28-OCT-1998; 98US-0106029P.  
PR 28-OCT-1998; 98US-0106030P.  
PR 28-OCT-1998; 98US-0106032P.  
PR 28-OCT-1998; 98US-0106033P.  
PR 28-OCT-1998; 98US-0106178P.  
PR 29-OCT-1998; 98US-0106248P.  
PR 29-OCT-1998; 98US-0106384P.  
PR 29-OCT-1998; 98US-0108500P.  
PR 30-OCT-1998; 98US-0106464P.  
PR 03-NOV-1998; 98US-0106856P.  
PR 03-NOV-1998; 98US-0106902P.  
PR 03-NOV-1998; 98US-0106905P.  
PR 03-NOV-1998; 98US-0106919P.  
PR 03-NOV-1998; 98US-0106932P.  
PR 03-NOV-1998; 98US-0106934P.  
PR 10-NOV-1998; 98US-0107783P.  
PR 17-NOV-1998; 98US-0108775P.  
PR 17-NOV-1998; 98US-0108779P.  
PR 17-NOV-1998; 98US-0108787P.  
PR 17-NOV-1998; 98US-0108788P.  
PR 17-NOV-1998; 98US-0108801P.  
PR 17-NOV-1998; 98US-0108802P.  
PR 17-NOV-1998; 98US-0108806P.  
PR 17-NOV-1998; 98US-0108807P.  
PR 17-NOV-1998; 98US-0108867P.  
PR 17-NOV-1998; 98US-0108925P.  
PR 18-NOV-1998; 98US-0108848P.  
PR 18-NOV-1998; 98US-0108849P.  
PR 18-NOV-1998; 98US-0108850P.  
PR 18-NOV-1998; 98US-0108851P.  
PR 18-NOV-1998; 98US-0108852P.  
PR 18-NOV-1998; 98US-0108858P.  
PR 18-NOV-1998; 98US-0108904P.  
PR 30-DEC-1998; 98US-0114223P.  
PR 05-JAN-1999; 99WO-US000106.  
PR 16-APR-1999; 99US-0129674P.  
PR 23-JUN-1999; 99US-0141037P.  
PR 20-JUL-1999; 99US-0144758P.  
PR 26-JUL-1999; 99US-0145698P.  
PR 01-SEP-1999; 99WO-US020111.  
PR 15-SEP-1999; 99WO-US021194.  
PR 29-OCT-1999; 99US-0162506P.  
PR 30-NOV-1999; 99WO-US028313.  
PR 02-DEC-1999; 99WO-US028551.  
PR 16-DEC-1999; 99WO-US030095.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 26-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006566.  
PR 01-JUN-2001; 2001WO-US017800.



XX 12-FEB-2004 (first entry)  
DT Human cDNA encoding secreted/transmembrane protein PRO1294.  
XX  
DE  
XX  
KW Human; ss; gene; secreted protein; transmembrane protein; PRO; tumour;  
KW immune response; cardiac insufficiency disorder; calcium flux;  
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;  
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;  
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;  
KW dermatitis; herpetiformis; Crohn's disease; thalassaemia.  
XX  
XX Homo sapiens.  
XX  
XX US2003195334-A1.  
XX  
XX 16-OCT-2003.  
XX  
XX 07-DEC-2001; 2001US-00012753.  
XX  
XX 01-SEP-1998; 98US-0098716P.  
XX 01-SEP-1998; 98US-0098723P.  
XX 01-SEP-1998; 98US-0098749P.  
XX 01-SEP-1998; 98US-0098750P.  
XX 02-SEP-1998; 98US-0098803P.  
XX 02-SEP-1998; 98US-0098821P.  
XX 02-SEP-1998; 98US-0098843P.  
XX 03-SEP-1998; 98US-0099336P.  
XX 03-SEP-1998; 98US-0099596P.  
XX 09-SEP-1998; 98US-0099598P.  
XX 09-SEP-1998; 98US-0099602P.  
XX 09-SEP-1998; 98US-0099642P.  
XX 10-SEP-1998; 98US-0099741P.  
XX 10-SEP-1998; 98US-0099754P.  
XX 10-SEP-1998; 98US-0099763P.  
XX 10-SEP-1998; 98US-0099792P.  
XX 10-SEP-1998; 98US-0099808P.  
XX 10-SEP-1998; 98US-0099812P.  
XX 10-SEP-1998; 98US-0099815P.  
XX 10-SEP-1998; 98US-0099816P.  
XX 15-SEP-1998; 98US-0100385P.  
XX 15-SEP-1998; 98US-0100388P.  
XX 15-SEP-1998; 98US-0100390P.  
XX 16-SEP-1998; 98US-0100594P.  
XX 16-SEP-1998; 98US-0100627P.  
XX 16-SEP-1998; 98US-0100661P.  
XX 16-SEP-1998; 98US-0100662P.  
XX 16-SEP-1998; 98US-0100664P.  
XX 17-SEP-1998; 98US-0100683P.  
XX 17-SEP-1998; 98US-0100684P.  
XX 17-SEP-1998; 98US-0100710P.  
XX 17-SEP-1998; 98US-0100711P.  
XX 17-SEP-1998; 98US-0100919P.  
XX 17-SEP-1998; 98US-0100930P.  
XX 18-SEP-1998; 98US-0100848P.  
XX 18-SEP-1998; 98US-0100849P.  
XX 18-SEP-1998; 98US-0101014P.  
XX 18-SEP-1998; 98US-0101016P.  
XX 18-SEP-1998; 98US-0101017P.  
XX 22-SEP-1998; 98US-0101279P.  
XX 23-SEP-1998; 98US-0101471P.  
XX 23-SEP-1998; 98US-0101472P.  
XX 23-SEP-1998; 98US-0101474P.  
XX 23-SEP-1998; 98US-0101475P.  
XX 23-SEP-1998; 98US-0101476P.  
XX 23-SEP-1998; 98US-0101479P.  
XX 24-SEP-1998; 98US-0101738P.  
XX 24-SEP-1998; 98US-0101741P.  
XX 24-SEP-1998; 98US-0101743P.  
XX 24-SEP-1998; 98US-0101915P.  
XX 24-SEP-1998; 98US-0101916P.  
XX 29-SEP-1998; 98US-0102207P.  
XX 29-SEP-1998; 98US-0102240P.  
XX 29-SEP-1998; 98US-0102307P.  
XX 29-SEP-1998; 98US-0102330P.  
XX 29-SEP-1998; 98US-0102331P.  
XX 30-SEP-1998; 98US-0102484P.  
XX 30-SEP-1998; 98US-0102487P.  
XX 30-SEP-1998; 98US-0102570P.  
XX 30-SEP-1998; 98US-0102571P.  
XX 01-OCT-1998; 98US-0102684P.  
XX 01-OCT-1998; 98US-0102687P.  
XX 02-OCT-1998; 98US-0102965P.  
XX 06-OCT-1998; 98US-0103258P.  
XX 06-OCT-1998; 98US-0103449P.  
XX 07-OCT-1998; 98US-0103314P.  
XX 07-OCT-1998; 98US-0103315P.  
XX 07-OCT-1998; 98US-0103328P.  
XX 07-OCT-1998; 98US-0103395P.  
XX 07-OCT-1998; 98US-0103396P.  
XX 07-OCT-1998; 98US-0103401P.  
XX 08-OCT-1998; 98US-0103633P.  
XX 08-OCT-1998; 98US-0103678P.  
XX 08-OCT-1998; 98US-0103679P.  
XX 14-OCT-1998; 98US-0103711P.  
XX 20-OCT-1998; 98US-0104257P.  
XX 20-OCT-1998; 98US-0104987P.  
XX 20-OCT-1998; 98US-0105000P.  
XX 21-OCT-1998; 98US-0105104P.  
XX 22-OCT-1998; 98US-0105169P.  
XX 22-OCT-1998; 98US-0105266P.  
XX 22-OCT-1998; 98US-0105693P.  
XX 26-OCT-1998; 98US-0105694P.  
XX 27-OCT-1998; 98US-0105807P.  
XX 27-OCT-1998; 98US-0105881P.  
XX 27-OCT-1998; 98US-0105882P.  
XX 27-OCT-1998; 98US-0106062P.  
XX 28-OCT-1998; 98US-0106023P.  
XX 28-OCT-1998; 98US-0106029P.  
XX 28-OCT-1998; 98US-0106030P.  
XX 28-OCT-1998; 98US-0106032P.  
XX 28-OCT-1998; 98US-0106033P.  
XX 28-OCT-1998; 98US-0106178P.  
XX 28-OCT-1998; 98US-0106248P.  
XX 29-OCT-1998; 98US-0106384P.  
XX 29-OCT-1998; 98US-0108500P.  
XX 30-OCT-1998; 98US-0106464P.  
XX 03-NOV-1998; 98US-0106856P.  
XX 03-NOV-1998; 98US-0106902P.  
XX 03-NOV-1998; 98US-0106905P.  
XX 03-NOV-1998; 98US-0106919P.  
XX 03-NOV-1998; 98US-0106932P.  
XX 03-NOV-1998; 98US-0106934P.  
XX 10-NOV-1998; 98US-0107783P.  
XX 17-NOV-1998; 98US-0108775P.  
XX 17-NOV-1998; 98US-0108779P.  
XX 17-NOV-1998; 98US-0108787P.  
XX 17-NOV-1998; 98US-0108788P.  
XX 17-NOV-1998; 98US-0108801P.  
XX 17-NOV-1998; 98US-0108802P.  
XX 17-NOV-1998; 98US-0108806P.  
XX 17-NOV-1998; 98US-0108807P.  
XX 17-NOV-1998; 98US-0108867P.  
XX 17-NOV-1998; 98US-0108925P.  
XX 18-NOV-1998; 98US-0108848P.  
XX 18-NOV-1998; 98US-0108849P.  
XX 18-NOV-1998; 98US-0108850P.  
XX 18-NOV-1998; 98US-0108851P.  
XX 18-NOV-1998; 98US-0108852P.  
XX 18-NOV-1998; 98US-0108858P.  
XX 18-NOV-1998; 98US-0108904P.  
XX 23-DEC-1998; 98US-0113266P.  
XX 30-DEC-1998; 98US-0114223P.  
XX 05-JAN-1999; 99WO-US000106.  
XX 16-APR-1999; 99US-0129674P.





PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 98WO-US000106.  
 PR 08-MAR-1999; 98WO-US005028.  
 PR 10-MAR-1999; 98WO-US005190.  
 PR 10-MAR-1999; 2000WO-US006319.  
 PR 20-APR-1999; 98WO-US008615.  
 PR 14-MAY-1999; 98WO-US010733.  
 PR 02-JUN-1999; 98WO-US012252.  
 PR 01-SEP-1999; 98WO-US020111.  
 PR 08-SEP-1999; 98WO-US020594.  
 PR 13-SEP-1999; 98WO-US020944.  
 PR 15-SEP-1999; 98WO-US021090.  
 PR 15-SEP-1999; 98WO-US021547.  
 PR 05-OCT-1999; 98WO-US023059.  
 PR 29-NOV-1999; 98WO-US028214.  
 PR 30-NOV-1999; 98WO-US028313.  
 PR 30-NOV-1999; 98WO-US028409.  
 PR 01-DEC-1999; 98WO-US028301.  
 PR 01-DEC-1999; 98WO-US028634.  
 PR 02-DEC-1999; 98WO-US028551.  
 PR 02-DEC-1999; 98WO-US028564.  
 PR 02-DEC-1999; 98WO-US028565.  
 PR 16-DEC-1999; 98WO-US030095.  
 PR 20-DEC-1999; 98WO-US030911.  
 PR 20-DEC-1999; 98WO-US030999.  
 PR 22-DEC-1999; 98WO-US030720.  
 PR 30-DEC-1999; 98WO-US031243.  
 PR 30-DEC-1999; 98WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 24-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 28-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.

PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-041361/04.  
 P-ESDB; ADE90692.

New PRO nucleic acid, useful for manufacturing a medicament for  
 diagnosing or treating tumor, for chromosome mapping or for tissue  
 typing.

Claim 2; SEQ ID NO 501; 636pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumor necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;

(GETH ) GENENTECH INC.





	. QY	2197 AA 2242       1820 AA 1665
Db		
	RESULT 1269	
	ADF98179	
	ADDF98179 standard; cDNA; 1883 BP.	
XX	AC	ADF98179;
XX	DT	26-FEB-2004 (first entry)
XX	DE	Human PRO polynucleotide #251.
XX	KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.
XX	OS	Homo sapiens.
XX	PX	US2003207422-A1.
XX	PD	06-NOV-2003.
XX	PX	08-MAY-2002; 2002US-00141754.
XX	PR	31-MAR-1997; 97WO-US005230. 12-JUN-1998; 98WO-US012456. 14-JUL-1998; 98WO-US014552. 28-AUG-1998; 98WO-US017888. 10-SEP-1998; 98WO-US018824. 14-SEP-1998; 98WO-US019093. 14-SEP-1998; 98WO-US019094. 14-SEP-1998; 98WO-US019177. 16-SEP-1998; 98WO-US019330. 17-SEP-1998; 98WO-US019437. 07-OCT-1998; 98WO-US021141. 29-OCT-1998; 98WO-US022991. 29-OCT-1998; 98WO-US022992. 20-NOV-1998; 98WO-US024855. 01-DEC-1998; 98WO-US025108. 05-JAN-1999; 98WO-US000106. 08-MAR-1999; 98WO-US005028. 10-MAR-1999; 98WO-US005190. 20-APR-1999; 98WO-US008615. 14-MAY-1999; 98WO-US010733. 02-JUN-1999; 98WO-US012252. 01-SEP-1999; 98WO-US020111. 08-SEP-1999; 98WO-US020594. 13-SEP-1999; 98WO-US020944. 15-SEP-1999; 98WO-US021090. 15-SEP-1999; 98WO-US021547. 05-OCT-1999; 98WO-US023089. 29-NOV-1999; 98WO-US028214. 30-NOV-1999; 98WO-US028313. 30-NOV-1999; 98WO-US028409. 01-DEC-1999; 98WO-US028301. 01-DEC-1999; 98WO-US028634. 02-DEC-1999; 98WO-US028551. 02-DEC-1999; 98WO-US028564. 02-DEC-1999; 98WO-US028565. 16-DEC-1999; 98WO-US030095. 20-DEC-1999; 98WO-US030911. 20-DEC-1999; 98WO-US030999.



cell differentiation; skeletal muscle cell; adipocyte cell;  
 pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
 endothelial cell tube formation; bone disorder; cartilage disorder;  
 sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;  
 immune system cell infiltration; chromosome mapping; gene mapping;  
 gene therapy; chromosome identification; chromosome marker; gene; ss.

Homo sapiens.

US2003207426-A1.

06-NOV-2003.

09-MAY-2002; 2002US-00143113.

31-MAR-1997; 97WO-US005230.  
 12-JUN-1998; 98WO-US012456.  
 14-JUL-1998; 98WO-US014552.  
 28-AUG-1998; 99WO-US017888.  
 10-SEP-1998; 98WO-US018824.  
 14-SEP-1998; 98WO-US019093.  
 14-SEP-1998; 98WO-US019094.  
 14-SEP-1998; 98WO-US019177.  
 16-SEP-1998; 98WO-US019330.  
 17-SEP-1998; 98WO-US019437.  
 07-OCT-1998; 98WO-US021141.  
 29-OCT-1998; 98WO-US022991.  
 29-OCT-1998; 98WO-US022992.  
 20-NOV-1998; 98WO-US024855.  
 01-DEC-1998; 98WO-US025108.  
 05-JAN-1999; 99WO-US000106.  
 08-MAR-1999; 99WO-US005028.  
 10-MAR-1999; 99WO-US005190.  
 10-MAR-1999; 2000WO-US006319.  
 20-APR-1999; 99WO-US008615.  
 14-MAY-1999; 99WO-US010733.  
 02-JUN-1999; 99WO-US012252.  
 01-SEP-1999; 99WO-US020111.  
 08-SEP-1999; 99WO-US020594.  
 13-SEP-1999; 99WO-US020944.  
 15-SEP-1999; 99WO-US021090.  
 15-SEP-1999; 99WO-US0211547.  
 05-OCT-1999; 99WO-US023089.  
 29-NOV-1999; 99WO-US028214.  
 30-NOV-1999; 99WO-US028313.  
 30-NOV-1999; 99WO-US028409.  
 01-DEC-1999; 99WO-US028301.  
 01-DEC-1999; 99WO-US028634.  
 02-DEC-1999; 99WO-US028551.  
 02-DEC-1999; 99WO-US028564.  
 02-DEC-1999; 99WO-US028565.  
 16-DEC-1999; 99WO-US030095.  
 20-DEC-1999; 99WO-US030911.  
 20-DEC-1999; 99WO-US030999.  
 22-DEC-1999; 99WO-US030720.  
 30-DEC-1999; 99WO-US031243.  
 30-DEC-1999; 99WO-US031274.  
 05-JAN-2000; 2000WO-US000219.  
 06-JAN-2000; 2000WO-US000277.  
 06-JAN-2000; 2000WO-US000376.  
 11-FEB-2000; 2000WO-US003565.  
 18-FEB-2000; 2000WO-US004341.  
 18-FEB-2000; 2000WO-US004342.  
 22-FEB-2000; 2000WO-US004414.  
 24-FEB-2000; 2000WO-US004914.  
 24-FEB-2000; 2000WO-US005004.  
 01-MAR-2000; 2000WO-US005601.  
 02-MAR-2000; 2000WO-US005746.  
 02-MAR-2000; 2000WO-US005841.  
 15-MAR-2000; 2000WO-US006884.  
 20-MAR-2000; 2000WO-US007377.  
 21-MAR-2000; 2000WO-US007532.

30-MAR-2000; 2000WO-US008439.  
 17-MAY-2000; 2000WO-US013705.  
 22-MAY-2000; 2000WO-US014042.  
 30-MAY-2000; 2000WO-US014941.  
 02-JUN-2000; 2000WO-US015264.  
 28-JUL-2000; 2000WO-US020710.  
 11-AUG-2000; 2000WO-US022031.  
 23-AUG-2000; 2000WO-US023522.  
 24-AUG-2000; 2000WO-US023328.  
 08-NOV-2000; 2000WO-US030952.  
 10-NOV-2000; 2000WO-US030873.  
 01-DEC-2000; 2000WO-US032678.  
 20-DEC-2000; 2000US-00747259.  
 20-DEC-2000; 2000WO-US034956.  
 28-FEB-2001; 2001US-00796498.  
 28-FEB-2001; 2001US-00796498.  
 01-MAR-2001; 2001WO-US006520.  
 09-MAR-2001; 2001US-00802706.  
 14-MAR-2001; 2001US-00808689.  
 22-MAR-2001; 2001US-00816744.  
 05-APR-2001; 2001US-00828366.  
 10-MAY-2001; 2001US-00854208.  
 10-MAY-2001; 2001US-00854280.  
 18-MAY-2001; 2001US-00860216.  
 25-MAY-2001; 2001US-00866028.  
 25-MAY-2001; 2001US-00866034.  
 01-JUN-2001; 2001US-00872035.  
 01-JUN-2001; 2001US-00872035.  
 05-JUN-2001; 2001US-00874503.  
 14-JUN-2001; 2001US-00882636.  
 19-JUN-2001; 2001US-00886342.  
 20-JUN-2001; 2001WO-US019692.  
 21-JUN-2001; 2001US-00887879.  
 22-JUN-2001; 2001WO-US020116.  
 29-JUN-2001; 2001WO-US021066.  
 09-JUL-2001; 2001WO-US021735.  
 18-JUL-2001; 2001US-00908827.  
 06-AUG-2001; 2001US-00924419.  
 09-AUG-2001; 2001US-00927796.  
 16-AUG-2001; 2001US-00931836.  
 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-051522/05.

P-PSDB; ADG24397.

New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.

Claim 2; SEQ ID NO 501; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
CC cells, for stimulating differentiation of adipocyte cells, for  
CC stimulating proliferation of or gene expression in pericyte cells, for  
CC stimulating the proliferation of inner ear utricular supporting cells or  
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
CC treating various bone and/or cartilage disorders such as sports injuries  
CC and arthritis. PRO polypeptides which stimulate the release of  
CC proteoglycans from cartilage are useful for treating sports-related joint  
CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
CC arthritis. PRO polypeptides are also useful for treating various  
CC mammalian haemoglobin-associated disorders such as various thalassaemias  
CC and conditions which may benefit from enhanced local immune system cell  
CC infiltration. This sequence represents a human PRO polynucleotide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.8; DB 12; Length 1883;  
Best Local Similarity 62.0%; Pred. No. 0.0003;  
Matches 103; Conservative 0; Mismatches 63; Indels 0;

QV 2077 GTCCTCAAGTCTCGTGACACATAATCATTCATCCCAATGATCGCCTTTGCTTTACCACT 2136

Db 1700 GACGTCCAGCTCTGTCTCTCTCTTCCCTCACCTCCTCCCTTCAGTGTCTTGAGGAACAGGACT 1759

QY 2137 CTTTCCTTTTATCTTATTATAAAAAATGTTGGTCTCCACCACTGCTGCTCCAAAAA 2196

Db 1760 TTCTCCACATGTTTGTGATTGCAACATTTTGCATTAAAGGAAATCCACAAAAAAA 1819

Qv 2197 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242

Db 1820 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1865

RESULT 1271

ADF98750

ID ADF98750 standard; cDNA; 1883 BP.

AC ADF98750;

DT 26-FEB-2004 (first entry)

Human PRO polynucleotide #251.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;  
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
liver; microvascular endothelial cell; glucose; FFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
immune system cell infiltration.

OS Homo sapiens.

AA  
PN  
US2003208055-A1.

06-NOV-2003.

29-MAY-2002: 2002US-00157786.

31-MAR-1997: 97WO-US005230.

PK IZ-JUN-1998; 98WO-US012438  
PR 14-JUL-1998; 98WO-US014552.

PK Z8-AUG-1998; 38WO-USOI7888  
PR 10-SEP-1998; 98WO-USOI8824

PR	14-SEP-1998;	98WO-US019093;
PR	14-SEP-1998;	98WO-US019094;
PR	14-SEP-1998;	98WO-US019177;
PR	16-SEP-1998;	98WO-US019330;
PR	17-SEP-1998;	98WO-US019437;
PR	07-OCT-1998;	98WO-US021141;
PR	29-OCT-1998;	98WO-US022991;
PR	29-OCT-1998;	98WO-US022992;
PR	20-NOV-1998;	98WO-US024855;
PR	01-DEC-1998;	98WO-US025108;
PR	05-JAN-1999;	99WO-US000106;
PR	08-MAR-1999;	99WO-US005028;
PR	10-MAR-1999;	99WO-US005190;
PR	20-APR-1999;	99WO-US008615;
PR	14-MAY-1999;	99WO-US010733;
PR	01-JUN-1999;	99WO-US012252;
PR	01-SEP-1999;	99WO-US020111;
PR	08-SEP-1999;	99WO-US020594;
PR	13-SEP-1999;	99WO-US020944;
PR	15-SEP-1999;	99WO-US021090;
PR	15-SEP-1999;	99WO-US021547;
PR	05-OCT-1999;	99WO-US023089;
PR	20-NOV-1999;	99WO-US028214;
PR	30-NOV-1999;	99WO-US028313;
PR	30-NOV-1999;	99WO-US028409;
PR	01-DEC-1999;	99WO-US028301;
PR	02-DEC-1999;	99WO-US028634;
PR	02-DEC-1999;	99WO-US028551;
PR	02-DEC-1999;	99WO-US028564;
PR	02-DEC-1999;	99WO-US028565;
PR	16-DEC-1999;	99WO-US030095;
PR	20-DEC-1999;	99WO-US030911;
PR	20-DEC-1999;	99WO-US030999;
PR	22-DEC-1999;	99WO-US030720;
PR	30-DEC-1999;	99WO-US031243;
PR	30-DEC-1999;	99WO-US031274;
PR	05-JAN-2000;	2000WO-US000219;
PR	06-JAN-2000;	2000WO-US000277;
PR	06-JAN-2000;	2000WO-US000376;
PR	11-FEB-2000;	2000WO-US003565;
PR	18-FEB-2000;	2000WO-US004341;
PR	18-FEB-2000;	2000WO-US004342;
PR	22-FEB-2000;	2000WO-US004414;
PR	24-FEB-2000;	2000WO-US004914;
PR	24-FEB-2000;	2000WO-US005004;
PR	01-MAR-2000;	2000WO-US005601;
PR	02-MAR-2000;	2000WO-US005746;
PR	02-MAR-2000;	2000WO-US005841;
PR	10-MAR-2000;	2000WO-US006319;
PR	15-MAR-2000;	2000WO-US006884;
PR	20-MAR-2000;	2000WO-US007377;
PR	21-MAR-2000;	2000WO-US007532;
PR	30-MAR-2000;	2000WO-US008439;
PR	17-MAY-2000;	2000WO-US013705;
PR	22-MAY-2000;	2000WO-US014042;
PR	30-MAY-2000;	2000WO-US014941;
PR	02-JUN-2000;	2000WO-US015264;
PR	28-JUL-2000;	2000WO-US020710;
PR	11-AUG-2000;	2000WO-US022031;
PR	23-AUG-2000;	2000WO-US023522;
PR	24-AUG-2000;	2000WO-US023328;
PR	08-NOV-2000;	2000WO-US030952;
PR	10-NOV-2000;	2000WO-US030873;
PR	01-DEC-2000;	2000WO-US032678;
PR	20-DEC-2000;	2000US-00747259;
PR	20-DEC-2000;	2000US-US034956;
PR	28-FEB-2001;	2001US-00796498;
PR	01-MAR-2001;	2001WO-US006520;
PR	01-MAR-2001;	2001WO-US006666;
PR	14-MAR-2001;	2001US-00802706;
PR	15-MAR-2001;	2001US-00808689;
PR	22-MAR-2001;	2001US-00816744;
PR	05-APR-2001;	2001US-US038365;





ADG16887

ID ADG16887 standard; cDNA; 1893 BP.

XX

AC ADG16887;

XX

DT 26-FEB-2004 (first entry)

XX

DE cDNA encoding human PRO polypeptide #251.

XX

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 liver; microvascular endothelial cell; glucose; PFA;  
 skeletal muscle cell; adipocyte cell; pericyte cell;  
 inner ear utricular supporting cell; T-lymphocyte cell;  
 endothelial cell tube formation; bone disorder; cartilage disorder;  
 sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 immune system cell infiltration.

XX

OS Homo sapiens.

XX

PN US2003207359-A1.

XX

PD 06-NOV-2003.

XX

PF 08-MAY-2002; 2002US-00141756.

XX

31-MAR-1997; 97WO-US005230.

PR

12-JUN-1998; 98WO-US012456.

PR

14-JUL-1998; 98WO-US014552.

PR

28-AUG-1998; 98WO-US017888.

PR

10-SEP-1998; 98WO-US018824.

PR

14-SEP-1998; 98WO-US019093.

PR

14-SEP-1998; 98WO-US019094.

PR

16-SEP-1998; 98WO-US019177.

PR

17-SEP-1998; 98WO-US019330.

PR

17-SEP-1998; 98WO-US019437.

PR

29-OCT-1998; 98WO-US022991.

PR

29-OCT-1998; 98WO-US022992.

PR

20-NOV-1998; 98WO-US024855.

PR

01-DEC-1998; 98WO-US025108.

PR

05-JAN-1999; 99WO-US000106.

PR

08-MAR-1999; 99WO-US005028.

PR

10-MAR-1999; 99WO-US005190.

PR

20-APR-1999; 99WO-US008615.

PR

14-MAY-1999; 99WO-US010733.

PR

02-JUN-1999; 99WO-US012252.

PR

01-SEP-1999; 99WO-US020111.

PR

08-SEP-1999; 99WO-US020594.

PR

13-SEP-1999; 99WO-US020944.

PR

15-SEP-1999; 99WO-US021090.

PR

15-SEP-1999; 99WO-US021547.

PR

05-OCT-1999; 99WO-US023089.

PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006894.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001US-00886342.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001US-00887879.  
 PR 29-JUN-2001; 2001US-00921066.  
 PR 09-JUL-2001; 2001US-00921735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2004-010595/01.

P-PSDB; ADG16888.

XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide  
 PT useful for stimulating the release of tumor necrosis factor-alpha from  
 PT human blood and for detecting the presence of a tumor.

XX Claim 2; Fig 501; 638pp; English.

XX

CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO



Db 1760 TTCTCCACATTTGTTGTTATTGCAACATTTTGCATTAAAGGAATCCACAAAAA 1819  
QY 2197 AA 2242  
Db 1820 AA 1865

RESULT 1276  
ADG19613  
ID ADG19613 standard; cDNA; 1883 BP.  
XX AC  
XX ADG19613;  
XX  
DT 26-FEB-2004 (first entry)  
XX  
DE cDNA encoding human PRO polypeptide #251.  
XX  
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX OS  
XX Homo sapiens.  
XX  
PN US2003207425-A1.  
XX  
PD 06-NOV-2003.  
XX  
PF 09-MAY-2002; 2002US-00142430.  
XX  
PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.

20-DEC-1999; 99WO-US030999.  
22-DEC-1999; 99WO-US030720.  
30-DEC-1999; 99WO-US031243.  
30-DEC-1999; 99WO-US031274.  
05-JAN-2000; 2000WO-US000219.  
06-JAN-2000; 2000WO-US000277.  
06-JAN-2000; 2000WO-US000376.  
11-FEB-2000; 2000WO-US003565.  
18-FEB-2000; 2000WO-US004341.  
18-FEB-2000; 2000WO-US004342.  
22-FEB-2000; 2000WO-US004414.  
24-FEB-2000; 2000WO-US004914.  
01-MAR-2000; 2000WO-US005004.  
02-MAR-2000; 2000WO-US005746.  
02-MAR-2000; 2000WO-US005841.  
10-MAR-2000; 2000WO-US006319.  
15-MAR-2000; 2000WO-US006884.  
20-MAR-2000; 2000WO-US007377.  
21-MAR-2000; 2000WO-US007532.  
30-MAR-2000; 2000WO-US008439.  
17-MAY-2000; 2000WO-US013705.  
22-MAY-2000; 2000WO-US014042.  
30-MAY-2000; 2000WO-US014941.  
02-JUN-2000; 2000WO-US015264.  
11-AUG-2000; 2000WO-US020710.  
23-AUG-2000; 2000WO-US023522.  
24-AUG-2000; 2000WO-US023328.  
08-NOV-2000; 2000WO-US030952.  
10-NOV-2000; 2000WO-US030873.  
01-DEC-2000; 2000WO-US032678.  
20-DEC-2000; 2000US-00747259.  
20-DEC-2000; 2000WO-US034956.  
28-FEB-2001; 2001US-00796498.  
28-FEB-2001; 2001WO-US006520.  
01-MAR-2001; 2001WO-US006666.  
09-MAR-2001; 2001US-00802706.  
14-MAR-2001; 2001US-00808689.  
22-MAR-2001; 2001US-00816744.  
05-APR-2001; 2001US-00828366.  
10-MAY-2001; 2001US-00854208.  
10-MAY-2001; 2001US-00854280.  
18-MAY-2001; 2001US-00860216.  
25-MAY-2001; 2001US-00866028.  
25-MAY-2001; 2001US-00866034.  
25-MAY-2001; 2001WO-US017092.  
01-JUN-2001; 2001US-00872035.  
01-JUN-2001; 2001WO-US017800.  
05-JUN-2001; 2001US-00874503.  
14-JUN-2001; 2001US-00882636.  
19-JUN-2001; 2001US-00886342.  
20-JUN-2001; 2001WO-US019692.  
21-JUN-2001; 2001US-00887879.  
22-JUN-2001; 2001WO-US020116.  
29-JUN-2001; 2001WO-US021066.  
09-JUL-2001; 2001WO-US021735.  
18-JUL-2001; 2001US-00908827.  
06-AUG-2001; 2001US-00924419.  
09-AUG-2001; 2001US-00927796.  
16-AUG-2001; 2001US-00931836.  
19-DEC-2001; 2001US-00028072.  
(GETH ) GENENTECH INC.  
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2004-021502/02.  
DR P-PSDB; ADG19614.  
XX  
PT New isolated, secreted and transmembrane PRO nucleic acid, useful for the



31-MAR-1997;	97WO-US005230.
PR	
12-JUN-1998;	98WO-US012456.
PR	
14-JUL-1998;	98WO-US014552.
PR	
28-AUG-1998;	98WO-US017898.
PR	
10-SEP-1998;	98WO-US018824.
PR	
14-SEP-1998;	98WO-US019093.
PR	
14-SEP-1998;	98WO-US019094.
PR	
14-SEP-1998;	98WO-US019177.
PR	
16-SEP-1998;	98WO-US019330.
PR	
17-SEP-1998;	98WO-US019437.
PR	
07-OCT-1998;	98WO-US021141.
PR	
29-OCT-1998;	98WO-US022991.
PR	
29-OCT-1998;	98WO-US022992.
PR	
20-NOV-1998;	98WO-US024855.
PR	
01-DEC-1998;	98WO-US025108.
PR	
05-JAN-1999;	99WO-US000106.
PR	
08-MAR-1999;	99WO-US005028.
PR	
10-MAR-1999;	99WO-US005190.
PR	
10-MAR-1999;	2000WO-US006319.
PR	
20-APR-1999;	99WO-US008615.
PR	
14-MAY-1999;	99WO-US010733.
PR	
02-JUN-1999;	99WO-US012252.
PR	
01-SEP-1999;	99WO-US020111.
PR	
08-SEP-1999;	99WO-US020594.
PR	
13-SEP-1999;	99WO-US020944.
PR	
15-SEP-1999;	99WO-US021090.
PR	
15-SEP-1999;	99WO-US021547.
PR	
05-OCT-1999;	99WO-US023089.
PR	
29-NOV-1999;	99WO-US028214.
PR	

Baker KP, Bersini M, Deforge L, Denoyers L, Filvaroff E, Gao W; Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2004-051521/05.  
P-PSEB; ADG08508.

New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.

Claim 2; SEQ ID NO 501; 638pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from BMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;

Query Match            2.9%; Score 65.8; DB 12; Length 1883;  
Best Local Similarity   62.0%; Pred. No. 0.0003;  
Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;

QY     2077 GTCTCAAGTGCTCGTGCACATATAATCATTCCTCCAAATGATCGCTTTGTCTTACCACCT 2136  
Db       1700 GAGTCAGACTGTCTCTCTCTCTCCTCACCTCTCGCTTCAGTGCTCTGAGGAACAGGACT 1759

QY     2137 CTITCTCTTTATTCTTTATTAATAAAAAATGGTGGTCTCCACCACTGNCTCCCCAAAAAAA 2196  
Db       1760 TTCTCCACATTGTTTTGTATTGCCAACATTTTGCAATTAAAGCAAATCCACAAAAAAA 1819

QY     2197 AA 2242  
Db       1820 AA 1865

RESULT 1279  
ADG15677  
ID      ADG15677 standard; cDNA; 1883 BP.  
XX  
AC      ADG15677;  
XX  
DT      26-FEB-2004 (first entry)  
XX  
DE      cDNA encoding human PRO polypeptide #251.  
XX  
KW      Human; gene: ss; PRO; secreted polypeptide; transmembrane polypeptide;



XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX Homo sapiens.  
OS  
XX US2003207374-A1.  
XX  
XX 06-NOV-2003.  
XX  
XX 14-MAY-2002; 2002US-00145878.  
XX  
XX 05-JUN-2000; 2000US-0209832P.  
XX PR 01-DEC-2000; 2000WO-US032678.  
XX PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2004-096981/10.  
XX P-PSDB; ADG06261.  
XX  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX  
XX Claim 2; SEQ ID NO 501; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX

SQ Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;  
Query Match 2.9%; Score 55.8; DB 12; Length 1883;  
Best Local Similarity 62.0%; Pred. No. 0.0003;  
Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;  
QY 2077 GTCTCAAGTCTCGTGACACATATCATTCATCCCAATGATCGCTTTTACCACCT 2136  
DB 1700 GACGTCACAGCTCTGCTCTCTTCTCTCACTCTCTCCCTTCAGTGTCTCGAGGACAGGACT 1759  
QY 2137 CTCTCTCTTATCTTATTAATAAATAATGTTCGCTCCACCACTGCTCCCAAAAAA 2196  
DB 1760 TTCTCCACATGTTTGTGATTCACACATTTTGCAATTAAGGAAAAATCCACAAAAAAA 1819  
QY 2197 AAAAAA 2242  
DB 1820 AAAAAA 1865  
RESULT 1282  
ADG23844  
ID ADG23844 standard; cDNA; 1883 BP.  
XX  
AC ADG23844;  
XX  
DT 26-FEB-2004 (first entry)  
XX  
XX Novel human secreted and transmembrane protein PRO1294 cDNA.  
XX  
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
KW rectum; kidney; liver; microvascular endothelial cell;  
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
KW cell differentiation; skeletal muscle cell; adipocyte cell;  
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
KW immune system cell infiltration; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker; gene; ss.  
XX  
XX Homo sapiens.  
OS  
XX US2003207389-A1.  
XX  
XX 06-NOV-2003.  
XX  
XX 30-MAY-2002; 2002US-00158784.  
XX  
XX 05-JUN-2000; 2000US-0209832P.  
XX PR 01-DEC-2000; 2000WO-US032678.  
XX PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2004-021493/02.  
XX P-PSDB; ADG23845.  
XX  
XX New PRO nucleic acid, useful for manufacturing a medicament for  
PT diagnosing or treating tumor, for chromosome mapping or for tissue  
PT typing.  
XX  
XX Claim 2; SEQ ID NO 501; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX







```
QY 2137 CTTTCCTTTTATCTAATAAATAAATGTTGGTCTCCACACTGCTCCCAAAAAA 2196
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1760 TTCTCCACATTGTTTCTGTTGCAACATTTTGCATTAAAGGAAATCCACAAAAA 1819
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2197 AAAAAA 2242
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1820 AAAAAA 1865
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 1285
ADG07331
ID ADG07331 standard; cDNA; 1883 BP.
XX
AC ADG07331;
XX
DT 26-FEB-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1294 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003207350-A1.
XX
PD 06-NOV-2003.
XX
PF 03-MAY-2002; 2002US-00137871.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-010588/01.
DR P-PSDB; ADG07332.
XX
PT New nucleic acid encoding a secreted and transmembrane PRO polypeptide
PT useful in stimulating the proliferation of inner ear utricular supporting
PT cells and detecting a tumor.
XX
PS Claim 2; SEQ ID NO 501; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
```

```
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;
    Query Match 2.9%; Score 65.8; DB 12; Length 1883;
    Best Local Similarity 62.0%; Pred. No. 0.0003;
    Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;
QY 2077 GTCTCAAGTGTCTGTGACACATAATCATTCACATCCATGCGCTTCTTTTACCAC 2136
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1700 GAGTCCAGCTGTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1759
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2137 CTTTCCTTTTATCTAATAAATAAATGTTGGTCTCCACACTGCTCCCAAAAAA 2196
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1760 TTCTCCACATTGTTTCTGTTGCAACATTTTGCATTAAAGGAAATCCACAAAAA 1819
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 2197 AAAAAA 2242
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1820 AAAAAA 1865
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 1286
ADG07883
ID ADG07883 standard; cDNA; 1883 BP.
XX
AC ADG07883;
XX
DT 26-FEB-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1294 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003207356-A1.
XX
PD 06-NOV-2003.
XX
PF 08-MAY-2002; 2002US-00141699.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-010592/01.
DR P-PSDB; ADG07884.
XX
PT New nucleic acid encoding a secreted and transmembrane PRO polypeptide
PT useful in detecting the presence of a tumor in a mammal and stimulating
PT the proliferation or differentiation of chondrocyte cells.
```









PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX	WPI; 2004-010594/01.
DR	P-PSDB; ADG82348.
DR	
XX	
XX	New nucleic acid encoding a secreted and transmembrane PRO polypeptide
PT	useful in stimulating the proliferation of inner ear utricular supporting
PT	cell, detecting the presence of a tumor and in treating cancer.
XX	
PS	Claim 2; SEQ ID NO 501; 637pp; English.
XX	
CC	The invention relates to isolated human PRO polypeptides (secreted and
CC	transmembrane polypeptides) and the polynucleotides encoding them. The
CC	invention also relates to an antibody which specifically binds to a PRO
CC	polypeptide, a method for stimulating the release of tumour necrosis
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC	proliferation or differentiation of chondrocyte cells and a method for
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC	polynucleotides are useful in molecular biology, including uses as
CC	hybridisation probes, in chromosome and gene mapping, in generating
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC	be used in preparing PRO polypeptides by recombinant techniques and in
CC	generating either transgenic animals or knock-out animals which are
CC	useful in the development and screening of therapeutically useful
CC	reagents. The PRO polypeptides or antibodies are used in preparing a
CC	medicament for treating a condition responsive to the polypeptides or
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation
CC	of human microvascular endothelial cells, for modulating the uptake of
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC	stimulating differentiation of adipocyte cells, for stimulating
CC	proliferation of or gene expression in pericyte cells, for stimulating
CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC	cells, for inducing endothelial cell tube formation and for treating
CC	various bone and/or cartilage disorders such as sports injuries and
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC	from cartilage are useful for treating sports-related joint problems,
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC	polypeptides are also useful for treating various mammalian haemoglobin-
CC	associated disorders such as various thalassemias and conditions which
CC	may benefit from enhanced local immune system cell infiltration. This
CC	sequence represents a human PRO polynucleotide of the invention. Note:
CC	The sequence data for this patent is also available in electronic format
CC	from USPTO at seqdata.uspto.gov/sequence.html.
XX	
SQ	Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;
	Query Match            2.9%; Score 65.8; DB 12; Length 1883;
	Best Local Similarity   62.0%; Pred. No. 0.0003;
	Matches 103; Conservative   0; Mismatches 63; Indels   0; Gaps   0;
QY	2077 GTCTCAAGTGTCTGGACACATAATCATTCATCCATCGCTTTGCTTTACCACCT 2136
Db	1700 GAGCTCAGCTGTCTCTCTTCCCTACTCTCCCTCTAGTCTCTGAGGAACAGCAGCT 1759
QY	2137 CTTTCTCTTTTATTCTTAATAAAAAAATGTGGTGCTCCACCCTGCNCTCCCAAAAAAAA 2196
Db	1760 TTCTCCACATGTTTGTATTGCAACATTTGCATTAAAGAAGAAATCCACAAAAAAA 1819
QY	2197 AAA 2242
Db	1820 AAA 1865
RESULT 1292	
ADG57586	
ID	ADG57586 standard; cDNA; 1883 BP.
XX	
AC	ADG57586;
XX	
DT	11-MAR-2004 (first entry)
XX	
DE	Novel human secreted and transmembrane protein PRO1294 CDNA.





CC is often transmitted by secreted polypeptides (for example mitogenic  
 CC factors, survival factors, cytotoxic factors, differentiation factors,  
 CC neuropeptides and hormones) which are received and interpreted by diverse  
 CC cell receptors or membrane bound proteins. These membrane bound proteins  
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such  
 CC as in the blocking of receptor-ligand interactions. The current invention  
 CC provides the amino acid sequences of novel human membrane bound receptors  
 CC and proteins, along with the cDNA sequences encoding them. The novel  
 CC proteins of the invention may have cytotstatic activities through the  
 CC stimulation of chondrocytes. The nucleic acids of the invention may be  
 CC useful for the manufacture of a medicament for diagnosing or treating a  
 CC tumour in a mammal. In addition, they may be useful for measuring or  
 CC detecting the expression of a tumour associated gene. The present  
 CC sequence is a cDNA sequence which encodes a human PRO protein of the  
 CC invention.  
 XX

SQ Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.8; DB 12; Length 1883;  
 Best Local Similarity 62.0%; Pred. No. 0.0003;  
 Matches 103; Conservative 0; Mismatches 63; Indels 0; Gaps 0;

QY 2077 GTCTCAAGTGCCTGTCACATAAATCATTTCCATCCAATGATCGCTTGCTTTACCAC 2136  
 Db 1700 GAGCTCAGCTGTGCTCTCTTCCTCACCTCCCTTCAGTCTCTGGAGAACAGCAGGAT 1759

QY 2137 CTTTCTCTTTTATCTTAATAAAAAATGTTGGTCTCCACCACCTGCTCCAAAAA 2196  
 Db 1760 TTCTCCACATGTTTGTATTGCAACATTTTGCAATTAAGAAGAAATCCACAAAAA 1819

QY 2197 AA 2242  
 Db 1820 AA 1865

RESULT 1296  
 ADG71056  
 ID ADG71056 standard; cDNA; 1883 BP.

XX  
 AC ADG71056;  
 XX

11-MAR-2004 (first entry)

Novel human secreted and transmembrane protein PRO1294 cDNA.

Human; secreted and transmembrane protein; PRO: secreted polypeptide;  
 transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
 chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
 rectum; kidney; cervix; liver; microvascular endothelial cell;  
 glucose uptake modulator; FFA uptake modulator; cell proliferation;  
 cell differentiation; skeletal muscle cell; adipocyte cell;  
 pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
 endothelial cell tube formation; bone disorder; cartilage disorder;  
 sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;  
 immune system cell infiltration; chromosome mapping; gene mapping;  
 gene therapy; chromosome identification; chromosome marker; gene; ss.

XX  
 OS Homo sapiens.  
 XX

US2003207420-A1.

XX  
 PD 06-NOV-2003.  
 XX

PF 07-MAY-2002; 2002US-00140865.  
 XX

PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 XX







CC	and receptors may be of use as pharmaceutical and diagnostic agents, such
CC	as in the blocking of receptor-ligand interactions. The current invention
CC	provides the amino acid sequences of novel human membrane bound receptors
CC	and proteins, along with the cDNA sequences encoding them. The novel
CC	proteins of the invention may have cytostatic activities through the
CC	stimulation of chondrocytes. The nucleic acids of the invention may be
CC	useful for the manufacture of a medicament for diagnosing or treating a
CC	tumour in a mammal. In addition, they may be useful for measuring or
CC	detecting the expression of a tumour associated gene. The present
CC	sequence is a cDNA sequence which encodes a human PRO protein of the
CC	invention.
SQ	Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;
Query Match	2.9%; Score 65.8; DB 12; Length 1883;
Best Local Similarity	62.0%; Pred. No. 0.0003;
Matches 103; Conservative	0; Mismatches 63; Indels 0; Gaps 0;
QY	2077 GTCTCAAGTGCTCGTGCACATATCATTCATCCTGATGTCCTTTGTACCCT 2136
Db	1700 GACGTCCAGCTCTGCTCTCTCTTCTCACCTCTCTCTGCTGAGGAACGAGACT 1759
QY	2137 CTTCCTTTTATTATAAATAAAATGTTGCTGCCACCACTGCTCCAAAAA 2196
Db	1760 TTCTCCACATGTTTGTATTGCAACATTTTGCAATTAAGAAGAAAATCCACAAAAA 1819
QY	2197 AA 2242
Db	1820 AA 1865
RESULT 1301	
ADG71608	
ID	ADG71608 standard; CDNA; 1883 BP.
XX	ADG71608;
XX	11-MAR-2004 (first entry)
DE	Novel human secreted and transmembrane protein PRO1294 CDNA.
XX	Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW	rectum; kidney; cervix; liver; microvascular endothelial cell;
KW	glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW	cell differentiation; skeletal muscle cell; adipocyte cell;
KW	pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW	rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW	immune system cell infiltration; chromosome mapping; gene mapping;
KW	gene therapy; chromosome identification; chromosome marker; gene; ss.
OS	Homo sapiens.
XX	US2003207421-A1.
PX	06-NOV-2003.
PD	08-MAY-2002; 2002US-00141701.
PF	31-MAR-1997; 97WO-US005230.
XX	12-JUN-1998; 98WO-US012456.
PR	14-JUL-1998; 98WO-US014552.
PR	28-AUG-1998; 98WO-US017888.
PR	10-SEP-1998; 98WO-US018824.
PR	14-SEP-1998; 98WO-US019093.
PR	14-SEP-1998; 98WO-US019094.
PR	14-SEP-1998; 98WO-US019177.
PR	16-SEP-1998; 98WO-US019330.
PR	17-SEP-1998; 98WO-US019437.
PR	07-OCT-1998; 98WO-US021141.
PR	02-MAR-2000; 2000WO-US005841.
PR	10-MAR-2000; 2000WO-US006319.
PR	15-MAR-2000; 2000WO-US006884.
PR	20-MAR-2000; 2000WO-US007377.
PR	21-MAR-2000; 2000WO-US007532.
PR	30-MAR-2000; 2000WO-US008439.
PR	17-MAY-2000; 2000WO-US013705.
PR	22-MAY-2000; 2000WO-US014042.
PR	30-MAY-2000; 2000WO-US014941.
PR	02-JUN-2000; 2000WO-US015264.
PR	28-JUL-2000; 2000WO-US020710.
PR	11-AUG-2000; 2000WO-US022031.
PR	23-AUG-2000; 2000WO-US023522.
PR	24-AUG-2000; 2000WO-US023328.
PR	08-NOV-2000; 2000WO-US030952.
PR	10-NOV-2000; 2000WO-US030873.
PR	01-DEC-2000; 2000WO-US032678.
PR	20-DEC-2000; 2000US-US0747259.
PR	28-FEB-2001; 2001US-US0796498.
PR	28-FEB-2001; 2001WO-US006520.
PR	01-MAR-2001; 2001WO-US006666.
PR	09-MAR-2001; 2001US-US0802706.
PR	14-MAR-2001; 2001US-US0808689.
PR	22-MAR-2001; 2001US-US0816744.
PR	05-APR-2001; 2001US-US0828366.
PR	10-MAY-2001; 2001US-US0854208.
PR	10-MAY-2001; 2001US-US0854280.
PR	18-MAY-2001; 2001US-US0860216.
PR	25-MAY-2001; 2001US-US0866028.
PR	25-MAY-2001; 2001US-US0866034.
PR	25-MAY-2001; 2001WO-US017092.
PR	01-JUN-2001; 2001US-US0872035.
PR	01-JUN-2001; 2001WO-US017800.
PR	05-JUN-2001; 2001US-US0874503.
PR	14-JUN-2001; 2001US-US0882636.
PR	19-JUN-2001; 2001US-US0886342.
PR	20-JUN-2001; 2001WO-US019692.
PR	21-JUN-2001; 2001US-US0887879.
PR	22-JUN-2001; 2001WO-US020116.
PR	29-JUN-2001; 2001WO-US021066.
PR	09-JUL-2001; 2001WO-US021735.
PR	18-JUL-2001; 2001US-US0908827.
PR	06-AUG-2001; 2001US-US0924419.
PR	09-AUG-2001; 2001US-US0927796.
PR	16-AUG-2001; 2001US-US0931836.
PR	19-DEC-2001; 2001US-US0028072.
(GETH ) GENENTECH INC.	
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	
Gerritsen WF, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;	
WPI; 2004-021497/02.	
P-PSDB; ADG53723.	
New PRO nucleic acid, useful for manufacturing a medicament for	
diagnosing or treating tumor, for chromosome mapping or for tissue	
typing.	
Claim 2; SEQ ID NO 501; 637pp; English.	
This invention relates to novel nucleic acids encoding human PRO secreted	
and transmembrane proteins. Extracellular proteins play important roles	
in the formation, differentiation and maintenance of multicellular	
organisms. The fate of many individual cells (for example proliferation,	
migration or differentiation) is typically governed by information	
received from other cells and the immediate environment. The information	
is often transmitted by secreted polypeptides (for example mitogenic	
factors, survival factors, cytotoxic factors, differentiation factors,	
neuropeptides and hormones) which are received and interpreted by diverse	
cell receptors or membrane bound proteins. These membrane bound proteins	













OS Homo sapiens.  
XX US2003207416-A1.  
XX 06-NOV-2003.  
XX  
XX 06-MAY-2002; 2002US-00140023.  
XX  
PR 31-MAR-1997; 97WO-US0052230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 10-MAR-1999; 2000WO-US006319.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US000365.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
XX  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US074759.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 09-JUL-2001; 2001WO-US021066.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
DR WPI; 2004-059757/06.  
XX P-PSDB; ADG54275.  
XX  
DR New PRO nucleic acid, useful for manufacturing a medicament for  
XX diagnosing or treating tumor, for chromosome mapping, or for tissue  
XX typing.  
XX  
PS Claim 2; SEQ ID NO 501; 637pp; English.  
XX  
CC This invention relates to novel nucleic acids encoding human PRO secreted  
CC and transmembrane proteins. Extracellular proteins play important roles  
CC in the formation, differentiation and maintenance of multicellular  
CC organisms. The fate of many individual cells (for example proliferation,  
CC migration or differentiation) is typically governed by information  
CC received from other cells and the immediate environment. The information  
CC is often transmitted by secreted polypeptides (for example mitogenic  
CC factors, survival factors, cytotoxic factors, differentiation factors,  
CC neuropeptides and hormones) which are received and interpreted by diverse  
CC cell receptors or membrane bound proteins. These membrane bound proteins  
CC and receptors may be of use as pharmaceutical and diagnostic agents, such  
CC as in the blocking of receptor-ligand interactions. The current invention  
CC provides the amino acid sequences of novel human membrane bound receptors  
CC and proteins, along with the cDNA sequences encoding them. The novel  
CC proteins of the invention may have cytostatic activities through the  
CC stimulation of chondrocytes. The nucleic acids of the invention may be  
CC useful for the manufacture of a medicament for diagnosing or treating a  
CC tumour in a mammal. In addition, they may be useful for measuring or  
CC detecting the expression of a tumour associated gene. The present  
CC sequence is a cDNA sequence which encodes a human PRO protein of the  
XX invention.  
XX  
SQ Sequence 1883 BP; 493 A; 496 C; 480 G; 414 T; 0 U; 0 Other;

15-SEP-1999;	PR	99WO-US021547.
05-OCT-1999;	PR	99WO-US023089.
29-NOV-1999;	PR	99WO-US028214.
30-NOV-1999;	PR	99WO-US028313.
30-NOV-1999;	PR	99WO-US028409.
01-DEC-1999;	PR	99WO-US028301.
01-DEC-1999;	PR	99WO-US028634.
02-DEC-1999;	PR	99WO-US028551.
02-DEC-1999;	PR	99WO-US028564.
02-DEC-1999;	PR	99WO-US028565.
16-DEC-1999;	PR	99WO-US030095.
20-DEC-1999;	PR	99WO-US030911.
20-DEC-1999;	PR	99WO-US030999.
22-DEC-1999;	PR	99WO-US030720.
30-DEC-1999;	PR	99WO-US031243.
30-DEC-1999;	PR	99WO-US031274.
05-JAN-2000;	PR	2000WO-US000219.
06-JAN-2000;	PR	2000WO-US000277.
06-JAN-2000;	PR	2000WO-US000376.
11-FEB-2000;	PR	2000WO-US003565.
18-FEB-2000;	PR	2000WO-US004341.
18-FEB-2000;	PR	2000WO-US004342.
24-FEB-2000;	PR	2000WO-US004414.
24-FEB-2000;	PR	2000WO-US004914.
24-FEB-2000;	PR	2000WO-US005004.
01-MAR-2000;	PR	2000WO-US005601.
02-MAR-2000;	PR	2000WO-US005746.
02-MAR-2000;	PR	2000WO-US005841.
15-MAR-2000;	PR	2000WO-US006884.
20-MAR-2000;	PR	2000WO-US007377.
21-MAR-2000;	PR	2000WO-US007532.
30-MAR-2000;	PR	2000WO-US008439.
17-MAY-2000;	PR	2000WO-US013705.
22-MAY-2000;	PR	2000WO-US014042.
30-MAY-2000;	PR	2000WO-US014941.
02-JUN-2000;	PR	2000WO-US015264.
28-JUL-2000;	PR	2000WO-US020710.
11-AUG-2000;	PR	2000WO-US022031.
23-AUG-2000;	PR	2000WO-US023522.
28-AUG-2000;	PR	2000WO-US023328.
04-NOV-2000;	PR	2000WO-US030952.
10-NOV-2000;	PR	2000WO-US030873.
01-DEC-2000;	PR	2000WO-US032678.
20-DEC-2000;	PR	2000US-00747259.
20-DEC-2000;	PR	2000WO-US034956.
28-FEB-2001;	PR	2001US-00736498.
01-FEB-2001;	PR	2001WO-US006520.
08-MAR-2001;	PR	2001WO-US006666.
09-MAR-2001;	PR	2001US-00802703.
12-MAR-2001;	PR	2001US-00802609.
14-MAR-2001;	PR	2001US-00816744.
19-JUN-2001;	PR	2001US-00863632.
20-JUN-2001;	PR	2001WO-US019692.
21-JUN-2001;	PR	2001US-00887879.
10-MAY-2001;	PR	2001US-00854280.
15-MAY-2001;	PR	2001US-00860216.
25-MAY-2001;	PR	2001US-00866034.
25-MAY-2001;	PR	2001WO-US017092.
01-JUN-2001;	PR	2001US-00872035.
01-JUN-2001;	PR	2001WO-US017800.
05-JUN-2001;	PR	2001US-00874503.
14-JUN-2001;	PR	2001US-00882636.
19-JUN-2001;	PR	2001US-00886342.
20-JUN-2001;	PR	2001US-00854208.
22-JUN-2001;	PR	2001US-00854280.
25-MAY-2001;	PR	2001US-00860216.
29-JUL-2001;	PR	2001WO-US021666.
18-JUL-2001;	PR	2001US-00201735.
06-AUG-2001;	PR	2001US-00908827.
09-AUG-2001;	PR	2001US-00924419.
16-AUG-2001;	PR	2001US-00927796.
19-DEC-2001;	PR	2001US-00931836.
19-DEC-2001;	PR	2001US-00028072.





RESULT 1311  
ADH28681

ID ADH28681 standard; cDNA; 1883 BP.  
 XX  
 AC ADH28681;  
 XX  
 DT 11-MAR-2004 (first entry)  
 XX  
 DE Human PRO polynucleotide #251.  
 XX  
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; PFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2003022331-A1.  
 PN  
 PD 30-JAN-2003.  
 XX  
 XX 06-MAY-2002; 2002US-00140470.  
 XX  
 PR 31-MAR-1997; 97WO-US0005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022391.  
 PR 29-OCT-1998; 98WO-US022392.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006566.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 23-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen WE, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 XX WPI; 2004-118831/12.  
 DR P-PSDB; ADH28682.  
 XX  
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic  
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,  
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver  
 PT tumors.  
 XX  
 XX Claim 2; SEQ ID NO 501; 660pp; English.  
 PS  
 XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO





PR 18-NOV-1998; 98US-0108858P.











glucose uptake modulator; PFA uptake modulator; cell proliferation;  
cell differentiation; skeletal muscle cell; adipocyte cell;  
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
immune system cell infiltration; chromosome mapping; gene mapping;  
gene therapy; chromosome identification; chromosome marker; Gene; ss.

Homo sapiens.

US2003207349-A1.

06-NOV-2003.

03-MAY-2002; 2002US-00137867.

31-MAR-1997; 97WO-US005230.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

28-AUG-1998; 98WO-US017888.

10-SEP-1998; 98WO-US018824.

14-SEP-1998; 98WO-US019093.

14-SEP-1998; 98WO-US019094.

14-SEP-1998; 98WO-US019177.

16-SEP-1998; 98WO-US019330.

17-SEP-1998; 98WO-US019437.

07-OCT-1998; 98WO-US022291.

29-OCT-1998; 98WO-US022992.

20-NOV-1998; 98WO-US024855.

01-DEC-1998; 98WO-US025108.

05-JAN-1999; 99WO-US000106.

08-MAR-1999; 99WO-US005028.

10-MAR-1999; 99WO-US005190.

20-APR-1999; 99WO-US008615.

14-MAY-1999; 99WO-US010733.

02-JUN-1999; 99WO-US012252.

01-SEP-1999; 99WO-US020111.

08-SEP-1999; 99WO-US020594.

13-SEP-1999; 99WO-US020944.

15-SEP-1999; 99WO-US021090.

15-SEP-1999; 99WO-US021547.

05-OCT-1999; 99WO-US023089.

29-NOV-1999; 99WO-US028214.

30-NOV-1999; 99WO-US028313.

30-NOV-1999; 99WO-US028409.

01-DEC-1999; 99WO-US028301.

01-DEC-1999; 99WO-US028634.

02-DEC-1999; 99WO-US028551.

02-DEC-1999; 99WO-US028565.

16-DEC-1999; 99WO-US030095.

20-DEC-1999; 99WO-US030911.

20-DEC-1999; 99WO-US030999.

22-DEC-1999; 99WO-US030720.

30-DEC-1999; 99WO-US031243.

30-DEC-1999; 99WO-US031274.

05-JAN-2000; 2000WO-US000219.

06-JAN-2000; 2000WO-US000277.

06-JAN-2000; 2000WO-US000376.

11-FEB-2000; 2000WO-US003565.

18-FEB-2000; 2000WO-US004341.

18-FEB-2000; 2000WO-US004342.

22-FEB-2000; 2000WO-US004414.

24-FEB-2000; 2000WO-US004914.

01-MAR-2000; 2000WO-US005004.

01-MAR-2000; 2000WO-US005601.

02-MAR-2000; 2000WO-US005746.

02-MAR-2000; 2000WO-US005841.

10-MAR-2000; 2000WO-US006319.

15-MAR-2000; 2000WO-US006884.

20-MAR-2000; 2000WO-US007377.

21-MAR-2000; 2000WO-US007532.  
30-MAR-2000; 2000WO-US008439.  
17-MAY-2000; 2000WO-US013705.  
22-MAY-2000; 2000WO-US014042.  
30-MAY-2000; 2000WO-US014941.  
02-JUN-2000; 2000WO-US015264.  
28-JUL-2000; 2000WO-US020710.  
11-AUG-2000; 2000WO-US022031.  
23-AUG-2000; 2000WO-US023522.  
24-AUG-2000; 2000WO-US023328.  
08-NOV-2000; 2000WO-US030952.  
10-NOV-2000; 2000WO-US030873.  
01-DEC-2000; 2000WO-US032678.  
20-DEC-2000; 2000US-00747259.  
20-DEC-2000; 2000WO-US034956.  
28-FEB-2001; 2001US-00796498.  
28-FEB-2001; 2001WO-US006520.  
01-MAR-2001; 2001WO-US006666.  
09-MAR-2001; 2001US-00802706.  
14-MAR-2001; 2001US-00808689.  
22-MAR-2001; 2001US-00816744.  
05-APR-2001; 2001US-00828366.  
10-MAY-2001; 2001US-00854208.  
10-MAY-2001; 2001US-00854280.  
18-MAY-2001; 2001US-00860216.  
25-MAY-2001; 2001US-00866028.  
25-MAY-2001; 2001US-00866034.  
25-MAY-2001; 2001WO-US017092.  
01-JUN-2001; 2001US-00872035.  
01-JUN-2001; 2001WO-US017800.  
05-JUN-2001; 2001US-00874503.  
14-JUN-2001; 2001US-00882636.  
19-JUN-2001; 2001US-00886342.  
20-JUN-2001; 2001WO-US019892.  
21-JUN-2001; 2001US-00887879.  
22-JUN-2001; 2001WO-US020116.  
29-JUN-2001; 2001WO-US021066.  
09-JUL-2001; 2001WO-US021735.  
18-JUL-2001; 2001US-00908827.  
06-AUG-2001; 2001US-00924419.  
09-AUG-2001; 2001US-00927796.  
16-AUG-2001; 2001US-00931836.  
19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-051513/05.

P-PSDB; ADI18432.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; SEQ ID NO 501; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful











## RESULT 1328

ADM28451

ID ADM28451 standard; cDNA; 1893 BP.

XX AC

XX ADM28451;

XX DT 15-JUL-2004 (first entry)

XX DE cDNA encoding human PRO polypeptide #251.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2004077064-A1.

XX PD 22-APR-2004.

XX PF 17-MAY-2002; 2002US-00147536.

XX PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 98WO-US000106.

PR 08-MAR-1999; 98WO-US005028.

PR 10-MAR-1999; 98WO-US005190.

PR 10-MAR-1999; 2000WO-US006319.

PR 20-APR-1999; 98WO-US008615.

PR 14-MAY-1999; 98WO-US010733.

PR 02-JUN-1999; 98WO-US012252.

PR 01-SEP-1999; 98WO-US020111.

PR 08-SEP-1999; 98WO-US020594.

PR 13-SEP-1999; 98WO-US020944.

PR 15-SEP-1999; 98WO-US021090.

PR 15-SEP-1999; 98WO-US021547.

PR 05-OCT-1999; 98WO-US023089.

PR 29-NOV-1999; 98WO-US028214.

PR 30-NOV-1999; 98WO-US028313.

PR 30-NOV-1999; 98WO-US028409.

PR 01-DEC-1999; 98WO-US028301.

PR 01-DEC-1999; 98WO-US028634.

PR 02-DEC-1999; 98WO-US028551.

PR 02-DEC-1999; 98WO-US028564.

PR 02-DEC-1999; 98WO-US028565.

PR 16-DEC-1999; 98WO-US030095.

PR 20-DEC-1999; 98WO-US030911.

PR 20-DEC-1999; 98WO-US030999.

PR 22-DEC-1999; 98WO-US030720.

PR 30-DEC-1999; 98WO-US031243.

PR 30-DEC-1999; 98WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00806899.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-340004/31.  
P-PSDB; ADM28452.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PRO4928, useful in molecular biology, chromosome and gene mapping, in  
generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 501; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and









```
RESULT 1334
ID ABK40026/c
XX ABK40026 standard; DNA; 17534 BP.
AC ABK40026;
XX 21-MAY-2002 (first entry)
XX Human chemically pretreated gene sequence #54 strand 2.
DE DE
XX Human; ds; bisulphite treatment; CpG; DNA methylation; cancer; tumour;
XX cytotatic; ALDH6; CYP11A; CYP11B1; CYP3A3; DPYD; EPHX2; OCLN; TXNRD1;
KW UGT8; MRP; pharmacogenomics; SNP; single nucleotide polymorphism.
XX Homo sapiens.
XX WO200202806-A2.
XX 10-JAN-2002.
XX 29-JUN-2001; 2001WO-EP007470.
XX 30-JUN-2000; 2000DE-01032529.
XX 01-SEP-2000; 2000DE-01043826.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2002-154757/20.
XX New nucleic acid, oligonucleotides and peptide nucleic acid-oligomers,
XX useful for detecting cytosine methylation state of genes associated with
XX pharmacogenomics and for therapy of diseases e.g. cancer.
XX Claim 1; SEQ ID NO 108; 24pp; English.
XX The invention relates to a nucleic acid comprising a sequence at least 18
XX bases in length of a segment of the chemically pretreated DNA of genes
XX associated with pharmacogenomics according to one of the sequences of the
XX genes ALDH6 (NM_000693), CYP11A (NM_000781), EPHX2 (NM_000497), CYP3A3
XX (NM_000776 and NM_017460), DPYD (NM_000110), EPHX2 (NM_001979), OCLN
XX (NM_002538), TXNRD1 (NM_003330), UGT8 (NM_003360), MRP (NM_004996,
XX NM_019900, NM_019901, NM_019902, NM_019862, NM_019898, NM_019899) and
XX their complementary sequences, or a sequence (S1) chosen from 87
XX sequences and their complements. The chemical pretreatment is bisulphite
XX treatment to convert cytosines (but not methyl-cytosines) into uracils.
XX Also included are an oligomer (II) in particular an oligonucleotide or a
XX peptide nucleic acid (PNA)-oligomer, comprising in each case at least one
XX base sequence having a length of 9 nucleotides which hybridises to or is
XX identical to a chemically pretreated DNA of genes associated with
XX pharmacogenomics and their complements, arranged in an array for
XX analysing diseases associated with the methylation state (CpG) and/or
XX detecting SNPs (single nucleotide polymorphisms) of the 87 sequences. The
XX oligomers may also be used as PCR primers. The set of 87 nucleic acids
XX and their complements is useful for diagnosis and therapy of solid
XX tumours and cancer. The present sequence represents one the 87 DNA
XX sequences or its complement. Note: the sequence data for this patent did
XX not form part of the printed specification, but was obtained in
XX electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 17534 BP; 5028 A; 197 C; 3605 G; 8704 T; 0 U; 0 Other;
Query Match
Best Local Similarity 2.9%; Score 65.8; DB 6; Length 17534;
Matches 88; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 2117 ATCGCTTCCTTACACCTTCCTTCCTTTATCTTATTAATAAATGTGCTCCACC 2176
DB 10017 ATCTATTCTACAAAATCTTAAATATTAAATTTTTTAAAAAATAAAATTCAAA 9958
QY 2177 ACTGNCCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2236
```

```
Db 9957 AAAAAACACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 9898
QY 2237 AAAAAA 2242
Db 9897 AAAAAA 9892
RESULT 1335
ADL38504/c
ID ADL38504 standard; DNA; 319 BP.
XX ADL38504;
XX 20-MAY-2004 (first entry)
XX Human ovarian cancer DNA marker #12394.
XX Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.
XX Homo sapiens.
XX WO200170979-A2.
XX 27-SEP-2001.
XX 21-MAR-2001; 2001WO-US009126.
XX 21-MAR-2000; 2000US-0191031P.
XX 25-MAY-2000; 2000US-0207124P.
XX 15-JUN-2000; 2000US-0211940P.
XX 07-JUL-2000; 2000US-0216820P.
XX 25-JUL-2000; 2000US-0220661P.
XX 21-DEC-2000; 2000US-0257672P.
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX Lee J, Lillie J;
XX WPI; 2001-611502/70.
XX Novel isolated nucleic acid molecules (markers) overexpressed in ovarian
XX cancer cells as compared to their normal non-cancerous ovarian cells are
XX used to characterize stage, grade, histological type of ovarian cancer.
XX Disclosure; SEQ ID NO 12394; 106pp; English.
XX The invention relates to nucleic acid markers which are overexpressed in
XX ovarian cancer cells as compared to their expression in normal (i.e. non-
XX cancerous) ovarian cells. The invention also relates to polypeptides
XX encoded by the markers, antibodies that selectively bind to the
XX polypeptides, a method of inhibiting ovarian cancer in a patient at risk
XX of developing ovarian cancer involving inhibiting expression of a gene
XX corresponding to a marker of the invention and a method of treating a
XX patient afflicted with ovarian cancer comprising providing to cells of
XX the patient an antisense oligonucleotide complementary to a marker of the
XX invention. The markers are useful for assessing if a patient is afflicted
XX with ovarian cancer, which involves comparing the level of expression of
XX a marker in a patient sample and a normal level of expression of the
XX marker in a control non-ovarian cancer sample. A difference between the
XX expression levels indicates ovarian cancer. The level of expression of a
XX marker corresponds to a secreted protein or to a transcribed
XX polynucleotide or its portion. The level of expression of the marker is
XX assessed by detecting the presence in the sample, a protein or protein
XX fragment corresponding to the marker. The presence of protein or protein
XX fragment is detected using an antibody that specifically binds with the
XX protein or protein fragment. Alternatively, the level of expression of
XX the marker is assessed by detecting the presence of a transcribed
XX polynucleotide which anneals with the marker or anneals with a portion of
XX the polynucleotide comprising the marker, under stringent conditions. The
XX marker is also used for monitoring the progression of ovarian cancer in a
XX patient which involves detecting expression of the marker in a patient
XX sample at a first point in time, repeating the method at a subsequent
```

CC time and comparing the level of expression. The method is carried out  
CC using an ovarian tissue sample. A composition comprising a marker,  
CC polypeptide or antibody of the invention is used to treat ovarian cancer.  
CC This sequence represents a human ovarian cancer DNA marker of the  
CC invention.

XX  
SQ Sequence 319 BP; 82 A; 21 C; 20 G; 153 T; 0 U; 43 Other;

Query Match 2.9%; Score 65.6; DB 5; Length 319;  
Best Local Similarity 69.2%; Pred. No. 0.00019;  
Matches 74; Conservative 0; Mismatches 33; Indels 0; Gaps 0;

Qy 2136 TCTTTCCTTTATCTTATTAATAAAATGTTGGTCTCCACCTGCTCCCAAAAAAAA 2195  
Db 207 TTTTNNNTTTTNNANNNANNNANNTNTTTTTTTGNGGNGTNTTTTNCNAAAAAAA 148

Qy 2196 AAAAAA AA 2242  
Db 147 AAAAAA AA 101

RESULT 1336

ID ADI73373/c  
AD I73373 standard; DNA; 319 BP.

XX  
AC ADI73373;

DT 20-MAY-2004 (first entry)

XX Human ovarian cancer DNA marker #6115.

DE Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.

XX Homo sapiens.

XX WO200170979-A2.

XX 27-SEP-2001.

XX 21-MAR-2001; 2001WO-US009126.

XX 21-MAR-2000; 2000US-0191031P.

XX 25-MAY-2000; 2000US-0207124P.

XX 15-JUN-2000; 2000US-0211940P.

XX 07-JUL-2000; 2000US-0216820P.

XX 25-JUL-2000; 2000US-0220661P.

XX 21-DEC-2000; 2000US-0257672P.

XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

XX Lee J, Lillie J;

XX WPI; 2001-611502/70.

XX Novel isolated nucleic acid molecules (markers) overexpressed in ovarian

XX cancer cells as compared to their normal non-cancerous ovarian cells are  
XX used to characterize stage, grade, histological type of ovarian cancer.

XX Disclosure; SEQ ID NO 6115; 106pp; English.

XX The invention relates to nucleic acid markers which are overexpressed in  
XX ovarian cancer cells as compared to their expression in normal (i.e. non-  
XX cancerous) ovarian cells. The invention also relates to polypeptides  
XX encoded by the markers, antibodies that selectively bind to the  
XX polypeptides, a method of inhibiting ovarian cancer in a patient at risk  
XX of developing ovarian cancer involving inhibiting expression of a gene  
XX corresponding to a marker of the invention and a method of treating a  
XX patient afflicted with ovarian cancer comprising providing to cells of  
XX the patient an antisense oligonucleotide complementary to a marker of the  
XX invention. The markers are useful for assessing if a patient is afflicted  
XX with ovarian cancer, which involves comparing the level of expression of  
XX a marker in a patient sample and a normal level of expression of the  
XX marker in a control non-ovarian cancer sample. A difference between the

CC expression levels indicates ovarian cancer. The level of expression of a  
CC marker corresponds to a secreted protein or to a transcribed  
CC polynucleotide or its portion. The level of expression of the marker is  
CC assessed by detecting the presence in the sample, a protein or protein  
CC fragment corresponding to the marker. The presence of protein or protein  
CC fragment is detected using an antibody that specifically binds with the  
CC protein or protein fragment. Alternatively, the level of expression of  
CC the polynucleotide which anneals with the marker or anneals with a portion of  
CC the polynucleotide comprising the marker, under stringent conditions. The  
CC marker is also used for monitoring the progression of ovarian cancer in a  
CC patient which involves detecting expression of the marker in a patient  
CC sample at a first point in time, repeating the method at a subsequent  
CC time and comparing the level of expression. The method is carried out  
CC using an ovarian tissue sample. A composition comprising a marker,  
CC polypeptide or antibody of the invention is used to treat ovarian cancer.  
CC This sequence represents a human ovarian cancer DNA marker of the  
CC invention. Note: The sequence data for this patent did not form part of  
CC the printed specification, but was obtained in electronic format directly  
CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences.

XX SQ Sequence 319 BP; 82 A; 21 C; 20 G; 153 T; 0 U; 43 Other;

Query Match 2.9%; Score 65.6; DB 5; Length 319;  
Best Local Similarity 69.2%; Pred. No. 0.00019;  
Matches 74; Conservative 0; Mismatches 33; Indels 0; Gaps 0;

Qy 2136 TCTTTCCTTTATCTTATTAATAAAATGTTGGTCTCCACCTGCTCCCAAAAAAAA 2195  
Db 207 TTTTNNNTTTTNNANNNANNNANNTNTTTTTTTGNGGNGTNTTTTNCNAAAAAAA 148

Qy 2196 AAAAAA AA 2242  
Db 147 AAAAAA AA 101

RESULT 1337

ACN87469/c  
ID ACN87469 standard; DNA; 361 BP.

XX  
AC ACN87469;

XX 02-DEC-2004 (first entry)

XX Breast cancer related marker, seq id 8619.

XX Cancer; breast; tumour; cytostatic; marker; detection; therapy; ds.

XX Homo sapiens.

XX US2003099974-A1.

XX 29-MAY-2003.

XX 18-JUL-2002; 2002US-00198846.

XX 18-JUL-2001; 2001US-0306220P.

XX (MILL-) MILLENNIUM PHARM INC.

XX Lillie J, Xu Y, Wang Y, Steinmann K;

XX WPI; 2003-787014/74.

XX Novel isolated polypeptide associated with breast cancer, useful for  
XX detecting presence of polypeptide in sample, as a marker for breast  
XX cancer.

XX Disclosure; SEQ ID NO 8619; 36pp; English.

XX The invention relates to an isolated polypeptide (I) associated with  
XX breast cancer which is encoded by a nucleic acid molecule comprising a  
XX nucleotide sequence (SI). Further disclosed is an antibody that binds to

CC the polypeptide of the invention. The activity of the polypeptide of the  
CC invention may be described as cycostatic. The antibody is useful for  
CC detecting the presence of (I) in a sample. Nucleic acid molecules of the  
CC invention are useful in the detection of breast tumours. (I) is useful as  
CC a marker for breast cancer and in breast cancer therapy. Sequences given  
CC in records ACN78851-ACN92394 represent nucleic acid markers associated  
CC with breast cancer. Note: The sequence listing does not form part of the  
CC specification but may be obtained in electronic format from the USPTO web  
CC site at [seqdata.uspto.gov/sequence.html?DocID=20030099974](http://seqdata.uspto.gov/sequence.html?DocID=20030099974)

[illegible]

RESULT	1338
ABV37528/c	
ID	ABV37528 standard; cDNA; 372 BP.
XX	
XX	
AC	ABV37528;
XX	
XX	
DT	16-SEP-2002 (first entry)
XX	
XX	
DE	Human prostate expression marker cDNA 37519.
XX	
XX	
KW	Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
KW	pharmacogenomic marker; gene; ss.
XX	
XX	
OS	Homo sapiens.
XX	
PN	WO200160860-A2.

XX	23-AUG-2001.	
PD		
XX		
XX	20-FEB-2001; 2001WO-US005171.	
PF		
XX		
XX	17-FEB-2000; 2000US-0183319P.	
PR		
PR	16-MAR-2000; 2000US-0189862P.	
PR	25-MAY-2000; 2000US-0207454P.	
PR	09-JUN-2000; 2000US-0211314P.	
PR	18-JUL-2000; 2000US-0219007P.	
PR	13-DEC-2000; 2000US-0255281P.	
XX		
XX	(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.	
PA		
XX		
XX	Schlegel R, Endege WO, Monahan JE;	
PI		
XX	WPI; 2001-662795/76.	
XX		
DR		

Novel isolated nucleic acid molecule associated with cancerous state of prostate cells and correlating with presence of prostate cancer, useful for detecting presence of prostate cancer, stage of prostate cancer.

Claim 1; Page 7697-7698; 11750pp; English.

CC (f) assessing the prostate cell carcinogenic potential of a compound; (g)  
 CC determining whether prostate cancer has metastasized in a patient; (h)  
 CC assessing the aggressiveness or indolence of prostate cancer in a patient  
 CC ; (i) is also useful as a pharmacodynamic or pharmacogenomic marker  
 XX  
 SQ Sequence 372 BP; 141 A; 37 C; 50 G; 144 T; 0 U; 0 Other;  
 XX

	Query Match	2.9%;	Score 65.6;	DB 5;	Length 372;
	Best Local Similarity	65.5%;	Pred. No. 0.0002;		
	Matches	95;	Conservative	0;	Mismatches 50;
					Indels 0;
					Gaps 0;
Qy	2098	ATAATCATTCACATCCCAATGATCGCCCTTGGTTTTTACCACTCTCTTCCCTTTTATCTTTATTAAT			2157
Db	246	ATTATTTTTTCTTTTAAATAATTTTTTTTTTTTTTTTTTAAATAACCCCTTTTTTTTTTAAATT			187
Qy	2158	AAAAATGTTGGTCTCCACCACCTGNCCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAA			2217
Db	186	TAAATAAATTTTTTTTTTGGTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA			127
Qy	2218	AAAAAAAAAAAAAAAAAAAAAAAAAAAAA			2242
Db	126	AAAAAAAAAAGAAAAAAAAAAAAAAAAA			102

RESULT 1339	
ADL44065/c	
ID ADL44065 standard; DNA; 394 BP.	
XX	
AC ADL44065;	
XX	
XX 20-MAY-2004 (first entry)	
DT	
XX	
XX Human ovarian cancer DNA marker #17955.	
DE	
XX Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.	
KW	
XX	
OS Homo sapiens.	
XX	
PN WO200170979-A2.	
XX	
XX 27-SEP-2001.	
PD	
XX	
PF 21-MAR-2001; 2001WO-US009126.	
XX	
XX 21-MAR-2000; 2000US-0191031P.	
PR 25-MAY-2000; 2000US-0207124P.	
PR 15-JUN-2000; 2000US-0211940P.	
PR 07-JUL-2000; 2000US-0216820P.	
PR 25-JUL-2000; 2000US-0220661P.	
PR 21-DEC-2000; 2000US-0257672P.	
XX	
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.	

PI Lee J, Lillie J;  
PI  
XX  
DR WFI; 2001-611502/70.  
XX  
PT Novel isolated nucleic acid molecules (markers) overexpressed in ovarian  
PT cancer cells as compared to their normal non-cancerous ovarian cells are  
PT used to characterize stage, grade, histological type of ovarian cancer.  
XX  
XX Disclosure; SEQ ID NO 17955; 106pp; English.  
XX  
XX The invention relates to nucleic acid markers which are overexpressed in  
CC ovarian cancer cells as compared to their expression in normal (i.e. non-  
CC cancerous) ovarian cells. The invention also relates to polypeptides  
CC encoded by the markers, antibodies that selectively bind to the  
CC polypeptides, a method of inhibiting ovarian cancer in a patient at risk  
CC of developing ovarian cancer involving inhibiting expression of a gene  
CC corresponding to a marker of the invention and a method of treating a  
CC patient afflicted with ovarian cancer comprising providing to cells of  
CC the patient an antisense oligonucleotide complementary to a marker of the  
CC invention. The markers are useful for assessing if a patient is afflicted

CC with ovarian cancer, which involves comparing the level of expression of  
 CC a marker in a patient sample and a normal level of expression of the  
 CC marker in a control non-ovarian cancer sample. A difference between the  
 CC expression levels indicates ovarian cancer. The level of expression of a  
 CC marker corresponds to a secreted protein or to a transcribed  
 CC polynucleotide or its portion. The level of expression of the marker is  
 CC assessed by detecting the presence in the sample, a protein or protein  
 CC fragment corresponding to the marker. The presence of protein or protein  
 CC fragment is detected using an antibody that specifically binds with the  
 CC protein or protein fragment. Alternatively, the level of expression of  
 CC the marker is assessed by detecting the presence of a transcribed  
 CC polynucleotide which anneals with the marker or anneals with a portion of  
 CC the polynucleotide comprising the marker, under stringent conditions. The  
 CC marker is also used for monitoring the progression of ovarian cancer in a  
 CC patient which involves detecting expression of the marker in a patient  
 CC sample at a first point in time, repeating the method at a subsequent  
 CC time and comparing the level of expression. The method is carried out  
 CC using an ovarian tissue sample. A composition comprising a marker,  
 CC polypeptide or antibody of the invention is used to treat ovarian cancer.  
 CC This sequence represents a human ovarian cancer DNA marker of the  
 CC invention. Note: The sequence data for this patent did not form part of  
 CC the printed specification, but was obtained in electronic format directly  
 CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences.

SQ Sequence 394 BP; 98 A; 62 C; 76 G; 158 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.6; DB 5; Length 394;

Best Local Similarity 83.1%; Pred. No. 0.00021;

Matches 74; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 2154 TAATATAAATGTTGCTCTCCACCTGCTCCCAAAAAAAAAAAAAAAAAAAAAA 2213

DB 218 TAAGAAAAATGTTTTATATAAGCAGGGGTCTCCCAAAAAAAAAAAAAAAAAAAAAA 159

QY 2214 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242

DB 158 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 130

RESULT 1340

ABV58465

ID ABV58465 standard; cDNA; 429 BP.

XX AC ABV58465;

XX DT 13-SEP-2002 (first entry)

XX DE Human prostate expression marker cDNA 58456.

XX KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;

XX KW pharmacogenomic marker; gene; ss.

XX OS Homo sapiens.

XX FN WO200160860-A2.

XX PD 23-AUG-2001.

XX PF 20-FEB-2001; 2001WO-US005171.

XX PR 17-FEB-2000; 2000US-0183319P.

XX PR 16-MAR-2000; 2000US-0189862P.

XX PR 25-MAY-2000; 2000US-0207454P.

XX PR 09-JUN-2000; 2000US-0211314P.

XX PR 18-JUL-2000; 2000US-0219007P.

XX PR 13-DEC-2000; 2000US-0255281P.

XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

XX PI Schlegel R, Endege WO, Monahan JE;

XX DR WPI; 2001-662795/76.

XX PT

PT Novel isolated nucleic acid molecule associated with cancerous state of  
 PT prostate cells and correlating with presence of prostate cancer, useful  
 XX for detecting presence of prostate cancer, stage of prostate cancer.

PS Claim 1; Page 11222; 11750pp; English.

XX CC The invention relates to an isolated nucleic acid molecule (I) comprising  
 CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the  
 CC specification or its complement. (I) is useful for: (a) assessing whether  
 CC a patient is afflicted with prostate cancer; (b) monitoring the  
 CC progression of prostate cancer in a patient; (c) assessing the efficacy  
 CC of a test compound to inhibit prostate cancer in a patient; (d) assessing  
 CC the efficacy of a therapy for inhibiting prostate cancer in a patient;  
 CC (e) selecting a composition for inhibiting prostate cancer in a patient;  
 CC (f) assessing the prostate cell carcinogenic potential of a compound; (g)  
 CC determining whether prostate cancer has metastasized in a patient; (h)  
 CC assessing the aggressiveness or indolence of prostate cancer in a patient  
 CC ; (i) is also useful as a pharmacodynamic or pharmacogenomic marker

SQ Sequence 429 BP; 155 A; 101 C; 79 G; 90 T; 0 U; 4 Other;

Query Match 2.9%; Score 65.6; DB 5; Length 429;

Best Local Similarity 69.0%; Pred. No. 0.00021;

Matches 89; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 2112 CAATGATCGCCTTTTGCTTTTACCACTCTTTCTCTTATTAATAAATGTTGCT 2171

DB 183 CATGATAATTTTGTCTTCTCCCTGTGTGATTTTGGCATCAAAATAAATTTGAGACT 242

QY 2172 CCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2231

DB 243 CGTTAAAAA 302

QY 2232 AAAAAAAAAA 2240

DB 303 AAAAAAAAAA 311

RESULT 1341

ABV54422

ID ABV54422 standard; cDNA; 442 BP.

XX AC ABV54422;

XX DT 17-SEP-2002 (first entry)

XX DE Human prostate expression marker cDNA 54413.

XX KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;

XX KW pharmacogenomic marker; gene; ss.

XX OS Homo sapiens.

XX FN WO200160860-A2.

XX PD 23-AUG-2001.

XX PF 20-FEB-2001; 2001WO-US005171.

XX PR 17-FEB-2000; 2000US-0183319P.

XX PR 16-MAR-2000; 2000US-0189862P.

XX PR 25-MAY-2000; 2000US-0207454P.

XX PR 09-JUN-2000; 2000US-0211314P.

XX PR 18-JUL-2000; 2000US-0219007P.

XX PR 13-DEC-2000; 2000US-0255281P.

XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

XX PI Schlegel R, Endege WO, Monahan JE;

XX DR WPI; 2001-662795/76.

XX PT

PT Novel isolated nucleic acid molecule associated with cancerous state of





OS	Homo sapiens.	AC	ADR59449;
XX		AD	
PN	WO200056751-A1.	DT	02-DEC-2004 (first entry)
XX		XX	
XX	28-SEP-2000.	DE	Cotton cDNA sequence, SEQ ID 230.
XX		XX	
XX	09-MAR-2000; 2000WO-US006013.	XX	
PF		KW	Cotton; ss; plant; cold tolerance; growth rate; cell cycle pathway;
XX		KW	drought tolerance; plant disease resistance; galactomannan; lignin;
XX		KW	plant growth regulator; heat tolerance; herbicide tolerance;
PR	19-MAR-1999; 99US-0125360P.	KW	homologous recombination; extreme osmotic condition tolerance;
PR	11-JUN-1999; 99US-0138626P.	KW	pathogen resistance; pest resistance; yield; photosynthesis; seed oil;
PR	03-DEC-1999; 99US-0168662P.	KW	stress resistance.
XX		XX	
PA	(HUMA-) HUMAN GENOME SCI INC.	OS	Gossypium hirsutum.
XX		OS	
XX		PI	Rosen CA, Ruben SM, Komatsoulis G;
XX		XX	
DR	WPI; 2000-579482/54.	PN	US2004181830-A1.
DR	P-PSDB; AAB34626.	PD	16-SEP-2004.
XX		XX	
XX	Isolated nucleic acid molecule encoding a human secreted protein is used	PF	29-JAN-2004; 2004US-00767795.
PT	in preventing, treating or ameliorating a medical condition.	XX	
XX		XX	
PS	Claim 1; Page 371; 419pp; English.	PR	07-MAY-2001; 2001US-00849529.
XX		PR	12-DEC-2001; 2001US-00021323.
XX		XX	
XX	The polynucleotide sequences given in AAC59738 to AAC59787 encode the	PA	(KOVA/) KOVALIC D K.
CC	human secreted proteins given in AAB34577 to AAB34626. AAB34627 to	PA	(ZHOU/) ZHOU Y.
CC	AAB34686 represent human secreted polypeptide sequences and proteins	PA	(CAOY/) CAO Y.
CC	homologous to them, which are given in the exemplification of the present	XX	
CC	invention. Human secreted proteins have activities based on the tissues	PI	Kovalic DK, Zhou Y, Cao Y;
CC	and cells the genes are expressed in. Example of activities include:	XX	
CC	antiarthritic; immunosuppressive; antirheumatic; antiproliferative;	XX	WPI; 2004-667718/65.
CC	cytostatic; cardiant; vasotropic; cerebroprotective; neurotropic;	DR	
CC	neuroprotective; antibacterial; virucide; fungicide; and	PT	New recombinant nucleic acid molecules and polypeptides from Gossypium
CC	ophthalmological. The polynucleotides and protein can be used to	PT	hirsutum, useful for producing plants with improved biological
CC	prevent, treat or ameliorate a medical condition in e.g. humans, mice,	PT	characteristics (e.g. improved plant cold or drought tolerance).
CC	rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used	XX	
CC	in diagnosing a pathological condition or susceptibility to a	PS	Claim 1; SEQ ID NO 230; 14pp; English.
CC	pathological condition. Disorders which are diagnosed or treated include	XX	
CC	autoimmune diseases, hyperproliferative disorders e.g. neoplasms and	XX	The invention relates to a recombinant polynucleotide comprising any of
CC	cancers of the breast or liver, cardiovascular disorders, cerebrovascular	CC	the 58798 Cotton plant cDNA sequences mentioned in the specification.
CC	disorders, angogenesis, nervous system disorders, infections caused by	CC	Also a recombinant polypeptide comprising any of the 58798 amino acid
CC	bacteria, viruses and fungi and ocular disorders. The proteins can also	CC	sequences mentioned in the specification and producing a plant having an
CC	be used to aid wound healing and epithelial cell proliferation, to	CC	improved property. Producing a plant having an improved property
CC	prevent skin aging due to sunburn, to maintain organs before	CC	comprises transforming a plant with a recombinant construct comprising a
CC	transplantation, for supporting cell culture of primary tissues, to	CC	promoter region functional in a plant cell operably joined to a
CC	regenerate tissues and in chemotaxis. The proteins can also be used as a	CC	polynucleotide comprising a coding sequence for a polypeptide associated
CC	food additive or preservative to increase or decrease storage	CC	with the property, and growing the transformed plant. The polypeptide is
CC	capabilities. AAC59729 to AAC59737 and AAB34576 represent sequences used	CC	useful for improving plant cold tolerance, manipulating growth rate in
CC	in the exemplification of the present invention	CC	plant cells by modification of the cell cycle pathway, improving plant
XX		CC	plant heat tolerance, providing increased resistance to plant disease,
SQ	Sequence 604 BP; 276 A; 100 C; 95 G; 133 T; 0 U; 0 Other;	CC	producing galactomannan (or lignin or plant growth regulators), improving
		CC	plant heat tolerance, improving plant tolerance to herbicides, increasing
		CC	the rate of homologous recombination in plants, improving plant yield
		CC	to extreme osmotic conditions or to pathogens or pests, improving yield
		CC	by modification of photosynthesis, modifying seed oil or protein yield
		CC	and/or content, improving yield by modification of carbohydrate, nitrogen
		CC	or phosphorus use and/or uptake, or improving yield by providing improved
		CC	plant growth and development under at least one stress condition. The
		CC	polynucleotide and polypeptide may also be used in recombinant DNA
		CC	constructs, in physical arrays of molecules, as plant breeding markers,
		CC	or in computer-based storage and analysis systems. The present sequence
		CC	is a Cotton plant cDNA of the invention. NOTE: The sequence data for this
		CC	patent did not form part of the printed specification, but was obtained
		CC	in electronic format directly from USPTO at
		CC	seqdata.uspto.gov/sequence.html?DocID=20040181830. However only 6585
		CC	polynucleotide sequences were available, the remaining 52213
		CC	polynucleotides and all 58798 protein sequences were not present.
		XX	
		SQ	Sequence 639 BP; 315 A; 67 C; 127 G; 130 T; 0 U; 0 Other;
			Query Match 2.9%; Score 65.6; DB 13; Length 639;
			Best Local Similarity 67.2%; Pred. No. 0.00024;
			Matches 92; Conservative 0; Mismatches 45; Indels 0; Gaps 0;
QY	2104 ATTCATCCATGATGCGCTTGGTTTACCACTCTCTTCCTTTATCTTTATTAATAAAT 2163		
Db	468 ATTAAATTAATGAGCAACTTTTTTTTAACTTTTACATTTTATTTCTATGGGAAAAA 527		
QY	2164 GTTGGTCTCCACCACTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAA 2223		
Db	528 TAAATATCTCTTCTTCAACCAAAAAAATAAAAAAATAAAAAAATAAAAAA 587		
QY	2224 AAAAAAATAAAAAA 2240		
Db	588 AAAAAAATAAAAAA 604		
			RESULT 1346
			ADR59449
			ID ADR59449 standard; cDNA; 639 BP.
			XX

cDNA clone DNA33085 codes for human Apo-2DCR (see AAW884408), a novel member of the tumour necrosis factor receptor family that binds to Apo-2 ligand. It was isolated by: transformation of yeast with a vector incorporating human breast carcinoma cDNA; isolation of yeast clones secreting amylase; PCR amplification (see AAW83439-50) of the insert directly from the yeast colony and purification of DNA for sequencing; use of an isolated sequence (DNA21705) as a probe to screen a human foetal lung library; and isolation of the full-length clone, which is deposited as ATCC 209087. An alternative translational initiation site encodes amino acid residues -40 to 259 of Apo-2DCR (see AAW88409). The

XX Novel isolated Apo-2DcR polypeptide useful for modulating apoptosis in  
PT mammalian cells.  
XX Example 1; Fig 1B; 59pp; English.  
XX  
CC The present invention relates to the isolation of novel human  
CC polypeptides, designated Apo-2DcR, and the polynucleotide sequences  
CC encoding them. Apo-2DcR is capable of binding Apo-2 ligand and is useful  
CC for modulating programmed cell death or apoptosis in mammalian cells. Apo  
CC -2DcR can be used to produce apo-2DcR antibodies which are useful  
CC therapeutically, and can cross-react with other receptors for Apo-2  
CC ligand to block excessive apoptosis in neurodegenerative diseases, or to  
CC block potentially autoimmune or inflammatory effects. Apo-2DcR antibodies  
CC are also useful in immunohistochemistry staining assays or diagnostic  
CC assays for Apo-2DcR, e.g. detecting its expression in specific cells,  
CC tissues or serum, and for the affinity purification of Apo-2DcR from  
CC recombinant cell culture or natural sources. The present sequence encodes  
CC native human Apo-2DcR #2  
XX  
SQ Sequence 1180 BP; 338 A; 326 C; 298 G; 218 T; 0 U; 0 Other;  
Query Match 2.9%; Score 65.6; DB 6; Length 1180;  
Best Local Similarity 71.1%; Pred. No. 0.00029;  
Matches 86; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2122 CTTTGCTTTACCACTCTTCCCTTTTATCTTATTATAAAATGTTGCTCCACCACTGN 2181  
DB 1055 CTCTGCCCTCCCTCTCTCTGTTTCCACAGACAGAACGCTGCCCTGCCCCCAA 1114  
QY 2182 CTCCTCAA 2241  
DB 1115 AA 1174  
QY 2242 A 2242  
DB 1175 A 1175  
RESULT 1349  
ABS53570  
ID ABS53570 standard; cDNA; 1180 BP.  
AC ABS53570;  
XX  
XX 21-NOV-2002 (first entry)  
XX cDNA encoding native human Apo-2DcR #1.  
XX  
XX Human; Apo-2DcR; Apo-2 ligand; programmed cell death; apoptosis;  
XX neurodegenerative disease; autoimmune; inflammatory; gene; ss.  
XX Homo sapiens.  
XX  
XX Key Location/Qualifiers  
XX CDS 193..972  
XX /\*tag= a  
XX /product= "Apo-2DcR #1"  
XX  
XX US2002102706-A1.  
XX  
XX 01-AUG-2002.  
XX  
XX 21-JUN-2001; 2001US-00887879.  
XX  
XX 18-JUN-1997; 97US-0049911P.  
XX 12-JUN-1998; 98US-00096500.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Ashkenazi AJ, Baker KP, Chuntharapai A, Gurney A, Kim KJ;  
XX Wood WI;  
XX

DR WPI; 2002-697823/75.  
XX P-PSDB; ABG31486.  
PT Novel isolated Apo-2DcR polypeptide useful for modulating apoptosis in  
XX mammalian cells.  
XX Claim 37; Fig 1A; 58pp; English.  
XX  
CC The present invention relates to the isolation of novel human  
CC polypeptides, designated Apo-2DcR, and the polynucleotide sequences  
CC encoding them. Apo-2DcR is capable of binding Apo-2 ligand and is useful  
CC for modulating programmed cell death or apoptosis in mammalian cells. Apo  
CC -2DcR can be used to produce apo-2DcR antibodies which are useful  
CC therapeutically, and can cross-react with other receptors for Apo-2  
CC ligand to block excessive apoptosis in neurodegenerative diseases, or to  
CC block potentially autoimmune or inflammatory effects. Apo-2DcR antibodies  
CC are also useful in immunohistochemistry staining assays or diagnostic  
CC assays for Apo-2DcR, e.g. detecting its expression in specific cells,  
CC tissues or serum, and for the affinity purification of Apo-2DcR from  
CC recombinant cell culture or natural sources. The present sequence encodes  
CC native human Apo-2DcR #1  
XX  
SQ Sequence 1180 BP; 338 A; 326 C; 298 G; 218 T; 0 U; 0 Other;  
Query Match 2.9%; Score 65.6; DB 6; Length 1180;  
Best Local Similarity 71.1%; Pred. No. 0.00029;  
Matches 86; Conservative 0; Mismatches 35; Indels 0; Gaps 0;  
QY 2122 CTTTGCTTTACCACTCTTCCCTTTTATCTTATTATAAAATGTTGCTCCACCACTGN 2181  
DB 1055 CTCTGCCCTCCCTCTCTGTTTCCACAGACAGAACGCTGCCCTGCCCCCAA 1114  
QY 2182 CTCCTCAA 2241  
DB 1115 AA 1174  
QY 2242 A 2242  
DB 1175 A 1175  
RESULT 1350  
AAD64037  
ID AAD64037 standard; cDNA; 1180 BP.  
AC AAD64037;  
XX  
XX 12-FEB-2004 (first entry)  
XX Human Apo-2DcR cDNA #1.  
XX  
XX Apo-2DcR; cancer; lupus; herpes virus infection; Parkinson's disease;  
XX amyotrophic lateral sclerosis; multiple sclerosis; reperfusion injury;  
XX aplastic anaemia; stroke; toxin-induced liver disease; gene therapy;  
XX acquired immune deficiency syndrome; AIDS; cerebellar degeneration;  
XX retinitis pigmentosa; Alzheimer's disease; myocardial infarction; human;  
XX gene; ss; apoptosis.  
XX Homo sapiens.  
XX  
XX Key Location/Qualifiers  
XX sig\_peptide 192..279  
XX /\*tag= b  
XX CDS 193..972  
XX /\*tag= a  
XX /product= "Human Apo-2DcR protein"  
XX mat\_peptide 280..969  
XX /\*tag= c  
XX /product= "Human mature Apo-2DcR protein"  
XX  
XX US2003138915-A1.  
XX  
XX 24-JUL-2003.  
XX PD

XX	11-SEP-2002; 2002US-00242383.
FF	
XX	18-JUN-1997; 97US-0049911P.
PR	12-JUN-1998; 98US-00096500.
PR	21-JUN-2001; 2001US-00887879.
XX	(GETH ) GENENTECH INC.
PA	
XX	Ashkenazi AJ, Baker KP, Chuntharapai A, Gurney A, Kim KJ;
PI	Wood WI;
PI	
XX	
DR	WPI; 2003-851734/79.
DR	P-PSDB; ABW02352.
XX	
XX	New Apo-2DcR polypeptide, useful for modulating apoptosis in mammalian
PT	cells for treating cancer, lupus, herpes virus infection, AIDS.
PT	Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis,
PT	multiple sclerosis.
XX	
XX	Claim 37; SEQ ID NO 2; 56pp; English.
XX	
CC	The invention relates to Apo-2DcR polypeptides which are capable of
CC	binding Apo-2 ligand. The Apo-2DcR polypeptides, antibodies and nucleic
CC	acids are useful for modulating apoptosis in mammalian cells for treating
CC	cancer, lupus, herpes virus infection, Parkinson's disease, acquired
CC	immune deficiency syndrome (AIDS), myocardial infarction, amyotrophic
CC	lateral sclerosis, multiple sclerosis, reperfusion injury, retinitis
CC	pigmentosa, cerebellar degeneration, Alzheimer's disease, aplastic
CC	anaemia, stroke or toxin-induced liver disease. The invention is also
CC	useful in gene therapy. The present sequence is human Apo-2DcR cDNA
XX	
SQ	Sequence 1180 BP; 338 A; 326 C; 298 G; 218 T; 0 U; 0 Other;
	Query Match 2.9%; Score 65.6; DB 10; Length 1180;
	Best Local Similarity 71.1%; Pred. No. 0.00029;
	Matches 86; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
Qy	2122 CTTTGCTTTTACCACCTCTTCCCTTTTATCTATTATTAATAAATGTGTCTCCACCACTGN 2181
Db	1055 CTCCTGCTGCTCCCTCTGCTGTTCCACACACGAAACGCTGCCCTGCCCCAAA 1114
Qy	2182 CTCCTCAA 2241
Db	1115 AA 1174
Qy	2242 A 2242
Db	1175 A 1175
	RESULT 1351
	AAD64038
ID	AAD64038 standard; cDNA; 1180 BP.
XX	
AC	AAD64038;
XX	
DT	12-FEB-2004 (first entry)
XX	
DE	Human Apo-2DcR cDNA #2.
XX	
KW	Apo-2DcR; cancer; lupus; herpes virus infection; Parkinson's disease;
KW	amyotrophic lateral sclerosis; multiple sclerosis; reperfusion injury;
KW	aplastic anaemia; stroke; toxin-induced liver disease; gene therapy;
KW	acquired immune deficiency syndrome; AIDS; cerebellar degeneration;
KW	retinitis pigmentosa; Alzheimer's disease; myocardial infarction; human;
KW	gene; ss; apoptosis.
XX	
OS	Homo sapiens.
XX	
PH	Key Location/Qualifiers
FT	CDS 73..972
FT	/*tag= a



CC and foetal deficiencies, blood disorders, diseases of the immune system,  
 CC autoimmune diseases, hepatic and renal disease, inflammation, allergies,  
 CC Alzheimer's and behavioural disorders, schizophrenia, osteoporosis,  
 CC arthritis, infections, AIDS, spinal cord injuries, transplant rejection,  
 CC diabetes, asthma, sepsis, acne, psoriasis, cardiovascular disorders,  
 CC reproductive disorders, gastrointestinal disorders, respiratory disorders  
 CC and metabolic disorders. The proteins or polynucleotides can also be used  
 CC as food additives or preservatives. The proteins are also useful for  
 CC identifying their binding partners. AAA26337 to AAA26345 and AAY91450 are  
 CC sequences used in the exemplification of the present invention

SQ Sequence 1342 BP; 405 A; 268 C; 300 G; 369 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.6; DB 3; Length 1342;

Best Local Similarity 76.2%; Pred. No. 0.0003;

Matches 80; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

Oy 2138 TTTCCTTTTATCTTATTAATAAATGTTGCTCCACACTGCTCCCAAAAAA 2197

Db 1224 TTTTCTTTTATCTGTTAAATAAATTTTCCAAAAA 1283

Oy 2198 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242

Db 1284 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1328

RESULT 1354

IDL71485

ID ADL71485 standard; cDNA; 1342 BP.

XX AC ADL71485;

DT 20-MAY-2004 (first entry)

DE Novel human secreted protein cDNA seqid 89.

KW antiinflammatory; neuroprotective; nootropic; antiparkinsonian;  
 KW anticonvulsant; antilipaeamic; CNS; gynaecological; antiarthritic;  
 KW antiasthmatic; anti-HIV; virucide; endocrine; cytostatic;  
 KW immunosuppressive; antiallergic; cardiovascular; respiratory;  
 KW dermatological; antimicrobial; gastrointestinal; gene therapy;  
 KW neurodegenerative disease; behavioral disorder; inflammatory condition;  
 KW hyperproliferative disorder; Alzheimer's disease; Parkinson's disease;  
 KW Huntington's disease; metabolic disorder; Tay-Sach's disease;  
 KW Leash-Nyhan syndrome; reproductive disorder; immunological disorder;  
 KW arthritis; asthma; AIDS; endocrine disorder; immune disorder;  
 KW Hodgkin's lymphoma; haematopoietic disorder; muscular disorder;  
 KW leukaemia; autoimmune disorder; allergy; cancer; cardiovascular disorder;  
 KW respiratory disorder; pulmonary disorder; connective tissue disorder;  
 KW skin disorder; CNS disorder; congenital disorder; infectious disorder;  
 KW gastrointestinal disorder; human; secreted protein; gene; ss.

OS Homo sapiens.

XX US2004034196-A1.

XX 19-FEB-2004.

XX 27-JAN-2003; 2003US-00351334.

XX 30-JUL-1998; 98US-0094657P.

XX 05-AUG-1998; 98US-0095486P.

XX 06-AUG-1998; 98US-0095454P.

XX 06-AUG-1998; 98US-0095455P.

XX 12-AUG-1998; 98US-0096319P.

XX 29-JUL-1999; 99WO-US017130.

XX 24-JAN-2000; 2000US-00489847.

XX 25-JAN-2002; 2002US-0350898P.

XX (KOMA/) KOMATSOUIS G A.

XX (ROSE/) ROSEN C A.

XX (RUBE/) RUBEN S M.

XX (DUAN/) DUAN D R.

PA (MOOR/) MOORE P A.

PA (SHIY/) SHI Y.

PA (LAPL/) LAFLEUR D W.

PA (WEIY/) WEI Y.

PI Komatsoulis CA, Rosen CA, Ruben SM, Duan DR, Moore PA, Shi Y;

PI Lafleur DW, Wei Y;

DR WPI; 2004-180094/17.

DR P-PSDB; ADL71601.

XX New human secreted nucleic acid, useful for diagnosing and treating  
 PT neurodegenerative, inflammatory, hyperproliferative, metabolic,  
 PT reproductive, cardiovascular, respiratory or immunological disorders or  
 PT diseases.

PS Claim 1; SEQ ID NO 89; 234pp; English.

XX The invention describes an isolated human nucleic acid molecule (I)  
 CC comprising a polynucleotide having a nucleotide sequence at least 95%  
 CC identical to: a sequence polynucleotide fragment of SEQ ID NO: X or of  
 CC the cDNA sequence included in ATCC deposit No: Z, which is hybridisable  
 CC to SEQ ID NO: X; or a sequence encoding a polypeptide fragment, domain or  
 CC epitope of SEQ ID NO: Y or a polypeptide sequence encoded by the cDNA  
 CC sequence included in ATCC deposit No: Z, which is hybridisable to SEQ ID  
 CC NO: X, having a biological activity. The nucleic acids and polypeptides,  
 CC pharmaceutical formulations and kits are useful in diagnosing and  
 CC treating neurodegenerative diseases states, behavioral disorders,  
 CC inflammatory conditions, hyperproliferative disorders (e.g. Alzheimer's  
 CC disease, Parkinson's disease or Huntington's disease), metabolic  
 CC disorders (e.g. Tay-Sach's disease or Leash-Nyhan syndrome), reproductive  
 CC disorders, immunological disorders (e.g. arthritis, asthma or AIDS),  
 CC endocrine and immune disorders (e.g. Hodgkin's lymphoma), haematopoietic  
 CC or muscular disorders (e.g. leukaemia), autoimmune disorders, allergy,  
 CC cancer, cardiovascular, respiratory or pulmonary disorders, disorders or  
 CC conditions afflicting connective tissue, skin disorders, CNS disorders,  
 CC congenital disorders, infectious disorders and gastrointestinal  
 CC disorders. This sequence encodes a novel human secreted protein of the  
 CC invention. Note: This sequence does not appear in the printed  
 CC specification but is available in electronic format from the US patent  
 CC office at ftp.seqdata.uspto.gov/seqdata.html?docID=20040034196.

SQ Sequence 1342 BP; 405 A; 268 C; 300 G; 369 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.6; DB 12; Length 1342;

Best Local Similarity 76.2%; Pred. No. 0.0003;

Matches 80; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

Oy 2138 TTTCCTTTTATCTTATTAATAAATGTTGCTCCACACTGCTCCCAAAAAA 2197

Db 1224 TTTTCTTTTATCTGTTAAATAAATTTTCCAAAAA 1283

Oy 2198 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242

Db 1284 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1328

RESULT 1355

AAC78016

ID AAC78016 standard; cDNA; 1401 BP.

XX AC AAC78016;

XX DT 08-FEB-2001 (first entry)

XX Human cancer associated gene sequence SEQ ID NO:410.

KW Human; cancer associated gene; cancer antigen; detection; cancer;  
 KW diagnosis; cytostatic; proliferative; vulnery; immunomodulator;  
 KW antidiabetic; antiasthmatic; antirheumatic; antiarthritic; antiviral;  
 KW antiinflammatory; antihypertoid; antiallergic; antibacterial; cardiac;  
 KW dermatological; neuroprotective; thrombolytic; coagulant; nootropic;  
 KW vasotropic; antipsoriatic; antiangiogenic; gene therapy; inflammation;

KW immune disorder; haematopoietic cell disorder; autoimmune disorder;  
 KW allergic reaction; graft versus host disease; organ rejection;  
 KW haemostatic; thrombolytic; cardiovascular disorder; infection;  
 KW neurological disease; drug screening; ss.  
 XX  
 XX Homo sapiens.  
 OS  
 XX W0200055350-A1.  
 PN  
 XX 21-SEP-2000.  
 PD  
 XX  
 XX 08-MAR-2000; 2000WO-US005882.  
 PF  
 XX 12-MAR-1999; 99US-0124270P.  
 PR  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 PA  
 XX Rosen CA, Ruben SM;  
 XX  
 XX WPI; 2000-587533/55.  
 DR  
 XX P-PSDB; AAB43807.  
 DR  
 XX  
 XX Novel isolated nucleic acids comprising sequences encoding peptides  
 PT useful for treating or diagnosing e.g. cancer.  
 PT  
 XX  
 XX Claim 1; Page 952; 2352pp; English.  
 PS  
 XX AAC77607 to AAC78448 encode the human cancer associated proteins given in  
 CC AAB43398 to AAB44239. The proteins can have activities based on the  
 CC tissues and cells the genes are expressed in. Example of activities  
 CC include: cytostatic; proliferative; vulnery; immunomodulator;  
 CC antidiabetic; antiasthmatic; antirheumatic; antiarthritic;  
 CC antiinflammatory; antithyroid; antiallergic; antibacterial; antiviral;  
 CC dermatological; neuroprotective; cardiac; thrombolytic; coagulant;  
 CC neotrophic; vasotropic; antipsoriatic and antiangiogenic. The  
 CC ameliorating medical conditions and diagnosing pathological conditions.  
 CC Polynucleotides, polypeptides, antibodies, agonists and antagonists from  
 CC the present invention may be used to treat immune disorders by activating  
 CC or inhibiting the proliferation, differentiation or mobilisation of  
 CC immune cells, to treat disorders of haematopoietic cells, autoimmune  
 CC disorders, allergic reactions, graft versus host disease and organ  
 CC rejection, modulate haemostatic or thrombolytic activity, modulate  
 CC inflammation, cancers, cardiovascular disorders, neurological disease and  
 CC bacterial or viral infections. The peptides, nucleotides, antibodies,  
 CC agonists and antagonists may be also used in drug screens. AAC78449 to  
 CC AAC78457 and AAB44240 represent sequences used in the exemplification of  
 CC the present invention  
 XX  
 SQ Sequence 1401 BP; 463 A; 243 C; 253 G; 440 T; 0 U; 2 Other;  
 XX  
 Query Match 2.9%; Score 65.6; DB 3; Length 1401;  
 Best Local Similarity 66.2%; Pred. No. 0.00031;  
 Matches 92; Conservative 1; Mismatches 46; Indels 0; Gaps 0;  
 QY 2104 ATTCCATCCATGATGCCCTTTCCTTTACCACTCTTCCCTTTATCTTATTAATAAT 2163  
 DB 1245 ACTGTATTATTTGCTGCTTCTCAGCATAACTTATCCCATGTATTTTATAATAA 1304  
 QY 2164 GTTGGTCTCCACCACTGCTCCCAAAAAAATAAAAAAAAAAAAAAAAAAAAAA 2223  
 DB 1305 ATATTTTGTGACTTTMAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1364  
 QY 2224 AAAAAAAAAAAAAAAAAAAAAA 2242  
 DB 1365 AAAAAAAAAAAAAAAAAAAAAA 1383  
 RESULT 1356  
 ACA98920  
 ID ACA98920 standard; cDNA; 2652 BP.  
 XX  
 AC ACA98920;

XX  
 DT 25-JUL-2003 (first entry)  
 XX  
 DE cDNA encoding human nucleic acid-associated protein (NAAP) #1.  
 XX  
 KW Human; nucleic acid-associated protein; cytostatic; antiarteriosclerotic;  
 KW anticonvulsant; neotropic; neuroprotective; cerebroprotective; anti-HIV;  
 KW antiallergic; antiinflammatory; thyromimetic; gene therapy;  
 KW cell proliferative disorder; cancer; atherosclerosis;  
 KW neurological disorder; epilepsy; Huntington's disease; stroke;  
 KW immune disorder; inflammatory disorder; AIDS; allergy;  
 KW developmental disorder; Hypothyroidism; Cushing's syndrome; infection;  
 KW protein-protein interaction; drug-target interaction;  
 KW gene expression profile; gene; ss.  
 XX  
 OS Homo sapiens.  
 PN  
 XX W02003023003-A2.  
 PN  
 XX 20-MAR-2003.  
 PD  
 XX  
 XX 05-SEP-2002; 2002WO-US028540.  
 PF  
 XX 07-SEP-2001; 2001US-0317792P.  
 PR  
 XX 07-SEP-2001; 2001US-0317912P.  
 PR  
 XX 14-SEP-2001; 2001US-0322270P.  
 PR  
 XX 21-SEP-2001; 2001US-0324040P.  
 PR  
 XX 28-SEP-2001; 2001US-0326732P.  
 PR  
 XX 19-OCT-2001; 2001US-0346716P.  
 PR  
 XX 25-JAN-2002; 2002US-0351749P.  
 PR  
 XX 22-FEB-2002; 2002US-0359498P.  
 PA (INCY-) INCYTE GENOMICS INC.  
 XX  
 XX Tang YT, Jackson JL, Griffin JA, Elliott VS, Forsythe IJ;  
 PI Becha SD, Richardson TW, Lee EA, Sprague WW, Emerling BM;  
 PI Thangavelu K, Warren BA, Tran UK, Yue H, Xu Y, Yue H, Li JX;  
 PI Hafalia AJA, Sanjanwala B, Marquis JP, Gorvad AE, Lee SY, Ison CH;  
 PI Baughn WR, Chawla NK, Nguyen DB, Swarnakar A, Zebarjadian Y, Shah P;  
 PI Thornton M, Yao MG, Khan FA, Gandhi AR, Yang J, Kable AE;  
 PI Burford N, Rankumar J;  
 XX WPI; 2003-313243/30.  
 DR P-PSDB; ABU96672.  
 DR  
 XX New human nucleic acid associated proteins (NAAP), useful for diagnosing,  
 PT treating and preventing diseases or conditions associated with the  
 PT aberrant NAAP expression e.g. cancer, AIDS, atherosclerosis, epilepsy, or  
 PT infections.  
 PT  
 XX Claim 5; Page 300-301; 345pp; English.  
 PS  
 XX The invention describes a novel human isolated nucleic acid-associated  
 CC polypeptide (NAAP). The polypeptides and polynucleotides are useful in  
 CC diagnosing, treating and preventing diseases or conditions associated  
 CC with the decreased expression or overexpression of NAAP, such as cell  
 CC proliferative (e.g. cancer, atherosclerosis), neurological (e.g. AIDS,  
 CC epilepsy, Huntington's disease, stroke), immune/inflammatory (e.g. AIDS,  
 CC allergies) and developmental (e.g. Hypothyroidism, Cushing's syndrome)  
 CC disorders, or infections. These are also useful in assessing the effects  
 CC of exogenous compounds on the expression of nucleic acid and amino acid  
 CC sequences of NAAP. The NAAP or its fragments are useful in screening  
 CC compounds for effectiveness as agonist or antagonist of the polypeptides,  
 CC or in altering the expression of the target polynucleotide and compounds  
 CC that specifically bind to or modulate the activity of the polypeptide.  
 CC The microarray is useful in monitoring or measuring protein-protein  
 CC interactions, drug-target interactions, and gene expression profiles.  
 CC This sequence encodes a novel human nucleic acid-associated protein  
 CC (NAAP)  
 CC  
 XX Sequence 2652 BP; 689 A; 698 C; 784 G; 481 T; 0 U; 0 Other;  
 SQ  
 Query Match 2.9%; Score 65.6; DB 9; Length 2652;

Best Local Similarity 76.2%; Pred. No. 0.00037;  
Matches 80; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 2138 TTTCCTTTTATCTTATTAATAAATGTTGGTCTCCACCTGCTCCCAAAAAA 2197  
DB 2231 TTACCTTTGTCATTTGTTATTAATAATATATGTTGTTATTAATAA 2290  
QY 2198 AAAAAA 2242  
DB 2291 AAAAAA 2335

RESULT 1357  
ID ADQ23993 standard; DNA; 5059 BP.  
AC ADQ23993;  
XX 26-AUG-2004 (first entry)  
DT Human soft tissue sarcoma-upregulated DNA - SEQ ID 6813.  
DE soft tissue sarcoma; cytostatic; gene therapy; vaccine; screening; human;  
KW ds.  
XX Homo sapiens.  
OS WO2004048938-A2.  
PN 10-JUN-2004.  
PD 26-NOV-2003; 2003WO-US038193.  
PF 26-NOV-2002; 2002ZUS-0429739P.  
PR (PROT-) PROTEIN DESIGN LABS INC.  
XX Aziz N, Ginsburg WM, Zlotnik A;  
PI WPI; 2004-441208/41.  
DR Early detection of soft tissue sarcoma comprises determining expression  
PT of a gene in a first soft tissue sample and a normal soft tissue sample  
PT and comparing the gene expression, also useful in treating soft tissue  
PT sarcoma.  
XX Example 2; SEQ ID NO 6813; 210pp; English.

CC The invention relates to a novel method for detecting soft tissue sarcoma  
CC which comprises obtaining a first soft tissue sample from an individual  
CC and a normal soft tissue sample from the same or different individual,  
CC determining the expression of a gene in both samples and comparing the  
CC expression of the gene in both soft tissue samples, where a higher level  
CC of protein expression in the first soft tissue sample indicates the  
CC presence of soft tissue sarcoma. The method of the invention has  
CC cytostatic applications and may be useful for detecting soft tissue  
CC sarcoma, possibly via gene therapy or vaccine production. The nucleic  
CC acid sequences may be useful in diagnostic and screening applications.  
CC The current sequence is that of a human soft tissue sarcoma-upregulated  
CC DNA of the invention. The current sequence is not shown within the  
CC specification per se but was submitted in CD format by the inventor.

XX SQ Sequence 5059 BP; 1220 A; 1430 C; 1419 G; 932 T; 0 U; 58 Other;

Query Match 2.9%; Score 65.6; DB 12; Length 5059;  
Best Local Similarity 79.4%; Pred. No. 0.00046;  
Matches 77; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 2146 TATCTTATTAATAAATGTTGGTCTCCACCTGCTCCCAAAAAA 2205  
DB 4934 TTTCAATTGTAATAAATAATGTAATGTTGACCACTTCAAAAAA 4993  
QY 2206 AAAAAA 2242

DB 4994 AAAAAA 5030

RESULT 1358  
ID ABL32347 standard; DNA; 5216 BP.  
XX ABL32347;  
XX 26-MAR-2002 (first entry)  
DT Human immune system associated gene SEQ ID NO: 320.  
DE Human; immune system disease; cytosine methylation; antiasthmatic;  
KW antiarteriosclerotic; antianaemic; cytostatic; neutropenic;  
KW neuroprotective; anti-HIV; anticonvulsant; ophthalmological;  
KW antirheumatic; antiarthritic; antidiabetic; antipsoriatic;  
KW antinflammatory; cancer; eye disease; arteriosclerosis; anaemia;  
KW acute myeloid leukaemia; Alzheimer's disease; AIDS; epilepsy;  
KW neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease; gene;  
KW ds.  
XX Homo sapiens.  
OS WO200200928-A2.  
PN 03-JAN-2002.  
PD 02-JUL-2001; 2001WO-EP007537.  
PF 30-JUN-2000; 2000DE-01032529.  
PR 01-SEP-2000; 2000DE-01043826.  
XX (EPIG-) EPIGENOMICS AG.  
FA Olek A, Piepenbrock C, Berlin K;  
PI WPI; 2002-130909/17.  
DR Nucleic acid comprising fragment of chemically modified gene, useful for  
PT diagnosis and treatment of diseases associated with abnormal cytosine  
PT methylation.  
XX Claim 1; SEQ ID NO 320; 32pp + Sequence Listing; German.

CC The present invention provides a number of human immune system associated  
CC genes which are modified by the methylation of cytosines. The sequences  
CC can be used in the diagnosis and treatment of immune system disorders,  
CC including eye diseases such as retinopathy, neovascular glaucoma and  
CC macular degeneration, arteriosclerosis, anaemia, cancer, acute myeloid  
CC leukaemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,  
CC rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel  
CC diseases. The present sequence is a gene of the invention

XX SQ Sequence 5216 BP; 1332 A; 73 C; 1196 G; 2615 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.6; DB 6; Length 5216;  
Best Local Similarity 64.1%; Pred. No. 0.00046;  
Matches 98; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 2090 CGTGACACATATTCATTCATCCATGATCGCTTTCCTTTTACCACCTTTCTTATC 2149  
DB 5106 CTTTACTAATAATCTTTTATTCGAATATTCATTTCCCTTTTAAACGTTATTC 5047

QY 2150 TTATTAATAAATGTTGGTCTCCACCTGCTCCCAAAAAA 2209  
DB 5046 TAAAAA 4987  
QY 2210 AAAAAA 2242  
DB 4986 AAAAAA 4954

```
RESULT 1359
ABL34459/c
ID ABL34459 standard; DNA; 5216 BP.
AC ABL34459;
XX
DT 26-MAR-2002 (first entry)
XX
DE Human metastasis associated gene SEQ ID NO: 12.
XX
KW Metastasis associated gene; cytostatic; gene therapy; cancer;
KW cytosine methylation; gene; ds.
XX
OS Homo sapiens.
XX
PN WO200177376-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-EP003970.
XX
PR 06-APR-2000; 2000DE-01019058.
PR 07-APR-2000; 2000DE-01019173.
PR 30-JUN-2000; 2000DE-01032529.
PR 01-SEP-2000; 2000DE-01043826.
XX
XX (EPIC-) EPITENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2002-010922/01.
XX
PT New nucleic acid derived from chemically treated metastasis genes, useful
PT for diagnosis of cancers by analysis of cytosine methylation, also for
PT treatment.
XX
PS Claim 1; SEQ ID NO 12; 23pp + Sequence Listing; English.
XX
CC The present invention provides a number of human metastasis associated
CC genes which are modified by cytosine methylation. The sequences can be
CC used in the diagnosis and treatment of cancer. The present sequence is
CC one of the genes of the invention
XX
SQ Sequence 5216 BP; 1332 A; 73 C; 1196 G; 2615 T; 0 U; 0 Other;

Query Match      2.9%; Score 65.6; DB 6; Length 5216;
Best Local Similarity 64.1%; Pred. No. 0.00046;
Matches 98; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 2090 CGTGACACATAATCCATCCATCAATGATCGCTTTGCTTTACCACTCTTTCTTTATC 2149
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
5106 CTTTACTAATAATCCCTTTATTCGAATATTCAATTTCCCTTAAATTTTAAACGTTATTC 5047

QY 2150 TTATTATAAATAATGTTGGTCTCCACCACTGNCCTCCAAAAAATAAAAAAAAAA 2209
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
5046 TAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 4987

QY 2210 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2242
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
4986 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 4954

RESULT 1360
ADS99720/c
ID ADS99720 standard; DNA; 5216 BP.
XX
AC ADS99720;
XX
DT 02-DEC-2004 (first entry)
XX
DE Complement of bisulphite treated metastasis-associated human gene #6.
XX
```

```
KW Human; ds; gene; Bisulphite; metastasis; cancer; cytostatic;
KW DNA methylation; matrix-assisted laser desorption/ionisation; MALDI;
KW electrospray; mass spectrometry; CpG dinucleotide; solid tumour.
XX
OS Homo sapiens.
XX
PN US2003148327-A1.
XX
PD 07-AUG-2003.
XX
PF 21-JAN-2003; 2003US-00240485.
XX
PR 06-APR-2000; 2000DE-01019058.
PR 07-APR-2000; 2000DE-01019173.
PR 30-JUN-2000; 2000DE-01032529.
PR 01-SEP-2000; 2000DE-01043826.
PR 06-APR-2001; 2001WO-EP003970.
XX
XX (OLEK/) OLEK A.
XX (PIEP/) PIEPENBROCK C.
XX (BERL/) BERLIN K.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2002-010922/01.
XX
PT New nucleic acid derived from chemically treated metastasis genes, useful
PT for diagnosis of cancers by analysis of cytosine methylation, also for
PT treatment.
XX
PS Claim 1; SEQ ID NO 12; 9pp; English.
XX
CC The invention relates to a nucleic acid comprising at least 18 bases from
CC a segment of the chemically pretreated DNA of genes associated with
CC metastasis, i.e. any of ADS99709-ADS99906 human genomic sequences or any
CC of the 19 sequences appearing as ADS99911-ADS99929. SEQ ID 2,4,6 etc are
CC the complements of SEQ ID 1,3,5, etc. Also included are an oligomer
CC (particularly an oligonucleotide or peptide nucleic acid) comprising at
CC least one base sequence of at least 9 bases which hybridises to (or is
CC identical with) the sequences referred to above, producing an array of
CC the oligomers on a carrier, obtaining genetic and/or epigenetic
CC parameters for diagnosis and/or therapy of diseases (or predisposition to
CC them) by analysis of cytosine methylation and a kit comprising a
CC bisulphite (disulphite or hydrogen sulphite) and the oligomers. In the
CC method of above 5-unmethylated cytosines in a genomic DNA sample are
CC converted chemically to uracil, or another base with hybridisation
CC properties different from those of cytosine, then fragments of the
CC treated DNA amplified (particularly by polymerase chain reaction) using
CC the oligomers and a polymerase (preferably heat stable) to produce of
CC labelled amplicons. These are tested for hybridisation to an array of
CC oligomers and any hybridisation detected. The amplicons are labelled with
CC fluorescent or radioactive markers, or with a detachable mass marker to
CC allow their detection by mass spectrometry, specifically using the matrix
CC -assisted laser desorption/ionisation (MALDI) or electrospray techniques.
CC To improve detection in the mass spectrometer, fragments formed in the
CC instrument have only a single net charge (positive or negative). The
CC genomic DNA is from e.g. a cell line, biopsy sample, blood, or paraffin-
CC embedded tissue sample. Oligonucleotides or peptide-nucleic acids that
CC are complementary to (or identical with) parts of the nucleic acids listed
CC above may be used as primers for amplification of the nucleic acids or
CC their complements, and for determining cytosine methylation status and/or
CC single nucleotide polymorphisms in metastasis-related genes. They can be
CC used for analysis of diseases associated with methylation of CpG
CC dinucleotides and to determine (epi)genetic parameters for diagnosis
CC and/or therapy of disease (or predisposition). The genomic DNA sequences
CC are useful for diagnosis and therapy of solid tumours and cancer. The
CC present sequence is the complementary sequence to a bisulphite treated
CC human gene associated with metastasis. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained
CC in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20030148327.
XX
XX Sequence 5216 BP; 1332 A; 73 C; 1196 G; 2615 T; 0 U; 0 Other;
```

Db 165 TTGCTTTTCTGTGTAGTAAAAATAATTTTTTATTATTTTGNVAAAANAAAAA 106

Qy 2198 AAA 2242  
|||||  
Db 105 AAA 61

RESULT 1362  
ABX35671/c  
ID ABX35671 standard; cDNA; 373 BP.  
XX AC ABX35671;  
XX DT DT  
XX DE 20-FEB-2003 (first entry)  
XX Bos Bovine EST associated with lactation/muscle/fat deposition #836.  
KW Bovine; ss; EST; expressed sequence tag; lactation; LMFD;  
KW muscle deposition; fat deposition; genome mapping; gene identification;  
XX KW gene analysis; cattle breeding.  
XX OS Bos Taurus.  
XX PN US2002137139-A1.  
XX PD 26-SEP-2002.  
XX PP 24-SEP-2001; 2001US-00960352.  
XX PR 12-JAN-1999; 99US-0115707P.  
XX PR 11-JAN-2000; 2000US-00480902.  
XX  
XX (BYAT/) BYATT J C.  
PA (MATH/) MATHIALAGAN N.  
PA (TAON/) TAO N.  
PA (WARR/) WARREN W C.  
XX  
XX Byatt JC, Mathialagan N, Tao N, Warren WC;  
PI WPI; 2003-110595/10.  
DR XX  
XX New nucleic acid associated with lactation, and muscle and fat  
PT deposition, useful for genome mapping, gene identification and analysis,  
PT cattle breeding, or for genetically improving cattle.  
XX  
PS Claim 2; SEQ ID NO 836; 245pp; English.  
XX  
CC The invention relates to a purified nucleic acid molecule associated with  
CC lactation or muscle and fat deposition (designated LMFD), derived from  
CC cattle, and the LMFD nucleic acid can specifically hybridise to a second  
CC nucleic acid molecule comprising any of 15112 nucleotide sequences,  
CC appearing as ABX34836-ABX49947, or complements of them. Also included are  
CC ; (1) a transformed cell having a nucleic acid comprising an LMFD nucleic  
CC acid linked to a promoter and a 3' non-translated sequence that  
CC functions in the cell to cause termination of transcription and addition  
CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and  
CC (2) determining a level or pattern of a molecule in a bovine cell or  
CC tissue comprising: (a) incubating a marker nucleic acid comprising any  
CC of the 15112 nucleic acid sequences or its complement or fragment) with a  
CC complementary nucleic acid molecule obtained from the bovine cell or  
CC tissue, where hybridisation between the marker nucleic acid and the  
CC complementary nucleic acid permits the detection of the molecule; and (b)  
CC detecting the level or pattern of the complementary nucleic acid, where  
CC the detection of the complementary nucleic acid is predictive of the  
CC level or pattern of the molecule. The LMFD nucleic acid is used for  
CC determining a level or pattern of a molecule in a bovine cell or tissue.  
CC It is useful for genome mapping, gene identification and analysis, cattle  
CC breeding, preparation of constructs for use in cattle gene expression, or  
CC for genetically improving cattle. The present sequence is one of the  
CC 15112 bovine LMFD EST (expressed sequence tag) nucleic acids. Note: The  
CC present sequence was not shown in the specification but was obtained in  
CC electronic format from the USPTO web site:  
CC seqdata.uspto.gov/sequence.html?DocID=20020137139



XX Claim 1; SEQ ID NO 3757; 1399pp + Sequence Listing; English.  
XX The invention relates to human polynucleotides (AA179941-AA193841) and  
CC the encoded proteins (AAO00010-AAO13910) that exhibit activity relating to  
CC cytokine, cell proliferation or cell differentiation or which may induce  
CC production of other cytokines in other cell populations. The  
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
CC peptide therapy. The polypeptides have various cytokine-like activities,  
CC e.g. stem cell growth factor activity, haematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activin/inhibin activity and may be useful in the diagnosis and/or  
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
CC inflammation. Note: The sequence data for this patent did not form part  
CC of the printed specification, but was obtained in electronic format  
CC directly from WIPO at [ftp.wipo.int/pub/published\\_pct\\_sequences](http://ftp.wipo.int/pub/published_pct_sequences)  
XX  
SQ Sequence 408 BP; 176 A; 62 C; 82 G; 88 T; 0 U; 0 Other;  
  
Query Match 2.9%; Score 65.4; DB 4; Length 408;  
Best Local Similarity 78.0%; Pred. No. 0.00023;  
Matches 78; Conservative 0; Mismatches 22; Indels 0; Gaps 0;  
  
QY 2143 TTTATCTTATTAATAAAGTTGGTCTCCACGCTGCTCCCAAAAAAAAAAAAAA 2202  
DB 104 TCTTAATTTAACTATTTATATATCTTAATCTACTACCGCATGCAAAAAAAAAA 163  
  
QY 2203 AA 2242  
DB 164 AA 203  
  
RESULT 1365  
AAL19684/c  
ID AAL19684 standard; cDNA; 413 BP.  
XX  
AC AAL19684;  
XX  
DT 07-DEC-2001 (first entry)  
XX  
DE Human breast cancer expressed polynucleotide 12141.  
XX  
KW Human; breast cancer; cell marker; cytostatic; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200151628-A2.  
XX  
PD 19-JUL-2001.  
XX  
PF 10-JAN-2001; 2001WO-US000798.  
XX  
PR 14-JAN-2000; 2000US-0176077P.  
PR 14-MAR-2000; 2000US-0189167P.  
PR 24-MAR-2000; 2000US-0192099P.  
PR 29-MAR-2000; 2000US-0193480P.  
PR 15-MAY-2000; 2000US-0205230P.  
PR 09-JUN-2000; 2000US-0211315P.  
PR 25-JUL-2000; 2000US-0220534P.  
XX  
FA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
XX  
PI Lillie J, Xu Y, Wang Y, Steinmann K;  
XX  
DR WPI; 2001-451856/48.  
XX  
PT New peptide useful as a marker for the diagnosis of breast cancer.  
XX  
PS Claim 1; Page 2147; 3695pp; English.  
XX  
CC The invention relates to human breast cancer expressed polynucleotides  
CC (AAL07544-AAL26789) and methods of assessing whether a patient is  
CC afflicted with breast cancer by examining the correlation between the

CC expression of certain markers and the cancerous state of breast cells.  
CC The polynucleotides and encoded polypeptides are potential markers for  
CC detecting, diagnosing, monitoring, characterising treating and  
CC potentially preventing breast cancer. The polynucleotides and encoded  
CC polypeptides are also useful for isolating compounds with cytostatic  
CC activity  
XX  
SQ Sequence 413 BP; 103 A; 96 C; 79 G; 135 T; 0 U; 0 Other;  
  
Query Match 2.9%; Score 65.4; DB 4; Length 413;  
Best Local Similarity 70.2%; Pred. No. 0.00023;  
Matches 87; Conservative 0; Mismatches 37; Indels 0; Gaps 0;  
  
QY 2119 GCGCTTTGCTTTTACCACCTCTTTCTTTTATCTTATTAATAAATGTTGGTCTCCACCAC 2178  
DB 161 CCCCTTTTAAAAAGGCCCTTTTGCCTTTTAAATAAATGGGGGGGCCAAA 102  
  
QY 2179 TGNCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2238  
DB 101 AA 42  
QY 2239 AAAA 2242  
DB 41 AAAA 38  
  
RESULT 1366  
ACH41045  
ID ACH41045 standard; cDNA; 430 BP.  
XX  
AC ACH41045;  
XX  
DT 13-OCT-2003 (first entry)  
XX  
DE Human foetal brain cDNA #2412.  
XX  
KW Human; ss; sequencing by hybridisation; SBH; expressed sequence tag; EST;  
XX genome mapping; biodiversity; genetic disorder.  
XX  
OS Homo sapiens.  
XX  
PN US2003073623-A1.  
XX  
PD 17-APR-2003.  
XX  
PF 30-JUL-2001; 2001US-00918995.  
XX  
PR 30-JUL-2001; 2001US-00918995.  
XX  
PA (DRMA/) DRMANAC R T.  
PA (LABA/) LABAT I.  
PA (STAC/) STACHE-CRAIN B.  
PA (DICK/) DICKSON M C.  
PA (JONE/) JONES L W.  
XX  
PI Drmanac RT, Labat I, Stache-Crain B, Dickson MC, Jones LW;  
XX  
DR WPI; 2003-615964/58.  
XX  
PT New polynucleotide sequences obtained from various cDNA libraries, useful  
XX as hybridization probes, as oligomers for PCR, for chromosome and gene  
XX mapping, in the recombinant production of protein, or in generating  
XX antisense DNA or RNA.  
XX  
PS Claim 1; SEQ ID NO 28257; 44pp; English.  
XX  
CC The invention relates to an isolated polynucleotide comprising any one of  
CC 38043.cDNA sequences, appearing as ACH12789-ACH50831, whose sequence was  
CC determined by the technique of SBH (sequencing by hybridisation). Also  
CC included is a purified polypeptide comprising a sequence corresponding to  
CC a reading frame of the novel polynucleotide. The nucleic acid sequences  
CC are useful in diagnostics as expressed sequence tags (EST) for  
CC identifying expressed genes or for physical mapping of the human genome,

xx CC The invention relates to human polynucleotides (AAI79941-AAI793841) and  
CC the encoded proteins (AAO00010-AAO13910) that exhibit activity relating to  
CC cytokine, cell proliferation or cell differentiation or which may induce  
CC production of other cytokines in other cell populations. The  
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
CC peptide therapy. The polypeptides have various cytokine-like activities,  
CC e.g. stem cell growth factor activity, haematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activating/inhibiting activity and may be useful in the diagnosis and/or

Claim 1; SEQ ID NO 5521; 1399pp + Sequence Listing; English.

CC of the printed specification, but was obtained in electronic format  
CC directly from Wipo at [ftp.wipo.int/pub/published\\_pct\\_sequences](http://ftp.wipo.int/pub/published_pct_sequences)  
XX  
SQ Sequence 457 BP; 162 A; 131 C; 87 G; 62 T; 0 U; 15 Other;  
Query Match 2.9%; Score 65.4; DB 4; Length 457;  
Best Local Similarity 68.2%; Pred. No. 0.00024;  
Matches 90; Conservative 0; Mismatches 42; Indels 0; Gaps 0;  
QY 2111 CCAATGATCGCTTGGCTTTACCACTCTTTCCCTTTATCTTATTAATAAATGTGTC 2170  
DB 225 CCGAGGGCCCTTTACATGCCCTCTCCCTTTTATAAATTTTCATTAAACACCTA 284  
QY 2171 TCCACCATGCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2230  
DB 285 TTTTCTAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 344  
QY 2231 AAAAAAAAAA 2242  
DB 345 AAAAAAAAAA 356  
RESULT 1369  
ACN45429/c  
ID ACN45429 standard; cDNA; 525 BP.  
XX AC ACN45429;  
XX  
XX 02-DEC-2004 (first entry)  
XX  
XX Cotton primed seed EST Clone ID: LIB3825-001-Q1-N6-H9, SEQ:210.  
XX  
XX Cotton; plant; EST; expressed sequence tag; transgenic plant; seed;  
KW variety DP50B; library LIB3825; molecular tag; molecular marker;  
KW genetic mapping; molecular mapping; seed germination; plant growth;  
KW plant quality; plant yield; plant breeding; tissue printing; ss.  
XX  
XX Gossypium hirsutum.  
OS  
XX ACN55415/c  
XX ID ACN55415 standard; cDNA; 536 BP.  
XX  
XX AC ACN55415;  
XX  
XX 02-DEC-2004 (first entry)  
XX  
XX Cotton androecium tissue EST Clone ID: LIB3828-023-Q6-N6-C9, SEQ:10196.  
XX  
XX Cotton; plant; EST; expressed sequence tag; transgenic plant; androecium;  
KW variety Nucotton33B; library LIB3828; molecular tag; molecular marker;  
KW genetic mapping; molecular mapping; seed germination; plant growth;  
KW plant quality; plant yield; plant breeding; tissue printing; ss.  
XX  
XX Gossypium hirsutum.  
OS  
XX US2004123340-A1.  
XX  
XX 24-JUN-2004.  
XX  
XX 12-DEC-2001; 2001US-00021323.  
XX  
XX 14-DEC-2000; 2000US-0255619P.  
XX  
XX (DEIK/) DEIKMAN J.  
XX (FENG/) FENG P C C.  
XX (FINC/) FINCHER K L.  
XX (ZIEG/) ZIEGLER T E.  
XX  
XX Deikman J, Feng PCC, Fincher KL, Ziegler TE;  
PI WPI; 2004-479808/45.  
XX  
XX New isolated nucleic acid molecule that encodes a plant protein or its  
PT fragment, useful for isolating a variety of agronomically significant  
PT genes associated with plant growth, quality or yield, and as molecular  
PT tags to map genes.  
XX  
XX Claim 1; SEQ ID NO 210; 34pp; English.  
XX  
XX The invention relates to 17880 cotton expressed sequence tags (ESTs;  
CC ACN45220-ACN3099). The ESTs were isolated from cDNA libraries generated  
CC from primed or non-primed seeds from variety DP50B, mature seeds from  
CC variety Cooper 312 Boswell 96 Field, and androecium tissue, gynoecium  
CC tissue, developing fibres, carpel walls and septa from variety  
CC Nucotton33B. The invention also relates to substantially purified  
CC proteins or their fragments encoded by nucleic acid molecules of the  
CC invention, and to transformed plants having a nucleic acid construct  
CC comprising a nucleic acid of the invention. The cotton ESTs are useful as  
CC molecular tags to isolate genetic regions, to isolate genes, to map

CC genes, to determine gene function and to determining whether genes are  
CC members of a particular gene family. The nucleic acid molecules may be  
CC used for isolating a variety of agronomically significant genes  
CC associated with plant growth, quality, yield, and could also serve as  
CC links in metabolic and catabolic pathways. The nucleic acid molecules are  
CC also useful for identifying genes important in initiating and maintaining  
CC seed germination or that may be used to mitigate stresses encountered  
CC during seed germination. The ESTs additionally enable the acquisition of  
CC promoters and cis-regulatory elements which will be useful to express,  
CC agronomically significant genes in these tissues and/or other tissues,  
CC and also permits the acquisition of molecular markers useful in breeding  
CC schemes, genetic and molecular mapping, and in cloning of agronomically  
CC significant genes. The nucleic acid molecules are further useful for  
CC detecting the presence or level or pattern of a protein or mRNA and for  
CC present sequence represents a specifically claimed EST isolated from a  
CC cotton variety DP50B primed seed cDNA library (LIB3825). The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format directly from the US patent office at  
CC [seqdata.uspto.gov/sequence.html?DocID=US20040123340](http://seqdata.uspto.gov/sequence.html?DocID=US20040123340)  
XX  
SQ Sequence 525 BP; 166 A; 97 C; 80 G; 182 T; 0 U; 0 Other;  
Query Match 2.9%; Score 65.4; DB 13; Length 525;  
Best Local Similarity 78.0%; Pred. No. 0.00025;  
Matches 78; Conservative 0; Mismatches 22; Indels 0; Gaps 0;  
QY 2143 TTTTATCTTATTAATAAATGTTGGTCTCCACCACTGCTCCCAAAAAAAAAAAAAA 2202  
DB 135 TTTTTCCTCAATTTATAAATGTTGGTCTCCCAAAAAAAAAAAAAA 76  
QY 2203 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242  
DB 75 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 36  
RESULT 1370  
ACN55415/c  
ID ACN55415 standard; cDNA; 536 BP.  
XX  
XX AC ACN55415;  
XX  
XX 02-DEC-2004 (first entry)  
XX  
XX Cotton androecium tissue EST Clone ID: LIB3828-023-Q6-N6-C9, SEQ:10196.  
XX  
XX Cotton; plant; EST; expressed sequence tag; transgenic plant; androecium;  
KW variety Nucotton33B; library LIB3828; molecular tag; molecular marker;  
KW genetic mapping; molecular mapping; seed germination; plant growth;  
KW plant quality; plant yield; plant breeding; tissue printing; ss.  
XX  
XX Gossypium hirsutum.  
OS  
XX US2004123340-A1.  
XX  
XX 24-JUN-2004.  
XX  
XX 12-DEC-2001; 2001US-00021323.  
XX  
XX 14-DEC-2000; 2000US-0255619P.  
XX  
XX (DEIK/) DEIKMAN J.  
XX (FENG/) FENG P C C.  
XX (FINC/) FINCHER K L.  
XX (ZIEG/) ZIEGLER T E.  
XX  
XX Deikman J, Feng PCC, Fincher KL, Ziegler TE;  
PI WPI; 2004-479808/45.  
XX  
XX New isolated nucleic acid molecule that encodes a plant protein or its  
PT fragment, useful for isolating a variety of agronomically significant  
PT genes associated with plant growth, quality or yield, and as molecular  
PT tags to map genes.



```

XX DT 07-FEB-2001 (first entry)
XX DE CDNA sequence of human breast tumour clone B511S.
XX KW Human; breast tumour antigen; cytostatic; immunotherapy; breast cancer;
XX KV vaccine; ss.
XX OS Homo sapiens.
XX PN WO200061756-A2.
XX PD 19-OCT-2000.
XX PF 10-APR-2000; 2000WO-US009688.
XX PR 09-APR-1999; 99US-00288950.
XX PR 02-JUL-1999; 99US-00346327.
XX PA (CORI-) CORIXA CORP.
XX PI Reed SG, Xu J, Dillon DC;
XX DR WPI; 2000-638568/61.
XX DR P-PSDB; AAB28525.
XX PT A novel isolated polypeptide comprising an immunogenic portion of a
XX PT breast cancer protein useful in the detection and treatment of breast
XX PT cancer.
XX PS Claim 4; Page 88; 95pp; English.
XX CC The present sequence was isolated from a breast tumour CDNA library. It
XX CC is provided in a specification relating to compounds for immunotherapy
XX CC and diagnosis of breast cancer. Breast tumour antigens and the
XX CC polynucleotides that encode them may be used in the production of a
XX CC pharmaceutical composition to be used in the treatment of breast cancer.
XX CC Proliferated T cells and incubated antigen presenting cells are also
XX CC required. The polypeptides and polynucleotides may also be used to
XX CC produce a vaccine
XX CC
XX SQ Sequence 578 BP; 206 A; 137 C; 88 G; 147 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.4; DB 3; Length 578;
Best Local Similarity 66.4%; Pred. No. 0.00026;
Matches 93; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 2103 CATTCCATCCCAATGATCGCTTTGCTTTTACCACTCTTTCTTTTATCTTATTAATAAAAA 2162
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
409 CCTTGCCTACGATATCCCTTTATCTCTATCATCAGTTTATTTCTTCAATATAAAAAATAA 468

QY 2163 TGTGGTCTCCACCTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAA 2222
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
469 CTATGAGCAACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 528

QY 2223 AAAAAAATAAAAAAATAAAAAA 2242
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
529 AAAAAAATAAAAAAATAAAAAA 548

RESULT 1373
AAI67224
ID AAI67224 standard; cDNA; 578 BP.
XX AC AAI67224;
XX XX
XX DT 11-FEB-2002 (first entry)
XX DE B511S CDNA sequence.
XX KW Genetic subtraction; DNA microarray analysis; polymerase chain reaction;
XX KW cancer; B511S; ss.
XX XX

```

```

OS Homo sapiens.
XX Key Location/Qualifiers
XX CDS 63..335
XX FT /*tag= a
XX PN WO200175171-A2.
XX PD 11-OCT-2001.
XX PF 02-APR-2001; 2001WO-US010631.
XX PR 03-APR-2000; 2000US-0194241P.
XX PR 20-JUL-2000; 2000US-0219862P.
XX PR 27-JUL-2000; 2000US-0221300P.
XX PR 18-DEC-2000; 2000US-0256592P.
XX PA (CORI-) CORIXA CORP.
XX PI Houghton RL, Dillon DC, Molesch DA, Xu J, Zehentner B, Persing DH;
XX DR WPI; 2001-626449/72.
XX DR P-PSDB; AAG65988.
XX PT Identifying tissue (tumor)-specific polynucleotides overexpressed in
XX PT tissue of interest as compared to control tissue, for detecting cancer
XX PT cells in patient, comprises DNA microarray analysis or quantitative
XX PT polymerase chain reaction.
XX PS Claim 4; Page 116; 127pp; English.
XX CC The invention relates to identifying tissue-specific polynucleotides (P)
XX CC that involves performing a genetic subtraction to identify pool of (P)
XX CC from tissue of interest (TI), performing DNA microarray analysis to
XX CC identify first subset of polynucleotides (SP1) at least 2-fold over
XX CC expressed in TI, and performing quantitative polymerase chain reaction
XX CC (PCR) analysis on SP1 to identify second subset of (P). The method is
XX CC useful for determining the presence or absence of a cancer cell in a
XX CC patient, monitoring the progression of cancer in a patient using a
XX CC biological sample such as blood, serum, lymph nodes, bone marrow, sputum,
XX CC urine or a tumour biopsy sample. The methods are useful for determining
XX CC the presence or absence of or monitoring progression of prostate, breast,
XX CC colon, ovarian, lung, head and neck, lymphoma, leukemia, melanoma, liver,
XX CC gastric, kidney, bladder, pancreatic or endometrial cancer. The present
XX CC sequence represents B511S CDNA
XX SQ Sequence 578 BP; 206 A; 137 C; 88 G; 147 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.4; DB 4; Length 578;
Best Local Similarity 66.4%; Pred. No. 0.00026;
Matches 93; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 2103 CATTCCATCCCAATGATCGCTTTGCTTTTACCACTCTTTCTTTTATCTTATTAATAAAAA 2162
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
409 CCTTGCCTACGATATCCCTTTATCTCTATCATCAGTTTATTTCTTCAATATAAAAAATAA 468

QY 2163 TGTGGTCTCCACCTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAA 2222
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
469 CTATGAGCAACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 528

QY 2223 AAAAAAATAAAAAAATAAAAAA 2242
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
529 AAAAAAATAAAAAAATAAAAAA 548

RESULT 1374
ABK29014
ID ABK29014 standard; cDNA; 578 BP.
XX AC ABK29014;
XX XX
XX DT 23-APR-2002 (first entry)
XX XX

```

DE Human breast tumour polypeptide full length cDNA clone #1.  
XX Human; breast tumour polypeptide; gene; ss; breast cancer; cytostatic;  
KW immunostimulant.  
XX Homo sapiens.  
XX WO200198339-A2.  
XX 27-DEC-2001.  
XX 12-JUN-2001; 2001WO-US019032.  
XX 22-JUN-2000; 2000US-00602877.  
XX 12-OCT-2000; 2000US-00687507.  
XX 06-FEB-2001; 2001US-00779381.  
XX (CORI-) CORIXA CORP.  
XX Reed SG, Xu J, Dillon DC, Retter MW, Harlocker SL;  
XX WPI; 2002-147792/19.  
XX P-PSDB; AAU82641.  
XX Polynucleotides encoding breast tumor polypeptides, useful for treating  
XX breast cancer or stimulating an immune response.  
XX Claim 1; Page 140-141; 150pp; English.  
XX The invention relates to polynucleotides encoding breast tumour  
XX polypeptides. The sequences are useful for treating cancer, preferably  
XX breast cancer, in a patient or for stimulating an immune response. The  
XX polynucleotides and polypeptides are also useful in the diagnosis and  
XX monitoring of breast cancer. A method for detecting the presence of a  
XX cancer in a patient, comprises obtaining a biological sample from the  
XX patient, contacting the biological sample with a binding agent that binds  
XX to a breast tumour polypeptide, detecting in the sample an amount of  
XX polypeptide that binds to the binding agent, and comparing the amount of  
XX polypeptide to a predetermined cut-off value, therefore determining the  
XX presence of a cancer in the patient. Sequences ABK28920-ABK29025  
XX represent cDNA clones encoding human breast tumour polypeptides of the  
XX invention  
SQ Sequence 578 BP; 206 A; 137 C; 88 G; 147 T; 0 U; 0 Other;  
  
Query Match 2.9%; Score 65.4; DB 6; Length 578;  
Best Local Similarity 66.4%; Pred. No. 0.00026;  
Matches 93; Conservative 0; Mismatches 47; Indels 0; Gaps 0;  
  
QY 2103 CATTCCATCCAATGATCGCTTTGGCTTTTACCACTCTTTCTCTTATCTTATTAATAAAA 2162  
Db 409 CCTTGCTAGATATCCCTTTTATCTCTATCATGTTATTTCTTCAATAATAATAATA 468  
  
QY 2163 TGTGTGCTCCACCACTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAA 2222  
Db 469 CTATGAGCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 528  
  
QY 2223 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2242  
Db 529 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 548  
  
RESULT 1375  
ACN87284/c  
ID ACN87284 standard; DNA; 600 BP.  
XX ACN87284;  
XX ACN87284;  
XX 02-DEC-2004 (first entry)  
XX Breast cancer related marker, seq id 8434.  
XX Cancer; breast; tumour; cytostatic; marker; detection; therapy; ds.

XX Homo sapiens.  
XX US2003099974-A1.  
XX 29-MAY-2003.  
XX 18-JUL-2002; 2002US-00198846.  
XX 18-JUL-2001; 2001US-0306220P.  
XX (MILL-) MILLENNIUM PHARM INC.  
XX Lillie J, Xu Y, Wang Y, Steinmann K;  
XX WPI; 2003-787014/74.  
XX Novel isolated polypeptide associated with breast cancer, useful for  
XX detecting presence of polypeptide in sample, as a marker for breast  
XX cancer.  
XX Disclosure; SEQ ID NO 8434; 36pp; English.  
XX The invention relates to an isolated polypeptide (I) associated with  
XX breast cancer which is encoded by a nucleic acid molecule comprising a  
XX nucleotide sequence (S1). Further disclosed is an antibody that binds to  
XX the polypeptide of the invention. The activity of the polypeptide of the  
XX invention may be described as cytostatic. The antibody is useful for  
XX detecting the presence of (I) in a sample. Nucleic acid molecules of the  
XX invention are useful in the detection of breast tumours. (I) is useful as  
XX a marker for breast cancer and in breast cancer therapy. Sequences given  
XX in records ACN78851-ACN92934 represent nucleic acid markers associated  
XX with breast cancer. Note: The sequence listing does not form part of the  
XX specification but may be obtained in electronic format from the USPTO web  
XX site at seqdata.uspto.gov/sequence.html?docID=20030099974  
SQ Sequence 600 BP; 247 A; 28 C; 103 G; 95 T; 0 U; 127 Other;  
  
Query Match 2.9%; Score 65.4; DB 11; Length 600;  
Best Local Similarity 57.3%; Pred. No. 0.00026;  
Matches 102; Conservative 0; Mismatches 76; Indels 0; Gaps 0;  
  
QY 2065 TTGTCTTCTAGTCTCTCAAGTCTGTCGACACATAATCATTCATCCATGATGCGCTT 2124  
Db 267 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTT 208  
  
QY 2125 TGTCTTACCACCTCTTCTCTTTTATCTTATTAATAATAAATGTTGGTCTCCACCACTGCTC 2184  
Db 207 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTT 148  
  
QY 2185 CCACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2242  
Db 147 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 90  
  
RESULT 1376  
AAL23455/c  
ID AAL23455 standard; cDNA; 752 BP.  
XX AAL23455;  
XX AAL23455;  
XX 07-DEC-2001 (first entry)  
XX Human breast cancer expressed polynucleotide 15912.  
XX Human; breast cancer; cell marker; cytostatic; ss.  
XX Homo sapiens.  
XX WO200151628-A2.  
XX 19-JUL-2001.  
XX

```

PF 10-JAN-2001; 2001WO-US000798.
XX
XX 14-JAN-2000; 2000US-0176077P.
PR 14-MAR-2000; 2000US-0189167P.
PR 24-MAR-2000; 2000US-0192099P.
PR 29-MAR-2000; 2000US-0193480P.
PR 15-MAY-2000; 2000US-0205230P.
PR 09-JUN-2000; 2000US-0211315P.
PR 25-JUL-2000; 2000US-0220534P.
XX
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
XX Lillie J, Xu Y, Wang Y, Steinmann K;
XX
XX WPI; 2001-451856/48.
XX
XX New peptide useful as a marker for the diagnosis of breast cancer.
XX
XX Claim 1; Page 2902-2903; 3695pp; English.
XX
XX The invention relates to human breast cancer expressed polynucleotides
XX (AAL07544-AAL26789) and methods of assessing whether a patient is
XX afflicted with breast cancer by examining the correlation between the
XX expression of certain markers and the cancerous state of breast cells.
XX The polynucleotides and encoded polypeptides are potential markers for
XX detecting, diagnosing, monitoring, characterising treating and
XX potentially preventing breast cancer. The polynucleotides and encoded
XX polypeptides are also useful for isolating compounds with cytostatic
XX activity
XX
XX SQ Sequence 752 BP; 170 A; 179 C; 165 G; 238 T; 0 U; 0 Other;
Query Match 2.9%; Score 65.4; DB 4; Length 752;
Best Local Similarity 70.2%; Pred. No. 0.00028;
Matches 87; Conservative 0; Mismatches 37; Indels 0; Gaps 0;
Qy 2119 CGCCTTTGCTTTACACACTCTTTCTTTATCTTATTAATAAAAGTTGGTCTCCACCAC 2178
Db 160 CCCCTTTGTTGAAGACATTTTGGAAACCCCATTTATATTTCATTAAAGGTGATAAA 101
Qy 2179 TGNCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2238
Db 100 AGCTTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 41
Qy 2239 AAAA 2242
Db 40 AAAA 37
RESULT 1377
AAD24774
ID AAD24774 standard; cDNA; 1312 BP.
XX
XX AAD24774;
XX
XX 12-MAR-2002 (first entry)
XX
XX Glycine max ankyrin-related protein 1 (GMA1) cDNA.
XX
XX Glycine max ankyrin-related protein; GMA1; GmSUT1; sugar transport;
XX sucrose/proton symporter; soybean ankyrin-related protein; SAR; ANK;
XX sugar allocation; nutritional value; ss.
XX
XX Glycine max.
XX
XX Key Location/Qualifiers
XX CDS 85..963
XX FT /*tag= a
XX FT /product= "GMA1 protein"
XX FT /transl_except= (pos:91..93, aa:Pro)
XX FT /transl_except= (pos:961..963, aa:Leu-Glx)
XX
XX WO200188139-A2.

```

```

XX 22-NOV-2001.
XX
XX 11-MAY-2001; 2001WO-US015315.
XX
XX 12-MAY-2000; 2000US-0203974P.
XX
XX (UNIW) UNIV WASHINGTON STATE RES FOUND.
XX
XX Grimes HD, Elmer AM, Murphy KA;
XX
XX WPI; 2002-062385/08.
XX
XX P-ESDB; AAE15308.
XX
XX New purified protein having Glycine max ankyrin-related (GMA) protein
XX biological activity, useful to alter GMA levels in plants to confer
XX altered sugar transport and/or altered sugar allocation properties.
XX
XX Claim 4; Page 53-54; 60pp; English.
XX
XX The invention relates to (soybean) Glycine max (Gm) ankyrin (ANK) -
XX related proteins 1 and 2 referred to as GMA1 and GMA2 and nucleic acid
XX molecules encoding them. GMA proteins also known as soybean ankyrin-
XX related (SAR) proteins interact with Gm sucrose/H+ (proton) symporter
XX designated as (SUT1). Manipulating the expression of GmSUT1 and GMA in
XX plants is useful to confer altered sugar transport and/or altered sugar
XX allocation properties. Alteration of GMA protein levels in plants could
XX be used to increase the nutritional value of plant tissues, for instance
XX plant seeds or grain. The present sequence is GMA1 cDNA
XX
XX SQ Sequence 1312 BP; 445 A; 222 C; 297 G; 348 T; 0 U; 0 Other;
Query Match 2.9%; Score 65.4; DB 6; Length 1312;
Best Local Similarity 70.2%; Pred. No. 0.00033;
Matches 87; Conservative 0; Mismatches 37; Indels 0; Gaps 0;
Qy 2119 CGCCTTTGCTTTACACACTCTTTCTTTATCTTATTAATAAAAGTTGGTCTCCACCAC 2178
Db 1181 CGTCATGATTTTATTAATGTTTCAATTTTACTTATAAAAAAATAAAAAAATAAAAAA 1240
Qy 2179 TGNCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2238
Db 1241 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1300
Qy 2239 AAAA 2242
Db 1301 AAAA 1304
RESULT 1378
AAS01160
ID AAS01160 standard; cDNA; 1626 BP.
XX
XX AAS01160;
XX
XX 12-SEP-2001 (first entry)
XX
XX Fertilisation-independent endosperm cDNA clone eec1c.pk003.e23.
XX
XX Fertilisation-independent endosperm; plant reproduction; apomixis; ss;
XX seed; pharmaceutical; nutraceutical; polymer; eec1c.pk003.e23; EST;
XX expressed sequence tag.
XX
XX Eucalyptus grandis.
XX
XX Key Location/Qualifiers
XX CDS 122..1241
XX FT /*tag= a
XX FT /partial
XX FT /notes= "Contains no start codon"
XX FT /product= "Fertilisation-independent endosperm protein"
XX
XX WO200116325-A2.

```

```
XX PD 08-MAR-2001.
XX PF
XX PP
XX PR 30-AUG-2000; 2000WO-US023735.
XX PR 31-AUG-1999; 99US-0151575P.
XX PA (DUPO ) DU PONT DE NEMOURS & CO E I.
XX PA (PION-) PIONEER HI-BRED INT INC.
XX PI Butler KH, Danilevskaya O, Miao G, Morgante M, Sakai H;
XX PI Simmons CR, Weng Z;
XX DR WPI; 2001-244407/25.
XX DR P-PSDB; AAU00313.
XX PT New plant fertilization independent endosperm protein for the production
XX PT of seed without fertilization is recombinantly produced.
XX PS Claim 7; Page 45; 94pp; English.
XX CC The sequence represents the coding sequence of fertilisation- independent
XX CC endosperm clone eecic.pk003.e23. Fertilisation-independent endosperm
XX CC proteins are plant reproduction proteins necessary for apomixis, the
XX CC formation of seeds without fertilisation. Apomixis is especially useful
XX CC to agriculture because it eliminates the necessity of selfing plants to
XX CC produce genetically identical seed. Such seed is useful to produce seeds
XX CC for human and animal food and for commercial milling and extraction,
XX CC including the production of useful recombinant products in the endosperm
XX CC e.g.pharmaceutical, nutraceutical, industrial compounds and polymers.
XX CC Embryolees seed production by transgenic plants is less likely to cause
XX CC ethical and environmental concern over transgenic plant production as no
XX CC gametes are being produced to cross pollinate with other crops and the
XX CC seeds cannot germinate
XX SQ Sequence 1626 BP; 455 A; 355 C; 404 G; 412 T; 0 U; 0 Other;
Query Match 2.9%; Score 65.4; DB 4; Length 1626;
Best Local Similarity 78.0%; Pred. No. 0.00036;
Matches 78; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
QY 2143 TTTTATCTTTATTAATAAAATGTTGGTCTCCACCTGNTCCCAAAAAA 2202
Db 1525 TTGTACCTTAGAACATCCATTTTAATCTACCTTCCAGAAAAA 1584
QY 2203 AAAAAA 2242
Db 1585 AAAAAA 1624
RESULT 1379
ADC29845
ID ADC29845 standard; DNA; 1626 BP.
XX AC ADC29845;
XX AC
XX DT 18-DEC-2003 (first entry)
XX DE Fertilization-independent endosperm protein gene #5.
XX KW da; gene; fertilization-independent endosperm; FIE; seed development;
XX KW plant; phenotype; fatty acid synthesis; amino acid content.
XX OS Eucalyptus grandis.
XX FH Location/Qualifiers
XX FT 123..1241
XX FT /*tag= a
XX FT /product= "fertilization-independent endosperm protein"
XX PN WO2003026390-A2.
XX PD 03-APR-2003.

XX XX
XX PF 27-SEP-2002; 2002WO-US030978.
XX PR 28-SEP-2001; 2001US-00967552.
XX PA (PION-) PIONEER HI-BRED INT INC.
XX PA (DUPO ) DU PONT DE NEMOURS & CO E I.
XX PI Danilevskaya O, Miao G, Morgante M, Sakai H, Simmons C, Weng Z;
XX PI Famodu OO, Hantke S, Butler KH;
XX DR WPI; 2003-44099/42.
XX DR P-PSDB; ADC29846.
XX PT Novel polynucleotide encoding fertilization-independent endosperm
XX PT polypeptide, useful for modulating seed development in a plant.
XX PS Claim 8; SEQ ID NO 9; 147pp; English.
XX CC The invention relates to an isolated polynucleotide encoding a functional
XX CC fertilization-independent endosperm (FIE) polypeptide or sequences having
XX CC at least 81% identity, based on GAP (GCG version 10) using default
XX CC parameters. The polynucleotide is useful for modulating seed development
XX CC in a plant, by transforming a plant cell with a recombinant expression
XX CC cassette comprising the polynucleotide, growing the plant cell under
XX CC conditions which favour plant regeneration, regenerating a plant from the
XX CC transformed plant cell, and growing the plant under conditions which
XX CC allow or induce expression of the polynucleotide. Vectors containing the
XX CC polynucleotide are useful for selectively expressing a nucleotide
XX CC sequence in a plant cell, and regenerating a stably transformed plant
XX CC from the transformed plant cell, where the expression of the first
XX CC nucleotide sequence alters the phenotype of the plant seed. The first
XX CC nucleotide sequence encodes a gene involved in fatty acid synthesis or a
XX CC gene providing enhanced amino acid content. This sequence corresponds to
XX CC the gene encoding one of the FIE proteins of the invention.
XX SQ Sequence 1626 BP; 455 A; 355 C; 404 G; 412 T; 0 U; 0 Other;
Query Match 2.9%; Score 65.4; DB 10; Length 1626;
Best Local Similarity 78.0%; Pred. No. 0.00036;
Matches 78; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
QY 2143 TTTTATCTTTATTAATAAAATGTTGGTCTCCACCTGNTCCCAAAAAA 2202
Db 1525 TTGTACCTTAGAACATCCATTTTAATCTACCTTCCAGAAAAA 1584
QY 2203 AAAAAA 2242
Db 1585 AAAAAA 1624
RESULT 1380
AAC59302
ID AAC59302 standard; cDNA; 1663 BP.
XX AC AAC59302;
XX AC
XX DT 02-FEB-2001 (first entry)
XX DE Human secreted protein cDNA #26.
XX KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
XX KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antitumor;
XX KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
XX KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
XX KW neurological disease; infection; human; secreted protein; ss.
XX OS Homo sapiens.
XX PN WO200056753-A1.
XX PD 28-SEP-2000.
XX XX
```

```
PF 16-MAR-2000; 2000WO-US006765.
XX
XX 23-MAR-1999; 99US-0126051P.
PR 10-DEC-1999; 99US-0169906P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Komatsoulis G;
XX
XX WPI; 2000-594570/56.
DR P-PSDB; AAB33742.
XX
XX Nucleic acid molecules encoding human secreted proteins, used in
PT preventing, treating or ameliorating a disorder.
PT
XX
XX Claim 1; Page 358-359; 410pp; English.
PS
CC The invention relates to the isolation of genes AAC59277-C59325 encoding
CC 49 human secreted proteins AAB33718-B33764. The genes can be used to
CC generate fusion proteins by linking to the gene for the human
CC immunoglobulin G Fc portion (SEQID1) for increasing the stability of the
CC fusion protein as compared to the human protein only. The genes and
CC proteins are useful for preventing, ameliorating or treating medical
CC conditions, e.g. by protein or gene therapy. The genes are isolated from
CC a range of human tissues disclosed in the specification. The nucleic
CC acids, proteins, antibodies and (ant)agonists are useful in the
CC diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
CC ovarian cancer, and other cancers of the adrenal gland, bone, bone
CC marrow, breast, gastrointestinal tract, liver, lung, or urogenital; (b)
CC immune disorders e.g. Addison's disease, allergies, autoimmune haemolytic
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
CC cardiovascular disorders such as myocardial ischaemia; (d) wound healing
CC; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
CC infectious diseases such as viral, bacterial, fungal and parasitic
CC infections
XX
SQ Sequence 1663 BP; 549 A; 250 C; 313 G; 551 T; 0 U; 0 Other;
Query Match 2.9%; Score 65.4; DB 3; Length 1663;
Best Local Similarity 72.4%; Pred. No. 0.00036;
Matches 84; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
Qy 2127 CTTTACCACCTCTTTCTTTTATCTTATTAATAAATAATGTTGGTCTCCACCACTGNCCTCCC 2186
Db 1540 CTCTGCTCTACTTAGCCCTTTGGATTAGAGTAAATAAAGTATCTCTGACTTTCGTGT 1599
Qy 2187 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db 1600 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1655
RESULT 1381
ABZ73679
ID ABZ73679 standard; cDNA; 1663 BP.
XX
XX AC ABZ73679;
XX
DT 12-MAY-2003 (first entry)
XX
DE Secreted protein-encoding gene 381 cDNA clone HE2CA60, SEQ ID NO:409.
XX
XX Human; secreted protein; cancer; tumour; hyperproliferative disorder;
XX autoimmune disorder; inflammation; angiogenic diseases; AIDS;
XX acquired immunodeficiency syndrome; hepatitis; anaemia; wound healing;
XX drug screening; chromosome identification; chromosome mapping;
XX cytostatic; gene therapy; antinflammatory; immunomodulator; anti-HIV;
XX antianaemic; vulnery; gene; ss.
XX
OS Homo sapiens.
XX
XX WO200277013-A2.
XX
```

```
PD 03-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-US009370.
XX
XX 27-MAR-2001; 2001US-0278650P.
PR 12-SEP-2001; 2001US-00950082.
PR 12-SEP-2001; 2001US-00950083.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Ruben SM;
XX
XX WPI; 2003-040578/03.
DR P-PSDB; ABR01345.
XX
XX New human secreted proteins and nucleic acids, useful for detecting or
PT treating cancer or other hyperproliferative disorders, autoimmune
PT disorders, inflammatory disorders, HIV disease, hepatitis or anemia.
XX
XX Claim 21; Page 1370-1371; 2474pp; English.
PS
CC ABZ73281-ABZ73697 represent cDNAs corresponding to 391 human secreted
CC protein genes, and ABP00947-ABP01363 represent the proteins they encode.
CC ABZ73698-ABZ74687 represent human secreted protein genomic fragments. The
CC invention also encompasses antibodies specific for the secreted proteins,
CC the use of the secreted proteins in drug screening and recombinant
CC vectors and host cells comprising a nucleic acid of the invention. The
CC secreted proteins are thought to be involved in biological activities
CC associated with cellular signalling, cellular differentiation, cell
CC migration, prohormone activation and neurotransmitter activity. The
CC secreted proteins, nucleic acids encoding them, antibodies or antibody
CC fragments specific for the secreted proteins, and modulators of protein
CC activity are useful for diagnosing or treating cancers or other
CC hyperproliferative disorders. Additionally, the secreted proteins and
CC their nucleic acids may also be used in the treatment of autoimmune
CC disorders, inflammatory disorders, diseases involving angiogenesis, AIDS
CC (acquired immunodeficiency syndrome), hepatitis, anaemia, and to promote
CC wound healing. Nucleic acids of the invention may be used for chromosome
CC identification, chromosome mapping, in gene therapy, for identifying
CC individuals from minute biological samples, as hybridisation probes, and
CC as molecular weight markers. The present sequence represents a human
CC secreted protein-encoding cDNA clone of the invention
XX
SQ Sequence 1663 BP; 549 A; 250 C; 313 G; 551 T; 0 U; 0 Other;
Query Match 2.9%; Score 65.4; DB 8; Length 1663;
Best Local Similarity 72.4%; Pred. No. 0.00036;
Matches 84; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
Qy 2127 CTTTACCACCTCTTTCTTTTATCTTATTAATAAATAATGTTGGTCTCCACCACTGNCCTCCC 2186
Db 1540 CTCTGCTCTACTTAGCCCTTTGGATTAGAGTAAATAAAGTATCTCTGACTTTCGTGT 1599
Qy 2187 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db 1600 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1655
RESULT 1382
ADA98154
ID ADA98154 standard; cDNA; 1663 BP.
XX
XX AC ADA98154;
XX
XX 20-NOV-2003 (first entry)
DT
XX
XX Human secreted protein cDNA sequence #248.
DE
XX
XX human; secreted protein; cardiovascular disorder; arrhythmia;
XX atherosclerosis; stroke; endocarditis; congestive heart failure;
XX rheumatic heart disease; cardiomyopathy; haemorrhoids; varicose veins;
XX migraine; thrombosis; neural disorder; immune system disorder;
XX muscular disorder; reproductive disorder; gastrointestinal disorder;
```



XX 26-MAR-2002; 2002WO-US009188.  
 XX 27-MAR-2001; 2001US-0278650P.  
 PR 12-SEP-2001; 2001US-00950082.  
 PR 12-SEP-2001; 2001US-00950083.  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 PA Rosen CA, Ruben SM;  
 XX WPI; 2003-040583/03.  
 XX P-PSDB; ABP99853.  
 DR New human secreted proteins encoded by genes contained in cDNA clones  
 XX (e.g. HGCA19), useful for preventing, treating or diagnosing e.g. AIDS,  
 PT multiple sclerosis, herpes virus, leukemia, tick-borne encephalitis or  
 PT West Nile fever.  
 XX Claim 7; Page 1378; 2423pp; English.  
 PS The invention relates to novel human genes (ABZ66891-ABZ68209) and the  
 CC encoded secreted proteins (ABP99470-ABP99872) useful for preventing,  
 CC treating or ameliorating medical conditions e.g. by protein or gene  
 CC therapy. The genes are isolated from a range of human tissues disclosed  
 CC in the specification. The nucleic acids, proteins, antibodies and  
 CC (ant)agonists are useful in the diagnosis, treatment and prevention of:  
 CC (a) cancer, e.g. breast and ovarian cancer and other cancers of the  
 CC adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver,  
 CC lung or urogenital; (b) immune disorders e.g. Addison's disease,  
 CC allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,  
 CC diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid  
 CC arthritis and ulcerative colitis; (c) cardiovascular disorders such as  
 CC myocardial ischaemia; (d) wound healing; (e) neurological diseases e.g.  
 CC cerebral anoxia and epilepsy; and (f) infectious diseases such as viral,  
 CC bacterial, fungal and parasitic infections  
 XX Sequence 1663 BP; 549 A; 250 C; 313 G; 551 T; 0 U; 0 Other;  
 SQ Query Match 2.9%; Score 65.4; DB 10; Length 1663;  
 Best Local Similarity 72.4%; Pred. No. 0.00036;  
 Matches 84; Conservative 0; Mismatches 32; Indels 0; Gaps 0;  
 Qy 2127 CTTTACCACTCTTTCTTTTATCTTATTAATAAATGTTGGTCTCCACCACTGCTCC 2186  
 Db 1540 CTCTGCTCTACTTAGCCCTTTGATTTAGAGTAAATAAAGTATCTCTGACTTCTGTT 1599  
 Qy 2187 AA 2242  
 Db 1600 AA 1655  
 RESULT 1385  
 AAS03892  
 ID AAS03892 standard; cDNA; 1691 BP.  
 XX AAS03892;  
 AC AAS03892;  
 XX 29-AUG-2001 (first entry)  
 DT Human secreted protein gene #11.  
 DE Human secreted protein; autoimmune disorder; hyperproliferative disorder;  
 KW cardiovascular disorder; cerebrovascular disorder; angiogenesis;  
 KW nervous system disorder; bacterial infection; viral infection; ss;  
 KW fungal infection; ocular disorder; wound healing; tissue regeneration;  
 KW epithelial cell proliferation; skin ageing; chemotaxis; IgG Fc region.  
 XX Homo sapiens.  
 OS Homo sapiens.  
 XX WO200123598-A1.  
 FN 05-APR-2001.  
 PD

XX 26-SEP-2000; 2000WO-US026324.  
 XX 27-SEP-1999; 99US-0155807P.  
 PR (HUMA-) HUMAN GENOME SCI INC.  
 PA Komatsoulis G, Ruben SM, Rosen CA;  
 XX WPI; 2001-281684/29.  
 XX P-PSDB; AAU01936, AAU01972, AAU01973.  
 DR Forty nucleic acid molecules encoding human secreted proteins, useful in  
 XX the prevention, treatment and diagnosis of cancer, immune disorders,  
 PT cardiovascular disorders and neurological diseases.  
 PT Disclosure; Page 451; 518pp; English.  
 PS Sequences AAS03873-AAS03922 represent isolated nucleic acid molecules and  
 CC PCR primers of the invention. acid of the invention. Secreted proteins  
 CC and their related nucleic acids can be used in the diagnosis of or  
 CC susceptibility to a pathological condition by determining the presence or  
 CC absence of a mutation in a nucleic acid or the presence or amount of  
 CC expression of a secreted protein. The sequences are used to prevent,  
 CC treat or ameliorate a medical condition in e.g. humans, mice, rabbits,  
 CC goats, horses, cats, dogs, chickens or sheep. The antibodies to the  
 CC polypeptides can also be used in alleviating symptoms associated with  
 CC disorders and in diagnostic immunoassays e.g. radioimmunoassays or enzyme  
 CC linked immunosorbent assays (ELISA). The disorders include autoimmune  
 CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.  
 CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac  
 CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,  
 CC nervous system disorders e.g. Alzheimer's disease, infections caused by  
 CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection.  
 CC The peptides can also be used to aid wound healing and epithelial cell  
 CC proliferation, to help prevent skin ageing due to sunburn, to maintain  
 CC organs before transplantation, to regenerate tissues, in chemotaxis and  
 CC as a food additive or preservative to alter storage capabilities  
 XX Sequence 1691 BP; 428 A; 330 C; 353 G; 580 T; 0 U; 0 Other;  
 SQ Query Match 2.9%; Score 65.4; DB 4; Length 1691;  
 Best Local Similarity 75.0%; Pred. No. 0.00036;  
 Matches 81; Conservative 0; Mismatches 27; Indels 0; Gaps 0;  
 Qy 2133 CACTCTTTCTTTTATCTTATTAATAAATGTTGGTCTCCACCACTGCTCCAAAAA 2192  
 Db 1584 CACATTGTTGTTCTTATTAATAAATGTTGGTCTCCACCACTGCTCCAAAAA 1643  
 Qy 2193 AA 2240  
 Db 1644 AA 1691  
 RESULT 1386  
 ADQ67271  
 ID ADQ67271 standard; cDNA; 2069 BP.  
 XX ADQ67271;  
 AC ADQ67271;  
 XX 07-OCT-2004 (first entry)  
 DT Novel human cDNA sequence #2244.  
 DE ss; gene; osteopathic; neuroprotective; nootropic; antiparkinsonian;  
 KW cycostatic; gene therapy; diagnostic marker; morbid state; osteoporosis;  
 KW neurological disease; Alzheimer's disease; Parkinson's disease; dementia;  
 KW cancer.  
 XX Homo sapiens.  
 OS Homo sapiens.  
 XX EP1440981-A2.  
 FN

```
PD 28-JUL-2004.
XX
XX 21-JAN-2004; 2004EP-00001196.
XX
XX 21-JAN-2003; 2003JP-00102206.
PR
XX 09-MAY-2003; 2003JP-00131392.
XX
XX (REAS-) RES ASSOC BIOTECHNOLOGY.
XX
XX Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
PI Yamamoto J, Isono Y, Nagai K, Irie R;
XX
XX WPI; 2004-535376/52.
XX P-PSDB; ADQ67578.
XX
XX Novel 2495 cDNA, useful for treating osteoporosis, neurological diseases,
PT Alzheimer's diseases, Parkinson's diseases, dementia and various cancers.
XX
XX Claim 1; SEQ ID NO 4432; 2449pp; English.
XX
XX The invention relates to 2495 novel polynucleotides (I) and their encoded
CC polypeptides, sequences hybridizing to these nucleotides, sequences
CC encoding partial polypeptides and sequences having 70% or 90% identity to
CC the nucleotide and protein sequences. The nucleotides and polypeptides
CC are useful as diagnostic markers or therapeutic target for the diseases
CC or morbid states. They are also useful for treating osteoporosis,
CC neurological diseases, Alzheimer's diseases, Parkinson's diseases,
CC dementia and various cancers. This sequence corresponds to a nucleotide
CC sequence of the invention.
XX
XX Sequence 2069 BP; 488 A; 552 C; 557 G; 472 T; 0 U; 0 Other;
SQ
Query Match 2.9%; Score 65.4; DB 12; Length 2069;
Best Local Similarity 72.4%; Pred. No. 0.00038;
Matches 84; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
QY 2127 CTTTACCACCTCTTCCTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTGCTCC 2186
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1945 CATTCCAGCTGTAGTCTGTTTAAATAGTAATAAAATGAAGACTTAAGACCTAA 2004
QY ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2187 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2005 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2060
RESULT 1387
ADQ22529
ID ADQ22529 standard; DNA; 2435 BP.
XX
XX AC ADQ22529;
XX
XX 26-AUG-2004 (first entry)
XX
XX Human soft tissue sarcoma-upregulated DNA - SEQ ID 5349.
XX
XX soft tissue sarcoma; cytostatic; gene therapy; vaccine; screening; human;
XX ds.
XX
XX Homo sapiens.
XX
XX WO2004048938-A2.
XX
XX 10-JUN-2004.
XX
XX 26-NOV-2003; 2003WO-US038193.
XX
XX 26-NOV-2002; 2002US-0429739P.
XX
XX (PROT-) PROTEIN DESIGN LABS INC.
XX
XX Aziz N, Ginsburg WM, Zlotnik A;
XX
XX WPI; 2004-441208/41.
XX
```

```
XX
XX Early detection of soft tissue sarcoma comprises determining expression
PT of a gene in a first soft tissue sample and a normal soft tissue sample
PT and comparing the gene expression, also useful in treating soft tissue
PT sarcoma.
XX
XX Example 2; SEQ ID NO 5349; 210pp; English.
XX
XX The invention relates to a novel method for detecting soft tissue sarcoma
CC which comprises obtaining a first soft tissue sample from an individual
CC and a normal soft tissue sample from the same or different individual,
CC determining the expression of a gene in both samples and comparing the
CC expression of the gene in both soft tissue samples, where a higher level
CC of protein expression in the first soft tissue sample indicates the
CC presence of soft tissue sarcoma. The method of the invention has
CC cytostatic applications and may be useful for detecting soft tissue
CC sarcoma, possibly via gene therapy or vaccine production. The nucleic
CC acid sequences may be useful in diagnostic and screening applications.
CC The current sequence is that of a human soft tissue sarcoma-upregulated
CC DNA of the invention. The current sequence is not shown within the
CC specification per se but was submitted in CD format by the inventor.
XX
XX Sequence 2435 BP; 637 A; 571 C; 538 G; 688 T; 0 U; 1 Other;
SQ
Query Match 2.9%; Score 65.4; DB 12; Length 2435;
Best Local Similarity 78.0%; Pred. No. 0.0004;
Matches 78; Conservative 0; Mismatches 22; Indels 0; Gaps 0;
QY 2143 TTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTGCTCCCAAAAAAAAAAAAAA 2202
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2322 TATGTTATCTTCAATAAAAGTTGGCTTTGTGCTAGCAAAAAAAAAAAAAAAAAA 2381
QY 2203 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
DB ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2382 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2421
RESULT 1388
AAC74241
ID AAC74241 standard; cDNA; 2608 BP.
XX
XX AC AAC74241;
XX
XX 02-FEB-2001 (first entry)
XX
XX Human secreted protein gene 19 SEQ ID NO:29.
XX
XX Human; secreted protein; immunosuppressive; antiarthritic; antirheumatic;
KW antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
KW neutropic; neuroprotective; antibacterial; virucide; fungicide; neoplasm;
KW ophthalmological; autoimmune disease; rheumatoid arthritis; angiogenesis;
KW hyperproliferative disorder; cardiovascular disorder; infection;
KW cerebrovascular disorder; nervous system disorder; ocular disorder;
KW wound healing; chemotaxis; ss.
XX
XX Homo sapiens.
XX
XX WO200056754-A1.
XX
XX 28-SEP-2000.
XX
XX 16-MAR-2000; 2000WO-US006792.
XX
XX 19-MAR-1999; 99US-0125362P.
PR
XX 10-DEC-1999; 99US-0169980P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen GA, Ruben SM, Komatsoulis G;
XX
XX WPI; 2000-579483/54.
XX
XX P-PSDB; AAB39197.
XX
```

PT Isolated nucleic acid molecule encoding a human secreted protein is used in preventing, treating or ameliorating a medical condition.

Claim 1; Page 348-349; 434pp; English.

The polynucleotide sequences given in AAC74223-C74279 encode the human secreted proteins represented in AAB391179-B39226. Sequences AAB39227-B39308 are alternative proteins encoded by the genes, and also protein sequences with which they share homology. The proteins have activities based on the tissues and cells in which they are expressed. Examples of activities include: immunosuppressive; antiarthritic; antiinflammatory; antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective; antitropic; neuroprotective; antibacterial; virucide; fungicide; and ophthalmological. The human secreted proteins, polynucleotides, antagonists and agonists of the invention may be useful in the treatment, prevention and/or diagnosis of various disease, disorders and conditions such as autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g. neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g. Alzheimer's disease, infections caused by bacteria, viruses and fungi and ocular disorders e.g. corneal infection. The polypeptides can also be used to aid wound healing and epithelial cell proliferation, to regenerate tissues, maintain organs before transplantation, in chemotaxis and as a food additive or preservative e.g. to increase storage capabilities. Sequences AAC74214-C74222 and AAB39178 are used during the isolation and characterisation of the genes of the invention.

Sequence 2608 BP; 889 A; 432 C; 412 G; 868 T; 0 U; 7 Other;

Query Match 2.9%; Score 65.4; DB 3; Length 2608;  
Best Local Similarity 64.4%; Pred. No. 0.00041;  
Matches 96; Conservative 0; Mismatches 53; Indels 0

QY 2094 ACACATAATCATTCACATCCAATGATCGCCCTTGGCTTTACCACTCTTTCCTTTTATCTTAT 2153

Db 2452 AAATAAAATTCAGCATTCCTATTTTAAATAATTGTATGCCACCAATTGTATATTGTC 2511

QY 2154 TAATAAAATGTTGGTCTCCACCACTGCTCCCAAAAAAATAAAAAA 2213

Db 2512 TCAATAAATAGTTCATCAAAAAAAAAAAAAAAAAAAAAAAAAA 2571

Qy 2214 AAAAAAAAAAAAAAAAAA 2242

Db  
2572 AAAAAAAAAAAAAAAAAAAAAAAAAA  
2600

**RESULT 1389**

ADQ22627  
ID ADQ22627 standard: DNA: 2785 BP.

AA  
AC ADQ22627;

DT 26-AUG-2004 (first entry)

Human soft tissue sarcoma-upregulated DNA - SEO ID 5447.

AA soft tissue sarcoma; cytostatic; gene therapy; vaccine; screening; human;  
KW ds.

XX Homo sapiens.

XX PN WO2004048938-A2

XX  
PD 10-JUN-2004

XX DE 26-NOV-2003.

PF 26-NOV-2003; 2003WO-US038193.  
YY

PR 26-NOV-2002; 2002US-0429739P.  
vv

PA (PROT-) PROTEIN DESIGN LABS INC.

PI Aziz N, Ginsburg WM, Zlotnik A;

XX, DR

WPI: 2004-441208/41.

Early detection of soft tissue sarcoma comprises determining expression of a gene in a first soft tissue sample and a normal soft tissue sample and comparing the gene expression, also useful in treating soft tissue sarcoma.

Example 2; SEQ ID NO 5447; 210pp; English.

The invention relates to a novel method for detecting soft tissue sarcoma which comprises obtaining a first soft tissue sample from an individual and a normal soft tissue sample from the same or different individual, determining the expression of a gene in both samples and comparing the expression of the gene in both soft tissue samples, where a higher level of protein expression in the first soft tissue sample indicates the presence of soft tissue sarcoma. The method of the invention has cycostatic applications and may be useful for detecting soft tissue sarcoma, possibly via gene therapy or vaccine production. The nucleic acid sequences may be useful in diagnostic and screening applications. The current sequence is that of a human soft tissue sarcoma-upregulated DNA of the invention. The current sequence is not shown within the specification per se but was submitted in CD format by the inventor.

SQ Sequence 2785 BP; 965 A; 583 C; 636 G; 565 T; 0 U; 36 Other;

Query Match 2.9%; Score 65.4; DB 12; Length 2785;  
Best Local Similarity 78.0%; Pred. No. 0.00042;  
Matches 78; Conservative 0; Mismatches 22; Index 0;

QY 2143 TTTTATCTTATTAAATAAAAAATGTTGGTCTCCACCCTGNCCTCCCAAAAAAAAAAAAAA 2202

Db 2027 TGTATCTTATGATAAAAAAGTAAAAACCTAAAAAGAAAAAAGAAAAAAGAAAAA 2086

Qy 2203 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242

db 2087 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2126

**RESULT 1390**

AAC77541  
ID AAC77541 standard; cDNA; 3021 BP.

AAC77541:

DT 08-FEB-2001 (first entry)

DE Human OREF3096 polynucleotide sequence SEQ ID NO:6191.

Human; open reading frame; ORF; detection; cytostatic; hepatotropic;  
vulnary; antipsoriatic; antiparkinsonian; nootropic; neuroprotective;  
anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiac;  
immunosuppressant; thrombolytic; coagulant; vasotropic; antidiabetic;  
hypotensive; dermatological; immunosuppressive; antiinflammatory;  
antiviral; antibacterial; antifungal; antirheumatic; antithyroid;  
antanaemic; gene therapy; cancer; proliferative disorder; hypertension;  
neurodegenerative disorder; osteoarthritis; graft vs host disease;  
cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;  
cholesterol ester storage; systemic lupus erythematosus; infection;  
severe combined immunodeficiency; malaria; autoimmune disorder; asthma;  
allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;  
bone damage; cartilage damage; antiinflammatory disease; coagulation;  
thrombosis; contraceptive; ss.

XX Homo sapiens.

XX PN WO200058473-A2.

XX PD 05-OCT-2000

XX  
PF 31-MAR-2000: 2000WO-IIS008621

XX  
PR 31-MAR-1999: 99TIS-0127607P

```
PR 02-APR-1999; 99US-0127636P.
PR 05-APR-1999; 99US-0127728P.
PR 30-MAR-2000; 2000US-00540763.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Shimkets RA, Leach M;
XX
XX WPI; 2000-602362/57.
DR P-PSDB; AAB43332.
XX
XX Novel nucleic acids and peptides derived from open reading frame X,
PT useful for treating e.g. cancers, proliferative disorders,
PT neurodegenerative disorders and cardiovascular disease.
XX
XX Claim 5; Page 5374-5376; 5507pp; English.
XX
XX AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,
CC which represent the human ORFX open reading frames 1 to 3161. The ORFX
CC sequences have activities such as: cytostatic; hepatotropic; vulnerary;
CC antiproliferative; antiparkinsonian; nontropic; neuroprotective; osteopathic;
CC anticonvulsant; antiarthritic; immunosuppressant; immunostimulant;
CC cardiant; thrombolytic; coagulant; vasotropic; antidiabetic; hypotensive;
CC dermatological; immunosuppressive; antiinflammatory; antibacterial;
CC antiviral; antifungal; antirheumatic; antithyroid; and antianemic. The
CC sequences can be used for determining the presence of or predisposition
CC to, or preventing or treating pathological conditions associated with an
CC ORFX-associated disorder. The nucleic acids can be used to express ORFX
CC proteins in gene therapy vectors. The proteins and nucleic acids may be
CC used to treat cancers, proliferative disorders, neurodegenerative
CC disorders, osteoarthritis, graft vs host disease, cardiovascular disease,
CC diabetes mellitus, hypertension, hypothyroidism, cholesterol ester
CC storage, systemic lupus erythematosus, severe combined immunodeficiency
CC (SCID), AIDS, viral, bacterial or fungal infection, malaria, autoimmune
CC disorders, asthma, allergies, aplastic anaemia, burns, wounds, bone and
CC cartilage damage, nocturnal haemoglobinuria, antiinflammatory disease; to
CC enhance coagulation; to inhibit thrombosis; and as a contraceptive
XX
XX Sequence 3021 BP; 732 A; 850 C; 881 G; 558 T; 0 U; 0 Other;
XX
Query Match 2.9%; Score 65.4; DB 3; Length 3021;
Best Local Similarity 63.5%; Pred. No. 0.00043;
Matches 99; Conservative 0; Mismatches 57; Indels 0; Gaps 0;
QY 2087 GCTGTCGACATCAATCCATCCATGATGCTGCTTTCCTTACACCTCTTCTCTTT 2146
DB 2841 GCACCTCACCCGACGACGATGCGCCCTTTCCTTACACCTCTTCTCTTT 2900
QY 2147 ATCTTATTAATAAAATGTTGGTCTCCACCACTGCTCCCAAAAAA 2206
DB 2901 CTGTTTACATTAATGTTCTGCCACAAAAA 2960
QY 2207 AAAAAA 2242
DB 2961 AAAAAA 2996
RESULT 1391
AAS03899
ID AAS03899 standard; cDNA; 3034 BP.
XX
XX AAS03899;
XX
XX 29-AUG-2001 (first entry)
XX
XX Human secreted protein gene #18.
XX
XX Human secreted protein; autoimmune disorder; hyperproliferative disorder;
XX cardiovascular disorder; cerebrovascular disorder; angiogenesis;
XX nervous system disorder; bacterial infection; viral infection; ss;
XX fungal infection; ocular disorder; wound healing; tissue regeneration;
XX epithelial cell proliferation; skin ageing; chemotaxis; IGF Fc region.
XX
XX
OS Homo sapiens.
XX
XX WO200123598-A1.
XX
XX 05-APR-2001.
XX
XX 26-SEP-2000; 2000WO-US026324.
XX
XX 27-SEP-1999; 99US-0155807P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Komatsoulis G, Ruben SM, Rosen CA;
XX
XX WPI; 2001-281684/29.
DR P-PSDB; AAU01943; AAU01981.
XX
XX Forty nucleic acid molecules encoding human secreted proteins, useful in
PT the prevention, treatment and diagnosis of cancer, immune disorders,
PT cardiovascular disorders and neurological diseases.
XX
XX Disclosure; Page 456-457; 518pp; English.
XX
XX Sequences AAS03873-AAS03922 represent isolated nucleic acid molecules and
CC PCR primers of the invention. acid of the invention. Secreted proteins
CC and their related nucleic acids can be used in the diagnosis of or
CC susceptibility to a pathological condition by determining the presence or
CC absence of a mutation in a nucleic acid or the presence or amount of
CC expression of a secreted protein. The sequences are used to prevent,
CC treat or ameliorate a medical condition in e.g. humans, mice, rabbits,
CC goats, horses, cats, dogs, chickens or sheep. The antibodies to the
CC polypeptides can also be used in alleviating symptoms associated with
CC disorders and in diagnostic immunoassays e.g. radioimmunoassays or enzyme
CC linked immunosorbent assays (ELISA). The disorders include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection.
CC The peptides can also be used to aid wound healing and epithelial cell
CC proliferation, to help prevent skin ageing due to sunburn, to maintain
CC organs before transplantation, to regenerate tissues, in chemotaxis and
CC as a food additive or preservative to alter storage capabilities
XX
XX Sequence 3034 BP; 1050 A; 459 C; 622 G; 900 T; 0 U; 3 Other;
XX
Query Match 2.9%; Score 65.4; DB 4; Length 3034;
Best Local Similarity 72.4%; Pred. No. 0.00043;
Matches 84; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
QY 2127 CTTTACCACTCTTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACTGCTCC 2186
DB 2911 CTCTGCTCTTACTTAGCTTGGATTAGAGTAAATAAAGTATCTCTGACTTCTGTT 2970
QY 2187 AAAAAA 2242
DB 2971 AAAAAA 3036
RESULT 1392
ABZ73661
ID ABZ73661 standard; cDNA; 3034 BP.
XX
XX ABZ73661;
XX
XX 12-MAY-2003 (first entry)
XX
XX Secreted protein-encoding gene 381 cDNA clone HE2CA60, SEQ ID NO:391.
XX
XX Human; secreted protein; cancer; tumour; hyperproliferative disorder;
XX autoimmune disorder; inflammation; angiogenic diseases; AIDS;
XX acquired immunodeficiency syndrome; hepatitis; anaemia; wound healing;
XX drug screening; chromosome identification; chromosome mapping;
```

```
KW cyostatic; gene therapy; antiinflammatory; immunomodulator; anti-HIV;
KW antianemic; vulnerary; gene; ss.
OS Homo sapiens.
PN WO200277013-A2.
PD 03-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-US009370.
XX
XX 27-MAR-2001; 2001US-0278650P.
PR 12-SEP-2001; 2001US-00950082.
PR 12-SEP-2001; 2001US-00950083.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Ruben SM;
XX
XX WPI; 2003-040578/03.
DR P-PSDB; ABR01327.
XX
XX New human secreted proteins and nucleic acids, useful for detecting or
PT treating cancer or other hyperproliferative disorders, autoimmune
PT disorders, inflammatory disorders, HIV disease, hepatitis or anemia.
XX
XX Claim 21; Page 1358-1359; 2474pp; English.
XX
XX ABZ73281-ABZ73697 represent cDNAs corresponding to 391 human secreted
CC protein genes, and ABP00947-ABP01363 represent the proteins they encode.
CC ABZ73698-ABZ74687 represent human secreted protein genomic fragments. The
CC invention also encompasses antibodies specific for the secreted proteins,
CC the use of the secreted proteins in drug screening and recombinant
CC vectors and host cells comprising a nucleic acid of the invention. The
CC secreted proteins are thought to be involved in biological activities
CC associated with cellular signalling, cellular differentiation, cell
CC migration, prohormone activation and neurotransmitter activity. The
CC secreted proteins, nucleic acids encoding them, antibodies or antibody
CC fragments specific for the secreted proteins, and modulators of protein
CC activity are useful for diagnosing or treating cancers or other
CC hyperproliferative disorders. Additionally, the secreted proteins and
CC their nucleic acids may also be used in the treatment of autoimmune
CC disorders, inflammatory disorders, diseases involving angiogenesis, AIDS
CC (acquired immunodeficiency syndrome), hepatitis, anaemia, and to promote
CC wound healing. Nucleic acids of the invention may be used for chromosome
CC identification, chromosome mapping, in gene therapy, for identifying
CC individuals from minute biological samples, as hybridisation probes, and
CC as molecular weight markers. The present sequence represents a human
CC secreted protein-encoding cDNA clone of the invention
XX
SQ Sequence 3034 BP; 1050 A; 459 C; 622 G; 900 T; 0 U; 3 Other;
Query Match 2.9%; Score 65.4; DB 8; Length 3034;
Best Local Similarity 72.4%; Pred. No. 0.00043;
Matches 84; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
Qy 2127 CTTTACCACCTCTTCTTTTATCTATTATAAATAATGTTGGTCTCCACCACCTGNCCTCC 2186
Db 2911 CTCTGCTCTACTAGCCCTTTGGATTAGAAATAAAGTATCTCTGACTTCTTCTGTT 2970
Qy 2187 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db 2971 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 3026
RESULT 1399
ADA98146
ID ADA98146 standard; cDNA; 3034 BP.
XX
XX ADA98146;
AC ADA98146;
XX
XX 20-NOV-2003 (first entry)
DT 20-NOV-2003 (first entry)
DE Human secreted protein gene sequence - SEQ ID No 103.
XX
```

```
DE Human secreted protein cDNA sequence #240.
XX
KW human; secreted protein; cardiovascular disorder; arrhythmia;
KW atherosclerosis; stroke; endocarditis; congestive heart failure;
KW rheumatic heart disease; cardiomyopathy; haemorrhoids; varicose veins;
KW migraine; thrombosis; neural disorder; immune system disorder;
KW muscular disorder; reproductive disorder; gastrointestinal disorder;
KW pulmonary disorder; renal disorder; proliferative disorder; cancer; gene;
KW ss.
XX
OS Homo sapiens.
XX
XX WO2003004623-A2.
XX
XX 16-JAN-2003.
XX
XX 26-MAR-2002; 2002WO-US009922.
XX
XX 27-MAR-2001; 2001US-0278650P.
PR 12-SEP-2001; 2001US-00950082.
PR 12-SEP-2001; 2001US-00950083.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Ruben SM;
XX
XX WPI; 2003-247946/24.
XX
XX New human secreted polypeptide and nucleic acid molecules, useful for
PT diagnosing, preventing, prognosticating or treating cardiovascular
PT disorders (e.g. arrhythmia, atherosclerosis, cardiomyopathy, or
PT thrombosis).
XX
XX Claim 1; SEQ ID NO 250; 1572pp; English.
XX
XX The invention comprises the amino acid and coding sequence of human
CC secreted proteins. The DNA and protein sequences of the invention are
CC useful in the treatment of cardiovascular disorders, such as: arrhythmia,
CC atherosclerosis, stroke, endocarditis, congestive heart failure,
CC rheumatic heart disease, cardiomyopathy, haemorrhoids, varicose veins,
CC migraine, or thrombosis. The DNA and protein sequences may also be used
CC for treating or preventing: neural disorders, immune system disorders,
CC muscular disorders, reproductive disorders, gastrointestinal disorders,
CC pulmonary disorders, renal disorders, proliferative disorders and/or
CC cancerous diseases. The present cDNA sequence encodes a human secreted
CC protein of the invention. NOTE: The present sequence is shown on the WIPO
CC website.
XX
SQ Sequence 3034 BP; 1050 A; 459 C; 622 G; 900 T; 0 U; 3 Other;
Query Match 2.9%; Score 65.4; DB 8; Length 3034;
Best Local Similarity 72.4%; Pred. No. 0.00043;
Matches 84; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
Qy 2127 CTTTACCACCTCTTCTTTTATCTATTATAAATAATGTTGGTCTCCACCACCTGNCCTCC 2186
Db 2911 CTCTGCTCTACTAGCCCTTTGGATTAGAAATAAAGTATCTCTGACTTCTTCTGTT 2970
Qy 2187 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db 2971 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 3026
RESULT 1394
ABT16854
ID ABT16854 standard; DNA; 3034 BP.
XX
XX ABT16854;
AC ABT16854;
XX
XX 03-APR-2003 (first entry)
DT 03-APR-2003 (first entry)
DE Human secreted protein gene sequence - SEQ ID No 103.
XX
```



```
XX FH Key Location/Qualifiers
XX FT CDS 1..4425
XX FT /*tag= a
XX FT /product= "Human CADECM protein"
XX PN WO2003047526-A2.
XX PD 12-JUN-2003.
XX PF 26-NOV-2002; 2002WO-US038437.
XX PR 30-NOV-2001; 2001US-0334343P.
XX PR 07-DEC-2001; 2001US-0340278P.
XX PR 04-JAN-2002; 2002US-0345069P.
XX PR 25-JAN-2002; 2002US-0351352P.
XX PR 14-FEB-2002; 2002US-0357168P.
XX PR 29-MAR-2002; 2002US-0369128P.
XX PR 05-APR-2002; 2002US-0370802P.
XX PA (INCY-) INCYTE GENOMICS INC.
XX PI Baughn MR, Becha SD, Bhatia U, Blake JJ, Borowsky ML, Burrill JD;
XX PI Deleageane AM, Elliott VS, Gandhi AR, Gietzen KJ, Corvad AE;
XX PI Griffin JA, Ho A, Jin P, Kable AE, Lal PG, Lee BA, Lee S, Lee SY;
XX PI Marquis JP, Lehr-Mason PM, Ramkumar J, Richardson TW, Sprague WM;
XX PI Swarnakar A, Tang TY, Tran B, Tran UK, Chawla NK, Warren BA, Xu Y;
XX PI Yue H, Zheng W;
XX PS WPI; 2003-513695/48.
XX DR P-PSDB; AAO30814.
XX PT New human cell adhesion and extracellular matrix proteins (CADECM)
XX PT polypeptide, useful for preparing a composition for treating a disease
XX PT associated with decreased expression or overexpression of CADECM e.g.,
XX PT cancer.
XX PS Claim 5; Page 339-340; 374pp; English.
XX CC The invention relates to human cell adhesion and extracellular matrix
XX CC proteins (CADECM) and nucleic acid molecules encoding such proteins.
XX CC CADECM proteins are useful for preparing a composition for diagnosing or
XX CC treating a disease or condition associated with decreased expression or
XX CC overexpression of functional CADECM e.g., immune disorders or cancer. The
XX CC invention is also useful in gene therapy. The present sequence is human
XX CC CADECM cDNA
XX SQ Sequence 4777 BP; 816 A; 1639 C; 1487 G; 835 T; 0 U; 0 Other;
Query Match 2.9%; Score 65.4; DB 9; Length 4777;
Best Local Similarity 68.2%; Pred. No. 0.0005;
Matches 90; Conservative 0; Mismatches 42; Indels 0; Gaps 0;
Qy 2111 CCAATGATCGCTTGGCTTACCACTCTTCCCTTTATCTTATTAATAAATGTTGGTC 2170
Db 4627 CCCAGGGGCCCTTTACATGCGCTCTCCCTTTTATATAAAATTTCCATTAACCACTA 4686
Qy 2171 TCCACCACTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2230
Db 4687 TTTTCTAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 4746
Qy 2231 AAAAAAATAAAAAA 2242
Db 4747 AAAAAAATAAAAAA 4758
RESULT 1397
AAS85462
ID AAS85462 standard; cDNA; 7295 BP.
XX AC AAS85462;
XX DT 13-FEB-2002 (first entry)
```

```
XX DE DNA encoding novel human diagnostic protein #21266.
XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
XX KW food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX OS Homo sapiens.
XX PN WO200175067-A2.
XX PD 11-OCT-2001.
XX PF 30-MAR-2001; 2001WO-US008631.
XX PR 31-MAR-2000; 2000US-00540217.
XX PR 23-AUG-2000; 2000US-00649167.
XX PA (HYSE-) HYSEQ INC.
XX PI Drmanac RT, Liu C, Tang YT;
XX PI WPI; 2001-639362/73.
XX DR P-PSDB; ABG21275.
XX PT New isolated polynucleotide and encoded polypeptides, useful in
XX PT diagnostics, forensics, gene mapping, identification of mutations
XX PT responsible for genetic disorders or other traits and to assess
XX PT biodiversity.
XX PS Claim 1; SEQ ID NO 21266; 103pp; English.
XX CC The invention relates to isolated polynucleotide (I) and polypeptide (II)
XX CC sequences. (I) is useful as hybridisation probes, polymerase chain
XX CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
XX CC and in recombinant production of (II). The polynucleotides are also used
XX CC in diagnostics as expressed sequence tags for identifying expressed
XX CC genes. (I) is useful in gene therapy techniques to restore normal
XX CC activity of (II) or to treat disease states involving (II). (II) is
XX CC polypeptide in tissue, as molecular weight markers and as a food
XX CC supplement. (II) and its binding partners are useful in medical imaging
XX CC of sites expressing (II). (I) and (II) are useful for treating disorders
XX CC involving aberrant protein expression or biological activity. The
XX CC polypeptide and polynucleotide sequences have applications in
XX CC diagnostics, forensics, gene mapping, identification of mutations
XX CC responsible for genetic disorders or other traits to assess biodiversity
XX CC and to produce other types of data and products dependent on DNA and
XX CC amino acid sequences. AAS64197-AAS94564 represent novel human diagnostic
XX CC coding sequences of the invention. Note: The sequence data for this
XX CC patent did not appear in the printed specification, but was obtained in
XX CC electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 7295 BP; 2239 A; 1437 C; 1505 G; 2114 T; 0 U; 0 Other;
Query Match 2.9%; Score 65.4; DB 5; Length 7295;
Best Local Similarity 72.4%; Pred. No. 0.00057;
Matches 84; Conservative 0; Mismatches 32; Indels 0; Gaps 0;
Qy 2127 CTTTACCACCTCTTTCCTTTTATCTTATTAATAAATGTTGGTCCACCACTGCTCC 2186
Db 6945 CTTTACCATGCCCAAAATCTCAATCATTAATAAAGCTGTTTCTCCAAAAA 7004
Qy 2187 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2242
Db 7005 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 7060
RESULT 1398
AAL34678
ID AAL34678 standard; cDNA; 181 BP.
XX AC AAL34678;
XX DT 13-FEB-2002 (first entry)
```

XX 08-JAN-2002 (first entry)  
DT Human musculoskeletal system related polynucleotide SEQ ID NO 20.  
DE  
DE  
XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;  
XX antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;  
KW vulnary; anticonvulsant; antibacterial; antifungal; antiparasitic;  
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;  
KW neurological disease; infection; human; secreted protein;  
KW musculoskeletal system; ss.  
OS  
OS Homo sapiens.  
XX  
XX W0200155367-A1.  
PN  
XX  
XX 02-AUG-2001.  
PD  
XX  
XX 17-JAN-2001; 2001WO-US001338.  
PF  
XX  
XX 31-JAN-2000; 2000US-0179065P.  
PR 04-FEB-2000; 2000US-0180628P.  
PR 24-FEB-2000; 2000US-0184664P.  
PR 02-MAR-2000; 2000US-0186350P.  
PR 16-MAR-2000; 2000US-0189874P.  
PR 17-MAR-2000; 2000US-0190076P.  
PR 18-APR-2000; 2000US-0198123P.  
PR 19-MAY-2000; 2000US-0205515P.  
PR 07-JUN-2000; 2000US-0209467P.  
PR 28-JUN-2000; 2000US-0214886P.  
PR 30-JUN-2000; 2000US-0215135P.  
PR 07-JUL-2000; 2000US-0216647P.  
PR 07-JUL-2000; 2000US-0216880P.  
PR 11-JUL-2000; 2000US-0217487P.  
PR 11-JUL-2000; 2000US-0217496P.  
PR 14-JUL-2000; 2000US-0218230P.  
PR 26-JUL-2000; 2000US-0220963P.  
PR 26-JUL-2000; 2000US-0220964P.  
PR 14-AUG-2000; 2000US-0224518P.  
PR 14-AUG-2000; 2000US-0224519P.  
PR 14-AUG-2000; 2000US-0225213P.  
PR 14-AUG-2000; 2000US-0225214P.  
PR 14-AUG-2000; 2000US-0225757P.  
PR 14-AUG-2000; 2000US-0225758P.  
PR 14-AUG-2000; 2000US-0225759P.  
PR 18-AUG-2000; 2000US-0226279P.  
PR 22-AUG-2000; 2000US-0226681P.  
PR 22-AUG-2000; 2000US-0226686P.  
PR 22-AUG-2000; 2000US-0227182P.  
PR 23-AUG-2000; 2000US-0227009P.  
PR 30-AUG-2000; 2000US-0228924P.  
PR 01-SEP-2000; 2000US-0229287P.  
PR 01-SEP-2000; 2000US-0229343P.  
PR 01-SEP-2000; 2000US-0229344P.  
PR 01-SEP-2000; 2000US-0229345P.  
PR 05-SEP-2000; 2000US-0229509P.  
PR 05-SEP-2000; 2000US-0229513P.  
PR 06-SEP-2000; 2000US-0230437P.  
PR 06-SEP-2000; 2000US-0230438P.  
PR 08-SEP-2000; 2000US-0231242P.  
PR 08-SEP-2000; 2000US-0231243P.  
PR 08-SEP-2000; 2000US-0231244P.  
PR 08-SEP-2000; 2000US-0231413P.  
PR 08-SEP-2000; 2000US-0231414P.  
PR 08-SEP-2000; 2000US-0232080P.  
PR 08-SEP-2000; 2000US-0232081P.  
PR 12-SEP-2000; 2000US-0231968P.  
PR 14-SEP-2000; 2000US-0232397P.  
PR 14-SEP-2000; 2000US-0232398P.  
PR 14-SEP-2000; 2000US-0232399P.  
PR 14-SEP-2000; 2000US-0232400P.  
PR 14-SEP-2000; 2000US-0232401P.  
PR 14-SEP-2000; 2000US-0233063P.  
PR 14-SEP-2000; 2000US-0233064P.  
PR 21-SEP-2000; 2000US-0233065P.  
PR 21-SEP-2000; 2000US-0234223P.  
PR 21-SEP-2000; 2000US-0234274P.  
PR 25-SEP-2000; 2000US-0234997P.  
PR 25-SEP-2000; 2000US-0234998P.  
PR 26-SEP-2000; 2000US-0235484P.  
PR 27-SEP-2000; 2000US-0235834P.  
PR 27-SEP-2000; 2000US-0235836P.  
PR 29-SEP-2000; 2000US-0236327P.  
PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 02-OCT-2000; 2000US-0237040P.  
PR 13-OCT-2000; 2000US-0239935P.  
PR 13-OCT-2000; 2000US-0239937P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-0241221P.  
PR 20-OCT-2000; 2000US-0241785P.  
PR 20-OCT-2000; 2000US-0241786P.  
PR 20-OCT-2000; 2000US-0241787P.  
PR 20-OCT-2000; 2000US-0241808P.  
PR 20-OCT-2000; 2000US-0241809P.  
PR 20-OCT-2000; 2000US-0241826P.  
PR 01-NOV-2000; 2000US-0244617P.  
PR 08-NOV-2000; 2000US-0246474P.  
PR 08-NOV-2000; 2000US-0246475P.  
PR 08-NOV-2000; 2000US-0246476P.  
PR 08-NOV-2000; 2000US-0246477P.  
PR 08-NOV-2000; 2000US-0246478P.  
PR 08-NOV-2000; 2000US-0246523P.  
PR 08-NOV-2000; 2000US-0246524P.  
PR 08-NOV-2000; 2000US-0246525P.  
PR 08-NOV-2000; 2000US-0246526P.  
PR 08-NOV-2000; 2000US-0246527P.  
PR 08-NOV-2000; 2000US-0246528P.  
PR 08-NOV-2000; 2000US-0246532P.  
PR 08-NOV-2000; 2000US-0246609P.  
PR 08-NOV-2000; 2000US-0246610P.  
PR 08-NOV-2000; 2000US-0246611P.  
PR 08-NOV-2000; 2000US-0246613P.  
PR 17-NOV-2000; 2000US-0249207P.  
PR 17-NOV-2000; 2000US-0249208P.  
PR 17-NOV-2000; 2000US-0249209P.  
PR 17-NOV-2000; 2000US-0249210P.  
PR 17-NOV-2000; 2000US-0249211P.  
PR 17-NOV-2000; 2000US-0249212P.  
PR 17-NOV-2000; 2000US-0249213P.  
PR 17-NOV-2000; 2000US-0249214P.  
PR 17-NOV-2000; 2000US-0249215P.  
PR 17-NOV-2000; 2000US-0249216P.  
PR 17-NOV-2000; 2000US-0249217P.  
PR 17-NOV-2000; 2000US-0249218P.  
PR 17-NOV-2000; 2000US-0249219P.  
PR 17-NOV-2000; 2000US-0249244P.  
PR 17-NOV-2000; 2000US-0249245P.  
PR 17-NOV-2000; 2000US-0249246P.  
PR 17-NOV-2000; 2000US-0249265P.  
PR 17-NOV-2000; 2000US-0249297P.  
PR 17-NOV-2000; 2000US-0249299P.  
PR 01-DEC-2000; 2000US-0249300P.  
PR 01-DEC-2000; 2000US-0250160P.  
PR 05-DEC-2000; 2000US-0250391P.  
PR 05-DEC-2000; 2000US-0251030P.

PR 05-DEC-2000; 2000US-0251988P.  
 PR 06-DEC-2000; 2000US-0256719P.  
 PR 06-DEC-2000; 2000US-0251479P.  
 PR 08-DEC-2000; 2000US-0251856P.  
 PR 08-DEC-2000; 2000US-0251868P.  
 PR 08-DEC-2000; 2000US-0251869P.  
 PR 08-DEC-2000; 2000US-0251989P.  
 PR 08-DEC-2000; 2000US-0251990P.  
 PR 11-DEC-2000; 2000US-0254097P.  
 PR 05-JAN-2001; 2001US-0259678P.  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 XX  
 XX Rosen CA, Barash SC, Ruben SM;  
 XX WPI; 2001-451937/48.  
 DR P-PSDB; ABB03096.  
 XX  
 XX Isolated polypeptide for treating, preventing and/ or prognosing  
 PT disorders related to the musculoskeletal system including musculoskeletal  
 PT cancers and also for testing and detection e.g. diagnosis.  
 XX  
 XX Claim 1; SEQ ID NO 20; 781pp + Sequence Listing; English.  
 PS  
 XX The invention relates to novel genes (AAL34669-AAL37666) and proteins  
 CC (ABB03087-ABB04109) associated with the musculoskeletal system useful for  
 CC preventing, treating or ameliorating medical conditions e.g. by protein  
 CC or gene therapy. The genes are isolated from a range of human tissues  
 CC disclosed in the specification. The nucleic acids, proteins, antibodies  
 CC and (ant)agonists are useful in the diagnosis, treatment and prevention  
 CC of: (a) cancer, e.g. breast and ovarian cancer and other cancers of the  
 CC adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver,  
 CC lung, or urogenital; (b) immune disorders e.g. Addison's disease,  
 CC allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,  
 CC diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid  
 CC arthritis and ulcerative colitis; (c) cardiovascular disorders such as  
 CC myocardial ischaemias; (d) wound healing; (e) neurological diseases e.g.  
 CC cerebral anoxia and epilepsy; and (f) infectious diseases such as viral,  
 CC bacterial, fungal and parasitic infections. Note: The sequence data for  
 CC this patent did not form part of the printed specification, but was  
 CC obtained in electronic format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 XX SQ Sequence 181 BP; 98 A; 15 C; 40 G; 27 T; 0 U; 1 Other;  
 Query Match 2.9%; Score 65.2; DB 4; Length 181;  
 Best Local Similarity 76.7%; Pred. No. 0.0002;  
 Matches 79; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
 Qy 2140 TCCTTTTATCTATTATAAATAATGTTGGTCTCCACCACTGCTCCCAAAAAA 2199  
 Db 52 TCGTTGGAGTTTAAATGAGGGTCTTGGCAAGTAACACTGATGTCGAAAAA 111  
 Qy 2200 AAAAAA 2242  
 Db 112 AAAAAA 154  
 RESULT 1399  
 ABX57666  
 ID ABX57666 standard; cDNA; 181 BP.  
 XX  
 XX AC ABX57666;  
 XX  
 XX 26-FEB-2003 (first entry)  
 XX cDNA encoding novel human musculoskeletal system antigen #10.  
 DE Gene; ss; musculoskeletal system antigen; cancer; metastasis;  
 XX re-vascularisation; thrombosis; arteriosclerosis; mineral content;  
 KW cardiovascular condition; wound; injury; burn; angiogenesis; ulcer;  
 KW post-operative tissue repair; limb regeneration; neuronal growth;  
 KW neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;

KW ADRS-related complex; chondrocyte growth; bone regeneration;  
 KW periodontal regeneration; tissue transport; bone graft; skin aging;  
 KW keratinocyte growth; hair loss; melanocyte growth; cell proliferation;  
 KW cell growth; organ transplant; cell differentiation; body height; weight;  
 KW hair colour; eye colour; skin; percentage of adipose tissue;  
 KW pigmentation; cosmetic surgery; metabolism; biorhythm; circadian rhythm;  
 KW depression; tendency for violence; pain; reproductive capability;  
 KW hormone level; endocrine level; appetite; libido; memory; stress;  
 KW storage capability; fat content; lipid content; protein content;  
 KW carbohydrate content; vitamin content; cofactor content;  
 KW nutritional component.  
 XX  
 XX Homo sapiens.  
 OS  
 XX US2002147140-A1.  
 XX  
 XX 10-OCT-2002.  
 PD  
 XX  
 XX 17-JAN-2001; 2001US-00764877.  
 PF  
 XX 31-JAN-2000; 2000US-0179065P.  
 PR 04-FEB-2000; 2000US-0180628P.  
 PR 28-JUN-2000; 2000US-0214896P.  
 PR 07-JUL-2000; 2000US-0216647P.  
 PR 07-JUL-2000; 2000US-0216880P.  
 PR 11-JUL-2000; 2000US-0217487P.  
 PR 11-JUL-2000; 2000US-0217496P.  
 PR 14-JUL-2000; 2000US-0218290P.  
 PR 26-JUL-2000; 2000US-0220963P.  
 PR 26-JUL-2000; 2000US-0220964P.  
 PR 14-AUG-2000; 2000US-0224518P.  
 PR 14-AUG-2000; 2000US-0224519P.  
 PR 14-AUG-2000; 2000US-0225267P.  
 PR 14-AUG-2000; 2000US-0225268P.  
 PR 14-AUG-2000; 2000US-0225270P.  
 PR 14-AUG-2000; 2000US-0225447P.  
 PR 14-AUG-2000; 2000US-0225757P.  
 PR 14-AUG-2000; 2000US-0225758P.  
 PR 22-AUG-2000; 2000US-0226868P.  
 PR 30-AUG-2000; 2000US-0228924P.  
 PR 01-SEP-2000; 2000US-0229287P.  
 PR 01-SEP-2000; 2000US-0229343P.  
 PR 01-SEP-2000; 2000US-0229344P.  
 PR 01-SEP-2000; 2000US-0229345P.  
 PR 05-SEP-2000; 2000US-0229509P.  
 PR 05-SEP-2000; 2000US-0229513P.  
 PR 08-SEP-2000; 2000US-0231413P.  
 PR 21-SEP-2000; 2000US-0234223P.  
 PR 21-SEP-2000; 2000US-0234274P.  
 PR 25-SEP-2000; 2000US-0234997P.  
 PR 27-SEP-2000; 2000US-0235834P.  
 PR 29-SEP-2000; 2000US-0236327P.  
 PR 29-SEP-2000; 2000US-0236367P.  
 PR 29-SEP-2000; 2000US-0236368P.  
 PR 29-SEP-2000; 2000US-0236369P.  
 PR 29-SEP-2000; 2000US-0236370P.  
 PR 02-OCT-2000; 2000US-0236802P.  
 PR 02-OCT-2000; 2000US-0237037P.  
 PR 02-OCT-2000; 2000US-0237038P.  
 PR 02-OCT-2000; 2000US-0237039P.  
 PR 02-OCT-2000; 2000US-0237040P.  
 PR 13-OCT-2000; 2000US-0239935P.  
 PR 20-OCT-2000; 2000US-0240960P.  
 PR 20-OCT-2000; 2000US-0241785P.  
 PR 20-OCT-2000; 2000US-0241809P.  
 PR 01-NOV-2000; 2000US-0244617P.  
 PR 17-NOV-2000; 2000US-0249299P.  
 PR 08-DEC-2000; 2000US-0251856P.  
 PR 08-DEC-2000; 2000US-0251868P.  
 PR 08-DEC-2000; 2000US-0251869P.  
 XX (ROSE/) ROSEN C A.  
 PA (RUBE/) RUBEN S M.



```
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241788P.
PR 20-OCT-2000; 2000US-0241789P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 01-DEC-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 06-DEC-2000; 2000US-0256719P.
PR 08-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251866P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.

PR 17-JAN-2001; 2001US-00764877.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Rosen CA, Ruben SM, Barash SC;
XX WPI; 2004-090458/09.
XX P-PSDB; ADJ28416.
XX New nucleic acid molecule, useful for preparing a medicament for
PT preventing, treating or ameliorating a medical condition e.g., cancer of
PT musculoskeletal tissues or osteoporosis.
XX Claim 4; SEQ ID NO 20; 289pp; English.
XX The invention relates to a novel isolated musculoskeletal system-
CC associated nucleic acid molecule. The nucleic acid of the invention
CC demonstrates cytostatic and osteopathic activities and may be useful for
CC preparing a medicament for preventing, treating or ameliorating a medical
CC condition such as cancer of the musculoskeletal tissues or osteoporosis,
CC possibly via gene therapy or vaccine production. The current sequence is
CC that of the human musculoskeletal system-associated contig DNA of the
CC invention. The current sequence is not shown within the specification per
CC se but is available on the USPTO web-site
CC http://seqdata.uspto.gov/sequence.html?DocID=20040009488.
XX
XX Sequence 181 BP; 98 A; 15 C; 40 G; 27 T; 0 U; 1 Other;
XX
XX Query Match 2.9%; Score 65.2; DB 12; Length 181;
XX Best Local Similarity 76.7%; Pred. No. 0.0002;
XX Matches 79; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 2140 TCCTTTTATCTTATTAATAAAATGTTGGTCTCCACCACCTGCTCCCAAAAAA 2199
DB 52 TCGTTGGAGTTTAAATGAGGGTCTTGGCAAGTAACACTGATCTCTGAAAAA 111
QY 2200 AAAAAA 2242
DB 112 AAAAAA 154
RESULT 1401
ADL10902
ID ADL10902 standard; cDNA; 273 BP.
XX
XX AC ADL10902;
XX
XX DT 01-JUL-2004 (first entry)
XX Cat flea hindgut and malpighian tubule (HMT) protein cDNA #1307.
XX DE
XX KW Flea; head and nerve cord protein; HNC;
XX KW hindgut and malpighian tubule protein; HMT; flea infestation;
XX KW anti-arthropod vaccine; chemotherapeutic drug; insecticide; gene; ss;
XX cat flea.
XX OS Ctenocephalides felis.
XX
XX FN US2004067516-A1.
XX
XX PD 08-APR-2004.
XX
XX PF 16-JUL-2003; 2003US-00621901.
XX
XX PR 22-JUL-2002; 2002US-0319414P.
XX (BRAN)/ BRANDT K S.
XX PA (GAIN)/ GAINES P J.
XX PA (STIN)/ STINCHCOMB D T.
XX PA (WISN)/ WISNEWSKI N.
XX Brandt KS, Gaines PJ, Stinchcomb DT, Wisniewski N;
XX
```



```
PR 21-MAR-2000; 2000US-0191031P.
PR 25-MAY-2000; 2000US-0207124P.
PR 15-JUN-2000; 2000US-0211940P.
PR 07-JUL-2000; 2000US-0216820P.
PR 25-JUL-2000; 2000US-0220661P.
PR 21-DEC-2000; 2000US-0257672P.
XX
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
XX Lee J, Lillie J;
XX WPI; 2001-611502/70.
XX
XX Novel isolated nucleic acid molecules (markers) overexpressed in ovarian
XX cancer cells as compared to their normal non-cancerous ovarian cells are
XX used to characterize stage, grade, histological type of ovarian cancer.
XX
XX Disclosure; SEQ ID NO 6389; 106pp; English.
XX
XX The invention relates to nucleic acid markers which are overexpressed in
XX ovarian cancer cells. The invention also relates to polypeptides
XX encoded by the markers, antibodies that selectively bind to the
XX polypeptides, a method of inhibiting ovarian cancer in a patient at risk
XX of developing ovarian cancer comprising providing to cells of
XX the patient an antisense oligonucleotide complementary to a marker of the
XX invention. The markers are useful for assessing if a patient is afflicted
XX with ovarian cancer, which involves comparing the level of expression of
XX a marker in a patient sample and a normal level of expression of the
XX marker in a control non-ovarian cancer sample. A difference between the
XX expression levels indicates ovarian cancer. The level of expression of a
XX marker corresponds to a secreted protein or to a transcribed
XX polynucleotide or its portion. The level of expression of the marker is
XX assessed by detecting the presence in the sample, a protein or protein
XX fragment corresponding to the marker. The presence of protein or protein
XX fragment is detected using an antibody that specifically binds with the
XX marker. The marker is assessed by detecting the presence of a transcribed
XX polynucleotide which anneals with the marker or anneals with a portion of
XX the polynucleotide comprising the marker, under stringent conditions. The
XX marker is also used for monitoring the progression of ovarian cancer in a
XX patient which involves detecting expression of the marker in a patient
XX sample at a first point in time, repeating the method at a subsequent
XX time and comparing the level of expression. The method is carried out
XX using an ovarian tissue sample. A composition comprising a marker,
XX polypeptide or antibody of the invention is used to treat ovarian cancer.
XX This sequence represents a human ovarian cancer DNA marker of the
XX invention. Note: The sequence data for this patent did not form part of
XX the printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 318 BP; 65 A; 25 C; 30 G; 158 T; 0 U; 40 Other;
XX
XX Query Match 2.9%; Score 65.2; DB 5; Length 318;
XX Best Local Similarity 71.0%; Pred. No. 0.00024;
XX Matches 76; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
XX
XX 2136 TCTTCTCTTTTATCTATTATAAATAATGTTGGTCTCCACCACCTGCTCCCAAAAAA 2195
XX 162 TNNNNNTTTTAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 103
XX
XX 2196 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2242
XX 102 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 56
XX
XX RESULT 1404
XX ADL38776/C
XX ID ADL38776 standard; DNA; 318 BP.
XX
XX AC ADL38776;
XX
XX 20-MAY-2004 (first entry)
XX Human ovarian cancer DNA marker #12666.
XX Human; ovarian cancer; ds; tumour; cytostatic; DNA marker.
XX Homo sapiens.
XX WO200170979-A2.
XX 27-SEP-2001.
XX
XX 21-MAR-2001; 2001WO-US009126.
XX 21-MAR-2000; 2000US-0191031P.
XX 25-MAY-2000; 2000US-0207124P.
XX 15-JUN-2000; 2000US-0211940P.
XX 07-JUL-2000; 2000US-0216820P.
XX 25-JUL-2000; 2000US-0220661P.
XX 21-DEC-2000; 2000US-0257672P.
XX
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
XX Lee J, Lillie J;
XX WPI; 2001-611502/70.
XX
XX Novel isolated nucleic acid molecules (markers) overexpressed in ovarian
XX cancer cells as compared to their normal non-cancerous ovarian cells are
XX used to characterize stage, grade, histological type of ovarian cancer.
XX
XX Disclosure; SEQ ID NO 12666; 106pp; English.
XX
XX The invention relates to nucleic acid markers which are overexpressed in
XX ovarian cancer cells as compared to their expression in normal (i.e. non-
XX cancerous) ovarian cells. The invention also relates to polypeptides
XX encoded by the markers, antibodies that selectively bind to the
XX polypeptides, a method of inhibiting ovarian cancer in a patient at risk
XX of developing ovarian cancer comprising providing to cells of
XX the patient an antisense oligonucleotide complementary to a marker of the
XX invention. The markers are useful for assessing if a patient is afflicted
XX with ovarian cancer, which involves comparing the level of expression of
XX a marker in a patient sample and a normal level of expression of the
XX marker in a control non-ovarian cancer sample. A difference between the
XX expression levels indicates ovarian cancer. The level of expression of a
XX marker corresponds to a secreted protein or to a transcribed
XX polynucleotide or its portion. The level of expression of the marker is
XX assessed by detecting the presence in the sample, a protein or protein
XX fragment corresponding to the marker. The presence of protein or protein
XX fragment is detected using an antibody that specifically binds with the
XX marker. The marker is assessed by detecting the presence of a transcribed
XX polynucleotide which anneals with the marker or anneals with a portion of
XX the polynucleotide comprising the marker, under stringent conditions. The
XX marker is also used for monitoring the progression of ovarian cancer in a
XX patient which involves detecting expression of the marker in a patient
XX sample at a first point in time, repeating the method at a subsequent
XX time and comparing the level of expression. The method is carried out
XX using an ovarian tissue sample. A composition comprising a marker,
XX polypeptide or antibody of the invention is used to treat ovarian cancer.
XX This sequence represents a human ovarian cancer DNA marker of the
XX invention. Note: The sequence data for this patent did not form part of
XX the printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 318 BP; 65 A; 25 C; 30 G; 158 T; 0 U; 40 Other;
XX
XX Query Match 2.9%; Score 65.2; DB 5; Length 318;
XX Best Local Similarity 71.0%; Pred. No. 0.00024;
XX Matches 76; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
XX
XX 2136 TCTTCTCTTTTATCTATTATAAATAATGTTGGTCTCCACCACCTGCTCCCAAAAAA 2195
XX 162 TNNNNNTTTTAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 103
XX
XX 2196 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 2242
XX 102 AAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 56
XX
XX RESULT 1404
XX ADL38776/C
XX ID ADL38776 standard; DNA; 318 BP.
XX
XX AC ADL38776;
XX
XX 2136 TCTTCTCTTTTATCTATTATAAATAATGTTGGTCTCCACCACCTGCTCCCAAAAAA 2195
```

```
Db      162 TNNNNNTTTTAAAAAATGGGCCNNNNNTNTTTTAAAAAATA 103
QY      2196 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
Db      102 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 56

RESULT 1405
ABV06120/c
ID ABV06120 standard; cDNA; 327 BP.
XX AC ABV06120;
XX XX
XX DT 13-SEP-2002 (first entry)
XX DE Human prostate expression marker cDNA 6111.
XX KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
XX KW pharmacogenomic marker; gene; ss.
XX OS Homo sapiens.
XX PN WO200160860-A2.
XX PD 23-AUG-2001.
XX PF 20-FEB-2001; 2001WO-US005171.
XX PR 17-FEB-2000; 2000US-0183319P.
XX PR 16-MAR-2000; 2000US-0189862P.
XX PR 25-MAY-2000; 2000US-0207454P.
XX PR 09-JUN-2000; 2000US-0211314P.
XX PR 18-JUL-2000; 2000US-0219007P.
XX PR 13-DEC-2000; 2000US-0255281P.
XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX PI Schlegel R, Endege WO, Monahan JE;
XX DR WPI; 2001-662795/76.
XX PT Novel isolated nucleic acid molecule associated with cancerous state of
XX PT prostate cells and correlating with presence of prostate cancer, useful
XX PT for detecting presence of prostate cancer, stage of prostate cancer.
XX PS Claim 1; Page 1012; 11750pp; English.
XX CC The invention relates to an isolated nucleic acid molecule (I) comprising
XX CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
XX CC specification or its complement. (I) is useful for: (a) assessing whether
XX CC a patient is afflicted with prostate cancer; (b) monitoring the efficacy
XX CC of progression of prostate cancer in a patient; (c) assessing the efficacy
XX CC of a test compound to inhibit prostate cancer in a patient; (d) assessing
XX CC the efficacy of a therapy for inhibiting prostate cancer in a patient;
XX CC (e) selecting a composition for inhibiting prostate cancer in a patient;
XX CC (f) assessing the prostate cell carcinogenic potential of a compound; (g)
XX CC determining whether prostate cancer has metastasized in a patient; (h)
XX CC assessing the aggressiveness or indolence of prostate cancer in a patient
XX CC ; (I) is also useful as a pharmacodynamic or pharmacogenomic marker
XX SQ Sequence 327 BP; 86 A; 30 C; 20 G; 150 T; 0 U; 41 Other;

Query Match      2.9%; Score 65.2; DB 5; Length 327;
Best Local Similarity 72.3%; Pred. No. 0.00024;
Matches 73; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY      2142 CTTTATCTTATTAATAAATGTGCTCCACCACTGCTCCCAAAAAAAAAAAAAA 2201
Db      159 CTTTANANNNTTANNNAANTTTGNTTACNTTAAAAAATAAAAAAAAAAAAAA 100
QY      2202 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2242
|||||
```

```
Db      99 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 59

RESULT 1406
ABV60906/c
ID ABV60906 standard; cDNA; 337 BP.
XX AC ABV60906;
XX DT 13-SEP-2002 (first entry)
XX DE Human prostate expression marker cDNA 60897.
XX KW Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
XX KW pharmacogenomic marker; gene; ss.
XX OS Homo sapiens.
XX PN WO200160860-A2.
XX PD 23-AUG-2001.
XX PF 20-FEB-2001; 2001WO-US005171.
XX PR 17-FEB-2000; 2000US-0183319P.
XX PR 16-MAR-2000; 2000US-0189862P.
XX PR 25-MAY-2000; 2000US-0207454P.
XX PR 09-JUN-2000; 2000US-0211314P.
XX PR 18-JUL-2000; 2000US-0219007P.
XX PR 13-DEC-2000; 2000US-0255281P.
XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX PI Schlegel R, Endege WO, Monahan JE;
XX DR WPI; 2001-662795/76.
XX PT Novel isolated nucleic acid molecule associated with cancerous state of
XX PT prostate cells and correlating with presence of prostate cancer, useful
XX PT for detecting presence of prostate cancer, stage of prostate cancer.
XX PS Claim 1; Page 11580; 11750pp; English.
XX CC The invention relates to an isolated nucleic acid molecule (I) comprising
XX CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
XX CC specification or its complement. (I) is useful for: (a) assessing whether
XX CC a patient is afflicted with prostate cancer; (b) monitoring the efficacy
XX CC of progression of prostate cancer in a patient; (c) assessing the efficacy
XX CC of a test compound to inhibit prostate cancer in a patient; (d) assessing
XX CC the efficacy of a therapy for inhibiting prostate cancer in a patient;
XX CC (e) selecting a composition for inhibiting prostate cancer in a patient;
XX CC (f) assessing the prostate cell carcinogenic potential of a compound; (g)
XX CC determining whether prostate cancer has metastasized in a patient; (h)
XX CC assessing the aggressiveness or indolence of prostate cancer in a patient
XX CC ; (I) is also useful as a pharmacodynamic or pharmacogenomic marker
XX SQ Sequence 337 BP; 87 A; 34 C; 84 G; 132 T; 0 U; 0 Other;

Query Match      2.9%; Score 65.2; DB 5; Length 337;
Best Local Similarity 83.9%; Pred. No. 0.00024;
Matches 73; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY      2156 ATAAAAATGTTGGTCTCCACCACTGCTCCCAAAAAAAAAAAAAA 2242
Db      96 AAAAAATTTGGGGTTCCTCCCAAAAAAAAAAAAAA 37
QY      2216 AAAAAAAAAAAAAAAAAAAAAA 2242
Db      36 AAAAAAAAAAGAAAAA 10

RESULT 1407
AAL14593/c
```

```
ID AAL14593 standard; cDNA; 368 BP.
AC AAL14593;
XX
XX
XX 07-DEC-2001 (first entry)
XX
XX Human breast cancer expressed polynucleotide 7050.
XX Human; breast cancer; cell marker; cytostatic; ss.
XX Homo sapiens.
OS
XX WO200151628-A2.
PN
XX 19-JUL-2001.
PD
XX
XX 10-JAN-2001; 2001WO-US000798.
PF
XX 14-JAN-2000; 2000US-0176077P.
PR
XX 14-MAR-2000; 2000US-0189167P.
PR
XX 24-MAR-2000; 2000US-0192099P.
PR
XX 29-MAR-2000; 2000US-0193480P.
PR
XX 15-MAY-2000; 2000US-0205230P.
PR
XX 09-JUN-2000; 2000US-0211315P.
PR
XX 25-JUL-2000; 2000US-0220534P.
XX
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
PA
XX Lillie J, Xu Y, Wang Y, Steinmann K;
XX WPI; 2001-451856/48.
XX
XX New peptide useful as a marker for the diagnosis of breast cancer.
XX
XX Claim 1; Page 1275; 3695pp; English.
XX
XX The invention relates to human breast cancer expressed polynucleotides
XX (AAL07544-AAL26789) and methods of assessing whether a patient is
XX afflicted with breast cancer by examining the correlation between the
XX expression of certain markers and the cancerous state of breast cells.
XX The polynucleotides and encoded polypeptides are potential markers for
XX detecting, diagnosing, monitoring, characterising treating and
XX potentially preventing breast cancer. The polynucleotides and encoded
XX polypeptides are also useful for isolating compounds with cytostatic
XX activity
XX
XX Sequence 368 BP; 86 A; 47 C; 26 G; 158 T; 0 U; 51 Other;
XX
XX Query Match 2.9%; Score 65.2; DB 4; Length 368;
XX Best Local Similarity 64.5%; Pred. No. 0.00025;
XX Matches 80; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
XX
QY 2119 CGCCTTTCCTTACCACCTCTTCTTTTATCTTATTAATAAAATGTTGCTCCACCAC 2178
Dy ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Dy 160 CCCCTTNTNTNANANANTTGNACCCTTNNATTTNNCTTCAATTAAGTNNNAAA 101
QY 2179 TGNCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2238
Dy ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Dy 100 AGNTTCNAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 41
QY 2239 AAAA 2242
Dy |||||
Dy 40 AAAA 37
XX
XX RESULT 1408
XX ACH48825
XX ID ACH48825 standard; cDNA; 410 BP.
XX AC ACH48825;
XX
XX 13-OCT-2003 (first entry)
XX
XX
```

```
DE Human leukocyte cDNA #419.
XX
XX Human; ss; sequencing by hybridisation; SBH; expressed sequence tag; EST;
XX genome mapping; biodiversity; genetic disorder.
XX
XX Homo sapiens.
XX
XX US2003073623-A1.
XX
XX 17-APR-2003.
XX
XX 30-JUL-2001; 2001US-00918995.
XX
XX 30-JUL-2001; 2001US-00918995.
XX
XX (DRMA/) DRMANAC R T.
XX (LABA/) LABAT I.
XX (STAC/) STACHE-CRAIN B.
XX (DICK/) DICKSON M C.
XX (JONE/) JONES L W.
XX
XX Drmanac RT, Labat I, Stache-Crain B, Dickson MC, Jones LW;
XX
XX WPI; 2003-615964/58.
XX
XX New polynucleotide sequences obtained from various cDNA libraries, useful
XX as hybridization probes, as oligomers for PCR, for chromosome and gene
XX mapping, in the recombinant production of protein, or in generating
XX antisense DNA or RNA.
XX
XX Claim 1; SEQ ID NO 36037; 44pp; English.
XX
XX The invention relates to an isolated polynucleotide comprising any one of
XX 38043 cDNA sequences, appearing as ACH12789-ACH50831, whose sequence was
XX determined by the technique of SBH (sequencing by hybridisation). Also
XX included is a purified polypeptide comprising a sequence corresponding to
XX a reading frame of the novel polynucleotide. The nucleic acid sequences
XX are useful in diagnostics as expressed sequence tags (EST) for
XX identifying expressed genes or for physical mapping of the human genome,
XX in forensics, in assessing biodiversity, or in identifying mutations
XX responsible for genetic disorders and other traits. The nucleotide
XX sequences are also useful as hybridisation probes, as oligomers for PCR,
XX for chromosome and gene mapping, in the recombinant production of
XX protein, or in generating antisense DNA or RNA. The purified polypeptide
XX is useful for generating antibodies specific for it. The present sequence
XX is one of the 38043 isolated cDNA/EST sequences. Note: The sequence data
XX for this patent did not form part of the printed specification, but was
XX obtained in electronic format directly from USPTO at
XX seqdata.uspto.gov/sequence.html?DocID=20030073623
XX
XX Sequence 410 BP; 173 A; 48 C; 83 G; 106 T; 0 U; 0 Other;
XX
XX Query Match 2.9%; Score 65.2; DB 9; Length 410;
XX Best Local Similarity 65.7%; Pred. No. 0.00026;
XX Matches 94; Conservative 0; Mismatches 49; Indels 0; Gaps 0;
XX
QY 2100 AATCATTTCCATCCATCATCGCTTTCCTTTTACCACCTCTTCTTTTATTAATAA 2159
Dy ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Dy 117 AATAGGCCCTTTTATGTGTTGCTTCTATTTTACTCTCAANTGTAGATATAGGGTAATCA 176
QY 2160 AAATGTTGGTCTCCACCACCTGNCCTCCCAAAAAAAAAAAAAAAAAAAAAA 2219
Dy ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Dy 177 TAAATCCATCCATCGCTTTCACACGCTAAAAAAAAAAAAAAAAAAAAA 236
QY 2220 AAAAAAAAAAAAAAAAAAAAAA 2242
Dy ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Dy 237 AAAAAAAAAAAAAAAAAAAAAA 259
XX
XX RESULT 1409
XX ACN45312/C
XX ID ACN45312 standard; cDNA; 552 BP.
XX
XX
```



Query Match      2.9%;    Score 65.2;    DB 4;    Length 643;

The invention relates to an isolated polypeptide encoded by a breast cancer marker gene comprising any of 1417-21-805 nucleotide sequences, given in the specification. The methods of the invention are useful for diagnosing patients having an identified breast mass or symptoms associated with breast cancer, to diagnose breast cancer or its precursors, and for monitoring the efficacy of treatment of a breast cancer patient (e.g. efficacy of chemotherapy). The methods are also useful for evaluating a patient before, after or during therapy, to evaluate the reduction in a tumour burden. The breast cancer marker genes are useful as immunogens for raising antibodies, by immunising mammal with a breast cancer marker protein. The marker proteins are useful as bait proteins in a two-hybrid or three-hybrid assay, to identify other proteins which bind to or interact with the marker proteins. The breast cancer marker genes are useful as surrogate marker genes for one or more disorders, disease states or conditions leading to disease states, in particular, breast cancers. The breast cancer marker genes are useful as pharmacodynamic marker genes. An antibody which selectively binds to a protein of a breast cancer marker gene is useful for treating cancers, particularly breast cancers. The host cell of the invention is useful for producing non-human transgenic animals. This





PS Claim 60a; Page 252-253; 282pp; English.

XX This invention describes novel human secreted proteins which are encoded by polynucleotides obtained from fetal brain, adult skin, adult brain, adult heart, adult thymus and adult aorta cDNA libraries. The polynucleotides and proteins are predicted to have biological activities which would make them suitable for treating, preventing or ameliorating medical conditions in humans and animals, although no supporting data is given. Suggested activities include nutritional activity, cytokine and cell proliferation/differentiation activity, immune stimulating (e.g. as vaccines) or suppressing activity, hematopoiesis regulating activity, tissue growth activity, activin/inhibin activity, chemotactic/chemokinetic activity, hemostatic and thrombolytic activity, receptor/ligand activity, anti-inflammatory activity, cadherin/tumor invasion suppressor activity, and tumor inhibition activity. The polynucleotides are also stated to be useful for gene therapy. AAZ43777-243808 represent the polynucleotides described in the invention which encode the proteins represented in AAV50905-Y50947

XX Sequence 1493 BP; 429 A; 356 C; 492 G; 216 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.2; DB 3; Length 1493;  
Best Local Similarity 67.4%; Pred. No. 0.00038;  
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCCAATGATGCGCTTTGCTTTTACCACCTCTTTCTTTTATCTTATTAATAAAATGTTG 2167  
DB 1333 CCTTAAACACGACCTCTCATCACTTAATCTAGCCCTTGCCCTTGAAATAACTTAGC 1392

QY 2168 GTCTCCACCACCTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227  
DB 1393 TGCCCCACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATA 1452

QY 2228 AAAAAAATAAAAAA 2242  
DB 1453 AAAAAAATAAAAAA 1467

RESULT 1417  
AAD20261/C  
ID AAD20261 standard; DNA; 1513 BP.  
XX  
AC AAD20261;  
XX  
DT 03-JAN-2002 (first entry)  
XX  
DE Rat integrin modulating agent responsive nucleic acid, KEANOX20.  
XX  
KW Rat; integrin modulating agent; KEANOX; cyclic peptide; fibronectin;  
KW collagen; laminin; cell surface protein; antiinflammatory; ds.  
XX  
OS Rattus sp.  
XX  
PN WO200174860-A2.  
XX  
PD 11-OCT-2001.  
XX  
PF 02-APR-2001; 2001WO-US040423.  
XX  
PD 31-MAR-2000; 2000US-0193629P.  
XX  
PA (CURA-) CURAGEN CORP.  
PA (BIOJ) BIOGEN INC.  
XX  
PI De Fougères A, Carulli J, Kotelianski V, Green C, Hsu A;  
XX WPI; 2001-626384/72.  
XX  
XX Identifying integrin modulating agent by identifying changes in  
PT expression patterns of multiple nucleic acid sequences expressed in  
PT monocytes following exposure to integrin modulating agents.  
XX  
PS Claim 13; Page 26-27; 67pp; English.

XX The present invention relates to a method for identifying integrin modulating agent, comprising contacting a test cell population having a cell expressing nucleic acid sequences chosen from KEANOX 1-259 and 260 with a test agent, measuring expression of one or more of the nucleic acid sequences in test cell population, comparing it to the expression of nucleic acid sequences in a reference cell population and identifying a difference in expression levels of the KEANOX sequence. The method is useful for identifying integrin modulating agents, which include integrin activators, integrin inhibitors, endogenous and exogenous ligands and integrin-binding proteins. The inhibitors include small molecules, e.g. cyclic peptides, peptidomimetics, antibodies, e.g. LM609, an alphabeta3-disrupting antibody and tight-binding inhibitors e.g. BIO-1211 which inhibits integrin-mediated inflammation and the integrin binding proteins include intracellular, extracellular and plasma membrane-associated proteins involved in cell shape, motility, proliferation, differentiation and adhesion. The integrin ligands include extracellular matrix proteins, such as fibronectin, collagen and laminin and other cell surface proteins. The integrin modulating agent is useful as an immunogen to generate antibodies that bind KEANOX which are useful as pharmacologically-active compounds, to isolate, purify and detect KEANOX proteins and to diagnostically monitor protein levels. The present sequence is a rat integrin modulating agent responsive nucleic acid

XX Sequence 1513 BP; 362 A; 348 C; 382 G; 413 T; 0 U; 8 Other;

Query Match 2.9%; Score 65.2; DB 5; Length 1513;  
Best Local Similarity 71.4%; Pred. No. 0.00038;  
Matches 85; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY 2124 TTGCTTTTACCACCTCTTCTCTTTTATCTTATTAATAAAATGTTGGTCTCCACCTGNC 2183  
DB 137 TTGTTTTAGCAACACGAGCTGTTTTGTGAATAAAACGAATGCATGTTTGTGCACGAAA 78

QY 2184 CCCAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2242  
DB 77 AAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATA 19

RESULT 1418  
AAA37036  
ID AAA37036 standard; cDNA; 1733 BP.  
XX  
AC AAA37036;  
XX  
DT 08-AUG-2000 (first entry)  
XX  
DE Human PRO1411 (UNQ729) cDNA sequence SEQ ID NO:51.  
XX  
KW Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;  
KW transmembrane; secretion; immunoadhesion; pharmaceutical; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200012708-A2.  
XX  
PD 09-MAR-2000.  
XX  
PF 01-SEP-1999; 99WO-US020111.  
XX  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098749P.  
PR 01-SEP-1998; 98US-0098750P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099536P.  
PR 09-SEP-1998; 98US-0099596P.  
PR 09-SEP-1998; 98US-0099598P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 09-SEP-1998; 98US-0099642P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
84

Qy	2108	CATCCAAATGATCGCCCTTTGGCTTTTACCACTCTTTCTCTTTATCTATTAAATAAAATGTTG	2167
Dβ	1555	CCTTAAACACACACCCCTCTCATCACTAAATCTCAGCCCTTGGCCCTTGAATAAATCAACTTAGC	1614

Qy 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227  
 Db 1615 TGCCCCACAAAAA 1674  
 Qy 2228 AAAAAAAAAAAAAA 2242  
 Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1422  
 AAF92083  
 ID AAF92083 standard; cDNA; 1734 BP.  
 XX  
 AC AAF92083;  
 XX  
 DT 15-MAY-2001 (first entry)  
 XX  
 DE Human PRO1411 cDNA.  
 XX  
 KW Human; PRO protein; mapping; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200116318-A2.  
 XX  
 PD 08-MAR-2001.  
 XX  
 PF 24-AUG-2000; 2000WO-US023328.  
 XX  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 07-DEC-1999; 99US-0169495P.  
 PR 09-DEC-1999; 99US-0170262P.  
 PR 11-JAN-2000; 2000US-0175481P.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 03-MAR-2000; 2000US-0187202P.  
 PR 21-MAR-2000; 2000US-0191007P.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 25-APR-2000; 2000US-0199397P.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 05-JUN-2000; 2000US-0209832P.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
 PI Grimaldi CJ, Gurney AL, Watanabe CK, Wood WI;  
 XX  
 DR WPI; 2001-183260/18.  
 DR P-PSDB; AAB87551.  
 XX  
 PT Eighty four nucleic acids encoding PRO polypeptides, useful in molecular  
 PT biology, including use as hybridization probes, and in chromosome and  
 PT gene mapping.  
 XX  
 PS Claim 2; Fig 51; 278pp; English.  
 XX  
 CC The present sequence is the coding sequence for a human PRO polypeptide  
 CC (secreted and transmembrane). The PRO protein, and PRO agonists, PRO  
 CC antagonists or anti-PRO antibodies are useful for preparation of a  
 CC medicament useful in the treatment of a condition which is responsive to  
 CC the PRO protein, agonists, antagonists or anti-PRO antibodies. The PRO  
 CC protein may also be employed as molecular weight markers for protein  
 CC electrophoresis. The PRO coding sequence has applications in molecular  
 CC biology, including use as hybridisation probes, and in chromosome and  
 CC gene mapping  
 XX  
 SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.2; DB 4; Length 1734;  
 Best Local Similarity 67.4%; Pred. No. 0.0004;

Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
 Qy 2108 CATCCATGATCGCCTTTGCTTTACCACTCTTCTTTTATCTTATTAATAAATGTTG 2167  
 Db 1555 CCTTAAACACCAACCTCTCATCACTAATCTCAGCCCTTGCCCTTGAAATAAACCTTAGC 1614  
 Qy 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227  
 Db 1615 TGCCCCACAAAAA 1674  
 Qy 2228 AAAAAAAAAAAAAA 2242  
 Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1423  
 ABK33613  
 ID ABK33613 standard; cDNA; 1734 BP.  
 XX  
 AC ABK33613;  
 XX  
 DT 08-MAY-2002 (first entry)  
 XX  
 DE cDNA encoding human PRO protein, Seq ID No 155.  
 XX  
 KW Human; secreted protein; PRO; tumour; lung cancer; colon cancer;  
 KW breast cancer; prostate tumour; rectal tumour; liver tumour;  
 KW pericyte cell proliferation; chondrocyte cell proliferation;  
 KW tumour necrosis factor-alpha; gene; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200208288-A2.  
 XX  
 PD 31-JAN-2002.  
 XX  
 PF 29-JUN-2001; 2001WO-US021066.  
 XX  
 PR 20-JUL-2000; 2000US-0219556P.  
 PR 25-JUL-2000; 2000US-0220585P.  
 PR 25-JUL-2000; 2000US-0220605P.  
 PR 25-JUL-2000; 2000US-0220607P.  
 PR 25-JUL-2000; 2000US-0220624P.  
 PR 25-JUL-2000; 2000US-0220638P.  
 PR 25-JUL-2000; 2000US-0220664P.  
 PR 25-JUL-2000; 2000US-0220666P.  
 PR 26-JUL-2000; 2000US-0220893P.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 01-AUG-2000; 2000US-022425P.  
 PR 22-AUG-2000; 2000US-0227133P.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 28-NOV-2000; 2000US-0253646P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2000WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 25-MAY-2001; 2001WO-US017092.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KF, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;  
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;  
 XX  
 DR WPI; 2002-172001/22.  
 DR P-PSDB; AAU83669.  
 XX  
 PT One hundred and twenty two nucleic acids encoding PRO polypeptides,

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI: 2002-731348/79.  
DR P-PSDB; ABG95876.  
XX  
PT New isolated secreted and transmembrane PRO polypeptide useful for  
PT modulating biological activity of a cell, or for treating sports-related  
PT joint problems, osteoarthritis or rheumatoid arthritis.  
XX  
XX  
PS Claim 2; Fig 51; 399pp; English.  
XX  
CC The invention relates to an isolated secreted and transmembrane PRO  
CC polypeptide having 80 % sequence identity to a sequence appearing as  
CC ABG95851-ABG95934 or their associated signal peptide, or a sequence of an  
CC extracellular domain of the proteins with their associated signal peptide  
CC or lacking its associated signal peptide. Also included are the nucleic  
CC acids encoding the proteins, vectors, host cells, fusion proteins and  
CC antibodies which specifically bind to the proteins. The proteins are  
CC useful for detecting a polypeptide designated as A, B, C or D in a sample  
CC suspected of containing an A, B, C or D polypeptide, by contacting the  
CC sample with a polypeptide designated as E, F, G, H or I (or vice versa)  
CC and determining the formation of a A/E, B/F, C/G, C/H or D/I polypeptide  
CC conjugate in the sample, where the formation of the conjugate is  
CC indicative of the presence of an A, B, C or D polypeptide in the sample,  
CC where A is a PRO10272 polypeptide, B is a PRO20110 polypeptide, C is a  
CC PRO10096 polypeptide, D is a PRO19760 polypeptide, E is a PRO5801  
CC polypeptide, F is a PRO1 polypeptide, G is a PRO20040 polypeptide, H is a  
CC PRO20233 polypeptide and I is a PRO1890 polypeptide. The sample comprises  
CC a cell suspected of expressing the A, B, C or D polypeptide. The E, F, G,  
CC H or I polypeptide is labeled with a detectable label or is attached to a  
CC solid support. The proteins are useful for linking a bioactive molecule  
CC to a cell expressing a polypeptide designated as A, B, C or D or E, F, G,  
CC H or I. The bioactive molecule is a toxin, a radiolabel or an antibody.  
CC The bioactive molecule causes death of the cell. A, B, C, D, E, F, G, H,  
CC or I, or antibodies against them are useful for modulating a biological  
CC activity of a cell expressing a polypeptide designated as A, B, C or D or  
CC E, F, G, H, or I. The cell is killed. The proteins are useful for  
CC identifying agonists or antagonists, for the preparation of a medicament  
CC useful in the treatment of a condition which is responsive to the  
CC proteins, as molecular weight markers for protein electrophoresis  
CC purposes, and as therapeutic agents for treating sports-related joint  
CC problems, articular cartilage defects, osteoarthritis or rheumatoid  
CC arthritis. Nucleic acids encoding the proteins are useful as  
CC hybridisation probes, in chromosome and gene mapping, in the generation  
CC of anti-sense RNA and DNA, for the preparation of the proteins, to  
CC generate transgenic or knockout animals which are useful in the  
CC development and screening of therapeutic useful reagents, for chromosome  
CC identification, and in gene therapy. The antibody is useful as a  
CC therapeutic agent, in a diagnostic assay and for affinity purification of  
CC the protein from recombinant cell culture natural sources. The present  
CC sequence encodes a novel secreted or transmembrane protein of the  
CC invention  
XX  
SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;  
Query Match 2.9%; Score 65.2; DB 6; Length 1734;  
Best Local Similarity 67.4%; Pred.No. 0.0004;  
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2108 CATCATATGATCGCTTGGTTTACCACTCTTTTCCTTTTATCTATTATTAATAAATGTG 2167  
Db 1555 CCTTAAACACCACTCTCTCATCTACTAATCTAGCCCTTGCCTTGAATAAACCTTAGC 1614  
QY 2168 GTCTCCCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227  
Db 1615 TGCCCCACAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674  
QY 2228 AAAAAAAAAAAAAA 2242  
Db 1675 AAAAAAAAAAAAAA 1689  
RESULT 1425  
ABL95635

ID XX ABL95635 standard; cDNA; 1734 BP.  
AC XX ABL95635;  
XX  
DT 19-JUL-2002 (first entry)  
XX  
DE Human angiogenesis related cDNA PRO1411 SEQ ID NO: 149.  
XX  
KW Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;  
KW atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;  
KW cardiant; cytostatic; antiangiogenic; hypotensive; vulnerary;  
KW antiarteriosclerotic; gene; ss.  
OS Homo sapiens.  
XX  
PN WO200208284-A2.  
PD  
XX 31-JAN-2002.  
XX  
PF 09-JUL-2001; 2001WO-US021735.  
XX  
PR 20-JUL-2000; 2000US-0219556P.  
PR 25-JUL-2000; 2000US-0220624P.  
PR 25-JUL-2000; 2000US-0220664P.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 02-AUG-2000; 2000US-0222695P.  
PR 17-AUG-2000; 2000US-00643657.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 07-SEP-2000; 2000US-0230978P.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 24-OCT-2000; 2000US-0242922P.  
PR 24-OCT-2000; 2000US-00709238.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 22-JAN-2001; 2001US-00767609.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00805689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 25-MAY-2001; 2001US-0086028.  
PR 25-MAY-2001; 2001US-0086034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 30-MAY-2001; 2001US-00870574.  
PR 30-MAY-2001; 2001WO-US017443.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 20-JUN-2001; 2001WO-US019692.  
XX  
XX (GETH ) GENENTECH INC.  
PA (BAKE/) BAKER K P.  
PA (FERR/) FERRARA N.  
PA (GERB/) GERBER H.  
PA (GERR/) GERRITSEN M E.  
PA (GODD/) GODDARD A.  
PA (GODO/) GODOWSKI P J.  
PA (GURN/) GURNEY A L.  
PA (HILL/) HILLAN K J.  
PA (MARS/) MARSTERS S A.  
PA (PANJ/) PAN J.  
PA (PAON/) PAONI N F.  
PA (STEP/) STEPHAN J F.  
PA (WATA/) WATANABE C K.  
PA (WILL/) WILLIAMS P M.  
PA (WOOD/) WOOD W I.

```

XX Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A; Paoni NF;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J,
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX WPI; 2002-171999/22.
DR P-PSDB; ABB95497.
XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX
PS Claim 1; Fig 149; 567pp; English.
XX
CC The present invention provides the protein and coding sequences of human
CC PRO proteins. These are useful for treating or diagnosing a
CC cardiovascular, endothelial or angiogenic disorder, including cardiac
CC hypertrophy, trauma, cancer, age-related macular degeneration,
CC atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC healing. The present sequence is a coding sequence of the invention
XX
SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;

Query Match          2.9%; Score 65.2; DB 6; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATGCGCTTGGCTTTACCACTCTTCTTTTATTAATAAATGTTG 2167
Db 1555 CCTTAAACACACCCCTCTCATCACTATCTCAGCCCTTGGCCTTGAATACCTTAGC 1614
QY 2168 GTCTCCACCACTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227
Db 1615 TGCCCCACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 1674
QY 2228 AAAAAAATAAAAAA 2242
Db 1675 AAAAAAATAAAAAA 1689

RESULT 1426
ACA89475
ID ACA89475 standard; cDNA; 1734 BP.
XX
AC ACA89475;
XX
DT 09-JUL-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #101.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW chromosome mapping; gene mapping; tumour; adrenal; lung; colon; breast;
KW prostate; rectal; cervical; liver; cancer; TNF-alpha;
KW tumour necrosis factor-alpha; proliferation; differentiation;
KW chondrocyte cell; bone disorder; cartilage disorder; sports injury;
KW arthritis; cytostatic; antiarthritic; osteopathic; gene therapy; gene;
KW ss.
XX
OS Homo sapiens.
XX
PN US2003036141-A1.
XX
PD 20-FEB-2003.
XX
PF 01-JUL-2002; 2002US-00187597.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.

```

```

PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088718P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.

```

PR 10-JUN-1998;	98US-0088826P.	PR 17-SEP-1998;	98US-0100683P.
PR 11-JUN-1998;	98US-0088861P.	PR 17-SEP-1998;	98US-0100684P.
PR 11-JUN-1998;	98US-0088863P.	PR 17-SEP-1998;	98US-0100919P.
PR 11-JUN-1998;	98US-0088876P.	PR 17-SEP-1998;	98US-0100930P.
PR 12-JUN-1998;	98US-0089090P.	PR 18-SEP-1998;	98US-0100849P.
PR 12-JUN-1998;	98US-0089105P.	PR 18-SEP-1998;	98US-0101014P.
PR 16-JUN-1998;	98US-0089512P.	PR 18-SEP-1998;	98US-0101068P.
PR 16-JUN-1998;	98US-0089514P.	PR 23-SEP-1998;	98US-0101471P.
PR 17-JUN-1998;	98US-0089538P.	PR 23-SEP-1998;	98US-0101472P.
PR 17-JUN-1998;	98US-0089598P.	PR 23-SEP-1998;	98US-0101475P.
PR 18-JUN-1998;	98US-0089653P.	PR 23-SEP-1998;	98US-0101477P.
PR 18-JUN-1998;	98US-0089908P.	PR 23-SEP-1998;	98US-0101738P.
PR 19-JUN-1998;	98US-0089952P.	PR 24-SEP-1998;	98US-0101739P.
PR 22-JUN-1998;	98US-0090246P.	PR 24-SEP-1998;	98US-0101743P.
PR 22-JUN-1998;	98US-0090252P.	PR 24-SEP-1998;	98US-0101922P.
PR 22-JUN-1998;	98US-0090254P.	PR 25-SEP-1998;	98US-0101786P.
PR 24-JUN-1998;	98US-0090429P.	PR 25-SEP-1998;	98US-0102207P.
PR 24-JUN-1998;	98US-0090435P.	PR 29-SEP-1998;	98US-0102240P.
PR 24-JUN-1998;	98US-0090444P.	PR 29-SEP-1998;	98US-0102330P.
PR 24-JUN-1998;	98US-0090461P.	PR 29-SEP-1998;	98US-0102331P.
PR 24-JUN-1998;	98US-0090535P.	PR 30-SEP-1998;	98US-0102487P.
PR 24-JUN-1998;	98US-0090540P.	PR 30-SEP-1998;	98US-0102570P.
PR 25-JUN-1998;	98US-0090676P.	PR 30-SEP-1998;	98US-0102571P.
PR 25-JUN-1998;	98US-0090678P.	PR 01-OCT-1998;	98US-0102684P.
PR 25-JUN-1998;	98US-0090688P.	PR 01-OCT-1998;	98US-0102687P.
PR 25-JUN-1998;	98US-0090690P.		
PR 25-JUN-1998;	98US-0090694P.		
PR 25-JUN-1998;	98US-0090695P.		
PR 25-JUN-1998;	98US-0090696P.		
PR 26-JUN-1998;	98US-00105413.		
PR 26-JUN-1998;	98US-0090862P.		
PR 26-JUN-1998;	98US-0090863P.		
PR 26-JUN-1998;	98US-0091010P.		
PR 01-JUL-1998;	98US-0091359P.		
PR 01-JUL-1998;	98US-0091544P.		
PR 02-JUL-1998;	98US-0091478P.		
PR 02-JUL-1998;	98US-0091486P.		
PR 02-JUL-1998;	98US-0091626P.		
PR 02-JUL-1998;	98US-0091628P.		
PR 02-JUL-1998;	98US-0091632P.		
PR 24-JUL-1998;	98US-0094006P.		
PR 04-AUG-1998;	98US-0095282P.		
PR 10-AUG-1998;	98US-0095998P.		
PR 10-AUG-1998;	98US-0096012P.		
PR 17-AUG-1998;	98US-0096757P.		
PR 17-AUG-1998;	98US-0096766P.		
PR 17-AUG-1998;	98US-0096867P.		
PR 17-AUG-1998;	98US-0096891P.		
PR 17-AUG-1998;	98US-0096897P.		
PR 18-AUG-1998;	98US-0096949P.		
PR 18-AUG-1998;	98US-0096959P.		
PR 18-AUG-1998;	98US-0097022P.		
PR 26-AUG-1998;	98US-0097952P.		
PR 26-AUG-1998;	98US-0097954P.		
PR 26-AUG-1998;	98US-0097955P.		
PR 26-AUG-1998;	98US-0097971P.		
PR 26-AUG-1998;	98US-0097974P.		
PR 26-AUG-1998;	98US-0098014P.		
PR 01-SEP-1998;	98US-0098716P.		
PR 01-SEP-1998;	98US-0098723P.		
PR 02-SEP-1998;	98US-0098803P.		
PR 02-SEP-1998;	98US-0098821P.		
PR 02-SEP-1998;	98US-0098843P.		
PR 09-SEP-1998;	98US-0098602P.		
PR 10-SEP-1998;	98US-0099741P.		
PR 10-SEP-1998;	98US-0099754P.		
PR 10-SEP-1998;	98US-0099763P.		
PR 10-SEP-1998;	98US-0099812P.		
PR 15-SEP-1998;	98US-0100389P.		
PR 16-SEP-1998;	98US-0100662P.		
PR 16-SEP-1998;	98US-0100664P.		
PR 16-SEP-1998;	98US-0101751P.		
PR 16-SEP-1998;	98WO-US019330.		
PR 10-JUN-1998;	98US-0088826P.	PR 17-SEP-1998;	98US-0100683P.
PR 11-JUN-1998;	98US-0088861P.	PR 17-SEP-1998;	98US-0100684P.
PR 11-JUN-1998;	98US-0088863P.	PR 17-SEP-19	

PR 08-MAR-1999; 99WO-US005028.  
 PR 14-MAY-1999; 99US-0031832.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 25-AUG-1999; 99US-00380137.  
 PR 25-AUG-1999; 99US-00380138.  
 PR 25-AUG-1999; 99US-00380139.  
 PR 25-AUG-1999; 99US-00380142.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 18-OCT-1999; 99US-0043297.  
 PR 12-NOV-1999; 99US-00423844.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 30-DEC-1999; 99WO-US013274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 22-AUG-2000; 2000US-00644848.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00664610.  
 PR 18-SEP-2000; 2000US-00665350.  
 PR 08-NOV-2000; 2000US-00709238.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 30-JUL-2001; 2001US-00918585.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 13-AUG-2001; 2001US-00929404.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 28-AUG-2001; 2001US-00941992.  
 PR 29-AUG-2001; 2001WO-US027099.  
 PR 04-SEP-2001; 2001US-00946374.  
 PR 15-JAN-2002; 2002US-00052586.

(GETH ) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PU, Gurney AL;  
 Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-332034/31.

P-PSDB; ABU86293.

Three hundred and five nucleic acids encoding PRO polypeptides, useful in gene therapy, chromosome identification, tissue typing, and for detecting the presence of tumor in a mammal.

Claim 2; Fig 201; 707pp; English.

The invention relates to three hundred and five nucleic acids encoding

CC PRO polypeptides (secreted and transmembrane), sequences 80% identical to  
 CC them, or encoding a PRO polypeptide lacking its associated signal peptide  
 CC or an extracellular domain of the PRO polypeptide, with or lacking its  
 CC associated signal peptide. Also included are the encoded PRO proteins,  
 CC PRO expression vectors, host cells transformed with the vector (used to  
 CC produce PRO proteins), a chimeric molecule comprising the PRO  
 CC polypeptide fused to a heterologous amino acid sequence, an anti-PRO  
 CC antibody, a method for stimulating the release of tumor necrosis factor  
 CC alpha (TNF-alpha) from human blood (by contacting the blood with PRO1079,  
 CC PRO827, PRO791, PRO1131, PRO1316, PRO1183, PRO1343, PRO1760, PRO1567 or  
 CC PRO4333), a method for stimulating the proliferation or differentiation  
 CC of chondrocyte cells by contacting the cells with a PRO6029 polypeptide,  
 CC a method for detecting the presence of tumor in a mammal and an  
 CC oligonucleotide probe derived from any of the nucleotide sequences cited  
 CC above. The PRO polypeptide or anti-PRO antibody is useful for preparing a  
 CC medicament for treating a condition that is responsive to the PRO  
 CC polypeptide or anti-PRO antibody. The PRO nucleotide sequences are useful  
 CC as hybridisation probes in chromosome and gene mapping, or in generating  
 CC antisense RNA and DNA. PRO nucleic acids are also useful in preparing PRO  
 CC polypeptides, in assays to identify other proteins or molecules involved  
 CC in a binding reaction, to generate transgenic animals or knockout  
 CC animals, which in turn are useful in the development and screening of  
 CC therapeutically useful reagents, for chromosome identification, and  
 CC tissue typing. The PRO polypeptides and nucleic acid molecules are also  
 CC useful for detecting the presence of a tumour in a mammal, stimulating  
 CC proliferation or differentiation of chondrocyte cells, stimulating the  
 CC release of tumour necrosis factor-alpha from human blood, in gene  
 CC therapy, or as molecular weight markers for protein electrophoresis  
 CC purposes. The anti-PRO antibodies may be used in diagnostic assays for  
 CC PRO, or for the affinity purification of PRO from recombinant cell  
 CC culture or natural sources. The present sequence is a cDNA encoding a PRO  
 CC protein

SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.2; DB 8; Length 1734;

Best Local Similarity 67.4%; Pred. No. 0.0004;

Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Oy 2108 CATCCATGATCGCTTGTGCTTACCACCTCTTCTTTATCTTATTAATAAATGTTG 2167

Db 1555 CCTTAAACACCCCTCTCATCACTATCTCAGCCCTTGAAATAAACCTTAGC 1614

Oy 2168 GTCTCCACCACTGCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227

Db 1615 TGCCCCACAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674

Oy 2228 AAAAAAAAAAAAAA 2242

Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1428

ACA05800

ID ACA05800 standard; cDNA; 1734 BP.

XX ACA05800;

AC ACA05800;

XX 29-MAY-2003 (first entry)

DT Human secreted/transmembrane protein (PRO) cDNA #101.

XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;

XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;

XX tissue typing.

XX Homo sapiens.

XX OS

XX US2003036162-A1.

PN

XX 20-FEB-2003.

XX 12-JUL-2002; 2002US-00194423.

XX

XX

XX

XX 26-JUN-1998; 98US-00105413.  
PR 16-SEP-1998; 98WO-US019330.  
PR 07-OCT-1998; 98US-00168978.  
PR 07-OCT-1998; 98WO-US021141.  
PR 06-NOV-1998; 98US-00187368.  
PR 01-DEC-1998; 98WO-US021508.  
PR 07-DEC-1998; 98US-00202054.  
PR 03-MAR-1999; 99US-00254311.  
PR 08-MAR-1999; 99WO-US005028.  
PR 14-MAY-1999; 99US-00311832.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 25-AUG-1999; 99US-00380137.  
PR 25-AUG-1999; 99US-00380138.  
PR 25-AUG-1999; 99US-00380139.  
PR 25-AUG-1999; 99US-00380142.  
PR 01-SEP-1999; 99WO-US020111.  
PR 15-SEP-1999; 99WO-US021090.  
PR 18-OCT-1999; 99US-00403297.  
PR 12-NOV-1999; 99US-00423844.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028551.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 24-AUG-2000; 2000US-00644848.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 18-SEP-2000; 2000US-00664610.  
PR 18-SEP-2000; 2000US-00665350.  
PR 08-NOV-2000; 2000US-00709238.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 22-MAR-2001; 2001US-00816744.  
PR 10-MAY-2001; 2001US-00854208.  
PR 25-MAY-2001; 2001US-00866028.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 30-JUL-2001; 2001US-00918585.  
PR 06-AUG-2001; 2001US-00924419.  
PR 13-AUG-2001; 2001US-00929404.  
PR 16-AUG-2001; 2001US-00931836.  
PR 28-AUG-2001; 2001US-00941992.  
PR 29-AUG-2001; 2001WO-US027099.  
PR 04-SEP-2001; 2001US-00946374.  
PR 15-JAN-2002; 2002US-00052586.  
XX (GETH ) GENENTECH INC.  
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-332039/31.  
XX

DR P-PSDB; ABU67506.  
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
PT in gene therapy, in chromosome and gene mapping, as chromosome markers,  
PT in tissue typing, and in chromosome identification.  
XX Claim 2; Fig 201; 706pp; English.  
PS The invention discloses human nucleic acids encoding secreted and  
XX transmembrane (PRO) polypeptides. Also disclosed is an antibody that  
CC specifically binds to the PRO polypeptide, a method for stimulating the  
CC release of tumour necrosis factor alpha (TNF-alpha) from human blood by  
CC contacting the blood a PRO polypeptide, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells by contacting the  
CC cells with a PRO polypeptide, a method for detecting the presence of a  
CC tumour in a mammal and an oligonucleotide probe derived from any of the  
CC PRO nucleotide sequences. The nucleotide sequences are useful as probes,  
CC in chromosome and gene mapping, in generating antisense RNA and DNA, in  
CC preparing PRO polypeptides by recombinant techniques and in gene therapy  
CC (e.g. for replacement of defective gene). The PRO polypeptides are useful  
CC as molecular weight markers for protein electrophoresis purposes, for  
CC chromosome identification, as chromosome markers, as therapeutic agents,  
CC for stimulating the release of TNF-alpha from human blood, for  
CC stimulating the proliferation or differentiation of chondrocytes and  
CC detecting the presence of a tumour. The PRO polypeptides and nucleic  
CC acids may also be used diagnostically for tissue typing. The sequences  
CC presented in ACA05700-ACA06004 are the cDNAs encoding the PRO  
CC polypeptides of the invention  
XX  
SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;  
Query Match 2.9%; Score 65.2; DB 8; Length 1734;  
Best Local Similarity 67.4%; Pred.No.0.0004;  
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2108 CATCCAAATGATCGCTTTGCTTTACCACTCTTCTCTTTATCTTATATAAAATGTTG 2167  
Db 1555 CCTTAAACACCACTCTCTCATCACTAATCTCAGCCCTTGCCCTTGAAATAAACCTTAGC 1614  
QY 2168 GTCTCCACCACTGCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227  
Db 1615 TGCCCAACAAAAA AA 1674  
QY 2228 AAAAAAAAAAAAAAAAAA 2242  
Db 1675 AAAAAAAAAAAAAAAAAA 1689  
RESULT 1429  
ACA66634  
ID ACA66634 standard; cDNA; 1734 BP.  
XX ACA66634;  
AC ACA66634;  
XX 23-JUN-2003 (first entry)  
DT cDNA encoding human PRO protein #101.  
XX Human; tumour; adrenal; lung; colon; breast; prostate; rectal; cervical;  
KW liver; PRO; gene therapy; gene; ss.  
XX Homo sapiens.  
XX OS  
XX US2003036137-A1.  
XX PD 20-FEB-2003.  
XX 27-JUN-2002; 2002US-00184640.  
XX 26-JUN-1998; 98US-00105413.  
PR 16-SEP-1998; 98WO-US019330.  
PR 07-OCT-1998; 98US-00168978.  
PR 07-OCT-1998; 98WO-US021141.



CC The invention describes an antibody that specifically binds to a PRO  
 CC polypeptide having a fully defined amino acid sequence given in the  
 CC specification. The antibody is useful in identifying PRO polypeptides  
 CC useful for various industrial applications, including pharmaceuticals,  
 CC diagnostics, biosensors and bioreactors. The antibody is also used for  
 CC affinity purification of PRO polypeptides from recombinant cell culture  
 CC or natural sources. The antibody, PRO polypeptide, or its agonists or  
 CC antagonists, may be used for preparing a medicament for diagnosing or  
 CC treating a condition responsive to the antibody, PRO polypeptide, or its  
 CC agonists or antagonists. This sequence encodes a novel human secreted and  
 CC transmembrane PRO polypeptide  
 SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;  
 Query Match 2.9%; Score 65.2; DB 8; Length 1734;  
 Best Local Similarity 67.4%; Pred. No. 0.0004;  
 Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
 QY 2108 CATCCATGATCGCTTGGCTTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTG 2167  
 Db 1555 CCTTAAACACCCCTCTCATCACTAATCTGAGCCCTTGCCTTGAATTAACCTTAGC 1614  
 QY 2168 GTCTCCACCACTGCTCCCAAAAAA 2227  
 Db 1615 TGCCCCACAAAAA 1674  
 QY 2228 AAAAAA 2242  
 Db 1675 AAAAAA 1689  
 RESULT 1431  
 ACDB1566  
 ID ACD81566 standard; cDNA; 1734 BP.  
 XX  
 AC ACD81566;  
 XX  
 DT 18-SEP-2003 (first entry)  
 XX  
 DE Human cDNA encoding secreted/transmembrane protein PRO411.  
 XX  
 KW Human; sb; gene; secreted/transmembrane protein; PRO; tumour; cancer;  
 KW cytostatic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US200309013-A1.  
 XX  
 PD 09-JAN-2003.  
 XX  
 PF 01-MAY-2002; 2002US-00063519.  
 XX  
 PR 30-DEC-1998; 98KR-000621142.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 14-MAY-1999; 99US-00311832.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 23-AUG-1999; 99US-00380137.  
 PR 25-AUG-1999; 99US-00380138.  
 PR 25-AUG-1999; 99US-00380139.  
 PR 25-AUG-1999; 99US-00380142.  
 PR 15-SEP-1999; 99US-00397342.  
 PR 18-OCT-1999; 99US-00403297.  
 PR 12-NOV-1999; 99US-00423844.  
 PR 30-DEC-1999; 99WO-US011274.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 02-JUN-2000; 2000WO-US0145264.  
 PR 22-AUG-2000; 2000WO-US064848.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00664610.

PR 18-SEP-2000; 2000US-00665350.  
 PR 08-NOV-2000; 2000US-00709238.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 30-MAY-2001; 2001US-00870574.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 29-JUN-2001; 2001US-00869599.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-DEC-2001; 2001US-00068667.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
 PI  
 XX WPI; 2003-447384/42.  
 DR P-PSDB; ABO33960.  
 XX  
 DR New isolated antibody specifically binding a PRO polypeptide, useful for  
 XX the preparation of a medicament for treating disorders with the aberrant  
 XX expression or activity of the PRO polypeptide, such as tumor conditions  
 XX and cancer.  
 XX  
 PS Disclosure; Fig 51; 223pp; English.  
 XX  
 CC The invention relates to an antibody that binds to a secreted or  
 CC transmembrane protein designated PRO1446 appearing as ABO33941. The  
 CC protein is one of 84 PRO polypeptides which (along with their encoding  
 CC nucleic acids) are disclosed in the specification. The methods and  
 CC compositions of the present invention are useful for the preparation of a  
 CC medicament for the treatment of disorders associated with the aberrant  
 CC expression or activity of the PRO polypeptide, such as tumour conditions  
 CC and cancer. They can also be used to generate transgenic or knockout  
 CC animals useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides and encoding nucleic acids can be used as  
 CC molecular weight markers for protein electrophoresis, chromosome  
 CC identification and tissue typing. The antibodies may be used in various  
 CC diagnostic, competitive binding and/or immunoprecipitation assays. The  
 CC present sequence encodes a PRO polypeptide  
 XX  
 SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;  
 Query Match 2.9%; Score 65.2; DB 8; Length 1734;  
 Best Local Similarity 67.4%; Pred. No. 0.0004;  
 Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
 QY 2108 CATCCATGATCGCTTGGCTTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTG 2167  
 Db 1555 CCTTAAACACCCCTCTCATCACTAATCTGAGCCCTTGCCTTGAATTAACCTTAGC 1614  
 QY 2168 GTCTCCACCACTGCTCCCAAAAAA 2227  
 Db 1615 TGCCCCACAAAAA 1674  
 QY 2228 AAAAAA 2242  
 Db 1675 AAAAAA 1689  
 RESULT 1432  
 ACF20209  
 ID ACF20209 standard; cDNA; 1734 BP.  
 XX  
 AC ACF20209;  
 XX  
 DT 18-SEP-2003 (first entry)

XX Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.  
DE KW Human; PRO; secreted protein; transmembrane protein;  
XX KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; proliferation; differentiation; cartilage disorder;  
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
KW liver; drug screening; transgenic animal; genetic analysis;  
XX KW antiarthritic; vulnery; gene therapy; gene; ss.  
OS Homo sapiens.  
XX  
XX US2003040063-A1.  
XX  
XX 27-FEB-2003.  
XX  
XX 26-JUN-2002; 2002US-00183006.  
XX  
XX 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 11-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.

PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-008861P.  
PR 11-JUN-1998; 98US-008863P.  
PR 11-JUN-1998; 98US-008876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.

PR	18-AUG-1998;	98US-0096949P.	DT	17-SEP-2003	(first entry)	Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.
PR	18-AUG-1998;	98US-0096959P.	XX			Human; PRO; secreted protein; transmembrane protein;
PR	18-AUG-1998;	98US-0097022P.	DE			extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
PR	26-AUG-1998;	98US-0097952P.	XX			chondrocyte; proliferation; differentiation; cartilage disorder;
PR	26-AUG-1998;	98US-0097954P.	KW			bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
PR	26-AUG-1998;	98US-0097955P.	KW			adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
PR	26-AUG-1998;	98US-0097971P.	KW			liver; drug screening; transgenic animal; genetic analysis;
PR	26-AUG-1998;	98US-0098014P.	KW			antiarthritic; vulnery; gene therapy; gene; ss.
PR	01-SEP-1998;	98US-0098716P.	KW			
PR	01-SEP-1998;	98US-0098723P.	XX			Homo sapiens.
PR	02-SEP-1998;	98US-0098803P.	OS			
PR	02-SEP-1998;	98US-0098821P.	XX			US2003040064-A1.
PR	02-SEP-1998;	98US-0098843P.	PN			
PR	09-SEP-1998;	98US-0099602P.	PN			
PR	10-SEP-1998;	98US-0099741P.	XX			27-FEB-2003.
PR	10-SEP-1998;	98US-0099754P.	XX			
PR	10-SEP-1998;	98US-0099763P.	XX			
PR	10-SEP-1998;	98US-0099763P.	XX			
PR	15-SEP-1998;	98US-0099812P.	XX			26-JUN-2002; 2002US-00183008.
PR	16-SEP-1998;	98US-0100388P.	XX			
PR	16-SEP-1998;	98US-0100662P.	PR	18-SEP-1997;	97US-0059263P.	
PR	16-SEP-1998;	98US-0100664P.	PR	18-SEP-1997;	97US-0059266P.	
PR	16-SEP-1998;	98US-0101751P.	PR	17-OCT-1997;	97US-0062250P.	
PR	16-SEP-1998;	98WO-US019330.	PR	21-OCT-1997;	97US-0063486P.	
PR	17-SEP-1998;	98US-0100683P.	PR	24-OCT-1997;	97US-0063120P.	
PR	17-SEP-1998;	98US-0100684P.	PR	24-OCT-1997;	97US-0063121P.	
PR	17-SEP-1998;	98US-0100919P.	PR	28-OCT-1997;	97US-0063540P.	
PR	17-SEP-1998;	98US-0100930P.	PR	28-OCT-1997;	97US-0063541P.	
PR	18-SEP-1998;	98US-0100849P.	PR	28-OCT-1997;	97US-0063544P.	
PR	18-SEP-1998;	98US-0101014P.	PR	28-OCT-1997;	97US-0063564P.	
PR	18-SEP-1998;	98US-0101068P.	PR	29-OCT-1997;	97US-0063734P.	
PR	23-SEP-1998;	98US-0101471P.	PR	31-OCT-1997;	97US-0063870P.	
PR	23-SEP-1998;	98US-0101472P.	PR	31-OCT-1997;	97US-0064103P.	
PR	23-SEP-1998;	98US-0101475P.	PR	13-NOV-1997;	97US-0065311P.	
PR	23-SEP-1998;	98US-0101477P.	PR	21-NOV-1997;	97US-0066120P.	
PR	24-SEP-1998;	98US-0101738P.	PR	24-NOV-1997;	97US-0066466P.	
PR	24-SEP-1998;	98US-0101739P.	PR	24-NOV-1997;	97US-0066772P.	
PR	24-SEP-1998;	98US-0101743P.	PR	11-DEC-1997;	97US-0069335P.	
PR	24-SEP-1998;	98US-0101922P.	PR	12-DEC-1997;	97US-0069425P.	
PR	25-SEP-1998;	98US-0101786P.	PR	17-DEC-1997;	97US-0069870P.	
PR	29-SEP-1998;	98US-0102207P.	PR	18-DEC-1997;	97US-0068017P.	
PR	29-SEP-1998;	98US-0102240P.	PR	10-MAR-1998;	98US-0077450P.	
PR	29-SEP-1998;	98US-0102330P.	PR	11-MAR-1998;	98US-0077632P.	
PR	29-SEP-1998;	98US-0102331P.	PR	11-MAR-1998;	98US-0077649P.	
PR	30-SEP-1998;	98US-0102487P.	PR	20-MAR-1998;	98US-0078886P.	
PR	30-SEP-1998;	98US-0102570P.	PR	20-MAR-1998;	98US-0078939P.	
PR	30-SEP-1998;	98US-0102571P.	PR	27-MAR-1998;	98US-0079664P.	
PR	01-OCT-1998;	98US-0102684P.	PR	27-MAR-1998;	98US-0079786P.	
PR	01-OCT-1998;	98US-0102687P.	PR	31-MAR-1998;	98US-0080107P.	
			PR	31-MAR-1998;	98US-0080194P.	
			PR	01-APR-1998;	98US-0080327P.	
			PR	01-APR-1998;	98US-0080333P.	
			PR	08-APR-1998;	98US-0081049P.	
			PR	08-APR-1998;	98US-0081070P.	
			PR	15-APR-1998;	98US-0081195P.	
			PR	15-APR-1998;	98US-0081838P.	
			PR	21-APR-1998;	98US-0082568P.	
			PR	21-APR-1998;	98US-0082569P.	
			PR	22-APR-1998;	98US-0082704P.	
			PR	22-APR-1998;	98US-0082797P.	
			PR	28-APR-1998;	98US-0083322P.	
			PR	29-APR-1998;	98US-0083495P.	
			PR	29-APR-1998;	98US-0083496P.	
			PR	29-APR-1998;	98US-0083499P.	
			PR	29-APR-1998;	98US-0083559P.	
			PR	05-MAY-1998;	98US-0084366P.	
			PR	06-MAY-1998;	98US-0084414P.	
			PR	07-MAY-1998;	98US-0084639P.	
			PR	07-MAY-1998;	98US-0084640P.	
			PR	15-MAY-1998;	98US-008579P.	
			PR	15-MAY-1998;	98US-0085580P.	
			PR	15-MAY-1998;	98US-0085582P.	

Query Match 2.9%; Score 65.2; DB 8; Length 1734;  
Best Local Similarity 67.4%; Pred. No. 0.0004;  
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2108 CATCCATGATCGCTTTGCTTTTACCACTCTTTCTTTTATCTTTATTAATAAATGTTG 2167  
Db 1555 CCTTAAACACCCCTCTCATCACTAATCTCAGCCCTTGCCTTGAATAAACCTTAGC 1614  
QY 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227  
Db 1615 TGCCCCCAA 1674  
QY 2228 AAAAAAAAAAAAAA 2242  
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1433  
ACF19595  
ID ACF19595 standard; cDNA; 1734 BP.  
XX  
AC ACF19595;  
XX

```
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087603P.
PR 02-JUN-1998; 98US-0087753P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088328P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088653P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088823P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089103P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 24-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090423P.
PR 24-JUN-1998; 98US-0090433P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090533P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.

PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 2108 CATCCAATGATCGCTTTGCTTTTACCACTCTTTCCTTTTATCTTATTATTAATAAATGTTG 2167
Db 1555 CCTTAAACACCCACCTCTCTATCATCTATCTCAGCCCTTGCCCTTGAAATTAACCTTAGC 1614

Qy 2168 GTCTCCACCACTGNCCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227
Db 1615 TGCCCCACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 1674

Qy 2228 AAAAAAATAAAAAA 2242
Db 1675 AAAAAAATAAAAAA 1689

RESULT 1434
ACD21883
ID ACD21883 standard; cDNA; 1734 BP.
XX
AC ACD21883;
```

XX 25-AUG-2003 (first entry)  
DT Human secreted/transmembrane protein (PRO) cDNA #101.  
XX  
DE  
XX  
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;  
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;  
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;  
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.  
XX  
OS Homo sapiens.  
XX  
XX US2003027267-A1.  
XX  
XX 06-FEB-2003.  
XX  
XX 19-JUN-2002; 2002US-00175739.  
XX  
XX 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083599P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089553P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.

```

PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATCGCCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAAATGTTG 2167
Db 1555 CCTTAAACACCACTCTTCACTAATCTCAGCCCTTGCCCTTGAATTAACCTTAGC 1614

QY 2168 GTCTCCACACTGNTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227
Db 1615 TGCCCCACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1674

QY 2228 AAAAAAATAAAAAA 2242
Db 1675 AAAAAAATAAAAAA 1689

RESULT 1435
ACFI3048
ID ACFI3048 standard; cDNA; 1734 BP.
XX

```

```

AC ACFI3048;
XX 13-SEP-2003 (first entry)
XX Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX Homo sapiens.
OS
XX US2003036160-A1.
PN
XX 20-FEB-2003.
PD
XX 02-JUL-2002; 2002US-00188781.
PF
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0069335P.
PR 17-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083455P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.

```

PR 15-MAY-1998;	98US-0085580P.	PR 17-AUG-1998;	98US-0096867P.
PR 15-MAY-1998;	98US-0085582P.	PR 17-AUG-1998;	98US-0096891P.
PR 15-MAY-1998;	98US-0085700P.	PR 17-AUG-1998;	98US-0096897P.
PR 18-MAY-1998;	98US-0086023P.	PR 18-AUG-1998;	98US-0096949P.
PR 22-MAY-1998;	98US-0086332P.	PR 18-AUG-1998;	98US-0096959P.
PR 22-MAY-1998;	98US-0086486P.	PR 18-AUG-1998;	98US-0097022P.
PR 28-MAY-1998;	98US-0087098P.	PR 26-AUG-1998;	98US-0097952P.
PR 28-MAY-1998;	98US-0087208P.	PR 26-AUG-1998;	98US-0097954P.
PR 02-JUN-1998;	98US-0087609P.	PR 26-AUG-1998;	98US-0097955P.
PR 02-JUN-1998;	98US-0087759P.	PR 26-AUG-1998;	98US-0097971P.
PR 03-JUN-1998;	98US-0087827P.	PR 26-AUG-1998;	98US-0097974P.
PR 04-JUN-1998;	98US-0088028P.	PR 26-AUG-1998;	98US-0098014P.
PR 04-JUN-1998;	98US-0088029P.	PR 01-SEP-1998;	98US-0098716P.
PR 04-JUN-1998;	98US-0088033P.	PR 01-SEP-1998;	98US-0098723P.
PR 04-JUN-1998;	98US-0088036P.	PR 02-SEP-1998;	98US-0098803P.
PR 05-JUN-1998;	98US-0088167P.	PR 02-SEP-1998;	98US-0098821P.
PR 05-JUN-1998;	98US-0088202P.	PR 02-SEP-1998;	98US-0098843P.
PR 05-JUN-1998;	98US-0088212P.	PR 09-SEP-1998;	98US-0099602P.
PR 09-JUN-1998;	98US-0088217P.	PR 10-SEP-1998;	98US-0099741P.
PR 09-JUN-1998;	98US-0088655P.	PR 10-SEP-1998;	98US-0099754P.
PR 10-JUN-1998;	98US-0088732P.	PR 10-SEP-1998;	98US-0099763P.
PR 10-JUN-1998;	98US-0088738P.	PR 15-SEP-1998;	98US-0100388P.
PR 10-JUN-1998;	98US-0088740P.	PR 16-SEP-1998;	98US-0100662P.
PR 10-JUN-1998;	98US-0088811P.	PR 16-SEP-1998;	98US-0100664P.
PR 10-JUN-1998;	98US-0088824P.	PR 16-SEP-1998;	98US-0101751P.
PR 10-JUN-1998;	98US-0088826P.	PR 16-SEP-1998;	98US-0101751P.
PR 11-JUN-1998;	98US-0088861P.	PR 17-SEP-1998;	98US-0100683P.
PR 11-JUN-1998;	98US-0088863P.	PR 17-SEP-1998;	98US-0100684P.
PR 11-JUN-1998;	98US-0088876P.	PR 17-SEP-1998;	98US-0100919P.
PR 12-JUN-1998;	98US-0089090P.	PR 18-SEP-1998;	98US-0100930P.
PR 12-JUN-1998;	98US-0089105P.	PR 18-SEP-1998;	98US-0100849P.
PR 16-JUN-1998;	98US-0089512P.	PR 18-SEP-1998;	98US-0101014P.
PR 16-JUN-1998;	98US-0089514P.	PR 18-SEP-1998;	98US-0101068P.
PR 17-JUN-1998;	98US-0089538P.	PR 23-SEP-1998;	98US-0101471P.
PR 17-JUN-1998;	98US-0089538P.	PR 23-SEP-1998;	98US-0101472P.
PR 17-JUN-1998;	98US-0089653P.	PR 23-SEP-1998;	98US-0101475P.
PR 18-JUN-1998;	98US-0089908P.	PR 24-SEP-1998;	98US-0101477P.
PR 19-JUN-1998;	98US-0089932P.	PR 24-SEP-1998;	98US-0101738P.
PR 22-JUN-1998;	98US-0090246P.	PR 24-SEP-1998;	98US-0101739P.
PR 22-JUN-1998;	98US-0090252P.	PR 24-SEP-1998;	98US-0101743P.
PR 22-JUN-1998;	98US-0090254P.	PR 25-SEP-1998;	98US-0101922P.
PR 24-JUN-1998;	98US-0090429P.	PR 25-SEP-1998;	98US-0101786P.
PR 24-JUN-1998;	98US-0090435P.	PR 29-SEP-1998;	98US-0102207P.
PR 24-JUN-1998;	98US-0090444P.	PR 29-SEP-1998;	98US-0102240P.
PR 24-JUN-1998;	98US-0090461P.	PR 29-SEP-1998;	98US-0102330P.
PR 24-JUN-1998;	98US-0090540P.	PR 29-SEP-1998;	98US-0102331P.
PR 24-JUN-1998;	98US-0090540P.	PR 30-SEP-1998;	98US-0102487P.
PR 25-JUN-1998;	98US-0090676P.	PR 30-SEP-1998;	98US-0102570P.
PR 25-JUN-1998;	98US-0090678P.	PR 30-SEP-1998;	98US-0102571P.
PR 25-JUN-1998;	98US-0090688P.	PR 01-OCT-1998;	98US-0102684P.
PR 25-JUN-1998;	98US-0090690P.	PR 01-OCT-1998;	98US-0102687P.
PR 25-JUN-1998;	98US-0090694P.		
PR 25-JUN-1998;	98US-0090695P.		
PR 25-JUN-1998;	98US-0090696P.		
PR 26-JUN-1998;	98US-00105413		
PR 26-JUN-1998;	98US-0090862P.		
PR 26-JUN-1998;	98US-0090863P.		
PR 26-JUN-1998;	98US-0091010P.		
PR 01-JUL-1998;	98US-0091359P.		
PR 01-JUL-1998;	98US-0091544P.		
PR 02-JUL-1998;	98US-0091478P.		
PR 02-JUL-1998;	98US-0091486P.		
PR 02-JUL-1998;	98US-0091626P.		
PR 02-JUL-1998;	98US-0091628P.		
PR 02-JUL-1998;	98US-0091632P.		
PR 04-JUL-1998;	98US-0094006P.		
PR 10-AUG-1998;	98US-0095282P.		
PR 10-AUG-1998;	98US-0095998P.		
PR 10-AUG-1998;	98US-0096012P.		
PR 17-AUG-1998;	98US-0096757P.		
PR 17-AUG-1998;	98US-0096756P.		

Query Match

Best Local Similarity 67.4%; Pred. NO. 0.0004;

Mismatches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY	2108	CATCCCAATGCTGCTTTCCTTACCACTCTTCCCTTTTATCTTATTAATAAAATGTTG	2167
Db	1555	CCTTAAACACCACCTCTCATCACTAATCTCAGCCCTTGCCCTTGAAATAAACCTTAGC	1614
QY	2168	GTCTCCCACTGCTGCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2227
Db	1615	TGCCCCACAAA	1674
QY	2228	AAAAAAAAAAAAA	2242
Db	1675	AAAAAAAAAAAAA	1689

RESULT 1436

ACD25151

ID ACD25151 standard; cDNA; 1734 BP.





CC gene mapping, in the generation of antisense RNA and DNA and in gene  
 CC therapy. The nucleic acids can also be used for mapping genes encoding  
 CC PRO polypeptides, for genetic analysis of individuals with genetic  
 CC disorders, and for generating either transgenic animals or knock-out  
 CC animals which are useful in the development and screening of  
 CC therapeutically useful compounds. Sequences ACF00100-00404 represent  
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the  
 CC invention. Note: The sequence data for this patent is also available in  
 CC electronic format from USPIO at seqdata.uspto.gov/sequence.html  
 XX  
 SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.2; DB 8; Length 1734;  
 Best Local Similarity 67.4%; Pred. No. 0.0004;  
 Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATCGCTTTGCTTTACCACTCTTTCTTTATCTTATTAATAAATGTTG 2167  
 DB 1555 CTTTAAACACACCCCTCTCATCTAATCTCAGCCCTTGCCCTTGAATTAACCTTAGC 1614

QY 2168 GTCTCCACCTGCTCCCAAAAAA 2242  
 DB 1615 TGCCCCACAAAAA 1675

RESULT 1438  
 ACA60388  
 ID ACA60388 standard; cDNA; 1734 BP.

XX ACA60388;  
 XX  
 DT 11-JUN-2003 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO1411 cDNA.  
 XX  
 KW Human; secreted and transmembrane polypeptide; gene;  
 KW ss. chromosome mapping; gene mapping; transgenic animal; knockout animal;  
 KW therapeutic agent screening; chromosome identification; tissue typing;  
 KW gene therapy.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003018183-A1.  
 XX  
 PD 23-JAN-2003.  
 XX  
 PF 01-MAY-2002; 2002US-00063512.  
 XX  
 PR 06-DEC-2001; 2001US-00006867.  
 XX  
 XX (GETH ) GENENTECH INC.  
 XX  
 XX Eaton DL, Fillvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
 PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
 XX WPI; 2003-330984/31.  
 DR P-PSDB; ABU71977.  
 XX  
 XX New secreted and transmembrane PRO polypeptides and nucleic acid  
 PT molecules encoding the polypeptides, useful in gene therapy or preparing  
 PT a medicament for treating a condition that is responsive to the PRO  
 PT polypeptide or antibody.  
 XX  
 XX Disclosure; Fig 51; 409pp; English.  
 XX  
 XX The invention describes novel isolated PRO polypeptides. The PRO  
 CC polypeptides or anti-PRO antibodies are useful in preparing a medicament  
 CC for treating a condition that is responsive to the PRO polypeptide or  
 CC antibody. The PRO nucleotide sequences may be used as hybridisation

CC probes in chromosome and gene mapping, or in generating antisense RNA and  
 CC DNA. PRO nucleic acids are also useful in preparing PRO polypeptides, in  
 CC assays to identify other proteins or molecules involved in binding  
 CC reaction, to generate transgenic animals or knockout animals, which in  
 CC turn are useful in the development and screening of therapeutically  
 CC useful reagents, for chromosome identification, and tissue typing. The  
 CC PRO polypeptides and nucleic acid molecules are also useful in gene  
 CC therapy, and as molecular weight markers for protein electrophoresis  
 CC purposes. The anti-PRO antibodies may be used in diagnostic assays for  
 CC PRO, or for the affinity purification of PRO from recombinant cell  
 CC culture or natural sources. This sequence encodes a novel human secreted  
 CC and transmembrane PRO polypeptide

Query Match 2.9%; Score 65.2; DB 8; Length 1734;  
 Best Local Similarity 67.4%; Pred. No. 0.0004;  
 Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATCGCTTTGCTTTACCACTCTTTCTTTATCTTATTAATAAATGTTG 2167  
 DB 1555 CTTTAAACACACCCCTCTCATCTAATCTCAGCCCTTGCCCTTGAATTAACCTTAGC 1614

QY 2168 GTCTCCACCTGCTCCCAAAAAA 2242  
 DB 1615 TGCCCCACAAAAA 1675

RESULT 1439  
 ACA72257  
 ID ACA72257 standard; cDNA; 1734 BP.

XX ACA72257;  
 XX  
 DT 30-JUN-2003 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO1411 cDNA.  
 XX  
 KW Human; secreted and transmembrane protein; PRO; cytostatic; gene therapy;  
 KW chondrocyte stimulator; chromosome mapping; gene mapping;  
 KW transgenic animal; knock-out animal; tumour; gene; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003032114-A1.  
 XX  
 PD 13-FEB-2003.  
 XX  
 PF 20-JUN-2002; 2002US-00176919.  
 XX  
 XX 18-SEP-1997; 97US-0059263P.  
 PR 18-SEP-1997; 97US-0059266P.  
 PR 17-OCT-1997; 97US-0062250P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 24-OCT-1997; 97US-0063121P.  
 PR 28-OCT-1997; 97US-0063540P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 28-OCT-1997; 97US-0063564P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 13-NOV-1997; 97US-0065311P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 11-DEC-1997; 97US-0069335P.  
 PR 12-DEC-1997; 97US-0069425P.

PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 28-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086332P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.

PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.  
PR 24-SEP-1998; 98US-0101743P.

```
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match          2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATCGCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAATGTTG 2167
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1555 CCTTAAACACACACCTCTCATCACTATCTCAGCCCTTGCCCTGGAATTAACCTTAGC 1614
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2168 GTCTCCACACTGNTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1615 TGCCCCACAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 2228 AAAAAAAAAAAAAA 2242
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1675 AAAAAAAAAAAAAA 1689
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 1440
ACD04781
ID ACD04781 standard; cDNA; 1734 BP.
XX
AC ACD04781;
XX
DT 06-AUG-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1411 cDNA.
XX
KW Human; ss; Gene therapy; tumour necrosis factor alpha; TNF-alpha;
KW chondrocyte stimulation; tumour; tissue typing; gene.
XX
OS Homo sapiens.
XX
PN US2003032101-A1.
XX
PD 13-FEB-2003.
XX
PF 17-JUN-2002; 2002US-00173695.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.

PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 31-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 01-APR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085799P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
```

```
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090453P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 01-SEP-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 15-SEP-1998; 98US-0099812P.
PR 16-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-U0019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.

PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 23-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0103395P.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCGAATGATCGCTTTCGTTTACCACTCTTCTCTTATCTTATTAATAAAATGTTG 2167
Db | | | | | | | | | | | | | | | | | | | | | |
1555 CCTTAAACACCACTCTCTCATCACTAATCTCAGCCCTTGCCCTTGAAATAAACCTTAGC 1614
QY 2168 GTCTCCACCACTGCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db | | | | | | | | | | | | | | | | | | | | | |
1615 TGCCCACAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674

QY 2228 AAAAAAAAAAAAAA 2242
Db | | | | | | | | | | | | | | | | | | | | | |
1675 AAAAAAAAAAAAAA 1689

RESULT 1441
ACD18242
ID ACD18242 standard; cDNA; 1734 BP.
XX
AC ACD18242;
XX
XX 26-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #101.
XX
KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
PN US2003036124-A1.
XX
PD 20-FEB-2003.
XX
PF 26-JUN-2002; 2002US-00180998.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
```

PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069333P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077642P.  
PR 20-MAR-1998; 98US-0078888P.  
PR 20-MAR-1998; 98US-0078933P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083493P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084633P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088325P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090439P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.

```

PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 25-SEP-1998; 98US-0102240P.
PR 25-SEP-1998; 98US-0102330P.
PR 25-SEP-1998; 98US-0102331P.
PR 25-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 2108 CATCCAAATGATCGCCTTGGCTTTACCACTCTTTCTTTTATCTATTAATAAAAAATGTTG 2167
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1555 CCTTAAACACACCCTCTCATCACTAATCTCAGCCCTTGCCCTTGAATAAATACCTTAGC 1614

Qy 2168 GTCTCCACCACTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1615 TGCCCAACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAA 1674

Qy 2228 AAAAAAATAAAAAA 2242
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1675 AAAAAAATAAAAAA 1689

RESULT 1442
ACD08249
ID ACD08249 standard; cDNA; 1734 BP.
XX
XX ACD08249;
XX
XX 09-AUG-2003 (first entry)
XX
XX Human secreted/transmembrane protein (PRO) cDNA #101.
XX
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
XX tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
XX tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
XX prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
XX Homo sapiens.
XX
XX US2003040054-A1.
XX
XX 27-FEB-2003.
XX
XX 20-JUN-2002; 2002US-00176479.
XX
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 31-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066120P.

97US-0066466P.
97US-0066772P.
97US-0069335P.
97US-0069425P.
97US-0069870P.
97US-00698017P.
98US-0077450P.
98US-0077632P.
98US-0077649P.
98US-0078886P.
98US-0078939P.
98US-0079664P.
98US-0079786P.
98US-0080107P.
98US-0080194P.
98US-0080327P.
98US-0080333P.
98US-0081049P.
98US-0081070P.
98US-0081195P.
98US-0081838P.
98US-0082568P.
98US-0082569P.
98US-0082704P.
98US-0083222P.
98US-0083495P.
98US-0083496P.
98US-0083499P.
98US-0083559P.
98US-0084366P.
98US-0084414P.
98US-0084639P.
98US-0084640P.
98US-0084643P.
98US-0085579P.
98US-0085580P.
98US-0085582P.
98US-0085700P.
98US-0086023P.
98US-0086392P.
98US-0086486P.
98US-0087098P.
98US-0087208P.
98US-0087609P.
98US-0087759P.
98US-0087827P.
98US-0088025P.
98US-0088028P.
98US-0088029P.
98US-0088033P.
98US-0088326P.
98US-0088167P.
98US-0088202P.
98US-0088212P.
98US-0088217P.
98US-0088655P.
98US-0088722P.
98US-0088738P.
98US-0088740P.
98US-0088811P.
98US-0088824P.
98US-0088825P.
98US-0088826P.
98US-0088861P.
98US-0088863P.
98US-0088876P.
98US-0089090P.
98US-0089105P.
98US-0089512P.
98US-0089514P.
98US-0089538P.
98US-0089598P.

```

```
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089508P.
PR 19-JUN-1998; 98US-0089552P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090422P.
PR 24-JUN-1998; 98US-0090433P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094008P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098718P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101477P.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATCGGCTTGCTTTACCACTCTTCTTTTATCTTATTAATAAATGTTG 2167
Db 1555 CTTTAAACACCCCTCTCATCTCATCTCTGAGCCCTTGCCCTTGAAATAAACCTTAGC 1614

QY 2168 GTCTCCACCACTGCTCCCAAAAAA 2242
Db 1615 TGCCCCACAAAAA 1689

QY 2228 AAAAAA 2242
Db 1675 AAAAAA 1689

RESULT 1443
ACA88683
ID ACA88683 standard; cDNA; 1734 BP.
XX ACA88683;
AC ACA88683;
XX 09-JUL-2003 (first entry)
DT Novel human secreted and transmembrane protein PRO1411 cDNA.
DE Human; ss; gene therapy; chondrocyte stimulation; TNF-alpha release;
KW chondrocyte proliferation; chondrocyte differentiation; tumour detection;
XX tissue typing; gene.
OS Homo sapiens.
XX US2003036133-A1.
XX 20-FEB-2003.
XX 27-JUN-2002; 2002US-00184630.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
```

PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 28-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088036P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088255P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 26-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100884P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.



```

XX WPI; 2003-341964/32.
DR P-PSDB; ABU67294.
XX
XX Thirty seven nucleic acids encoding novel secreted and transmembrane PRO
PT polypeptides, useful for modulating biological activity of cell
PT expressing the polypeptide, and in chromosome and gene mapping.
XX
XX Claim 2; Fig 53; 255pp; English.
XX
XX The invention describes an isolated, secreted and transmembrane
CC polypeptide (I), termed PRO polypeptide. (I) is useful for detecting
CC PRO533, PRO301, PRO187, PRO337, PRO1411, PRO10096, PRO246, PRO6307,
CC PRO6003, PRO6004, PRO4356, PRO2630, PRO265, PRO941, fibroblast growth
CC factor receptor (FGFR)-4, FGFR-3, FGFR-2 or FGFR-1 polypeptide, and for
CC linking a bioactive molecule e.g. toxin, radiolabel or antibody, to a
CC cell expressing the polypeptides. The bioactive molecule causes cell
CC death. (ii) Is useful as hybridisation probes, in chromosome and gene
CC mapping, in generation of antisense RNA and DNA, in the preparation of
CC PRO polypeptide, for generating transgenic animals or knockout animals
CC which in turn are useful in the development and screening of
CC therapeutically useful reagents, and for the genetic analysis of
CC individuals with genetic disorders, in gene therapy, and for chromosome
CC identification. (i) Or Ab is useful for the preparation of medicament for
CC treating conditions which are responsive to the PRO polypeptide or anti-
CC PRO antibody e.g. a tumour. (i) is useful for treating obesity, diabetes
CC or hypo- or hyper-insulinaemia, and cardiac insufficiency disorders, for
CC inhibiting tumour growth, enhances vascular permeability and immune
CC response, for inducing regeneration of auditory hair cells and for
CC treating hearing loss in mammals, and for treating bone and/or cartilage
CC disorders such as sports injuries and arthritis. This sequence encodes a
CC novel human secreted and transmembrane polypeptide associated
CC oligonucleotide
XX
SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;

Query Match          2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCCAATGATCGCTTGGTTGTTTACCACTCTTTCCTTTTATCTTATATAAAAAATGTTG 2167
    |||||
Db 1555 CCTTAAACACCACTCTCATCACTAATCTCAGCCCTTGCCCTTGAAATAAACCTTAGC 1614

QY 2168 GTCTCCACCACTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227
    |||||
Db 1615 TGCCCCACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1674

QY 2228 AAAAAAATAAAAAA 2242
    |||||
Db 1675 AAAAAAATAAAAAA 1689

RESULT 1445
ACA70125
ID ACA70125 standard; cDNA; 1734 BP.
XX
AC ACA70125;
XX
XX 11-AUG-2003 (first entry)
DT
XX Human secreted/transmembrane protein (PRO) cDNA #101.
DE
XX Human; gene; ss; secreted and transmembrane protein; PRO;
KW Chromosome mapping; gene mapping; gene therapy;
KW tumour necrosis factor alpha; TNF-alpha; chondrocyte; tumour.
XX
OS Homo sapiens.
XX
FN US2003036134-A1.
XX
PD 20-FEB-2003.
XX

```

```

PF 27-JUN-2002; 2002US-00184631.
XX
XX 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 20-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 18-MAY-1998; 98US-0085700P.
PR 22-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 28-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.

```



PN US2003022294-A1.  
XX 30-JAN-2003.  
XX  
XX 19-JUN-2002; 2002US-00175738.  
XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 15-MAY-1998; 98US-0084640P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087088P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 03-JUN-1998; 98US-0087837P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 26-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.

```
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101933P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101473P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 25-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Oy 2108 CATCAATGATGCGCTTGTGCTTTACCACTCTTCTCTTTTATCTATTTATTAATAAATGTTG 2167
Db 1555 CTTTAAACACACCCTCTCATCTACTATCTCAGCCCTTGCCCTTGAATAAATACCTTAGC 1614

Oy 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674

Oy 2228 AAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1447
ACCT74262
ID ACC74262 standard; cDNA; 1734 BP.
XX AC ACCT74262;
XX
XX 28-JUL-2003 (first entry)
XX Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.
XX
XX Human; PRO; secreted protein; transmembrane protein;
XX extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; proliferation; differentiation; cartilage disorder;
XX bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX liver; drug screening; transgenic animal; genetic analysis;
XX antiarthritic; vulnery; gene therapy; gene; ss.
XX
```

```
OS Homo sapiens.
XX US2003027275-A1.
XX 06-FEB-2003.
XX
XX 20-JUN-2002; 2002US-00176918.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0083120P.
PR 24-OCT-1997; 97US-0083121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0083734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
```



PN US2003027324-A1.  
XX PD 06-FEB-2003.  
XX PF 21-JUN-2002; 2002US-00176991.  
XX XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-00698017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077642P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078933P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 15-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084633P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.

```
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101933P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 25-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CAICCATGATGCGCTTGTGCTTTACCACTCTTTCCTTTTATCTATTATAAATAAAGCTTG 2167
Db 1555 CCTTAAACACCAACCCCTCTCATCACTAATCTCAGCCCTTGCCCTTGAATAAACCTTAGC 1614

QY 2168 GTCTCCACCACTGNCCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674

QY 2228 AAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1449
ACD25458
ID ACD25458 standard; cDNA; 1734 BP.
XX
AC ACD25458;
XX
DT 27-AUG-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1411 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; chromosome mapping;
KW gene mapping; transgenic animal; knockout animal; tissue typing;
KW chromosome identification; tumour; chondrocyte proliferation;
KW chondrocyte differentiation; tumour necrosis factor-alpha release;
KW gene therapy; gene; ss.
XX
```

```
OS
XX Homo sapiens.
PN US2003036118-A1.
XX
XX 20-FEB-2003.
XX
XX 21-JUN-2002; 2002US-00176760.
XX
XX 26-JUN-1998; 98US-00105413.
PR 16-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028551.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005061.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 22-AUG-2000; 2000US-00644848.
PR 18-SEP-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 25-MAY-2001; 2001US-00854280.
PR 01-JUN-2001; 2001US-00866028.
PR 05-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001WO-US019692.
PR 03-JUL-2001; 2001WO-US021066.
PR 18-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00918585.
PR 13-AUG-2001; 2001US-00924419.
PR 15-AUG-2001; 2001US-00929404.
PR 28-AUG-2001; 2001US-00931836.
PR 28-AUG-2001; 2001US-00941992.
PR 04-SEP-2001; 2001WO-US027099.
PR 15-JAN-2002; 2002US-00946374.
PR 2002US-00052586.
```



PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088555P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089588P.  
PR 17-JUN-1998; 98US-0089553P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090354P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 02-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.

PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101922P.  
PR 25-SEP-1998; 98US-0101786P.  
PR 25-SEP-1998; 98US-0102207P.  
PR 25-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102330P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 30-SEP-1998; 98US-0102571P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 01-OCT-1998; 98US-0102687P.  
PR 02-OCT-1998; 98US-0102965P.  
PR 06-OCT-1998; 98US-0103258P.  
PR 06-OCT-1998; 98US-0103449P.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;

Best Local Similarity 67.4%; Pred. No. 0.0004; Indels 0; Gaps 0;  
Matches 91; Conservative 0; Mismatches 44;

QY 2108 CATCCAATGATCGCTTTGCTTTACCACTCTTTCCCTTTTATCTTATTAATAAATGTTG 2167  
Db 1555 CCTTAAACACACCTCTCATCACTAATCTGACCTTGCCCTTGAAATAACCTTAGC 1614  
QY 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227  
Db 1615 TGCCCCACAA 1674  
QY 2228 AAAAAAAAAAAAAA 2242  
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1451

ACC88222  
ID ACC88222 standard; cDNA; 1734 BP.

XX  
AC ACC88222;

XX 05-AUG-2003 (first entry)

XX Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.

XX Human; PRO; secreted protein; transmembrane protein;  
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; proliferation; differentiation; cartilage disorder;  
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
KW liver; drug screening; transgenic animal; genetic analysis;  
KW antiarthritic; vulnerability; gene therapy; gene; ss.







OS Homo sapiens.  
XX US2003044916-A1.  
XX 06-MAR-2003.  
XX  
XX 20-JUN-2002; 2002US-00176484.  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069342P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086332P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 12-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 16-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 28-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.

```
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2108 CATCCAATGATCGCCTTGCTTTACCACTCTTCTCTTTATCTTATTAATAAATGTTG 2167
Db 1555 CCTTAAACACACCCCTCTCATCTAATCTCAGCCCTTGCCCTTGAATAAACCTTAGC 1614
QY 2168 GTCTCCACCACTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227
Db 1615 TGCCCCACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATA 1674
QY 2228 AAAAAAATAAAAAA 2242
Db 1675 AAAAAAATAAAAAA 1689
```

```
RESULT 1454
ACAS58835
ID ACA58835 standard; cDNA; 1734 BP.
XX
AC ACA58835;
XX
DT 10-JUN-2003 (first entry)
XX
DE cDNA encoding human secreted polypeptide PRO1411.
XX
KW Human; ss; gene; gene therapy; tumour; cancer.
XX
OS Homo sapiens.
XX
```

```
PN US2003013855-A1.
XX 16-JAN-2003.
XX
XX 03-MAY-2002; 2002US-00063616.
XX
PR 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US02328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX (GETH ) GENENTECH INC.
```

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
WPI; 2003-330485/31.  
P-PSDB; ABU71531.

New isolated antibody specifically binding a PRO polypeptide, useful for the preparation of a medicament for treating disorders with the aberrant expression or activity of the PRO polypeptide, such as tumor conditions and cancer.

Example 4; Page 117-118; 406pp; English.

The invention relates to an antibody that binds to a polypeptide with a fully defined sequence given in the specification. The methods and compositions (containing antibodies that specifically bind a PRO polypeptide) of the present invention are useful for the preparation of a medicament for the treatment of disorders associated with the aberrant expression or activity of the PRO polypeptide, such as tumour conditions and cancer. They can also be used to generate transgenic or knockout animals useful in the development and screening of therapeutically useful reagents. The PRO polypeptides and encoding nucleic acids can be used as molecular weight markers for protein electrophoresis, chromosome identification and tissue typing. The PRO polypeptides are useful to induce angiogenesis e.g wound healing; in the treatment of sports-related joint problems, articular cartilage defects, osteoarthritis or rheumatoid arthritis; diabetes; hyperinsulinaemia and hypoinsulinaemia. The

CC antibodies may be used in various diagnostic, competitive binding and/or  
CC immunoprecipitation assays. The present sequence represents a cDNA  
CC encoding a PRO polypeptide of the invention  
XX  
SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.2; DB 8; Length 1734;  
Best Local Similarity 67.4%; Pred. No. 0.0004;  
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 2108 CATCCCAATGATCCCTTGCTTGTACACATCTTTCCTTTTAATCTTATTAATAAAATGTTG 2167  
Db 1555 CCTTAAACACACCTCTCATCACTAATCTGAGCCCTTGCCCTTGAATAAACCTTAGC 1614  
Qy 2168 GTCTCCACCACTGNTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227  
Db 1615 TGCCCAACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1674

Qy 2228 AAAAAAATAAAAAA 2242  
Db 1675 AAAAAAATAAAAAA 1689

RESULT 1455  
ABX98253  
ID ABX98253 standard; cDNA; 1734 BP.  
XX  
AC ABX98253;  
DT 19-MAY-2003 (first entry)  
XX  
DE Human cDNA encoding a secreted/transmembrane protein, SEQ ID 201.  
XX  
KW Human; ss; gene; PRO; secreted protein; transmembrane protein;  
KW cystostatic; antiarthritic; osteopathic; adrenal tumour; lung tumour;  
KW colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; TNF-alpha release; arthritis;  
KW tumour necrosis factor alpha; chondrocyte cell; bone disorder;  
KW cartilage disorder; sports injury.  
XX  
OS Homo sapiens.  
XX  
XX US2003036156-A1.  
XX  
PD 20-FEB-2003.  
XX  
XX 02-JUL-2002; 2002US-00188767.  
XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0082250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063112P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.

20-MAR-1998; 98US-0078939P.  
27-MAR-1998; 98US-0079664P.  
27-MAR-1998; 98US-0079786P.  
31-MAR-1998; 98US-0080107P.  
31-MAR-1998; 98US-0080134P.  
01-APR-1998; 98US-0080327P.  
01-APR-1998; 98US-0080333P.  
08-APR-1998; 98US-0081049P.  
08-APR-1998; 98US-0081070P.  
09-APR-1998; 98US-0081195P.  
15-APR-1998; 98US-0081838P.  
21-APR-1998; 98US-0082568P.  
21-APR-1998; 98US-0082569P.  
22-APR-1998; 98US-0082704P.  
22-APR-1998; 98US-0082797P.  
28-APR-1998; 98US-0083322P.  
29-APR-1998; 98US-0083495P.  
29-APR-1998; 98US-0083496P.  
29-APR-1998; 98US-0083499P.  
29-APR-1998; 98US-0083559P.  
05-MAY-1998; 98US-0084366P.  
06-MAY-1998; 98US-0084414P.  
07-MAY-1998; 98US-0084639P.  
07-MAY-1998; 98US-0084640P.  
07-MAY-1998; 98US-0084643P.  
15-MAY-1998; 98US-0085579P.  
15-MAY-1998; 98US-0085580P.  
15-MAY-1998; 98US-0085582P.  
15-MAY-1998; 98US-0085700P.  
18-MAY-1998; 98US-0086023P.  
22-MAY-1998; 98US-0086392P.  
22-MAY-1998; 98US-0086486P.  
28-MAY-1998; 98US-0087098P.  
28-MAY-1998; 98US-0087208P.  
02-JUN-1998; 98US-0087609P.  
02-JUN-1998; 98US-0087759P.  
03-JUN-1998; 98US-0087822P.  
04-JUN-1998; 98US-0088025P.  
04-JUN-1998; 98US-0088028P.  
04-JUN-1998; 98US-0088029P.  
04-JUN-1998; 98US-0088033P.  
04-JUN-1998; 98US-0088326P.  
05-JUN-1998; 98US-0088167P.  
05-JUN-1998; 98US-0088202P.  
05-JUN-1998; 98US-0088212P.  
05-JUN-1998; 98US-0088217P.  
09-JUN-1998; 98US-0088655P.  
10-JUN-1998; 98US-0088722P.  
10-JUN-1998; 98US-0088738P.  
10-JUN-1998; 98US-0088740P.  
10-JUN-1998; 98US-0088811P.  
10-JUN-1998; 98US-0088824P.  
10-JUN-1998; 98US-0088825P.  
10-JUN-1998; 98US-0088826P.  
11-JUN-1998; 98US-0088861P.  
11-JUN-1998; 98US-0088863P.  
11-JUN-1998; 98US-0088876P.  
12-JUN-1998; 98US-0089090P.  
16-JUN-1998; 98US-0089512P.  
16-JUN-1998; 98US-0089514P.  
17-JUN-1998; 98US-0089538P.  
17-JUN-1998; 98US-0089598P.  
18-JUN-1998; 98US-0089908P.  
19-JUN-1998; 98US-0089952P.  
22-JUN-1998; 98US-0090246P.  
22-JUN-1998; 98US-0090252P.  
22-JUN-1998; 98US-0090354P.  
24-JUN-1998; 98US-0090429P.  
24-JUN-1998; 98US-0090435P.  
24-JUN-1998; 98US-0090444P.  
24-JUN-1998; 98US-0090461P.

```
PR 24-JUN-1998; 98US-0090533P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090693P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.

PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.

Query Match          2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATCGGCTTGGCTTTTACCACTCTTCTCTTTTATCTTATTAATAAATGTTG 2167
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1555 CCTTAAACACCAACCCTCTCATCTCACTATCTCAGCCCTTGCCTTGAATAAACCCTTAGC 1614
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1615 TGCCCCACCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2228 AAAAAAAAAAAAAA 2242
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1675 AAAAAAAAAAAAAA 1689
   ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 1456
ACD14004
ID ACD14004 standard; cDNA; 1734 BP.
XX AC ACD14004;
XX DT 18-AUG-2003 (first entry)
XX DE Human PRO polynucleotide #101.
XX KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
   cytosolic; tumour necrosis factor-alpha; TNF-alpha; blood; tumour;
   chondrocyte cell; cancer.
XX OS Homo sapiens.
XX PN US2003032117-A1.
XX PD 13-FEB-2003.
XX PF 24-JUN-2002; 2002US-00179510.
XX PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 21-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
```

PR	27-MAR-1998;	98US-0079786P.	PR	25-JUN-1998;	98US-0090676P.
PR	31-MAR-1998;	98US-0080107P.	PR	25-JUN-1998;	98US-0090678P.
PR	31-MAR-1998;	98US-0080194P.	PR	25-JUN-1998;	98US-0090688P.
PR	01-APR-1998;	98US-0080327P.	PR	25-JUN-1998;	98US-0090690P.
PR	01-APR-1998;	98US-0080333P.	PR	25-JUN-1998;	98US-0090694P.
PR	08-APR-1998;	98US-0081049P.	PR	25-JUN-1998;	98US-0090695P.
PR	08-APR-1998;	98US-0081070P.	PR	25-JUN-1998;	98US-0090696P.
PR	09-APR-1998;	98US-0081195P.	PR	26-JUN-1998;	98US-00105413.
PR	15-APR-1998;	98US-0081838P.	PR	26-JUN-1998;	98US-0090862P.
PR	21-APR-1998;	98US-0082568P.	PR	26-JUN-1998;	98US-0090863P.
PR	21-APR-1998;	98US-0082569P.	PR	26-JUN-1998;	98US-0091010P.
PR	22-APR-1998;	98US-0082704P.	PR	01-JUL-1998;	98US-0091359P.
PR	22-APR-1998;	98US-0082797P.	PR	01-JUL-1998;	98US-0091544P.
PR	28-APR-1998;	98US-0083322P.	PR	02-JUL-1998;	98US-0091478P.
PR	28-APR-1998;	98US-0083495P.	PR	02-JUL-1998;	98US-0091486P.
PR	29-APR-1998;	98US-0083496P.	PR	02-JUL-1998;	98US-0091628P.
PR	29-APR-1998;	98US-0083499P.	PR	02-JUL-1998;	98US-0091628P.
PR	29-APR-1998;	98US-0083559P.	PR	02-JUL-1998;	98US-0091628P.
PR	05-MAY-1998;	98US-0084366P.	PR	04-AUG-1998;	98US-0094006P.
PR	06-MAY-1998;	98US-0084414P.	PR	10-AUG-1998;	98US-0095282P.
PR	07-MAY-1998;	98US-0084639P.	PR	10-AUG-1998;	98US-0095598P.
PR	07-MAY-1998;	98US-0084640P.	PR	10-AUG-1998;	98US-0095598P.
PR	07-MAY-1998;	98US-0084643P.	PR	10-AUG-1998;	98US-0096012P.
PR	15-MAY-1998;	98US-0085579P.	PR	17-AUG-1998;	98US-0096757P.
PR	15-MAY-1998;	98US-0085580P.	PR	17-AUG-1998;	98US-0096766P.
PR	15-MAY-1998;	98US-0085582P.	PR	17-AUG-1998;	98US-0096867P.
PR	15-MAY-1998;	98US-0085700P.	PR	17-AUG-1998;	98US-0096891P.
PR	18-MAY-1998;	98US-0086023P.	PR	17-AUG-1998;	98US-0096897P.
PR	22-MAY-1998;	98US-0086392P.	PR	18-AUG-1998;	98US-0096949P.
PR	22-MAY-1998;	98US-0086486P.	PR	18-AUG-1998;	98US-0096949P.
PR	28-MAY-1998;	98US-0087038P.	PR	18-AUG-1998;	98US-0096959P.
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097022P.
PR	02-JUN-1998;	98US-0087609P.	PR	26-AUG-1998;	98US-0097022P.
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097552P.
PR	03-JUN-1998;	98US-0087827P.	PR	26-AUG-1998;	98US-0097552P.
PR	04-JUN-1998;	98US-0088025P.	PR	26-AUG-1998;	98US-0097954P.
PR	04-JUN-1998;	98US-0088028P.	PR	26-AUG-1998;	98US-0097971P.
PR	04-JUN-1998;	98US-0088029P.	PR	26-AUG-1998;	98US-0097974P.
PR	04-JUN-1998;	98US-0088033P.	PR	26-AUG-1998;	98US-0098014P.
PR	04-JUN-1998;	98US-0088036P.	PR	01-SEP-1998;	98US-0098716P.
PR	05-JUN-1998;	98US-0088167P.	PR	01-SEP-1998;	98US-0098723P.
PR	05-JUN-1998;	98US-0088202P.	PR	02-SEP-1998;	98US-0098803P.
PR	05-JUN-1998;	98US-0088212P.	PR	02-SEP-1998;	98US-0098821P.
PR	05-JUN-1998;	98US-0088217P.	PR	02-SEP-1998;	98US-0098843P.
PR	09-JUN-1998;	98US-0088655P.	PR	02-SEP-1998;	98US-0098843P.
PR	10-JUN-1998;	98US-0088722P.	PR	09-SEP-1998;	98US-0099602P.
PR	10-JUN-1998;	98US-0088738P.	PR	10-SEP-1998;	98US-0099741P.
PR	10-JUN-1998;	98US-0088740P.	PR	10-SEP-1998;	98US-0099754P.
PR	10-JUN-1998;	98US-0088811P.	PR	10-SEP-1998;	98US-0099763P.
PR	10-JUN-1998;	98US-0088824P.	PR	10-SEP-1998;	98US-0099812P.
PR	10-JUN-1998;	98US-0088825P.	PR	15-SEP-1998;	98US-0100388P.
PR	10-JUN-1998;	98US-0088826P.	PR	15-SEP-1998;	98US-0100388P.
PR	11-JUN-1998;	98US-0088861P.	PR	16-SEP-1998;	98US-0100662P.
PR	11-JUN-1998;	98US-0088863P.	PR	16-SEP-1998;	98US-0100664P.
PR	11-JUN-1998;	98US-0088876P.	PR	16-SEP-1998;	98US-0101751P.
PR	12-JUN-1998;	98US-0089090P.	PR	16-SEP-1998;	98US-0101751P.
PR	12-JUN-1998;	98US-0089105P.	PR	17-SEP-1998;	98US-0100684P.
PR	16-JUN-1998;	98US-00895112P.	PR	17-SEP-1998;	98US-0100684P.
PR	16-JUN-1998;	98US-0089514P.	PR	17-SEP-1998;	98US-0100919P.
PR	17-JUN-1998;	98US-0089538P.	PR	17-SEP-1998;	98US-0100930P.
PR	17-JUN-1998;	98US-0089598P.	PR	18-SEP-1998;	98US-0100849P.
PR	17-JUN-1998;	98US-0089653P.	PR	18-SEP-1998;	98US-0101014P.
PR	18-JUN-1998;	98US-0089908P.	PR	18-SEP-1998;	98US-0101014P.
PR	19-JUN-1998;	98US-0089952P.	PR	23-SEP-1998;	98US-0101471P.
PR	22-JUN-1998;	98US-0090246P.	PR	23-SEP-1998;	98US-0101472P.
PR	22-JUN-1998;	98US-0090252P.	PR	23-SEP-1998;	98US-0101475P.
PR	22-JUN-1998;	98US-0090254P.	PR	23-SEP-1998;	98US-0101477P.
PR	24-JUN-1998;	98US-0090429P.	PR	24-SEP-1998;	98US-0101738P.
PR	24-JUN-1998;	98US-0090435P.	PR	24-SEP-1998;	98US-0101739P.
PR	24-JUN-1998;	98US-0090444P.	PR	24-SEP-1998;	98US-0101743P.
PR	24-JUN-1998;	98US-0090461P.	PR	25-SEP-1998;	98US-0101922P.
PR	24-JUN-1998;	98US-0090535P.	PR	25-SEP-1998;	98US-0101786P.
PR	24-JUN-1998;	98US-0090540P.	PR	29-SEP-1998;	98US-0102207P.
PR	24-JUN-1998;	98US-0090540P.	PR	29-SEP-1998;	98US-0102240P.
PR	24-JUN-1998;	98US-0090540P.	PR	30-SEP-1998;	98US-0102330P.
PR	24-JUN-1998;	98US-0090540P.	PR	30-SEP-1998;	98US-0102331P.
PR	24-JUN-1998;	98US-0090540P.	PR	30-SEP-1998;	98US-0102487P.
PR	24-JUN-1998;	98US-0090540P.	PR	30-SEP-1998;	98US-0102570P.

```
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAAGATCGCTTGGCTTTACCACTCTTCTTTATCTTATTAATAAATGTTG 2167
Db 1555 CTTTAAACACCACTCTTCTATCACTAATCTGAGCTTGGCTTGAATAAACCTTAGC 1614
QY 2168 GTCTCCACCACTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227
Db 1615 TGCCCCACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATA 1674
QY 2228 AAAAAAATAAAAAA 2242
Db 1675 AAAAAAATAAAAAA 1689

RESULT 1457
ACD09784
ID ACD09784 standard; cDNA; 1734 BP.
XX AC ACD09784;
XX AC ACD09784;
XX DT 10-AUG-2003 (first entry)
XX DE Human secreted/transmembrane protein (PRO) cDNA #101.
XX KW Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX OS Homo sapiens.
XX XX
XX FN US2003036128-A1.
XX PD
XX PF 20-FEB-2003.
XX PF 27-JUN-2002; 2002US-00184616.
XX PF 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 06-MAY-1998; 98US-0084366P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
```

PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;  
 Best Local Similarity 67.4%; Pred. NO. 0.0004;  
 Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY	2108	CATCCAATGATCGCTTTGGCTTTTACCACTCTTCTCTTTATCTATTATTAATAAATGTTG	2167
Db	1555	CCTTAAACACACACCTCTCATCTAATCTCAGCCCTTGCCCTTGAAATAAACCTTAGC	1614
QY	2168	GTCTCCACCACTGCTCCCAA	2227
Db	1615	TGCCCCACAAA	1674
QY	2228	AAAAAAAAAAAAAAAAAAAA 2242	
Db	1675	AAAAAAAAAAAAAAAAAAAA 1689	

RESULT 1458  
 ACC88529  
 ID ACC88529 standard; cDNA; 1734 BP.  
 XX ACC88529;  
 XX 05-AUG-2003 (first entry)  
 DE Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.  
 XX Human; PRO; secreted protein; transmembrane protein;  
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;  
 KW chondrocyte; proliferation; differentiation; cartilage disorder;  
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
 KW liver; drug screening; transgenic animal; genetic analysis;  
 KW antiarthritic; vulnery; gene therapy; gene; ss.  
 OS Homo sapiens.  
 XX US2003027266-A1.  
 PN 06-FEB-2003.  
 PD 18-JUN-2002; 2002US-00174588.  
 PF 18-SEP-1997; 97US-0059263P.  
 XX 18-SEP-1997; 97US-0059266P.  
 PR 17-OCT-1997; 97US-0062250P.  
 PR 21-OCT-1997; 97US-0063486P.  
 PR 24-OCT-1997; 97US-0063120P.  
 PR 28-OCT-1997; 97US-0063121P.  
 PR 28-OCT-1997; 97US-0063540P.  
 PR 28-OCT-1997; 97US-0063541P.  
 PR 28-OCT-1997; 97US-0063544P.  
 PR 29-OCT-1997; 97US-0063734P.  
 PR 31-OCT-1997; 97US-0063870P.  
 PR 31-OCT-1997; 97US-0064103P.  
 PR 13-NOV-1997; 97US-0065311P.  
 PR 21-NOV-1997; 97US-0066120P.  
 PR 24-NOV-1997; 97US-0066466P.  
 PR 24-NOV-1997; 97US-0066772P.  
 PR 11-DEC-1997; 97US-0069335P.  
 PR 12-DEC-1997; 97US-0069425P.  
 PR 17-DEC-1997; 97US-0069870P.  
 PR 18-DEC-1997; 97US-0068017P.

PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 08-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081193P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 15-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088023P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089511P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 24-JUL-1998; 98US-0091632P.  
PR 04-AUG-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98US-01019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101922P.  
PR 25-SEP-1998; 98US-0101786P.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;  
 Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
 WPI: 2003-479876/45.  
 P-PSDB; ABO15755.  
 Three hundred and five nucleic acids encoding PRO polypeptides, useful  
 for the manufacture of a medicament for diagnosing or treating tumor or  
 for measuring or detecting expression of an associated gene.  
 Claim 2; Fig 201; 699pp; English.  
 The invention discloses human nucleic acids encoding secreted and  
 transmembrane (PRO) polypeptides, with or without their associated signal  
 peptide. Also disclosed is an antibody that specifically binds to the PRO  
 polypeptide, a method for stimulating the release of tumour necrosis  
 factor alpha (TNF-alpha) from human blood by contacting the blood with a

RESULT 1460	
ABX75641	
ID	ABX75641 standard; cDNA; 1734 BP.
XX	
XX	
AC	ABX75641;
XX	
DT	26-MAR-2003 (first entry)
XX	
DE	Human cDNA encoding secreted/transmembrane protein, PRO1411.
XX	
KW	Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW	antiarthritic; vulnery; tumour necrosis factor-alpha;
KW	chondrocyte cell proliferation; chondrocyte cell differentiation; tumour;
KW	adrenal tumour; lung tumour; colon tumour; breast tumour;
KW	prostate tumour; rectal tumour; cervical tumour; liver tumour;
KW	bone disorder; cartilage disorder; arthritis; sports injury.
XX	
OS	Homo sapiens.
XX	
PN	US2003022298-A1.
XX	
PD	30-JAN-2003.
XX	
PF	20-JUN-2002; 2002US-00176913.
XX	
PR	18-SEP-1997; 97US-0059263P.
PR	18-SEP-1997; 97US-0059266P.
PR	17-OCT-1997; 97US-0062250P.
PR	21-OCT-1997; 97US-0063486P.
PR	24-OCT-1997; 97US-0063120P.
PR	24-OCT-1997; 97US-0063121P.
PR	28-OCT-1997; 97US-0063540P.
PR	28-OCT-1997; 97US-0063541P.
PR	28-OCT-1997; 97US-0063544P.



```

PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 24-AUG-2000; 2000WO-US023328.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00863599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
XX
XX (GETH ) GENENTECH INC.
XX
XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-328612/04.
XX P-PSDB; ABU72312.
XX
XX An isolated secreted transmembrane polypeptide designated PRO, useful as
XX a therapeutic agent.
XX
XX Disclosure; Fig 51; 236pp; English.
XX
XX The present invention relates to the isolation of novel human PRO
XX polypeptides, and the polynucleotide sequences encoding them. The PRO
XX polypeptides are secreted and transmembrane proteins. The PRO
XX polypeptides and polynucleotides are useful for preparing a medicament
XX useful in the treatment of a condition responsive to anti-PRO antibody.
XX Anti-PRO antibodies are useful in diagnostic assays for PRO, by detecting
XX its expression in specific cells, tissues or serum, and for affinity
XX purification of PRO from recombinant cell culture or natural sources.
XX ACA63986-ACA64069 represent cDNA sequences encoding the human PRO
XX polypeptides of the invention
XX
XX Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;
XX
XX Query Match 2.9%; Score 65.2; DB 8; Length 1734;
XX Best Local Similarity 67.4%; Pred. No. 0.0004;
XX Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
XX
XX 2108 CATCCAATGATGCGCTTTGGCTTTACCACTCTTCCTTTATCTATTAATAAAATCTTG 2167
XX 1555 CCTTAAACACCAACCCCTCTCATCACTAATCTGACCCCTTGCCCTTGAAATAAACCTTAGC 1614
XX
XX 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
XX 1615 TGCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
XX
XX 2228 AAAAAAAAAAAAAA 2242
XX 1675 AAAAAAAAAAAAAA 1689
XX
XX RESULT 1462
XX ABX97844
XX ID ABX97844 standard; cDNA; 1734 BP.
XX

```

AC ABX97844;  
XX 16-MAY-2003 (first entry)  
XX  
XX Human PRO polynucleotide #101.  
KW Human; PRO; gene; ss; cytostatic; chromosome mapping; gene mapping;  
KW protein electrophoresis; tumour necrosis factor-alpha; TNF-alpha; blood;  
KW chondrocyte differentiation; chondrocyte proliferation; tumour.  
XX  
XX Homo sapiens.  
XX  
XX US2003032102-A1.  
XX  
XX 13-FEB-2003.  
XX  
XX 17-JUN-2002; 2002US-00173697.  
XX  
PR 18-SEP-1997; 97US-005263P.  
PR 18-SEP-1997; 97US-005266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069333P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.

```
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 03-SEP-1998; 98US-0098902P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 25-SEP-1998; 98US-0102207P.
PR 25-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 08-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATGCGCTTGTGCTTACCACTCTTCTTTTATCTTATTAATAAAATGTTG 2167
    |||||
Db 1555 CCTTAAACACCACTCTCTCATCACTAATCTCAGCCCTTGCCCTTGAATAAATACCTTAGC 1614
    |||||

QY 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
    |||||
Db 1615 TGCCCCACAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
    |||||

QY 2228 AAAAAAAAAAAAAA 2242
    |||||
Db 1675 AAAAAAAAAAAAAA 1689
    |||||

RESULT 1463
ACA97320
ID ACA97320 standard; cDNA; 1734 BP.
```

```
XX AC ACA97320;
XX DT 24-JUL-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO1411 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; cytostatic; gene therapy;
XX KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
XX KW tumour; gene; ss.
XX OS Homo sapiens.
XX PN US2003036117-A1.
XX PD 20-FEB-2003.
XX PF 21-JUN-2002; 2002US-00176751.
XX PR 18-SEP-1997; 97US-0059263P.
XX PR 18-SEP-1997; 97US-0059266P.
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 21-OCT-1997; 97US-0063486P.
XX PR 24-OCT-1997; 97US-0063120P.
XX PR 24-OCT-1997; 97US-0063121P.
XX PR 28-OCT-1997; 97US-0063540P.
XX PR 28-OCT-1997; 97US-0063541P.
XX PR 28-OCT-1997; 97US-0063544P.
XX PR 28-OCT-1997; 97US-0063564P.
XX PR 29-OCT-1997; 97US-0063734P.
XX PR 31-OCT-1997; 97US-0063870P.
XX PR 31-OCT-1997; 97US-0064103P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 21-NOV-1997; 97US-0066120P.
XX PR 24-NOV-1997; 97US-0066466P.
XX PR 24-NOV-1997; 97US-0066772P.
XX PR 11-DEC-1997; 97US-0069335P.
XX PR 12-DEC-1997; 97US-0069425P.
XX PR 17-DEC-1997; 97US-0069870P.
XX PR 18-DEC-1997; 97US-0068017P.
XX PR 10-MAR-1998; 98US-0077450P.
XX PR 11-MAR-1998; 98US-0077632P.
XX PR 11-MAR-1998; 98US-0077649P.
XX PR 20-MAR-1998; 98US-0078886P.
XX PR 20-MAR-1998; 98US-0078939P.
XX PR 27-MAR-1998; 98US-0079664P.
XX PR 27-MAR-1998; 98US-0079786P.
XX PR 31-MAR-1998; 98US-0080194P.
XX PR 31-MAR-1998; 98US-0080194P.
XX PR 01-APR-1998; 98US-0080327P.
XX PR 01-APR-1998; 98US-0080333P.
XX PR 08-APR-1998; 98US-0081049P.
XX PR 08-APR-1998; 98US-0081070P.
XX PR 09-APR-1998; 98US-0081195P.
XX PR 15-APR-1998; 98US-0081838P.
XX PR 21-APR-1998; 98US-0082568P.
XX PR 21-APR-1998; 98US-0082569P.
XX PR 22-APR-1998; 98US-0082704P.
XX PR 22-APR-1998; 98US-0082797P.
XX PR 28-APR-1998; 98US-0083322P.
XX PR 28-APR-1998; 98US-0083495P.
XX PR 29-APR-1998; 98US-0083496P.
XX PR 29-APR-1998; 98US-0083499P.
XX PR 29-APR-1998; 98US-0083559P.
XX PR 05-MAY-1998; 98US-0084366P.
XX PR 06-MAY-1998; 98US-0084414P.
XX PR 07-MAY-1998; 98US-0084639P.
XX PR 07-MAY-1998; 98US-0084640P.
XX PR 07-MAY-1998; 98US-0084643P.
XX PR 15-MAY-1998; 98US-0085579P.
XX PR 15-MAY-1998; 98US-0085580P.
XX PR 15-MAY-1998; 98US-0085582P.
XX PR 15-MAY-1998; 98US-0085700P.
```

```
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087603P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088328P.
PR 05-JUN-1998; 98US-0088616P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088555P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088828P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 01-SEP-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 02-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 15-SEP-1998; 98US-0099812P.
PR 16-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 30-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 2108 CATCCAATGATCGCCTTTGCTTTACCACTCTTTTCTTTTATCTTATTAATAAATGTTG 2167
    |||||
Db 1555 CCTTAAACACCACTCTCTCATCACTAATCTCAGCCCTTGCCCTTGAATAAACCTTAGC 1614
    |||||

Qy 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
    |||||
Db 1615 TGCCCCACAAAAA 2242
    |||||
Qy 2228 AAAAAAAAAAAAAA 2242
    |||||
Db 1675 AAAAAAAAAAAAAA 1689
    |||||

RESULT 1464
ACA57783
```

ID ACA57783 standard; cDNA; 1734 BP.  
XX  
AC ACA57783;  
XX  
DT 10-JUN-2003 (first entry)  
XX  
XX Human PRO1411 cDNA.  
DE  
XX Human; PRO; secreted; transmembrane; cytostatic; TNF-alpha; blood; gene;  
KW tumour necrosis factor alpha release; chondrocyte cell; proliferation;  
KW differentiation; tumour; gene therapy; ss.  
XX  
XX Homo sapiens.  
XX  
XX US2003036143-A1.  
XX  
XX 20-FEB-2003.  
XX  
XX 02-JUL-2002; 2002US-00187600.  
XX 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069435P.  
PR 12-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078866P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086192P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 24-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 26-JUN-1998; 98US-0090896P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 02-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 04-AUG-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.

```
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097552P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101753P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101922P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 2108 CATCAATGATGGCTTTGCTTTTACCACTCTTTCTTTTATCTTATTAATAAATGTTG 2167
Db 1555 CCTTAAACACACACCTCTCATCTACTATCTCAGCCCTTGCCCTTGAATAAATCCTTAGC 1614
Qy 2168 GTCTCCCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
Qy 2228 AAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1465
```

```
ACD14311
ID ACD14311 standard; cDNA; 1734 BP.
XX
AC ACD14311;
XX
DT 18-AUG-2003 (first entry)
XX
DE Human PRO polynucleotide #101.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW cytosolic; tumour necrosis factor-alpha; TNF-alpha; blood; tumour;
KW chondrocyte cell; cancer; adrenal; lung; colon; breast; prostate; rectum;
KW cervix; liver.
XX
OS Homo sapiens.
XX
PN US2003032130-A1.
XX
PD 13-FEB-2003.
XX
XX 28-JUN-2002; 2002US-00184635.
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 21-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0084103P.
PR 13-NOV-1997; 97US-0085311P.
PR 21-NOV-1997; 97US-0086120P.
PR 24-NOV-1997; 97US-0086466P.
PR 24-NOV-1997; 97US-0086772P.
PR 11-DEC-1997; 97US-0089335P.
PR 12-DEC-1997; 97US-0089425P.
PR 17-DEC-1997; 97US-0089870P.
PR 18-DEC-1997; 97US-0088017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 20-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 27-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 31-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 22-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083455P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
```

PR	15-MAY-1998;	98US-0085580P.	PR	17-AUG-1998;	98US-0096867P.
PR	15-MAY-1998;	98US-0085582P.	PR	17-AUG-1998;	98US-0096891P.
PR	15-MAY-1998;	98US-0085700P.	PR	17-AUG-1998;	98US-0096897P.
PR	18-MAY-1998;	98US-0086023P.	PR	18-AUG-1998;	98US-0096949P.
PR	22-MAY-1998;	98US-0086392P.	PR	18-AUG-1998;	98US-0096959P.
PR	22-MAY-1998;	98US-0086486P.	PR	18-AUG-1998;	98US-0097022P.
PR	28-MAY-1998;	98US-0087098P.	PR	26-AUG-1998;	98US-0097952P.
PR	28-MAY-1998;	98US-0087208P.	PR	26-AUG-1998;	98US-0097954P.
PR	28-MAY-1998;	98US-0087609P.	PR	26-AUG-1998;	98US-0097955P.
PR	02-JUN-1998;	98US-0087759P.	PR	26-AUG-1998;	98US-0097971P.
PR	03-JUN-1998;	98US-0087827P.	PR	26-AUG-1998;	98US-0097974P.
PR	04-JUN-1998;	98US-0088025P.	PR	26-AUG-1998;	98US-0098014P.
PR	04-JUN-1998;	98US-0088028P.	PR	01-SEP-1998;	98US-0098716P.
PR	04-JUN-1998;	98US-0088029P.	PR	01-SEP-1998;	98US-0098723P.
PR	04-JUN-1998;	98US-0088033P.	PR	02-SEP-1998;	98US-0098803P.
PR	04-JUN-1998;	98US-0088036P.	PR	02-SEP-1998;	98US-0098821P.
PR	05-JUN-1998;	98US-0088167P.	PR	02-SEP-1998;	98US-0098843P.
PR	05-JUN-1998;	98US-0088202P.	PR	09-SEP-1998;	98US-0099602P.
PR	05-JUN-1998;	98US-0088212P.	PR	10-SEP-1998;	98US-0099741P.
PR	05-JUN-1998;	98US-0088217P.	PR	10-SEP-1998;	98US-0099754P.
PR	09-JUN-1998;	98US-0088655P.	PR	10-SEP-1998;	98US-0099763P.
PR	10-JUN-1998;	98US-0088722P.	PR	10-SEP-1998;	98US-0099812P.
PR	10-JUN-1998;	98US-0088738P.	PR	15-SEP-1998;	98US-0100388P.
PR	10-JUN-1998;	98US-0088740P.	PR	16-SEP-1998;	98US-0100662P.
PR	10-JUN-1998;	98US-0088811P.	PR	16-SEP-1998;	98US-0100664P.
PR	10-JUN-1998;	98US-0088824P.	PR	16-SEP-1998;	98US-0101751P.
PR	10-JUN-1998;	98US-0088825P.	PR	16-SEP-1998;	98US-0101751P.
PR	10-JUN-1998;	98US-0088826P.	PR	16-SEP-1998;	98US-0101933P.
PR	11-JUN-1998;	98US-0088861P.	PR	16-SEP-1998;	98US-0100683P.
PR	11-JUN-1998;	98US-0088863P.	PR	17-SEP-1998;	98US-0100684P.
PR	11-JUN-1998;	98US-0088876P.	PR	17-SEP-1998;	98US-0100919P.
PR	11-JUN-1998;	98US-0089050P.	PR	17-SEP-1998;	98US-0100930P.
PR	12-JUN-1998;	98US-0089105P.	PR	18-SEP-1998;	98US-0100849P.
PR	12-JUN-1998;	98US-0089152P.	PR	18-SEP-1998;	98US-0101014P.
PR	16-JUN-1998;	98US-0089514P.	PR	18-SEP-1998;	98US-0101068P.
PR	16-JUN-1998;	98US-0089538P.	PR	23-SEP-1998;	98US-0101471P.
PR	17-JUN-1998;	98US-0089598P.	PR	23-SEP-1998;	98US-0101472P.
PR	17-JUN-1998;	98US-0089653P.	PR	23-SEP-1998;	98US-0101475P.
PR	18-JUN-1998;	98US-0089908P.	PR	23-SEP-1998;	98US-0101477P.
PR	19-JUN-1998;	98US-0089952P.	PR	23-SEP-1998;	98US-0101738P.
PR	22-JUN-1998;	98US-0090246P.	PR	24-SEP-1998;	98US-0101739P.
PR	22-JUN-1998;	98US-0090252P.	PR	24-SEP-1998;	98US-0101743P.
PR	22-JUN-1998;	98US-0090254P.	PR	24-SEP-1998;	98US-0101922P.
PR	24-JUN-1998;	98US-0090429P.	PR	25-SEP-1998;	98US-0101786P.
PR	24-JUN-1998;	98US-0090435P.	PR	25-SEP-1998;	98US-0102207P.
PR	24-JUN-1998;	98US-0090444P.	PR	29-SEP-1998;	98US-0102240P.
PR	24-JUN-1998;	98US-0090461P.	PR	29-SEP-1998;	98US-0102330P.
PR	24-JUN-1998;	98US-0090535P.	PR	29-SEP-1998;	98US-0102331P.
PR	24-JUN-1998;	98US-0090540P.	PR	30-SEP-1998;	98US-0102487P.
PR	24-JUN-1998;	98US-0090676P.	PR	30-SEP-1998;	98US-0102570P.
PR	25-JUN-1998;	98US-0090678P.	PR	30-SEP-1998;	98US-0102571P.
PR	25-JUN-1998;	98US-0090688P.	PR	01-OCT-1998;	98US-0102684P.
PR	25-JUN-1998;	98US-0090690P.	PR	01-OCT-1998;	98US-0102687P.
PR	25-JUN-1998;	98US-0090694P.	PR	02-OCT-1998;	98US-0102965P.
PR	25-JUN-1998;	98US-0090695P.	PR	02-OCT-1998;	98US-0102965P.
PR	25-JUN-1998;	98US-0090699P.	PR	06-OCT-1998;	98US-0103258P.
PR	26-JUN-1998;	98US-00105413.	PR	06-OCT-1998;	98US-0103449P.
PR	26-JUN-1998;	98US-0090826P.			
PR	26-JUN-1998;	98US-0090863P.			
PR	26-JUN-1998;	98US-0091010P.			
PR	01-JUL-1998;	98US-0091359P.			
PR	01-JUL-1998;	98US-0091544P.			
PR	02-JUL-1998;	98US-0091478P.			
PR	02-JUL-1998;	98US-0091486P.			
PR	02-JUL-1998;	98US-0091626P.			
PR	02-JUL-1998;	98US-0091628P.			
PR	02-JUL-1998;	98US-0091632P.			
PR	24-JUL-1998;	98US-0094006P.			
PR	04-AUG-1998;	98US-0095282P.			
PR	10-AUG-1998;	98US-0095998P.			
PR	10-AUG-1998;	98US-0096012P.			
PR	17-AUG-1998;	98US-0096757P.			
PR	17-AUG-1998;	98US-0096766P.			
					Query Match
					Best Local Similarity 2.9%; Score 65.2; DB 8; Length 1734;
					Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
Qy	2108	CATCCAAATGATCGCTTTGCTTTACCACTCTTTCCTTTTATCTTTATTAATAAATGTTG	2167		
Db	1555	CCTTAAACACCACTCTCATCACTAACTCAGCCCTTGCCTTGAATAAACCTTAGC	1614		
Qy	2168	GTCTCCCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2227		
Db	1615	TGCCCCACAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	1674		
Qy	2228	AAAAAAAAAAAAA 2242			
Db	1675	AAAAAAAAAAAAA 1689			

RESULT 1466  
 ID ACC91094 standard; cDNA; 1734 BP.  
 XX AC ACC91094;  
 XX DT 19-AUG-2003 (first entry)  
 XX DE Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.  
 XX KW Human; PRO; secreted protein; transmembrane protein;  
 KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;  
 KW chondrocyte; proliferation; differentiation; cartilage disorder;  
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
 KW liver; drug screening; transgenic animal; genetic analysis;  
 KW antiarthritic; vulnary; gene therapy; gene; ss.  
 XX OS Homo sapiens.  
 XX PN US2003032138-A1.  
 XX PD 13-FEB-2003.  
 XX PF 02-JUL-2002; 2002US-00187885.  
 XX PR 24-JUN-1998; 98US-0090540P.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 25-AUG-1999; 99US-00360137.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 01-DEC-1999; 99WO-US028409.  
 PR 02-DEC-1999; 99WO-US028531.  
 PR 02-DEC-1999; 99WO-US028555.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 22-FEB-2000; 2000WO-US004342.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.  
 PR 29-AUG-2001; 2001WO-US027099.  
 PR 15-JAN-2002; 2002US-00052586.  
 XX PA (GETH ) GENENTECH INC.  
 XX PI Baker KP, Chen J, Deenoyers L, Goddard A, Godowski PJ, Gurney AL;  
 PI Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;  
 XX DR WPI; 2003-341977/32.  
 DR P-PSDB; ABR70063.  
 XX PT New secreted and transmembrane PRO polypeptide useful in preparing a  
 PT medicament for treating a condition that is responsive to the PRO  
 PT polypeptide or anti-PRO antibody.  
 XX PS Claim 2; Fig 201; 707pp; English.  
 XX CC The invention relates to human PRO secreted/transmembrane polypeptides  
 CC (ABR69963-ABR70267) and nucleic acids encoding them (ACC90994-ACC91298).  
 CC The invention also relates to sequences at least 80% identical to the PRO  
 CC nucleic acid and polypeptide sequences of the invention, recombinant  
 CC vectors and host cells comprising a PRO nucleic acid, a method for the  
 CC recombinant production of a PRO polypeptide, antibodies against a PRO  
 CC polypeptide, and fusion proteins comprising a PRO polypeptide. Nucleic  
 CC acids encoding PRO polypeptides of the invention were initially  
 CC identified via homology screening using consensus sequences based on the  
 CC extracellular domain sequences from known secreted proteins. Human CDNA  
 CC libraries containing sequences of interest were identified using  
 CC oligonucleotides based on the consensus sequences, and cDNA clones were  
 CC isolated and characterised. The PRO polypeptides are useful for  
 CC stimulating release of tumour necrosis factor-alpha (TNF-alpha) from  
 CC human blood and may thus be used in the treatment of conditions in which  
 CC enhanced TNF-alpha release would be beneficial. They are also useful for  
 CC stimulating the proliferation or differentiation of chondrocytes and as  
 CC such may be used in the treatment of various bone and/or cartilage  
 CC disorders such as arthritis and sports injuries. The PRO polypeptides may  
 CC be used in a method for detecting the presence of a tumour (e.g., an  
 CC adrenal tumour, lung tumour, colon tumour, breast tumour, prostate  
 CC tumour, rectal tumour, cervical tumour or liver tumour) in a mammal. This  
 CC method involves comparing the level of expression of the PRO polypeptide  
 CC in test and control samples, where a higher level of expression of PRO  
 CC polypeptide in the test sample as compared to the control sample is  
 CC indicative of the presence of a tumour. The PRO polypeptides are  
 CC additionally useful for in drug screening to identify agonists and  
 CC antagonists of PRO polypeptides. PRO nucleic acids are useful as  
 CC hybridisation probes (for isolation of cDNA molecules), in chromosome and  
 CC gene mapping, in the generation of antisense RNA and DNA and in gene  
 CC therapy. The nucleic acids can also be used for mapping genes encoding  
 CC PRO polypeptides, for genetic analysis of individuals with genetic  
 CC disorders, and for generating either transgenic animals or knock-out  
 CC animals which are useful in the development and screening of  
 CC therapeutically useful compounds. Sequences ACC90994-ACC91298 represent  
 CC cDNAs encoding the human PRO secreted/transmembrane polypeptides of the  
 CC invention. Note: The sequence data for this patent is also available in  
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html  
 XX SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;  
 Query Match 2.9%; Score 65.2; DB 8; Length 1734;  
 Best Local Similarity 67.4%; Pred. No. 0.0004;  
 Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
 QY 2108 CATCAATGATCGCTTTGCTTTACCACTCTTTCTTTATCTTATTAATAATGTTG 2167  
 Db 1555 CTTTAAACACCACTCTCTATCTATCTCAGCCCTTGCCTTGAATAACTTACG 1614  
 QY 2168 GTCTCCACCACTGCTGCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227  
 Db 1615 TGCCCCACAAA 1674  
 QY 2228 AAAAAAAAAAAAAA 2242

[illegible]

```
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98MO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 01-OCT-1998; 98US-0102687P.

Query Match
Best Local Similarity 2.9%; Score 65.2; DB 8; Length 1734;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
Pred. NO. 0.0004;

Qy 2108 CATCAATGATCGCTTGGCTTTTACCACCTCTTCTCTTTATCTTATTAATAAATGTTG 2167
Db 1555 CCTTAAACACACCCTCTCATCTATCTCAGCCCTTGCCTTGAATAAACCCTTAGC 1614
Qy 2168 GTCTCCACCACTGNTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227
Db 1615 TGCCCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1674
Qy 2228 AAAAAAATAAAAAA 2242
```

```
Db 1675 AAAAAAAAAAAAAA 1689
RESULT 1468
ACD07033
ID ACD07033 standard; cDNA; 1734 BP.
XX ACD07033;
XX ACD07033;
XX 07-AUG-2003 (first entry)
XX Human PRO polynucleotide #101.
XX Human; PRO; gene; ss; tumour; cytostatic; cancer; secreted protein; lung;
XX transmembrane protein; tumour necrosis factor alpha; TNF-alpha; adrenal;
XX chondrocyte cell; colon; breast; prostate; rectum; cervix; liver.
XX Homo sapiens.
XX US2003008353-A1.
XX 09-JAN-2003.
XX 21-JUN-2002; 2002US-00176758.
XX 18-SEP-1997; 97US-0059263P.
XX 18-SEP-1997; 97US-0059266P.
XX 17-OCT-1997; 97US-0062250P.
XX 21-OCT-1997; 97US-0063486P.
XX 24-OCT-1997; 97US-0063120P.
XX 24-OCT-1997; 97US-0063121P.
XX 28-OCT-1997; 97US-0063540P.
XX 28-OCT-1997; 97US-0063541P.
XX 28-OCT-1997; 97US-0063544P.
XX 28-OCT-1997; 97US-0063564P.
XX 29-OCT-1997; 97US-0063734P.
XX 31-OCT-1997; 97US-0063870P.
XX 31-OCT-1997; 97US-0064103P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066120P.
XX 24-NOV-1997; 97US-0066466P.
XX 24-NOV-1997; 97US-0066772P.
XX 11-DEC-1997; 97US-0069335P.
XX 12-DEC-1997; 97US-0069425P.
XX 12-DEC-1997; 97US-0069870P.
XX 18-DEC-1997; 97US-0068017P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0078896P.
XX 20-MAR-1998; 98US-0078939P.
XX 20-MAR-1998; 98US-0078939P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079786P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080333P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 09-APR-1998; 98US-0081195P.
XX 15-APR-1998; 98US-0081838P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082704P.
XX 22-APR-1998; 98US-0082797P.
XX 28-APR-1998; 98US-0083322P.
XX 29-APR-1998; 98US-0083495P.
XX 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
XX 29-APR-1998; 98US-0083559P.
XX 05-MAY-1998; 98US-0084366P.
XX 06-MAY-1998; 98US-0084414P.
```

PR	07-MAY-1998;	98US-0084639P.	Query Match	2.9%;	Score 65.2;	DB 8;	Length 1734;
PR	07-MAY-1998;	98US-0084640P.	Best Local Similarity	67.4%;	Pred No. 0.0004;		
PR	16-SEP-1998;	98WO-US019330.	Matches	91;	Conservative	0;	Mismatches 44; Indels 0; Gaps 0;
PR	07-OCT-1998;	98WO-US021141.					
PR	01-DEC-1998;	98WO-US025108.					
PR	08-MAR-1999;	99WO-US005028.					
PR	14-MAY-1999;	99WO-US010733.					
PR	02-JUN-1999;	99WO-US012252.					
PR	01-SEP-1999;	99WO-US020111.					
PR	15-SEP-1999;	99WO-US021090.					
PR	01-DEC-1999;	99WO-US028301.					
PR	02-DEC-1999;	99WO-US028551.					
PR	30-DEC-1999;	99WO-US031274.					
PR	05-JAN-2000;	2000WO-US000219.					
PR	18-FEB-2000;	2000WO-US004341.					
PR	18-FEB-2000;	2000WO-US004342.					
PR	22-FEB-2000;	2000WO-US004414.					
PR	24-FEB-2000;	2000WO-US005004.					
PR	01-MAR-2000;	2000WO-US005601.					
PR	02-MAR-2000;	2000WO-US005841.					
PR	15-MAR-2000;	2000WO-US006884.					
PR	30-MAR-2000;	2000WO-US008439.					
PR	17-MAY-2000;	2000WO-US013705.					
PR	22-MAY-2000;	2000WO-US014042.					
PR	30-MAY-2000;	2000WO-US014941.					
PR	02-JUN-2000;	2000WO-US015264.					
PR	28-JUL-2000;	2000WO-US020710.					
PR	24-AUG-2000;	2000WO-US023328.					
PR	08-NOV-2000;	2000WO-US030952.					
PR	01-DEC-2000;	2000WO-US032678.					
PR	20-DEC-2000;	2000WO-US034956.					
PR	28-FEB-2001;	2001WO-US006520.					
PR	01-JUN-2001;	2001WO-US017800.					
PR	20-JUN-2001;	2001WO-US019692.					
PR	29-JUN-2001;	2001WO-US021066.					
PR	09-JUL-2001;	2001WO-US021735.					
PR	29-AUG-2001;	2001WO-US027099.					
PR	15-JAN-2002;	2002US-00052586.					
XX	(GETH ) GENENTECH INC.						
XX	Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;						
PI	Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;						
XX	WPI; 2003-341328/32.						
DR	P-PSDB; ABO01537.						
XX	Three hundred and five nucleic acids encoding secreted and transmembrane						
PT	polypeptides, designated as PRO, useful for detecting the presence of, or						
PT	treating tumor, e.g. adrenal, lung, colon, breast, prostate, rectal,						
PT	cervical or liver tumor.						
XX	Claim 2; Fig 201; 707pp; English.						
XX	The invention relates to human PRO polypeptides (secreted and						
CC	transmembrane polypeptides) and the polynucleotides encoding them. The						
CC	invention also relates to an antibody that specifically binds to a PRO						
CC	polypeptide, a method for stimulating the release of tumor necrosis						
CC	factor alpha (TNF-alpha) from human blood by contacting the blood with a						
CC	PRO polypeptide and a method for stimulating the proliferation or						
CC	differentiation of chondrocyte cells by contacting the cells with a PRO						
CC	polypeptide. The polypeptides and polynucleotides are useful for						
CC	detecting the presence of a tumor, such as an adrenal, lung, colon,						
CC	breast, prostate, rectal, cervical or liver tumor, and for treating such						
CC	tumours. The polynucleotides are useful as hybridisation probes, in						
CC	chromosome and gene mapping and in generating antisense RNA or DNA. The						
CC	polypeptides are useful as pharmaceuticals, diagnostics, biosensors or						
CC	bioreactors. Both are useful in tissue typing. Sequences ACD06933-						
CC	ACD07237 represent human PRO polynucleotides of the invention. Note: The						
CC	sequence data for this patent is also available in electronic format from						
CC	USPTO at <a href="http://seqdata.uspto.gov/sequence.html">seqdata.uspto.gov/sequence.html</a>						
XX	Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;						

QY	2108	CATCCAATGATCGCCTTTTCCTTTTACACACTCTTTTCTTTTATCTTTATATAAATGTTG	2167
DB	1555	CCTTAAACACACACCTCTCATCATCTCTCAGCCCTTGCCCTTGAATAAACCTTAGC	1614
QY	2168	GTCTCCACCACCTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2227
DB	1615	TGCCCCACAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	1674
QY	2228	AAAAAAAAAAAAAAAAA 2242	
DB	1675	AAAAAAAAAAAAAAAAA 1689	
RESULT 1469			
ACA67484			
ID	ACA67484 standard; cDNA; 1734 BP.		
XX	ACA67484;		
AC	XX		
XX	XX		
DT	24-JUN-2003 (first entry)		
XX	Human PRO polynucleotide #101.		
DE	Human; PRO; gene; ss; tumour necrosis factor-alpha; TNF-alpha; blood;		
XX	chondrocyte cell; tumour; adrenal; kidney; lung; colon; breast; prostate;		
KW	rectum; cervix; liver; cytostatic.		
KW	Homo sapiens.		
OS	US2003017542-A1.		
XX	23-JAN-2003.		
PN	20-JUN-2002; 2002US-00176749.		
XX	18-SEP-1997; 97US-0059263P.		
PR	18-SEP-1997; 97US-0059266P.		
PR	17-OCT-1997; 97US-0062250P.		
PR	21-OCT-1997; 97US-0063486P.		
PR	24-OCT-1997; 97US-0063120P.		
PR	24-OCT-1997; 97US-0063121P.		
PR	28-OCT-1997; 97US-0063540P.		
PR	28-OCT-1997; 97US-0063541P.		
PR	28-OCT-1997; 97US-0063544P.		
PR	28-OCT-1997; 97US-0063564P.		
PR	29-OCT-1997; 97US-0063734P.		
PR	31-OCT-1997; 97US-0063870P.		
PR	31-OCT-1997; 97US-0064103P.		
PR	13-NOV-1997; 97US-0065311P.		
PR	21-NOV-1997; 97US-0066120P.		
PR	24-NOV-1997; 97US-0066466P.		
PR	24-NOV-1997; 97US-0066772P.		
PR	11-DEC-1997; 97US-0069335P.		
PR	12-DEC-1997; 97US-0069425P.		
PR	17-DEC-1997; 97US-0069870P.		
PR	18-DEC-1997; 97US-0068017P.		
PR	10-MAR-1998; 98US-0077450P.		
PR	11-MAR-1998; 98US-0077632P.		
PR	11-MAR-1998; 98US-0077649P.		
PR	20-MAR-1998; 98US-0078886P.		
PR	27-MAR-1998; 98US-0078939P.		
PR	27-MAR-1998; 98US-0079664P.		
PR	27-MAR-1998; 98US-0079786P.		
PR	31-MAR-1998; 98US-0080107P.		
PR	31-MAR-1998; 98US-0080194P.		
PR	01-APR-1998; 98US-0080327P.		
PR	01-APR-1998; 98US-0080333P.		
PR	08-APR-1998; 98US-0081049P.		



```
PR 07-OCT-1998; 98US-00168978.
Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2108 CATCCATGATCGCTTGTGTTTACCACTCTTCTCTTTTATCTTATTAATAAATGTTG 2167
Db 1555 CCTTAAACACCACTCTCTATCACTAATCTCAGCCCTTGCCCTGAAATAAACCTTAGC 1614
QY 2168 GTCTCCACCACTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227
Db 1615 TGCCCCACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1674
QY 2228 AAAAAAATAAAAAA 2242
Db 1675 AAAAAAATAAAAAA 1689

RESULT 1470
ACC81539
ID ACC81539 standard; cDNA; 1734 BP.
XX AC ACC81539;
XX AC
DT 28-JUL-2003 (first entry)
DE Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.
XX KW Human; PRO; secreted protein; transmembrane protein;
XX KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX KW chondrocyte; proliferation; differentiation; cartilage disorder;
XX KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX KW liver; drug screening; transgenic animal; genetic analysis;
XX KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS Homo sapiens.
XX XN
XX PD US2003032137-A1.
XX PD 13-FEB-2003.
XX PF 02-JUL-2002; 2002US-00187745.
XX PF 18-SEP-1997; 97US-0059263P.
XX PF 18-SEP-1997; 97US-0059266P.
XX PF 17-OCT-1997; 97US-0062250P.
XX PF 21-OCT-1997; 97US-0063486P.
XX PF 24-OCT-1997; 97US-0063120P.
XX PF 24-OCT-1997; 97US-0063121P.
XX PF 28-OCT-1997; 97US-0063540P.
XX PF 28-OCT-1997; 97US-0063541P.
XX PF 28-OCT-1997; 97US-0063544P.
XX PF 28-OCT-1997; 97US-0063564P.
XX PF 29-OCT-1997; 97US-0063734P.
XX PF 31-OCT-1997; 97US-0063870P.
XX PF 31-OCT-1997; 97US-0064103P.
XX PF 13-NOV-1997; 97US-0065311P.
XX PF 21-NOV-1997; 97US-0066120P.
XX PF 24-NOV-1997; 97US-0066466P.
XX PF 24-NOV-1997; 97US-0066772P.
XX PF 11-DEC-1997; 97US-0069335P.
XX PF 12-DEC-1997; 97US-0069425P.
XX PF 17-DEC-1997; 97US-0069870P.
XX PF 18-DEC-1997; 97US-0068017P.
XX PF 10-MAR-1998; 98US-0077450P.
XX PF 11-MAR-1998; 98US-0077632P.
XX PF 11-MAR-1998; 98US-0077649P.
XX PF 20-MAR-1998; 98US-0078866P.
XX PF 20-MAR-1998; 98US-0078939P.
XX PF 27-MAR-1998; 98US-0079664P.
XX PF 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 03-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085799P.
PR 15-MAY-1998; 98US-0085809P.
PR 15-MAY-1998; 98US-008582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
```

```
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101933P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.

PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match          2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATCGCTTTGCTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTG 2167
Db 1555 CCTTAAACACACCCCTCTCATCTATCTCAGCCCTTGCCCTTGAATAAACCTTAGC 1614
QY 2168 GTCTCCACCACTGCTCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCACAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
QY 2228 AAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1471
ACA91275
ID ACA91275 standard; cDNA; 1734 BP.
AC ACA91275;
XX
DT 14-JUL-2003 (first entry)
DE cDNA encoding human PRO polypeptide #26.
KW Human; PRO polypeptide; secreted protein; transmembrane protein; rectal;
KW lung; stomach; oesophageal; skin; tumour; cancer; cytostatic;
KW gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003018168-A1.
PD
PD 23-JAN-2003.
XX
XX 02-MAY-2002; 2002US-00063569.
XX
XX 30-DEC-1998; 98XR-00062142.
XX 08-MAR-1999; 99WO-US005028.
XX 14-MAY-1999; 99US-00311832.
XX 14-MAY-1999; 99WO-US010733.
XX 25-AUG-1999; 99US-00380137.
XX 25-AUG-1999; 99US-00380138.
XX 25-AUG-1999; 99US-00380139.
XX 15-SEP-1999; 99US-00380142.
XX 15-SEP-1999; 99US-00397342.
XX 18-OCT-1999; 99US-00403297.
XX 12-NOV-1999; 99US-00423844.
XX 30-DEC-1999; 99WO-US031274.
XX 01-MAR-2000; 2000WO-US004341.
XX 02-MAR-2000; 2000WO-US005601.
XX 21-MAR-2000; 2000WO-US007532.
XX 22-MAY-2000; 2000WO-US014042.
XX 02-JUN-2000; 2000WO-US015264.
XX 24-AUG-2000; 2000US-0064848.
XX 18-SEP-2000; 2000WO-US023328.
XX 18-SEP-2000; 2000US-00664610.
XX 18-SEP-2000; 2000US-00665350.
XX 08-NOV-2000; 2000US-00709238.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001WO-US006520.
XX 22-MAR-2001; 2001US-00816744.
XX 10-MAY-2001; 2001US-00854208.
XX 10-MAY-2001; 2001US-00854280.
```

```

PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
XX
PA (GETH ) GENENTECH INC.
XX
XX Baton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
XX
XX WPI; 2003-401699/38.
DR P-PSDB; ABU90985.
XX
XX New isolated, secreted and transmembrane PRO polypeptide, useful for the
PT diagnosis, prevention and treatment of rectal, lung, stomach, esophageal
PT or skin cancers.
XX
XX Disclosure; Fig 51; 235pp; English.
XX
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO polypeptide
CC and polynucleotide sequences are useful for the diagnosis, prevention and
CC treatment of rectal, lung, stomach, oesophageal or skin tumours, and/or
CC cancers. The PRO polypeptides are also useful as molecular weight
CC markers. The PRO polynucleotide sequences are useful for chromosome
CC identification, hybridisation probes, and for screening libraries of
CC human cDNA, genomic DNA or mRNA. They may also be used in gene therapy,
CC particularly for replacing a defective gene. ACA91250-ACA91333 represent
CC cDNA sequences encoding the human PRO polypeptides of the invention
XX
XX Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;
SQ
Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2108 CATCCATGATGCGCTTGTGTTTACCACTCTTCCCTTTATCTTATTAATAAAGTTG 2167
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1555 CCTTAAACACCAACCCCTCTCATCACTAATCTGAGCCCTGCCCTTGAATAACCTTAGC 1614
QY ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
1615 TGCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
QY 2228 AAAAAAAAAAAAAA 2242
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1675 AAAAAAAAAAAAAA 1689
RESULT 1472
ACC89143
ID ACC89143 standard; cDNA; 1734 BP.
XX
XX ACC89143;
AC
XX 11-AUG-2003 (first entry)
DT
XX
XX Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.
DE
XX
XX Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnery; gene therapy; gene; ss.
XX
XX Homo sapiens.
XX
XX US2003027269-A1.

```

```

XX
PD 06-FEB-2003.
XX
PF 19-JUN-2002; 2002US-00175743.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 28-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.

```

```
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0088909P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089511P.
PR 17-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090423P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 04-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 25-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Oy 2108 CATCCATGATCGCTTGCTTTACCACTCTTCTCTTTATCTTATTAATAAATGTTG 2167
Db 1555 CCTTAAACACCCACCCTCTCATCACTATCTCAGCCCTTGCCCTTGAATAAACCTTAGC 1614

Oy 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674

Oy 2228 AAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1473
ACC86499
ID ACC86499 standard; cDNA; 1734 BP.
XX AC ACC86499;
XX DT 28-JUL-2003 (first entry)
XX DE Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.
XX KW Human; PRO; secreted protein; transmembrane protein;
XX KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
XX KW chondrocyte; proliferation; differentiation; cartilage disorder;
XX KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
XX KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
XX KW liver; drug screening; transgenic animal; genetic analysis;
XX KW antiarthritic; vulnery; gene therapy; gene; ss.
XX OS Homo sapiens.
XX XX
```

PN US2003027268-A1.  
XX 06-FEB-2003.  
XX 18-JUN-2002; 2002US-00175740.  
XX 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 11-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082737P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 03-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087837P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089658P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098603P.  
PR 02-SEP-1998; 98US-0098821P.

PR	02-SEP-1998;	98US-0098843P.	
PR	09-SEP-1998;	98US-0099602P.	
PR	10-SEP-1998;	98US-0099741P.	
PR	10-SEP-1998;	98US-0099754P.	
PR	10-SEP-1998;	98US-0099763P.	
PR	10-SEP-1998;	98US-0099812P.	
PR	15-SEP-1998;	98US-0100388P.	
PR	16-SEP-1998;	98US-0100662P.	
PR	16-SEP-1998;	98US-0100664P.	
PR	16-SEP-1998;	98US-0101751P.	
PR	16-SEP-1998;	98US-0101751P.	
PR	17-SEP-1998;	98US-0100683P.	
PR	17-SEP-1998;	98US-0100684P.	
PR	17-SEP-1998;	98US-0100919P.	
PR	17-SEP-1998;	98US-0100930P.	
PR	18-SEP-1998;	98US-0100849P.	
PR	18-SEP-1998;	98US-0101014P.	
PR	18-SEP-1998;	98US-0101068P.	
PR	23-SEP-1998;	98US-0101471P.	
PR	23-SEP-1998;	98US-0101472P.	
PR	23-SEP-1998;	98US-0101475P.	
PR	23-SEP-1998;	98US-0101477P.	
PR	24-SEP-1998;	98US-0101738P.	
PR	24-SEP-1998;	98US-0101739P.	
PR	24-SEP-1998;	98US-0101743P.	
PR	24-SEP-1998;	98US-0101922P.	
PR	25-SEP-1998;	98US-0101786P.	
PR	29-SEP-1998;	98US-0102207P.	
PR	29-SEP-1998;	98US-0102240P.	
PR	29-SEP-1998;	98US-0102330P.	
PR	29-SEP-1998;	98US-0102331P.	
PR	30-SEP-1998;	98US-0102487P.	
PR	30-SEP-1998;	98US-0102570P.	
PR	30-SEP-1998;	98US-0102571P.	
PR	01-OCT-1998;	98US-0102684P.	
PR	01-OCT-1998;	98US-0102687P.	

Query Match

Best Local Similarity 2.9%; Score 65.2; DB 8; Length 1734;

Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy	2108 CATCCAATGATCGCCTTGGCTTTACCACTCTTCTCTTTTCT
----	---

XX	US2003027274-A1.
PN	06-FEB-2003.
XX	21-JUN-2002; 2002US-00176750.
XX	18-SEP-1997; 97US-0059263P.
PR	18-SEP-1997; 97US-0059266P.
PR	17-OCT-1997; 97US-0062250P.
PR	21-OCT-1997; 97US-0063486P.
PR	24-OCT-1997; 97US-0063120P.
PR	24-OCT-1997; 97US-0063121P.
PR	28-OCT-1997; 97US-0063540P.
PR	28-OCT-1997; 97US-0063541P.
PR	28-OCT-1997; 97US-0063544P.
PR	29-OCT-1997; 97US-0063564P.
PR	29-OCT-1997; 97US-0063734P.
PR	31-OCT-1997; 97US-0063870P.
PR	31-OCT-1997; 97US-0064103P.
PR	13-NOV-1997; 97US-0065311P.
PR	21-NOV-1997; 97US-0066120P.
PR	24-NOV-1997; 97US-0066466P.
PR	11-DEC-1997; 97US-0066772P.
PR	12-DEC-1997; 97US-0069335P.
PR	12-DEC-1997; 97US-0069425P.
PR	17-DEC-1997; 97US-0069870P.
PR	18-DEC-1997; 97US-0068017P.
PR	10-MAR-1998; 98US-0077450P.
PR	11-MAR-1998; 98US-0077632P.
PR	11-MAR-1998; 98US-0077649P.
PR	20-MAR-1998; 98US-0078886P.
PR	27-MAR-1998; 98US-0078939P.
PR	27-MAR-1998; 98US-0079664P.
PR	27-MAR-1998; 98US-0079786P.
PR	31-MAR-1998; 98US-0080107P.
PR	31-MAR-1998; 98US-0080194P.
PR	01-APR-1998; 98US-0080327P.
PR	01-APR-1998; 98US-0080333P.
PR	08-APR-1998; 98US-0081049P.
PR	08-APR-1998; 98US-0081070P.
PR	09-APR-1998; 98US-0081195P.
PR	15-APR-1998; 98US-0081838P.
PR	21-APR-1998; 98US-0082568P.
PR	21-APR-1998; 98US-0082569P.
PR	22-APR-1998; 98US-0082704P.
PR	22-APR-1998; 98US-0082797P.
PR	28-APR-1998; 98US-0083322P.
PR	29-APR-1998; 98US-0083495P.
PR	29-APR-1998; 98US-0083496P.
PR	29-APR-1998; 98US-0083499P.
PR	29-APR-1998; 98US-0083559P.
PR	05-MAY-1998; 98US-0084366P.
PR	06-MAY-1998; 98US-0084414P.
PR	07-MAY-1998; 98US-0084639P.
PR	07-MAY-1998; 98US-0084640P.
PR	07-MAY-1998; 98US-0084643P.
PR	15-MAY-1998; 98US-0085579P.
PR	15-MAY-1998; 98US-0085580P.
PR	15-MAY-1998; 98US-0085582P.
PR	15-MAY-1998; 98US-0085700P.
PR	18-MAY-1998; 98US-0086023P.
PR	22-MAY-1998; 98US-0086392P.
PR	22-MAY-1998; 98US-0086486P.
PR	28-MAY-1998; 98US-0087098P.
PR	28-MAY-1998; 98US-0087208P.
PR	02-JUN-1998; 98US-0087609P.
PR	02-JUN-1998; 98US-0087759P.
PR	03-JUN-1998; 98US-0087827P.
PR	04-JUN-1998; 98US-0088025P.
PR	04-JUN-1998; 98US-0088028P.
PR	04-JUN-1998; 98US-0088029P.
PR	04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998;	98US-0088326P.	PR 02-SEP-1998;	98US-0098821P.
PR 05-JUN-1998;	98US-0088167P.	PR 02-SEP-1998;	98US-0098843P.
PR 05-JUN-1998;	98US-0088202P.	PR 02-SEP-1998;	98US-0098602P.
PR 05-JUN-1998;	98US-0088212P.	PR 10-SEP-1998;	98US-0099741P.
PR 05-JUN-1998;	98US-0088217P.	PR 10-SEP-1998;	98US-0099754P.
PR 09-JUN-1998;	98US-0088655P.	PR 10-SEP-1998;	98US-0099763P.
PR 10-JUN-1998;	98US-0088722P.	PR 10-SEP-1998;	98US-0099812P.
PR 10-JUN-1998;	98US-0088738P.	PR 15-SEP-1998;	98US-0100388P.
PR 10-JUN-1998;	98US-0088740P.	PR 16-SEP-1998;	98US-0100662P.
PR 10-JUN-1998;	98US-0088811P.	PR 16-SEP-1998;	98US-0100664P.
PR 10-JUN-1998;	98US-0088824P.	PR 16-SEP-1998;	98US-0101751P.
PR 10-JUN-1998;	98US-0088825P.	PR 16-SEP-1998;	98US-0101751P.
PR 10-JUN-1998;	98US-0088826P.	PR 17-SEP-1998;	98US-0100683P.
PR 11-JUN-1998;	98US-0088861P.	PR 17-SEP-1998;	98US-0100684P.
PR 11-JUN-1998;	98US-0088863P.	PR 17-SEP-1998;	98US-0100919P.
PR 11-JUN-1998;	98US-0088866P.	PR 17-SEP-1998;	98US-0100930P.
PR 12-JUN-1998;	98US-0089090P.	PR 18-SEP-1998;	98US-0100849P.
PR 12-JUN-1998;	98US-0089105P.	PR 18-SEP-1998;	98US-0101014P.
PR 16-JUN-1998;	98US-0089512P.	PR 18-SEP-1998;	98US-0101068P.
PR 16-JUN-1998;	98US-0089514P.	PR 23-SEP-1998;	98US-0101471P.
PR 17-JUN-1998;	98US-0089538P.	PR 23-SEP-1998;	98US-0101472P.
PR 17-JUN-1998;	98US-0089538P.	PR 23-SEP-1998;	98US-0101475P.
PR 17-JUN-1998;	98US-0089538P.	PR 23-SEP-1998;	98US-0101477P.
PR 17-JUN-1998;	98US-0089653P.	PR 24-SEP-1998;	98US-0101738P.
PR 18-JUN-1998;	98US-0089908P.	PR 24-SEP-1998;	98US-0101739P.
PR 19-JUN-1998;	98US-0089952P.	PR 24-SEP-1998;	98US-0101743P.
PR 22-JUN-1998;	98US-0090246P.	PR 24-SEP-1998;	98US-0101922P.
PR 22-JUN-1998;	98US-0090254P.	PR 25-SEP-1998;	98US-0101786P.
PR 24-JUN-1998;	98US-0090429P.	PR 29-SEP-1998;	98US-0102207P.
PR 24-JUN-1998;	98US-0090435P.	PR 29-SEP-1998;	98US-0102240P.
PR 24-JUN-1998;	98US-0090444P.	PR 29-SEP-1998;	98US-0102330P.
PR 24-JUN-1998;	98US-0090461P.	PR 29-SEP-1998;	98US-0102331P.
PR 24-JUN-1998;	98US-0090535P.	PR 30-SEP-1998;	98US-0102487P.
PR 24-JUN-1998;	98US-0090540P.	PR 30-SEP-1998;	98US-0102570P.
PR 25-JUN-1998;	98US-0090676P.	PR 30-SEP-1998;	98US-0102571P.
PR 25-JUN-1998;	98US-0090678P.	PR 01-OCT-1998;	98US-0102684P.
PR 25-JUN-1998;	98US-0090688P.	PR 01-OCT-1998;	98US-0102687P.
PR 25-JUN-1998;	98US-0090690P.		
PR 25-JUN-1998;	98US-0090694P.		
PR 25-JUN-1998;	98US-0090695P.		
PR 25-JUN-1998;	98US-0090696P.		
PR 26-JUN-1998;	98US-0090696P.		
PR 26-JUN-1998;	98US-0090862P.		
PR 26-JUN-1998;	98US-0090863P.		
PR 26-JUN-1998;	98US-0091010P.		
PR 01-JUL-1998;	98US-0091359P.		
PR 01-JUL-1998;	98US-0091544P.		
PR 02-JUL-1998;	98US-0091478P.		
PR 02-JUL-1998;	98US-0091486P.		
PR 02-JUL-1998;	98US-0091626P.		
PR 02-JUL-1998;	98US-0091628P.		
PR 02-JUL-1998;	98US-0091632P.		
PR 24-JUL-1998;	98US-0094006P.		
PR 04-AUG-1998;	98US-0095282P.		
PR 10-AUG-1998;	98US-0095998P.		
PR 10-AUG-1998;	98US-0096012P.		
PR 17-AUG-1998;	98US-0096757P.		
PR 17-AUG-1998;	98US-0096766P.		
PR 17-AUG-1998;	98US-0096867P.		
PR 17-AUG-1998;	98US-0096892P.		
PR 17-AUG-1998;	98US-0096897P.		
PR 18-AUG-1998;	98US-0096949P.		
PR 18-AUG-1998;	98US-0096959P.		
PR 18-AUG-1998;	98US-0097022P.		
PR 26-AUG-1998;	98US-0097952P.		
PR 26-AUG-1998;	98US-0097954P.		
PR 26-AUG-1998;	98US-0097955P.		
PR 26-AUG-1998;	98US-0097971P.		
PR 26-AUG-1998;	98US-0097974P.		
PR 26-AUG-1998;	98US-0098014P.		
PR 01-SEP-1998;	98US-0098016P.		
PR 01-SEP-1998;	98US-0098723P.		
PR 02-SEP-1998;	98US-0098803P.		
<div>Query Match 2.9%; Score 65.2; DB 8; Length 1734; Best Local Similarity 67.4%; Pred. No. 0.0004; Mismatches 44; Indels 0; Gaps 0; Matches 91; Conservative 0</div>			
QY 2108 CATCAATGATCGCCCTTTCCTTTACCACTCTTTTCCTTTTATCTATCTATTAATAAATGTTG 2167			
Db 1555 CCTTAAACACCACTCTCATCACTAATCTCAGCCCTTGCCCTTGAATAAACCTTAGC 1614			
QY 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227			
Db 1615 TGCCCCACCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674			
QY 2228 AAAAAAAAAAAAAA 2242			
Db 1675 AAAAAAAAAAAAAA 1689			
RESULT 1475			
ACC92936			
ID ACC92936 standard; cDNA; 1734 BP.			
XX ACC92936;			
XX ACC92936;			
DT 22-AUG-2003 (first entry)			
XX Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.			
XX Human; PRO; secreted protein; transmembrane protein;			
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;			
KW chondrocyte; proliferation; differentiation; cartilage disorder;			
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;			
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum;			
KW liver; drug screening; transgenic animal; genetic analysis;			
XX antiarthritic; vulnerary; gene therapy; gene; ss.			



RESULT 1476  
ACA72564  
ID ACA72564 standard; cDNA; 1734 BP.  
XX  
XX ACA72564;  
AC  
XX 02-JUL-2003 (first entry)  
DT  
XX Human PRO polynucleotide #101.  
DE  
XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;  
KW cancer; adrenal tumour; lung tumour; colon tumour; breast tumour;  
KW prostate tumour; rectal tumour; cervical tumour; liver tumour; TNF-alpha;  
KW tumour necrosis factor-alpha; chondrocyte cell.  
XX  
OS Homo sapiens.  
XX  
XX US2003022295-A1.  
PN  
XX 30-JAN-2003.  
PD  
XX 19-JUN-2002; 2002US-00175752.  
PF  
XX 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 28-OCT-1997; 97US-0063724P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 08-APR-1998; 98US-0081955P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 28-APR-1998; 98US-0083495P.  
PR 28-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088262P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 12-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 17-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.

```
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098602P.
PR 10-SEP-1998; 98US-0098741P.
PR 10-SEP-1998; 98US-0098754P.
PR 10-SEP-1998; 98US-0098763P.
PR 15-SEP-1998; 98US-0098812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100913P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103256P.
PR 06-OCT-1998; 98US-0103449P.

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 2108 CATCAATGATGCGCTTTGCTTTACCACTCTTTCTTTTATCTTTATTAATAATAAATGTTG 2167
Db 1555 CTTTAAACACCCCTCTCATCTAATCTCAGCCCTTGCCCTTGAATAAACCTTAGC 1614

Qy 2168 GTCTGCACCACTGNTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227
Db 1615 TGCCCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1674

Qy 2228 AAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAA 1689
```

```
RESULT 1477
ACA89082
ID ACA89082 standard; cDNA; 1734 BP.
XX
AC ACA89082;
XX
DT 08-JUL-2003 (first entry)
XX
Human secreted/transmembrane protein (PRO) cDNA #101.
XX
Human; ss; gene; secreted protein; transmembrane protein; PRO;
tumour necrosis factor-alpha; TNF-alpha; blood; tumour;
chondrocyte cell proliferation; chondrocyte cell differentiation;
adrenal tumour; lung tumour; colon tumour; breast tumour; gene therapy;
prostate tumour; rectal tumour; cervical tumour; liver tumour;
bone disorder; cartilage disorder; sports injury; arthritis; cytostatic;
antiarthritic; osteopathic.
XX
Homo sapiens.
OS
XX
US2003022297-A1.
XX
30-JAN-2003.
XX
20-JUN-2002; 2002US-00176757.
XX
18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 22-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 28-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
```

PR 06-MAY-1998; 98US-00844141P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086332P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-008787P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-008836P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089030P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090439P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090451P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.

PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101922P.  
PR 25-SEP-1998; 98US-0101786P.  
PR 29-SEP-1998; 98US-0102207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102330P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 30-SEP-1998; 98US-0102571P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 01-OCT-1998; 98US-0102687P.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;  
Best Local Similarity 67.4%; Pred. No. 0.0004;  
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2108 CATCAATGATCGCTTTGCTTTTACCACTCTTTTCTTTTATCTTATTAATAAAATGTTG 2167  
Db 1555 CCTTAAACACCACTCTCATCATCTCAGCCTTGCCCTTGAATAAACCTTACG 1614  
QY 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227  
Db 1615 TGCCCAAA 1674  
QY 2228 AAAAAAAAAAAAAA 2242  
Db 1675 AAAAAAAAAAAAAA 1689

## RESULT 1478

ACA69818

ID ACA69818 standard; cDNA; 1734 BP.

XX AC ACA69818;

XX DT 11-AUG-2003 (first entry)

XX Human secreted/transmembrane protein (PRO) cDNA #101.

KW Human; gene; ss; cytosolic; secreted and transmembrane protein; PRO;  
chromosome mapping; gene mapping; gene therapy;

KW tumour necrosis factor alpha; TNF-alpha; chondrocyte; tumour.

XX OS Homo sapiens.

XX FN US2003032105-A1.

XX PD 13-FEB-2003.

XX PF 18-JUN-2002; 2002US-00174585.

XX PR 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 28-OCT-1997; 97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063734P.

PR 31-OCT-1997; 97US-0063870P.

PR 31-OCT-1997; 97US-0064103P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066120P.

PR 24-NOV-1997; 97US-0066466P.

PR 24-NOV-1997; 97US-0066772P.

PR 11-DEC-1997; 97US-0069333P.

PR 12-DEC-1997; 97US-0069425P.

PR 17-DEC-1997; 97US-0069870P.

PR 18-DEC-1997; 97US-0068017P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077649P.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078939P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079786P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080194P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080333P.

PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.

PR 09-APR-1998; 98US-0081195P.

PR 15-APR-1998; 98US-0081838P.

PR 21-APR-1998; 98US-0082568P.

PR 21-APR-1998; 98US-0082569P.

PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.

PR 28-APR-1998; 98US-0083322P.

PR 29-APR-1998; 98US-0083495P.

PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083499P.

PR 29-APR-1998; 98US-0083559P.

PR 05-MAY-1998; 98US-0084366P.

PR 06-MAY-1998; 98US-0084414P.

PR 07-MAY-1998; 98US-0084639P.

PR 07-MAY-1998; 98US-0084640P.

PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086352P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.

```
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096877P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 17-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCTCAATGATCGCTTGTGCTTTACCACTCTTTCCTTTTATCTATTATAAAAAATGTTG 2167
    |||||
Db 1555 CCTTAAACACCACTCTCTCATCACTAATCTCAGCCCTTGCCCTTGAAATAAACCTTAGC 1614
    |||||
QY 2168 GTCTCCACCACTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227
    |||||
Db 1615 TGCCCAACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1674
    |||||
QY 2228 AAAAAAATAAAAAA 2242
    |||||
```

```
Db 1675 AAAAAAAAAAAAAA 1689
RESULT 1479
ACA96961
ID ACA96961 standard; cDNA; 1734 BP.
XX
AC ACA96961;
XX
DT 24-JUL-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1411 cDNA.
XX
KW Human; secreted and transmembrane protein: PRO; cytostatic; gene therapy;
KW tumour; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003032123-A1.
XX
PD 13-FEB-2003.
XX
PF 25-JUN-2002; 2002US-00180555.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 20-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 27-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
```



Db 1675 AAAAAAAAAAAAAA 1689  
RESULT 1480  
ACA90957  
ID ACA90957 standard; cdna; 1734 BP.  
XX AC ACA90957;  
XX AC ACA90957;  
DT 14-JUL-2003 (first entry)  
XX Novel human secreted and transmembrane protein PRO1411 cdna.  
DE Human; secreted and transmembrane protein; PRO; cytostatic; gene therapy;  
KW chondrocyte stimulator; chromosome mapping; gene mapping; tumour; gene;  
KW ss.  
XX Homo sapiens.  
XX OS  
XX PN US2003032108-A1.  
XX PD 13-FEB-2003.  
XX PF 21-JUN-2002; 2002US-00176481.  
XX PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 21-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 04-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.

```
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 26-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098721P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099811P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100843P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match
Best Local Similarity 2.9%; Score 65.2; DB 8; Length 1734;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATGCGCTTTGCTTTACCACTCTTCTTTTATCTTTATTAATAAATGTTG 2167
Db 1555 COTTAACACACCACTCTCATCACTAATCTCAGCCCTTGCCCTTGAATAAACCTTAGC 1614
QY 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCACAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
```

QY 2228 AAAAAAAAAAAAAA 2242  
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1481  
ACA70739  
ID ACA70739 standard; cDNA; 1734 BP.  
XX AC ACA70739;  
XX 11-AUG-2003 (first entry)  
XX Human secreted/transmembrane protein (PRO) cDNA #101.  
XX Human; Gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;  
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;  
KW tissue typing; cytostatic.  
XX Homo sapiens.  
XX US2003032111-A1.  
XX 13-FEB-2003.  
XX 20-JUN-2002; 2002US-00176493.  
XX 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078866P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.

```
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 05-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088327P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089588P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.

PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98MO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 18-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 02-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCCAATGATCGCCTTTTCCTTTTACCACTCTTTTCTTTTATCTATCTATTAATAAATGTTG 2167
DB 1555 CCTTAAACACCACTCTCATCACTATCTCAGCCTTGCCCTTGAATATAACCTTAGC 1614
QY 2168 GTCTCCACCACTGNCCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
DB 1615 TGCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
```

```
QY      2228 AAAAAAAAAAAAAA 2242
PR      |||||||
Db      1675 AAAAAAAAAAAAAA 1689

RESULT 1482
ACA95249
ID      ACA95249 standard; cDNA; 1734 BP.
XX
AC      ACA95249;
XX
DT      11-AUG-2003 (first entry)
XX
DE      Novel human secreted and transmembrane protein PRO1411 cDNA.
XX
KW      Human; ss; gene; gene therapy; chondrocyte stimulator; tumour; TNF-alpha;
KW      tumour necrosis factor alpha.
XX
OS      Homo sapiens.
XX
PN      US2003032119-A1.
XX
PD      13-FEB-2003.
XX
PF      25-JUN-2002; 2002US-00180544.
XX
PR      26-JUN-1998; 98US-00105413.
PR      16-SEP-1998; 98WO-US019330.
PR      07-OCT-1998; 98US-00168978.
PR      07-OCT-1998; 98WO-US021141.
PR      06-NOV-1998; 98US-00187368.
PR      01-DEC-1998; 98WO-US025108.
PR      07-DEC-1998; 98US-00202054.
PR      03-MAR-1999; 99US-00254311.
PR      08-MAR-1999; 99WO-US005028.
PR      14-MAY-1999; 99US-00311832.
PR      02-JUN-1999; 99WO-US010733.
PR      14-MAY-1999; 99WO-US012252.
PR      25-AUG-1999; 99US-00380137.
PR      25-AUG-1999; 99US-00380138.
PR      25-AUG-1999; 99US-00380139.
PR      25-AUG-1999; 99US-00380142.
PR      01-SEP-1999; 99WO-US020111.
PR      15-SEP-1999; 99WO-US021090.
PR      18-OCT-1999; 99US-00403297.
PR      12-NOV-1999; 99US-00423844.
PR      01-DEC-1999; 99WO-US028301.
PR      02-DEC-1999; 99WO-US028551.
PR      30-DEC-1999; 99WO-US031274.
PR      05-JAN-2000; 2000WO-US000219.
PR      18-FEB-2000; 2000WO-US004341.
PR      18-FEB-2000; 2000WO-US004342.
PR      22-FEB-2000; 2000WO-US004414.
PR      24-FEB-2000; 2000WO-US005004.
PR      01-MAR-2000; 2000WO-US005601.
PR      02-MAR-2000; 2000WO-US005841.
PR      15-MAR-2000; 2000WO-US006884.
PR      30-MAR-2000; 2000WO-US008439.
PR      17-MAY-2000; 2000WO-US013705.
PR      22-MAY-2000; 2000WO-US014042.
PR      30-MAY-2000; 2000WO-US014941.
PR      02-JUN-2000; 2000WO-US015264.
PR      28-JUL-2000; 2000WO-US020710.
PR      22-AUG-2000; 2000US-00844848.
PR      24-AUG-2000; 2000WO-US023328.
PR      18-SEP-2000; 2000US-00654610.
PR      18-SEP-2000; 2000US-00655350.
PR      08-NOV-2000; 2000US-00709238.
PR      08-NOV-2000; 2000WO-US030952.
PR      01-DEC-2000; 2000WO-US032678.
PR      20-DEC-2000; 2000US-00747259.
PR      20-DEC-2000; 2000WO-US034956.
```

```
PR      28-FEB-2001; 2001WO-US006520.
PR      22-MAR-2001; 2001US-00816744.
PR      10-MAY-2001; 2001US-00854208.
PR      10-MAY-2001; 2001US-00854280.
PR      25-MAY-2001; 2001US-00866028.
PR      01-JUN-2001; 2001WO-US017800.
PR      05-JUN-2001; 2001US-00874503.
PR      20-JUN-2001; 2001WO-US019692.
PR      29-JUN-2001; 2001WO-US021066.
PR      09-JUL-2001; 2001WO-US021735.
PR      18-JUL-2001; 2001US-00908827.
PR      30-JUL-2001; 2001US-00918585.
PR      06-AUG-2001; 2001US-00924419.
PR      13-AUG-2001; 2001US-00929404.
PR      16-AUG-2001; 2001US-00931836.
PR      28-AUG-2001; 2001US-00941992.
PR      29-AUG-2001; 2001WO-US027099.
PR      04-SEP-2001; 2001US-00946374.
PR      15-JAN-2002; 2002US-00052586.
XX
PA      (GETH ) GENENTECH INC.
XX
XX      Baker KP, Chen J, Deenoyers L, Goddard A, Godowski PJ, Gurney AL;
XX      Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX      WPI; 2003-341973/32.
DR      P-PSDB; ABU93709.
XX
XX      Three hundred and five nucleic acids encoding PRO polypeptides, useful
XX      for the manufacture of a medicament for diagnosing or treating tumor or
XX      for measuring or detecting expression of an associated gene.
XX
XX      Claim 2; Fig 201; 707pp; English.
XX
XX      The invention relates to three hundred and five nucleic acids encoding
XX      PRO polypeptides (secreted and transmembrane). The PRO nucleic acids and
XX      polypeptides are useful for the manufacture of a medicament for
XX      diagnosing or treating tumour in a mammal, for measuring or detecting
XX      expression of an associated gene, for stimulation of chondrocytes and for
XX      stimulating the release of tumour necrosis factor alpha (TNF-alpha) from
XX      human blood. The present sequence represents cDNA encoding a secreted and
XX      transmembrane PRO protein. Note: The sequence data for this patent did
XX      not form part of the printed specification but was obtained in electronic
XX      format directly from USPTO at
XX      seqdata.uspto.gov/sequence.html?docID=20030032199
XX
SQ      Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY      2108 CATCCATGATGCGCTTGTCTTACCACTCTTCTTTTATCTTATTATAAATAATGTG 2167
PR      |||||
Db      1555 CCTTAAACACCAACCCCTCTCATCACTAATCTGACCCCTTGCCCTTGAATAACCTTAGC 1614
QY      2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
PR      |||||
Db      1615 TGCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
QY      2228 AAAAAAAAAAAAAA 2242
PR      |||||
Db      1675 AAAAAAAAAAAAAA 1689

RESULT 1483
ACC86192
ID      ACC86192 standard; cDNA; 1734 BP.
XX
AC      ACC86192;
XX
XX      28-JUL-2003 (first entry)
XX
```

DE Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.  
XX Human; PRO; secreted protein; transmembrane protein;  
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;  
KW chondrocyte; proliferation; differentiation; cartilage disorder;  
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
KW liver; drug screening; transgenic animal; genetic analysis;  
KW antiarthritic; vulnery; gene therapy; gene; ss.  
XX Homo sapiens.  
OS  
XX  
XX US2003027263-A1.  
XX  
XX 06-FEB-2003.  
XX  
XX 18-JUN-2002; 2002US-00174572.  
XX  
XX 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 28-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078919P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 28-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 03-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 11-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 24-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.

```
PR 18-AUG-1998; 98US-0095959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098841P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 24-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101473P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATCGCTTTCCTTACCACTCTTCTTTTATCTTATTAATAAATGTTG 2167
Db 1555 CTTTAAACACACCCCTCTCATCTATCTCAGCCCTTGCCCTGAAATTAACCTTAGC 1614
QY 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
QY 2228 AAAAAAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAAAAAA 1689

RESULT 1484
ACD45174
ID ACD45174 standard; cDNA; 1734 BP.
XX AC ACD45174;
XX DT 11-SEP-2003 (first entry)
```

```
XX Human secreted/transmembrane polypeptide PRO411 cDNA.
DE Human; ss; tumour; cancer; gene therapy; tissue typing; gene.
XX Homo sapiens.
OS US2003009012-A1.
PN 09-JAN-2003.
PD 01-MAY-2002; 2002US-00063517.
PF 30-DEC-1998; 98KR-00062142.
PR 08-MAR-1999; 99WO-US005028.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 25-AUG-1999; 99US-00380142.
PR 15-SEP-1999; 99US-00397342.
PR 18-OCT-1999; 99US-00403297.
PR 12-NOV-1999; 99US-00423844.
PR 30-DEC-1999; 99WO-US031274.
PR 18-FEB-2000; 2000WO-US004341.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US015264.
PR 22-AUG-2000; 2000US-00644848.
PR 18-SEP-2000; 2000US-00656410.
PR 18-SEP-2000; 2000US-00665350.
PR 08-NOV-2000; 2000US-00709238.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 10-MAY-2001; 2001US-00854208.
PR 30-MAY-2001; 2001US-00870574.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 29-JUN-2001; 2001US-00869599.
PR 18-JUL-2001; 2001US-00908827.
PR 06-DEC-2001; 2001US-00006867.
(GETH ) GENENTECH INC.
PA Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PU;
XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
PI WPI; 2003-447383/42.
XX P-PSDB; ABO27306.
DR New isolated antibody specifically binding a PRO polypeptide, useful for
XX the preparation of a medicament for treating disorders with the aberrant
PT expression or activity of the PRO polypeptide, such as tumor conditions
PT and cancer.
XX Dislosure; Fig 51; 223pp; English.
PS The invention relates to an antibody that binds to a secreted and
XX transmembrane PRO polypeptide. The methods and compositions of the
CC present invention are useful for the preparation of a medicament for the
CC treatment of disorders associated with the aberrant expression or
CC activity of the PRO polypeptide, such as tumour conditions and cancer.
CC They can also be used to generate transgenic or knockout animals useful
CC in the development and screening of therapeutically useful reagents. The
```



```
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091632P.
PR 02-JUL-1998; 98US-0091633P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096881P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.

PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 2108 CATCCAATGATCGCCTTTGCTTTTACCACTCTTCTTTTATCTTATTAATAAATGTTG 2167
Db 1555 CCTTAAACACCCCTCTCATCACTAATCTCAGCCCTTGCCCTTGAAATTAACCTTAGC 1614

Qy 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674

Qy 2228 AAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1486
ACD12672
ID ACD12672 standard; cDNA; 1734 BP.
XX ACD12672;
AC ACD12672;
XX
DT 17-AUG-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) cDNA #101.
KW Human; Gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour.
XX
OS Homo sapiens.
XX
FN US2003036125-A1.
XX
PD 20-FEB-2003.
XX
PF 26-JUN-2002; 2002US-00180999.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 12-DEC-1997; 97US-0069335P.
PR 17-DEC-1997; 97US-0069425P.
PR 18-DEC-1997; 97US-0069870P.
PR 10-MAR-1998; 97US-0068017P.
PR 11-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
```

PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 20-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 03-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 10-AUG-1998; 98US-0095988P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 18-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101922P.  
PR 25-SEP-1998; 98US-0101786P.  
PR 29-SEP-1998; 98US-010207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102330P.

```
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 01-OCT-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match          2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATGGCTTGGCTTTACCACTCTTCTTTTATCTTATTAATAAATGTTG 2167
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1555 CCTTAAACACACCCCTCTCATCTATCTCAGCCCTTGGCCCTTGAATTAACCTTAGC 1614
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2168 GTCTCCACCACTGCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1615 TGCCCCACAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 2228 AAAAAAAAAAAAAA 2242
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1675 AAAAAAAAAAAAAA 1689
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 1487
ACFI9902
ID ACF19902 standard; cDNA; 1734 BP.
XX
AC ACF19902;
XX
DT 17-SEP-2003 (first entry)
XX
DE Human secreted polypeptide PRO1411-encoding cDNA, SEQ ID NO:201.
XX
KW Human; PRO; secreted protein; transmembrane protein;
KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; proliferation; differentiation; cartilage disorder;
KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;
KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;
KW liver; drug screening; transgenic animal; genetic analysis;
KW antiarthritic; vulnerability; gene therapy; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003040068-A1.
XX
PD 27-FEB-2003.
XX
XX 28-JUN-2002; 2002US-00184625.
XX
PF 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.

97US-0068017P.
98US-0077450P.
98US-0077632P.
98US-0077649P.
98US-0078886P.
98US-0078939P.
98US-0079664P.
98US-0079786P.
98US-0080107P.
98US-0080194P.
98US-0080327P.
98US-0080333P.
98US-0080493P.
98US-0081070P.
98US-0081195P.
98US-0081838P.
98US-0082568P.
98US-0082589P.
98US-0082704P.
98US-0082797P.
98US-0083322P.
98US-0083495P.
98US-0083496P.
98US-0083499P.
98US-0083559P.
98US-0084366P.
98US-0084414P.
98US-0084639P.
98US-0084640P.
98US-0084643P.
98US-0085579P.
98US-0085580P.
98US-0085582P.
98US-0085700P.
98US-0086023P.
98US-0086332P.
98US-0086486P.
98US-0087098P.
98US-0087208P.
98US-0087609P.
98US-0087759P.
98US-0087827P.
98US-0088025P.
98US-0088028P.
98US-0088033P.
98US-0088326P.
98US-0088167P.
98US-0088202P.
98US-0088212P.
98US-0088217P.
98US-0088655P.
98US-0088722P.
98US-0088738P.
98US-0088740P.
98US-0088811P.
98US-0088824P.
98US-0088825P.
98US-0088826P.
98US-0088861P.
98US-0088863P.
98US-0088876P.
98US-0089090P.
98US-0089105P.
98US-0089512P.
98US-0089514P.
98US-0089538P.
98US-0089598P.
98US-0089653P.
98US-0089908P.
98US-0089952P.
98US-0090246P.
98US-0090252P.
```

PR 22-JUN-1998;	98US-0090354P.
PR 24-JUN-1998;	98US-0090429P.
PR 24-JUN-1998;	98US-0090435P.
PR 24-JUN-1998;	98US-0090444P.
PR 24-JUN-1998;	98US-0090461P.
PR 24-JUN-1998;	98US-0090535P.
PR 24-JUN-1998;	98US-0090540P.
PR 25-JUN-1998;	98US-0090676P.
PR 25-JUN-1998;	98US-0090678P.
PR 25-JUN-1998;	98US-0090688P.
PR 25-JUN-1998;	98US-0090690P.
PR 25-JUN-1998;	98US-0090694P.
PR 25-JUN-1998;	98US-0090695P.
PR 25-JUN-1998;	98US-0090696P.
PR 26-JUN-1998;	98US-00105413.
PR 26-JUN-1998;	98US-0090862P.
PR 26-JUN-1998;	98US-0090863P.
PR 26-JUN-1998;	98US-0091010P.
PR 01-JUL-1998;	98US-0091359P.
PR 01-JUL-1998;	98US-0091544P.
PR 02-JUL-1998;	98US-0091478P.
PR 02-JUL-1998;	98US-0091486P.
PR 02-JUL-1998;	98US-0091626P.
PR 02-JUL-1998;	98US-0091628P.
PR 02-JUL-1998;	98US-0091632P.
PR 24-JUL-1998;	98US-0094006P.
PR 04-AUG-1998;	98US-0095282P.
PR 10-AUG-1998;	98US-0095998P.
PR 10-AUG-1998;	98US-0096012P.
PR 17-AUG-1998;	98US-0096757P.
PR 17-AUG-1998;	98US-0096766P.
PR 17-AUG-1998;	98US-0096867P.
PR 17-AUG-1998;	98US-0096891P.
PR 17-AUG-1998;	98US-0096897P.
PR 18-AUG-1998;	98US-0096949P.
PR 18-AUG-1998;	98US-0097022P.
PR 18-AUG-1998;	98US-0097952P.
PR 26-AUG-1998;	98US-0097954P.
PR 26-AUG-1998;	98US-0097955P.
PR 26-AUG-1998;	98US-0097971P.
PR 26-AUG-1998;	98US-0097974P.
PR 26-AUG-1998;	98US-0098014P.
PR 01-SEP-1998;	98US-0098716P.
PR 01-SEP-1998;	98US-0098723P.
PR 02-SEP-1998;	98US-0098803P.
PR 02-SEP-1998;	98US-0098821P.
PR 02-SEP-1998;	98US-0098843P.
PR 09-SEP-1998;	98US-0099602P.
PR 10-SEP-1998;	98US-0099741P.
PR 10-SEP-1998;	98US-0099754P.
PR 10-SEP-1998;	98US-0099763P.
PR 10-SEP-1998;	98US-0099812P.
PR 15-SEP-1998;	98US-0100388P.
PR 16-SEP-1998;	98US-0100662P.
PR 16-SEP-1998;	98US-0100664P.
PR 16-SEP-1998;	98US-0101751P.
PR 16-SEP-1998;	98US-01019330.
PR 17-SEP-1998;	98US-0100683P.
PR 17-SEP-1998;	98US-0100684P.
PR 17-SEP-1998;	98US-0100689P.
PR 17-SEP-1998;	98US-0100930P.
PR 18-SEP-1998;	98US-0100849P.
PR 18-SEP-1998;	98US-0101014P.
PR 18-SEP-1998;	98US-0101068P.
PR 23-SEP-1998;	98US-0101471P.
PR 23-SEP-1998;	98US-0101472P.
PR 23-SEP-1998;	98US-0101475P.
PR 23-SEP-1998;	98US-0101477P.
PR 24-SEP-1998;	98US-0101738P.
PR 24-SEP-1998;	98US-0101739P.
PR 24-SEP-1998;	98US-0101743P.
PR 24-SEP-1998;	98US-0101922P.
PR 25-SEP-1998;	98US-0090354P.
PR 29-SEP-1998;	98US-0102207P.
PR 29-SEP-1998;	98US-0102240P.
PR 29-SEP-1998;	98US-0102330P.
PR 29-SEP-1998;	98US-0102331P.
PR 30-SEP-1998;	98US-0102487P.
PR 30-SEP-1998;	98US-0102570P.
PR 30-SEP-1998;	98US-0102571P.
PR 01-OCT-1998;	98US-0102684P.
PR 01-OCT-1998;	98US-0102687P.
Query Match 2.9%; Score 65.2; DB 8; Length 1734; Best Local Similarity 67.4%; Pred. No. 0.0004; Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;	
QY 2108 CATCCAAATGATCGCTTTCCTTACCACTCTTTCCTTTATCTTATATAAAATGTTG 2167	
DB 1555 CCTTAAACACCACTCTCTCATCACTAATCTCAGCCCTTGCCCTTGAATAAACCTTAGC 1614	
QY 2168 GTCTCCACCACTGCTCCCAAAAAA 2227	
DB 1615 TGCCCAACAAAAA 1674	
QY 2228 AAAAAA 2242	
DB 1675 AAAAAA 1689	
RESULT 1488	
ABX76846	
ID ABX76846 standard; cDNA; 1734 BP.	
XX AC ABX76846;	
XX DT 04-APR-2003 (first entry)	
XX DE Human PRO polynucleotide #101.	
XX KW Human; PRO; gene; ss; tumour necrosis factor-alpha; blood; cancer;	
XX KW chondrocyte cell; tumour; adrenal tumour; lung; colon; breast; prostate;	
XX KW kidney; rectum; cervix; liver; bone disorder; cartilage disorder;	
XX KW arthritis; sports injury; genetic disorder; antiarthritic; vulnary.	
OS Homo sapiens.	
XX OS US2003027280-A1.	
XX PD 06-FEB-2003.	
XX PF 20-JUN-2002; 2002US-00176993.	
XX PR 18-SEP-1997; 97US-0059263P.	
XX PR 18-SEP-1997; 97US-0059266P.	
XX PR 17-OCT-1997; 97US-0062250P.	
XX PR 21-OCT-1997; 97US-0063486P.	
XX PR 24-OCT-1997; 97US-0063120P.	
XX PR 24-OCT-1997; 97US-0063121P.	
XX PR 28-OCT-1997; 97US-0063540P.	
XX PR 28-OCT-1997; 97US-0063541P.	
XX PR 28-OCT-1997; 97US-0063544P.	
XX PR 28-OCT-1997; 97US-0063564P.	
XX PR 31-OCT-1997; 97US-0063734P.	
XX PR 31-OCT-1997; 97US-0063870P.	
XX PR 31-OCT-1997; 97US-0064103P.	
XX PR 13-NOV-1997; 97US-0065311P.	
XX PR 21-NOV-1997; 97US-0066120P.	
XX PR 24-NOV-1997; 97US-0066466P.	
XX PR 24-NOV-1997; 97US-0066772P.	
XX PR 11-DEC-1997; 97US-0069335P.	
XX PR 12-DEC-1997; 97US-0069425P.	
XX PR 17-DEC-1997; 97US-0069870P.	
XX PR 18-DEC-1997; 97US-0068017P.	
XX PR 10-MAR-1998; 98US-0077450P.	

PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083493P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084633P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088723P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.

PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 04-AUG-1998; 98US-00934006P.  
PR 10-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096765P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100682P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101922P.  
PR 25-SEP-1998; 98US-0101786P.  
PR 29-SEP-1998; 98US-0102207P.

```

PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match          2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY ( 2108 CATCAATGATCGCTTGGCTTTTACCACTCTTTCCTTTTATCTATTAATAAAATGTTG 2167
      |||||
Dd 1555 CCTTAAACACCACTCTCTCATCACTAATCTCAGCCCTTGCCCTTGAATATAAACCTTAGC 1614
      |||||
QY 2168 GTCTCCACCACTGCTCCCAAAAAA 2242
      |||||
Dd 1615 TGCCCAAAAAA 1674

QY 2228 AAAAAA 2242
      |||||
Dd 1675 AAAAAA 1689

RESULT 1489
ACA60527
ID ACA60527 standard; cDNA; 1734 BP.
XX
AC ACA60527;
XX
DT 11-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1411 cDNA.
XX
KW Human; secreted and transmembrane polypeptide; PRO;
KW fibroblast growth factor receptor; PRO533; PRO301; PRO187; PRO337;
KW PRO1411; PRO10096; PRO246; PRO6307; PRO6003; FGFR-3; FGFR-4; FGFR-1;
KW FGFR-2; PRO6004; PRO2630; PRO265; PRO951; bioactive molecule;
KW toxin; radiolabel; antibody; cell death; chromosome mapping;
KW gene mapping; transgenic animal; knockout animal; gene therapy;
KW tissue typing; gene; ss.
XX
OS Homo sapiens.
XX
PN US2002177165-A1.
XX
PD 28-NOV-2002.
XX
PF 01-FEB-2002; 2002US-0006500.
XX
XX 26-AUG-1997; 97US-0056974P.
XX 17-SEP-1997; 97US-0059115P.
XX 18-SEP-1997; 97US-0059263P.
XX 19-SEP-1997; 97US-0059588P.
XX 17-OCT-1997; 97US-0062285P.
XX 24-OCT-1997; 97US-0062816P.
XX 24-OCT-1997; 97US-0063082P.
XX 27-OCT-1997; 97US-0063329P.
XX 29-OCT-1997; 97US-0063733P.
XX 21-NOV-1997; 97US-0066364P.
XX 25-NOV-1997; 97US-0066840P.
XX 16-DEC-1997; 97US-0069694P.
XX 09-FEB-1998; 98US-0074086P.
XX 09-FEB-1998; 98US-0074092P.
XX 25-MAR-1998; 98US-0079294P.
XX 08-APR-1998; 98US-0081049P.
XX 14-JUL-1998; 98WO-US014552.
XX 10-AUG-1998; 98US-0095998P.

```

```

PR 18-AUG-1998; 98US-0097000P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099811P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 16-SEP-1998; 98US-019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 24-SEP-1998; 98US-0101922P.
PR 28-OCT-1998; 98US-0106032P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 25-NOV-1998; 98WO-US025190.
PR 01-DEC-1998; 98WO-US035108.
PR 08-MAR-1999; 99WO-US005028.
PR 23-MAR-1999; 99US-0125778P.
PR 02-JUN-1999; 99WO-US012252.
PR 15-JUN-1999; 99US-0139695P.
PR 20-JUL-1999; 99US-0145070P.
PR 26-JUL-1999; 99US-0145698P.
PR 17-AUG-1999; 99US-0149396P.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028565.
PR 07-DEC-1999; 99US-0169495P.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 09-MAR-2000; 2000WO-US006471.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 11-AUG-2000; 2000WO-US020311.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 30-MAY-2001; 2001WO-US017443.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 15-NOV-2001; 2001US-0002796.
XX
XX (GETH ) GENENTECH INC.
PA
XX Ashkenazi AJ, Baker KP, Botstein DA, Desnoyers L, Eaton DL;
XX Ferrara N, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;
XX Godowski PJ, Gurney AL, Klijavin IJ, Mather JP, Napier MA, Pan J;
XX Faoni NF, Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM;
XX Wood WI, Zhang Z;
XX WPI; 2003-328482/31.
XX P-PSDB; ABU72062.
XX
XX Novel secreted and transmembrane polypeptide for modulating biological
XX activity of cell expressing the polypeptide, for identifying agonists or
XX antagonists of polypeptide, and as molecular weight markers.
XX

```

PS Claim 2; Fig 53; 254pp; English.

XX The invention describes an isolated, secreted and transmembrane  
CC polypeptide (PP), termed PRO PP or fibroblast growth factor receptor PP  
CC (I). (I) is useful for detecting PRO533, PRO301, PRO187, PRO337, PRO1411,  
CC PRO10096, PRO246, PRO6307, PRO6003, fibroblast growth factor receptor  
CC (FGFR)-3, FGFR-4, FGFR-1, FGFR-2, PRO6004, PRO4356, PRO2630, PRO265 or  
CC PRO951 polypeptide, and for linking a bioactive molecule to a cell  
CC expressing the above polypeptides. The bioactive molecule, a toxin,  
CC radiolabel or an antibody, causes cell death. PRO is useful in assays to  
CC identify other proteins or molecules involved in binding interaction. The  
CC polynucleotide (II) encoding (I) is useful in chromosome and gene  
CC mapping, in generation of antisense RNA and DNA, for generating  
CC transgenic animals or knockout animals which in turn are useful in the  
CC development and screening of therapeutically useful reagents, to  
CC construct hybridisation probes for mapping the gene which encodes the PRO  
CC and for the genetic analysis of individuals with genetic disorders in  
CC gene therapy, for chromosome identification and as a chromosome marker.  
CC (I) and (II) are useful for tissue typing. This sequence encodes a novel  
CC human secreted and transmembrane PRO polypeptide

XX SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.2; DB 8; Length 1734;  
Best Local Similarity 67.4%; Pred. No. 0.0004;  
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
QY 2108 CATCAATGATCGCTTGGCTTACCACTCTTCTTTTATCTTATTAATAAATGTTG 2167  
DB 1555 CCTTAACACACACCTCTCATCTATCTAGCCCTTGGCTTGAATAAACCTTAGC 1614  
QY 2168 GTCTCCACCACTGCTCCCAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227  
DB 1615 TGCCCAACAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 1674  
QY 2228 AAAAAAATAAAAAA 2242  
DB 1675 AAAAAAATAAAAAA 1689

RESULT 1490

ACA73178  
ID ACA73178 standard; cDNA; 1734 BP.

XX AC ACA73178;

XX DT 01-JUL-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO1411 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; chromosome mapping;  
XX KW gene mapping; transgenic animal; knockout animal; tissue typing; tumour;  
XX KW chondrocyte cell proliferation; gene therapy;  
XX KW chondrocyte cell differentiation; tumour necrosis factor-alpha release;  
XX KW gene; ss.

XX OS Homo sapiens.

XX PN US2003022300-A1.

XX PD 30-JAN-2003.

XX PF 25-JUN-2002; 2002US-00180552.

XX PR 18-SEP-1997; 97US-0059263P.

XX PR 18-SEP-1997; 97US-0059266P.

XX PR 17-OCT-1997; 97US-0062250P.

XX PR 21-OCT-1997; 97US-0063486P.

XX PR 24-OCT-1997; 97US-0063120P.

XX PR 24-OCT-1997; 97US-0063121P.

XX PR 28-OCT-1997; 97US-0063540P.

XX PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 13-NOV-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086352P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 02-JUN-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 03-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 05-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.

```
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089922P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 13-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-01018330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.

PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 25-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCCAATGATCGCCTTTGCTTTTACCACTCTTTTCCTTTTATCTTATTTATATAAAATGTTG 2167
Db 1555 CCTTAAACACACACCCTCTCATCACTAATCTCAGCCCTTGCCCTTGAAATAAACCTTAGC 1614
QY 2168 GTCTCCACCACCTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
QY 2228 AAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1491
ACA68721
ID ACA68721 standard; cDNA; 1734 BP.
XX ACA68721;
XX
DT 09-JUL-2003 (revised)
DT 26-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1411 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; cytostatic; gene therapy;
KW TNF-Agonist-Alpha; chondrocyte stimulator; tumour; adrenal tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003036136-A1.
XX
PD 20-FEB-2003.
XX
PF 28-JUN-2002; 2002US-00184636.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
```

PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066130P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0077886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086332P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088326P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.

PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 04-AUG-1998; 98US-0094006P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.

```

PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 2108 CATCAATGATCGCTTGTGCTTTTACCACTCTTTCTTTTATCTTATTAATAAAATGTTG 2167
    |||||
Db 1555 CCTTAAACACCACTCTCATCTAATCTCAGCCCTTGCCCTTGAATAAATACCTTAGC 1614
    |||||

QY 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
    |||||
Db 1615 TGCCCAACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674

QY 2228 AAAAAAAAAAAAAA 2242
    |||||
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1492
ACA74565
ID ACA74565 standard; cDNA; 1734 BP.
XX
AC ACA74565;
XX
XX 07-JUL-2003 (first entry)
XX
XX cDNA encoding human PRO polypeptide #101.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW chromosome mapping; gene mapping; tumour; adrenal; lung; colon; breast;
KW prostate; rectal; cervical; liver; cancer; cytostatic; gene therapy;
KW gene; ss.
XX
XX Homo sapiens.
XX
XX US2003036138-A1.
XX
XX 20-FEB-2003.
XX
XX 28-JUN-2002; 2002US-00184650.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-0063120P.
PR 24-OCT-1997; 97US-0063121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 21-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.
PR 11-DEC-1997; 97US-0069335P.
PR 12-DEC-1997; 97US-0069425P.
PR 17-DEC-1997; 97US-0069870P.
PR 18-DEC-1997; 97US-0068017P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077649P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078939P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079786P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080333P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 09-APR-1998; 98US-0081195P.
PR 15-APR-1998; 98US-0081838P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083599P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085808P.
PR 15-MAY-1998; 98US-0085822P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087208P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.

```

```
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0094006P.
PR 10-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 04-AUG-1998; 98US-0094006P.
PR 10-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099812P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
Qy 2108 CATCCAATGATCGCCTTTGCTTTTACCACTCTTCTTTTATCTTATTATAATAAATGTTG 2167
Db 1555 CCTTAAACACCACCTCTCATCACTAATCTCAGCCCTTGCCTTGAATAAACCTTAGC 1614
Qy 2168 GTCTCCGACACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
Qy 2228 AAAAAAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAAAAAA 1689
RESULT 1493
ACA04517
ID ACA04517 standard; cDNA; 1734 BP.
XX ACA04517;
AC ACA04517;
XX
DT 28-MAY-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1411 DNA.
XX
KW Secreted and transmembrane polypeptide; PRO polypeptide; PRO533; PRO301;
KW PRO187; PRO337; PRO1411; PRO10096; PRO246; PRO6307; PRO6003; PRO6004;
KW PRO4356; PRO2630; PRO265; PRO941; FGFR; bioactive molecule;
KW fibroblast growth factor receptor; cell death; chromosome mapping;
KW gene mapping; transgenic animal; knockout animal; gene therapy; tumour;
KW obesity; diabetes; insulinemia; vascular permeability;
KW cardiac insufficiency disorder; immune response; hearing loss;
KW auditory hair cell regeneration; bone disorder; cartilage disorder;
KW sports injury; arthritis; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003032062-A1.
XX
PD 13-FEB-2003.
XX
PF 01-FEB-2002; 2002US-00066273.
XX
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059115P.
```

```

PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059588P.
PR 17-OCT-1997; 97US-0062285P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063082P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063733P.
PR 21-NOV-1997; 97US-0066364P.
PR 25-NOV-1997; 97US-0066840P.
PR 16-DEC-1997; 97US-0069694P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 25-MAR-1998; 98US-0079294P.
PR 08-APR-1998; 98US-0081049P.
PR 14-JUL-1998; 98WO-US014552.
PR 10-AUG-1998; 98US-0095998P.
PR 18-AUG-1998; 98US-0097000P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099811P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 24-SEP-1998; 98US-0101922P.
PR 28-OCT-1998; 98US-0106032P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 25-NOV-1998; 98WO-US025190.
PR 01-DEC-1998; 98WO-US025108.
PR 08-MAR-1999; 99WO-US005028.
PR 23-MAR-1999; 99US-0125778P.
PR 02-JUN-1999; 99WO-US012252.
PR 15-JUN-1999; 99US-0133969P.
PR 20-JUL-1999; 99US-0145070P.
PR 26-JUL-1999; 99US-0145698P.
PR 17-AUG-1999; 99US-0149396P.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028565.
PR 07-DEC-1999; 99US-0169495P.
PR 20-DEC-1999; 99WO-US030999.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 09-MAR-2000; 2000WO-US006471.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 30-MAY-2001; 2001WO-US017443.
PR 01-JUN-2001; 2001WO-US017400.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 15-NOV-2001; 2001US-00002796.

XX (GETH ) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein DA, Desnoyers L, Eaton DL;
XX Pi Ferrara N, Fong S, Gao W, Gerber H, Grittens ME, Goddard A;
PI Godowski PJ, Gurney AL, Kljavin IJ, Mather JP, Napier MA, Pan J;
PI Paoni NF, Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM;
PI Wood WI, Zhang Z;
XX WPI; 2003-341963/32.
DR P-PSDB; ABU67163.
XX
XX New secreted and transmembrane polypeptide for modulating biological
PT activity of a cell expressing the polypeptide, identifying agonists or
PT antagonists of the polypeptide, and as molecular weight markers.
XX
XX Claim 2; Fig 53; 254pp; English.
XX
XX The invention describes an isolated, secreted and transmembrane
CC polypeptide (I), termed PRO polypeptide. (I) Is useful for detecting
CC PRO533, PRO301, PRO187, PRO337, PRO1411, PRO10096, PRO246, PRO6307,
CC PRO6003, PRO6004, PRO4356, PRO2630, PRO265, PRO941, fibroblast growth
CC factor receptor (FGFR)-4, FGFR-3, FGFR-2 or FGFR-1 polypeptide, and for
CC linking a bioactive molecule e.g. toxin, radiolabel or antibody, to a
CC cell expressing the polypeptides. The bioactive molecule causes cell
CC death. (II) Is useful as hybridisation probes, in chromosome and gene
CC mapping, in generation of antisense RNA and DNA, in the preparation of
CC PRO polypeptide, for generating transgenic animals or knockout animals
CC which in turn are useful in the development and screening of
CC therapeutically useful reagents, and for the genetic analysis of
CC individuals with genetic disorders, in gene therapy, and for chromosome
CC identification. (I) Or Ab is useful for the preparation of medicament for
CC treating conditions which are responsive to the PRO polypeptide or anti-
CC PRO antibody e.g. a tumour. (I) is useful for treating obesity, diabetes
CC or hypo- or hyper-insulinaemia, and cardiac insufficiency disorders, for
CC inhibiting tumour growth, enhances vascular permeability and immune
CC response, for inducing regeneration of auditory hair cells and for
CC treating hearing loss in mammals, and for treating bone and/or cartilage
CC disorders such as sports injuries and arthritis. This sequence encodes a
CC novel human secreted and transmembrane polypeptide
XX
XX Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;
SQ
Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
QY 2108 CATCCAATGATCGCTTTGCTTTTACCACCTCTTTCCTTTTATCTTATTAATAAAATGTTG 2167
Db 1555 CCTTAAACACACCACCTCTCATCACTAATCTCAGCCCTTGCCCTTGAATAAACCTTAGC 1614
QY 2168 GTCTCCACCACCTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
QY 2228 AAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAA 1689
RESULT 1494
ACA70432
ID ACA70432 standard; cDNA; 1734 BP.
XX
XX ACA70432;
AC
XX
XX 11-AUG-2003 (first entry)
XX
XX Human secreted/transmembrane protein (PRO) cDNA #101.
XX
XX Human; gene; ss; secreted and transmembrane protein; PRO; TNF-alpha;
KW tumour necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
KW tissue typing; cytostatic.

```

XX OS Homo sapiens.  
XX PN US2003032109-A1.  
XX XX  
XX PD 13-FEB-2003.  
XX PF  
XX FF 20-JUN-2002; 2002US-00176485.  
XX XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0022250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 24-NOV-1997; 97US-0066772P.  
PR 11-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078933P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083222P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088030P.  
PR 04-JUN-1998; 98US-0088031P.  
PR 04-JUN-1998; 98US-0088032P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088034P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088555P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.  
PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090678P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 25-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-00105413.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.

PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 02-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100622P.  
PR 16-SEP-1998; 98US-0100644P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98US-01019330.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100919P.  
PR 17-SEP-1998; 98US-0100930P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101743P.  
PR 24-SEP-1998; 98US-0101922P.  
PR 25-SEP-1998; 98US-0101786P.  
PR 29-SEP-1998; 98US-0102207P.  
PR 29-SEP-1998; 98US-0102240P.  
PR 29-SEP-1998; 98US-0102330P.  
PR 29-SEP-1998; 98US-0102331P.  
PR 30-SEP-1998; 98US-0102487P.  
PR 30-SEP-1998; 98US-0102570P.  
PR 30-SEP-1998; 98US-0102571P.  
PR 01-OCT-1998; 98US-0102684P.  
PR 01-OCT-1998; 98US-0102687P.  
PR 02-OCT-1998; 98US-0102965P.  
PR 06-OCT-1998; 98US-0103258P.  
PR 06-OCT-1998; 98US-0103449P.  
PR 07-OCT-1998; 98US-00168978.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;  
Best Local Similarity 67.4%; Pred. No. 0.0004;  
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;  
Qy 2108 CATCAATGATCGCTTTGGCTTTTACCACTCTTTCTTTTATCTTATTAATAAATGTTG 2167  
Db 1555 CCTTAAACACACCCCTCTCATCACTAATCTCAGCCCTTGCCCTTGAATATAACCTTAGC 1614  
Qy 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227  
Db 1615 TGCCCCACAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674  
Qy 2228 AAAAAAAAAAAAAA 2242  
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1495  
ACD14618  
ID ACD14618 standard; cdna; 1734 BP.  
XX  
AC ACD14618;  
XX  
DT 19-AUG-2003 (first entry)  
XX  
DE Human PRO polynucleotide #101.  
XX  
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;  
KW cyostatic; tumour necrosis factor-alpha; TNF-alpha; blood; tumour;

KW chondrocyte cell; cancer.  
XX  
OS Homo sapiens.  
XX  
PN US2003040066-A1.  
XX  
PD 27-FEB-2003.  
XX  
XX  
PF 26-JUN-2002; 2002US-00183019.  
XX  
PR 18-SEP-1997; 97US-0059263P.  
PR 18-SEP-1997; 97US-0059266P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 21-OCT-1997; 97US-0063486P.  
PR 24-OCT-1997; 97US-0063120P.  
PR 24-OCT-1997; 97US-0063121P.  
PR 28-OCT-1997; 97US-0063540P.  
PR 28-OCT-1997; 97US-0063541P.  
PR 28-OCT-1997; 97US-0063544P.  
PR 28-OCT-1997; 97US-0063564P.  
PR 29-OCT-1997; 97US-0063734P.  
PR 31-OCT-1997; 97US-0063870P.  
PR 31-OCT-1997; 97US-0064103P.  
PR 13-NOV-1997; 97US-0065311P.  
PR 21-NOV-1997; 97US-0066120P.  
PR 24-NOV-1997; 97US-0066466P.  
PR 11-DEC-1997; 97US-0066772P.  
PR 12-DEC-1997; 97US-0069335P.  
PR 12-DEC-1997; 97US-0069425P.  
PR 18-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077632P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078866P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081070P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 28-APR-1998; 98US-0083222P.  
PR 29-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083559P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084639P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085822P.  
PR 18-MAY-1998; 98US-0085700P.  
PR 22-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 02-JUN-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.

```
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088211P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088739P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088873P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089808P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090689P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090693P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096953P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.

PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 15-SEP-1998; 98US-0100388P.
PR 16-SEP-1998; 98US-0100682P.
PR 16-SEP-1998; 98US-0100684P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-00168978.

Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 2108 CATCAATGATCGCTTTGCTTTTACCACTCTTTCTTTTATCTTATTAATAAATGTTG 2167
Db 1555 CCTTAAACACCACCTCTCATCACTAATCTCAGCCCTTGCCCTTGAATTAACCTTAGC 1614

Qy 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674

Qy 2228 AAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1496
ACA93722
ID ACA93722 standard; cDNA; 1734 BP.
XX AC ACA93722;
XX 17-JUL-2003 (first entry)
DT Human cDNA encoding secreted/transmembrane protein PRO1411.
DE Human; ss; gene; PRO; secreted protein; transmembrane protein;
KW
```

KW cytostatic; vulnary; osteopathic; antiarthritic; antirheumatic;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW liver tumour; tumour necrosis factor; pericyte cell proliferation;  
KW TNF-alpha; proteoglycans release; cartilage; cancer; wound healing;  
KW cartilage defect; osteoarthritis; rheumatoid arthritis.

XX Homo sapiens.

XX US2003045684-A1.

XX 06-MAR-2003.

XX 02-MAY-2002; 2002US-00063553.

XX 30-DEC-1998; 98KR-00062142.

XX 08-MAR-1999; 99WO-US005028.

XX 14-MAY-1999; 99WO-US011832.

XX 25-AUG-1999; 99WO-US010733.

XX 25-AUG-1999; 99US-00380137.

XX 25-AUG-1999; 99US-00380138.

XX 25-AUG-1999; 99US-00380139.

XX 25-AUG-1999; 99US-00380142.

XX 15-SEP-1999; 99US-00397342.

XX 18-OCT-1999; 99US-00403297.

XX 12-NOV-1999; 99US-00423844.

XX 30-DEC-1999; 99WO-US011274.

XX 18-FEB-2000; 2000WO-US004341.

XX 01-MAR-2000; 2000WO-US005601.

XX 02-MAR-2000; 2000WO-US005841.

XX 21-MAR-2000; 2000WO-US007532.

XX 22-MAY-2000; 2000WO-US014042.

XX 02-JUN-2000; 2000WO-US015264.

XX 22-AUG-2000; 2000US-00644848.

XX 24-AUG-2000; 2000WO-US023328.

XX 18-SEP-2000; 2000US-00864810.

XX 18-SEP-2000; 2000US-00665350.

XX 08-NOV-2000; 2000US-00709238.

XX 10-NOV-2000; 2000WO-US030873.

XX 01-DEC-2000; 2000WO-US032678.

XX 20-DEC-2000; 2000US-00747259.

XX 20-DEC-2000; 2000WO-US034956.

XX 28-FEB-2001; 2001WO-US006520.

XX 22-MAR-2001; 2001US-00816744.

XX 10-MAY-2001; 2001US-00854208.

XX 10-MAY-2001; 2001US-00854280.

XX 30-MAY-2001; 2001US-00870574.

XX 01-JUN-2001; 2001WO-US017800.

XX 05-JUN-2001; 2001US-00874503.

XX 29-JUN-2001; 2001US-00869599.

XX 18-JUL-2001; 2001US-00908827.

XX 06-DEC-2001; 2001US-00006867.

XX (GETH ) GENENTECH INC.

XX Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

XX WPI; 2003-392892/37.

XX P-PSDB; ABU92501.

XX New PRO994 polypeptide, useful for detecting tumors, or for stimulating  
XX Tumor Necrosis Factor alpha, or pericyte proliferation, especially for  
XX treating cancer, cartilage defects, osteoarthritis and rheumatoid  
XX arthritis in a mammal.

XX Disclosure; Fig 51; 235pp; English.

XX The invention relates to a new isolated PRO994 polypeptide comprises an  
XX amino acid sequence appearing as ABU92499, PRO994 lacking its associated  
XX signal peptide, the extracellular domain of PRO994, the extracellular  
XX domain of PRO994 (lacking its associated signal peptide) or the protein  
XX encoded by the full-length coding sequence of the cDNA ATCC 203018. Also  
XX included is a chimaeric molecule comprising the PRO994 polypeptide fused

CC to a heterologous amino acid sequence. The PRO polypeptide is useful in  
CC pharmaceuticals, diagnostics, biosensors or bioreactors. It is  
CC particularly useful for detecting tumours (e.g. lung tumour, colon  
CC tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)  
CC in a mammal, for stimulating the release of tumour necrosis factor (TNF)-  
CC alpha from human blood, for stimulating the proliferation of pericyte  
CC cells, or stimulating the release of proteoglycans from cartilage. The  
CC polypeptide may be employed for a variety of therapeutic purposes, e.g.  
CC for treating cancer, wound healing, cartilage defects, osteoarthritis,  
CC rheumatoid arthritis. Also disclosed are the cDNA encoding PRO994, 83  
CC other PRO polypeptides and their encoding cDNAs. The present sequence  
XX encodes a PRO polypeptide of the invention

SQ Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;

Query Match 2.9%; Score 65.2; DB 8; Length 1734;

Best Local Similarity 67.4%; Pred. No. 0.0004;

Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 2108 CATCCAATGATCGCTTTCCTTACCACTCTTCTTTTATCTTATTAATAAAATGTTG 2167

Db 1555 CCTTAAACACCACTCTTCTTACCACTCTTCTTTTATCTTATTAATAAAATGTTG 2167

Qy 2168 GTCTCCACCACTGCTCCCAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227

Db 1615 TGCCCCACAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674

Qy 2228 AAAAAAAAAAAAAA 2242

Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1497

ACA68290

ID ACA68290 standard; cDNA; 1734 BP.

XX ACA68290;

XX 25-JUN-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1411 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene therapy;

XX Chromosome mapping; gene mapping; tumor necrosis factor-alpha; blood;

XX chondrocyte differentiation stimulator;

XX chondrocyte proliferation stimulator; tumour; tissue typing; gene; ss.

XX Homo sapiens.

XX US2003032104-A1.

XX 13-FEB-2003.

XX 18-JUN-2002; 2002US-00174576.

XX 18-SEP-1997; 97US-0059263P.

XX 18-SEP-1997; 97US-0059266P.

XX 17-OCT-1997; 97US-0062250P.

XX 21-OCT-1997; 97US-0063486P.

XX 24-OCT-1997; 97US-0063120P.

XX 24-OCT-1997; 97US-0063121P.

XX 28-OCT-1997; 97US-0063540P.

XX 28-OCT-1997; 97US-0063541P.

XX 28-OCT-1997; 97US-0063544P.

XX 28-OCT-1997; 97US-0063564P.

XX 29-OCT-1997; 97US-0063734P.

XX 31-OCT-1997; 97US-0063870P.

XX 31-OCT-1997; 97US-0064103P.

XX 13-NOV-1997; 97US-0065311P.

XX 21-NOV-1997; 97US-0066120P.

XX 24-NOV-1997; 97US-0066466P.

XX 24-NOV-1997; 97US-0066772P.

XX 11-DEC-1997; 97US-0069335P.

PR 12-DEC-1997; 97US-0069425P.  
PR 17-DEC-1997; 97US-0069870P.  
PR 18-DEC-1997; 97US-0068017P.  
PR 10-MAR-1998; 98US-0077450P.  
PR 11-MAR-1998; 98US-0077633P.  
PR 11-MAR-1998; 98US-0077649P.  
PR 20-MAR-1998; 98US-0078886P.  
PR 20-MAR-1998; 98US-0078939P.  
PR 27-MAR-1998; 98US-0079664P.  
PR 27-MAR-1998; 98US-0079786P.  
PR 31-MAR-1998; 98US-0080107P.  
PR 31-MAR-1998; 98US-0080194P.  
PR 01-APR-1998; 98US-0080327P.  
PR 01-APR-1998; 98US-0080333P.  
PR 08-APR-1998; 98US-0081049P.  
PR 08-APR-1998; 98US-0081107P.  
PR 09-APR-1998; 98US-0081195P.  
PR 15-APR-1998; 98US-0081838P.  
PR 21-APR-1998; 98US-0082568P.  
PR 21-APR-1998; 98US-0082569P.  
PR 22-APR-1998; 98US-0082704P.  
PR 22-APR-1998; 98US-0082797P.  
PR 28-APR-1998; 98US-0083322P.  
PR 28-APR-1998; 98US-0083495P.  
PR 29-APR-1998; 98US-0083496P.  
PR 29-APR-1998; 98US-0083499P.  
PR 29-APR-1998; 98US-0083593P.  
PR 05-MAY-1998; 98US-0084366P.  
PR 06-MAY-1998; 98US-0084414P.  
PR 07-MAY-1998; 98US-0084633P.  
PR 07-MAY-1998; 98US-0084640P.  
PR 07-MAY-1998; 98US-0084643P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085580P.  
PR 15-MAY-1998; 98US-0085582P.  
PR 15-MAY-1998; 98US-0085700P.  
PR 18-MAY-1998; 98US-0086023P.  
PR 22-MAY-1998; 98US-0086392P.  
PR 22-MAY-1998; 98US-0086486P.  
PR 28-MAY-1998; 98US-0087098P.  
PR 28-MAY-1998; 98US-0087208P.  
PR 02-JUN-1998; 98US-0087609P.  
PR 02-JUN-1998; 98US-0087759P.  
PR 03-JUN-1998; 98US-0087827P.  
PR 04-JUN-1998; 98US-0088025P.  
PR 04-JUN-1998; 98US-0088028P.  
PR 04-JUN-1998; 98US-0088029P.  
PR 04-JUN-1998; 98US-0088033P.  
PR 04-JUN-1998; 98US-0088032P.  
PR 05-JUN-1998; 98US-0088167P.  
PR 05-JUN-1998; 98US-0088202P.  
PR 05-JUN-1998; 98US-0088212P.  
PR 05-JUN-1998; 98US-0088217P.  
PR 09-JUN-1998; 98US-0088655P.  
PR 10-JUN-1998; 98US-0088722P.  
PR 10-JUN-1998; 98US-0088738P.  
PR 10-JUN-1998; 98US-0088740P.  
PR 10-JUN-1998; 98US-0088811P.  
PR 10-JUN-1998; 98US-0088824P.  
PR 10-JUN-1998; 98US-0088825P.  
PR 10-JUN-1998; 98US-0088826P.  
PR 11-JUN-1998; 98US-0088861P.  
PR 11-JUN-1998; 98US-0088863P.  
PR 11-JUN-1998; 98US-0088876P.  
PR 12-JUN-1998; 98US-0089090P.  
PR 12-JUN-1998; 98US-0089105P.  
PR 16-JUN-1998; 98US-0089512P.  
PR 16-JUN-1998; 98US-0089514P.  
PR 17-JUN-1998; 98US-0089538P.  
PR 17-JUN-1998; 98US-0089598P.  
PR 17-JUN-1998; 98US-0089653P.  
PR 18-JUN-1998; 98US-0089908P.  
PR 19-JUN-1998; 98US-0089952P.

PR 22-JUN-1998; 98US-0090246P.  
PR 22-JUN-1998; 98US-0090252P.  
PR 22-JUN-1998; 98US-0090254P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090435P.  
PR 24-JUN-1998; 98US-0090444P.  
PR 24-JUN-1998; 98US-0090461P.  
PR 24-JUN-1998; 98US-0090535P.  
PR 24-JUN-1998; 98US-0090540P.  
PR 25-JUN-1998; 98US-0090676P.  
PR 25-JUN-1998; 98US-0090688P.  
PR 25-JUN-1998; 98US-0090689P.  
PR 25-JUN-1998; 98US-0090690P.  
PR 25-JUN-1998; 98US-0090694P.  
PR 25-JUN-1998; 98US-0090695P.  
PR 26-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090696P.  
PR 26-JUN-1998; 98US-0090862P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 26-JUN-1998; 98US-0091010P.  
PR 01-JUL-1998; 98US-0091359P.  
PR 01-JUL-1998; 98US-0091544P.  
PR 02-JUL-1998; 98US-0091478P.  
PR 02-JUL-1998; 98US-0091486P.  
PR 02-JUL-1998; 98US-0091626P.  
PR 02-JUL-1998; 98US-0091628P.  
PR 02-JUL-1998; 98US-0091632P.  
PR 24-JUL-1998; 98US-0094006P.  
PR 04-AUG-1998; 98US-0095282P.  
PR 10-AUG-1998; 98US-0095998P.  
PR 10-AUG-1998; 98US-0096012P.  
PR 17-AUG-1998; 98US-0096757P.  
PR 17-AUG-1998; 98US-0096766P.  
PR 17-AUG-1998; 98US-0096867P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096897P.  
PR 18-AUG-1998; 98US-0096949P.  
PR 18-AUG-1998; 98US-0096959P.  
PR 18-AUG-1998; 98US-0097022P.  
PR 26-AUG-1998; 98US-0097952P.  
PR 26-AUG-1998; 98US-0097954P.  
PR 26-AUG-1998; 98US-0097955P.  
PR 26-AUG-1998; 98US-0097971P.  
PR 26-AUG-1998; 98US-0097974P.  
PR 26-AUG-1998; 98US-0098014P.  
PR 01-SEP-1998; 98US-0098716P.  
PR 01-SEP-1998; 98US-0098723P.  
PR 02-SEP-1998; 98US-0098803P.  
PR 02-SEP-1998; 98US-0098821P.  
PR 09-SEP-1998; 98US-0098843P.  
PR 09-SEP-1998; 98US-0099602P.  
PR 10-SEP-1998; 98US-0099741P.  
PR 10-SEP-1998; 98US-0099754P.  
PR 10-SEP-1998; 98US-0099763P.  
PR 10-SEP-1998; 98US-0099812P.  
PR 15-SEP-1998; 98US-0100388P.  
PR 16-SEP-1998; 98US-0100662P.  
PR 16-SEP-1998; 98US-0100664P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 16-SEP-1998; 98US-0101751P.  
PR 17-SEP-1998; 98US-0100683P.  
PR 17-SEP-1998; 98US-0100684P.  
PR 17-SEP-1998; 98US-0100691P.  
PR 17-SEP-1998; 98US-0100910P.  
PR 18-SEP-1998; 98US-0100849P.  
PR 18-SEP-1998; 98US-0101014P.  
PR 18-SEP-1998; 98US-0101068P.  
PR 23-SEP-1998; 98US-0101471P.  
PR 23-SEP-1998; 98US-0101472P.  
PR 23-SEP-1998; 98US-0101475P.  
PR 23-SEP-1998; 98US-0101477P.  
PR 24-SEP-1998; 98US-0101738P.  
PR 24-SEP-1998; 98US-0101739P.

```
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.

Query Match      2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 2108 CATCAATGATCGCTTGCTTTACCACTCTTTCCTTTTATCTTATTAATAAAATGTTG 2167
Db 1555 CCTTAAACACCAACCCTCTCATCACTAATCTCAGCCCTTGCCCTTGAATAAAACCTTAGC 1614
Qy 2168 GTCTCCCACTGCTGCCAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCACAAAAAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674

Qy 2228 AAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAA 1689

RESULT 1498
ABX98755
ID ABX98755 standard; cDNA; 1734 BP.
AC ABX98755;
XX
DT 20-MAY-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1411 cDNA.
XX
KW Human; secreted protein; transmembrane protein; cytostatic; gene therapy;
KW TNF-Agonist-Alpha; chondrocyte stimulator; tumour; adrenal tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003036157-A1.
XX
PD 20-FEB-2003.
XX
PF 02-JUL-2002; 2002US-00188769.
XX
PR 18-SEP-1997; 97US-0059263P.
PR 18-SEP-1997; 97US-0059266P.
PR 17-OCT-1997; 97US-0062250P.
PR 21-OCT-1997; 97US-0063486P.
PR 24-OCT-1997; 97US-00631120P.
PR 24-OCT-1997; 97US-00631121P.
PR 28-OCT-1997; 97US-0063540P.
PR 28-OCT-1997; 97US-0063541P.
PR 28-OCT-1997; 97US-0063544P.
PR 28-OCT-1997; 97US-0063564P.
PR 29-OCT-1997; 97US-0063734P.
PR 31-OCT-1997; 97US-0063870P.
PR 31-OCT-1997; 97US-0064103P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066120P.
PR 24-NOV-1997; 97US-0066466P.
PR 24-NOV-1997; 97US-0066772P.

11-DEC-1997; 97US-0069335P.
12-DEC-1997; 97US-0069425P.
17-DEC-1997; 97US-0069870P.
18-DEC-1997; 98US-0068017P.
10-MAR-1998; 98US-0077450P.
11-MAR-1998; 98US-0077632P.
11-MAR-1998; 98US-0077649P.
20-MAR-1998; 98US-0078866P.
20-MAR-1998; 98US-0078939P.
27-MAR-1998; 98US-0079664P.
27-MAR-1998; 98US-0079786P.
31-MAR-1998; 98US-0080107P.
31-MAR-1998; 98US-0080194P.
01-APR-1998; 98US-0080327P.
01-APR-1998; 98US-0080333P.
08-APR-1998; 98US-0081049P.
08-APR-1998; 98US-0081070P.
03-APR-1998; 98US-0081195P.
15-APR-1998; 98US-0081818P.
21-APR-1998; 98US-0082568P.
21-APR-1998; 98US-0082569P.
22-APR-1998; 98US-0082704P.
22-APR-1998; 98US-0082797P.
28-APR-1998; 98US-0083322P.
29-APR-1998; 98US-0083495P.
29-APR-1998; 98US-0083496P.
29-APR-1998; 98US-0083499P.
29-APR-1998; 98US-0083559P.
05-MAY-1998; 98US-0084366P.
07-MAY-1998; 98US-0084639P.
07-MAY-1998; 98US-0084640P.
07-MAY-1998; 98US-0084643P.
15-MAY-1998; 98US-0085579P.
15-MAY-1998; 98US-0085580P.
15-MAY-1998; 98US-0085582P.
18-MAY-1998; 98US-0085700P.
22-MAY-1998; 98US-0086023P.
22-MAY-1998; 98US-0086392P.
22-MAY-1998; 98US-0086486P.
28-MAY-1998; 98US-0087098P.
02-JUN-1998; 98US-0087609P.
03-JUN-1998; 98US-0087827P.
04-JUN-1998; 98US-0088025P.
04-JUN-1998; 98US-0088028P.
04-JUN-1998; 98US-0088029P.
04-JUN-1998; 98US-0088033P.
04-JUN-1998; 98US-0088326P.
05-JUN-1998; 98US-0088167P.
05-JUN-1998; 98US-0088202P.
05-JUN-1998; 98US-0088212P.
09-JUN-1998; 98US-0088655P.
10-JUN-1998; 98US-0088722P.
10-JUN-1998; 98US-0088738P.
10-JUN-1998; 98US-0088740P.
10-JUN-1998; 98US-0088811P.
10-JUN-1998; 98US-0088824P.
10-JUN-1998; 98US-0088825P.
10-JUN-1998; 98US-0088826P.
11-JUN-1998; 98US-0088861P.
11-JUN-1998; 98US-0088863P.
11-JUN-1998; 98US-0088876P.
12-JUN-1998; 98US-0089090P.
12-JUN-1998; 98US-0089105P.
16-JUN-1998; 98US-0089512P.
16-JUN-1998; 98US-0089514P.
17-JUN-1998; 98US-0089538P.
17-JUN-1998; 98US-0089598P.
17-JUN-1998; 98US-0089653P.
18-JUN-1998; 98US-0089908P.
```

PR	19-JUN-1998;	98US-0089952P.
PR	22-JUN-1998;	98US-0090246P.
PR	22-JUN-1998;	98US-0090252P.
PR	22-JUN-1998;	98US-0090254P.
PR	24-JUN-1998;	98US-0090429P.
PR	24-JUN-1998;	98US-0090435P.
PR	24-JUN-1998;	98US-0090444P.
PR	24-JUN-1998;	98US-0090461P.
PR	24-JUN-1998;	98US-0090535P.
PR	24-JUN-1998;	98US-0090540P.
PR	25-JUN-1998;	98US-0090676P.
PR	25-JUN-1998;	98US-0090678P.
PR	25-JUN-1998;	98US-0090688P.
PR	25-JUN-1998;	98US-0090690P.
PR	25-JUN-1998;	98US-0090694P.
PR	25-JUN-1998;	98US-0090695P.
PR	25-JUN-1998;	98US-0090696P.
PR	26-JUN-1998;	98US-00105413.
PR	26-JUN-1998;	98US-0090862P.
PR	26-JUN-1998;	98US-0090863P.
PR	26-JUN-1998;	98US-0091010P.
PR	01-JUL-1998;	98US-0091359P.
PR	01-JUL-1998;	98US-0091544P.
PR	02-JUL-1998;	98US-0091478P.
PR	02-JUL-1998;	98US-0091486P.
PR	02-JUL-1998;	98US-0091626P.
PR	02-JUL-1998;	98US-0091628P.
PR	02-JUL-1998;	98US-0091632P.
PR	24-JUL-1998;	98US-0094006P.
PR	04-AUG-1998;	98US-0095282P.
PR	10-AUG-1998;	98US-0095998P.
PR	10-AUG-1998;	98US-0096012P.
PR	17-AUG-1998;	98US-0096757P.
PR	17-AUG-1998;	98US-0096766P.
PR	17-AUG-1998;	98US-0096867P.
PR	17-AUG-1998;	98US-0096891P.
PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0097022P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100388P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101473P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.
Query Match		
Best Local Similarity 2.9%; Score 65.2; DB 8; Length 1734;		
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;		
QY	2108 CATCCAATGATCGCTTGGCTTTACCACTCTTTCTTTTATTCTTTATTAATAAAAGTTTG	2167
Db	1555 CCTTAAAACACCACCTCTCATCCTAATCTCAGCCCTTCGCCCTTGAAATAAACCTTAGC	1614
QY	2168 GTCTCCCACTGNCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2227
Db	1615 TGCCCCACAAA	1674
QY	2228 AAAAAAAAAAAAAA 2242	
Db	1675 AAAAAAAAAAAAAA 1689	
RESULT 1499		
ID	ACA67296 standard; cDNA; 1734 BP.	

PR	19-JUN-1998;	98US-0089952P.
PR	22-JUN-1998;	98US-0090246P.
PR	22-JUN-1998;	98US-0090252P.
PR	22-JUN-1998;	98US-0090254P.
PR	24-JUN-1998;	98US-0090429P.
PR	24-JUN-1998;	98US-0090435P.
PR	24-JUN-1998;	98US-0090444P.
PR	24-JUN-1998;	98US-0090461P.
PR	24-JUN-1998;	98US-0090535P.
PR	24-JUN-1998;	98US-0090540P.
PR	25-JUN-1998;	98US-0090676P.
PR	25-JUN-1998;	98US-0090678P.
PR	25-JUN-1998;	98US-0090688P.
PR	25-JUN-1998;	98US-0090690P.
PR	25-JUN-1998;	98US-0090694P.
PR	25-JUN-1998;	98US-0090695P.
PR	25-JUN-1998;	98US-0090696P.
PR	26-JUN-1998;	98US-00105411.
PR	26-JUN-1998;	98US-0090862P.
PR	26-JUN-1998;	98US-0090863P.
PR	26-JUN-1998;	98US-0091010P.
PR	01-JUL-1998;	98US-0091359P.
PR	01-JUL-1998;	98US-0091544P.
PR	02-JUL-1998;	98US-0091478P.
PR	02-JUL-1998;	98US-0091486P.
PR	02-JUL-1998;	98US-0091626P.
PR	02-JUL-1998;	98US-0091628P.
PR	02-JUL-1998;	98US-0091632P.
PR	24-JUL-1998;	98US-0094006P.
PR	04-AUG-1998;	98US-0095282P.
PR	10-AUG-1998;	98US-0095998P.
PR	10-AUG-1998;	98US-0096012P.
PR	17-AUG-1998;	98US-0096757P.
PR	17-AUG-1998;	98US-0096766P.
PR	17-AUG-1998;	98US-0096867P.
PR	17-AUG-1998;	98US-0096891P.
PR	17-AUG-1998;	98US-0096897P.
PR	18-AUG-1998;	98US-0096949P.
PR	18-AUG-1998;	98US-0096959P.
PR	18-AUG-1998;	98US-0097022P.
PR	26-AUG-1998;	98US-0097952P.
PR	26-AUG-1998;	98US-0097954P.
PR	26-AUG-1998;	98US-0097955P.
PR	26-AUG-1998;	98US-0097971P.
PR	26-AUG-1998;	98US-0097974P.
PR	26-AUG-1998;	98US-0098014P.
PR	01-SEP-1998;	98US-0098716P.
PR	01-SEP-1998;	98US-0098723P.
PR	02-SEP-1998;	98US-0098803P.
PR	02-SEP-1998;	98US-0098821P.
PR	02-SEP-1998;	98US-0098843P.
PR	09-SEP-1998;	98US-0099602P.
PR	10-SEP-1998;	98US-0099741P.
PR	10-SEP-1998;	98US-0099754P.
PR	10-SEP-1998;	98US-0099763P.
PR	10-SEP-1998;	98US-0099812P.
PR	15-SEP-1998;	98US-0100389P.
PR	16-SEP-1998;	98US-0100662P.
PR	16-SEP-1998;	98US-0100664P.
PR	16-SEP-1998;	98US-0101751P.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98US-0100684P.
PR	17-SEP-1998;	98US-0100919P.
PR	17-SEP-1998;	98US-0100930P.
PR	18-SEP-1998;	98US-0100849P.
PR	18-SEP-1998;	98US-0101014P.
PR	18-SEP-1998;	98US-0101068P.
PR	23-SEP-1998;	98US-0101471P.
PR	23-SEP-1998;	98US-0101472P.
PR	23-SEP-1998;	98US-0101473P.
PR	23-SEP-1998;	98US-0101477P.
PR	24-SEP-1998;	98US-0101738P.
PR	24-SEP-1998;	98US-0101739P.
PR	24-SEP-1998;	98US-0101743P.
PR	24-SEP-1998;	98US-0101922P.
PR	25-SEP-1998;	98US-0101786P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102330P.
PR	29-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.
Query Match	2.9%; Score 65.2; DB 8; Length 1734;	
Best Local Similarity	67.4%; Pred. No. 0.0004;	
Matches	91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;	
QY	2108 CATCCAATGATCGCTTTGGCTTTTACCACTCTTTCTTTTATTCTTTATTAATAAAAGTTTG	2167
Db	1555 CCTTAAACACCACCTCTCATCCTAATCTCAGCCCTTCGCCCTTGAAATAAACCTTAGC	1614
QY	2168 GTCTCCCACTGNCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	2227
Db	1615 TGCCCCACAAA	1674
QY	2228 AAAAAAAAAAAAAA	2242
Db	1675 AAAAAAAAAAAAAA	1689
RESULT 1499		
ACA67296		
ID	ACA67296 standard; cDNA; 1734 BP.	
AC	ACA67296;	</

PR 24-AUG-2000; 2000WO-US023328.  
 PR 18-SEP-2000; 2000US-00664610.  
 PR 18-SEP-2000; 2000US-00665350.  
 PR 08-NOV-2000; 2000US-00709238.  
 PR 01-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 30-MAY-2001; 2001US-00870574.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 29-JUN-2001; 2001US-00869599.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-DEC-2001; 2001US-00006867.  
 XX  
 PA (GETH ) GENENTECH INC.

XX  
 XX  
 PI Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;  
 FI Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;  
 XX P-PSDB; ABU81171.

DR WPI; 2003-341840/32.  
 DR P-PSDB; ABU81171.

PT New monoclonal antibody that binds to a secreted and transmembrane  
 PT polypeptide, useful for detecting and purifying the polypeptide and also  
 PT for treating conditions responsive to the antibody.

XX Example 4; Fig 51; 235pp; English.

XX The invention relates to an antibody that binds to a secreted and  
 CC transmembrane polypeptide, PRO1136. The antibody is useful for preparing  
 CC a medicament useful in the treatment of a condition responsive to anti-  
 CC PRO antibody. The antibody is also useful in diagnostic assays for PRO,  
 CC by detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. The present sequence represents a cDNA encoding a PRO  
 CC polypeptide of the invention

XX Sequence 1734 BP; 503 A; 397 C; 580 G; 254 T; 0 U; 0 Other;

Query Match 2.98; Score 65.2; DB 8; Length 1734;

Best Local Similarity 67.44; Pred. No. 0.0004;

Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

Qy 2108 CATCCATGATCGCTTGTGTTTACCACTCTTCTCTTTATCTATTAATAAATAAATGTTG 2167

Db 1555 CCTTAACACACCCCTCTCATCTAATCTCAGCCCTTGCCCTTGAAATAAACCTTAGC 1614

Qy 2168 GTCTCCACCTGCTGCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAA 2227

Db 1615 TGCCCAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATA 1674

Qy 2228 AAAAAAATAAAAAA 2242

Db 1675 AAAAAAATAAAAAA 1689

RESULT 1500

ACC81232

ID ACC81232 standard; cDNA; 1734 BP.

XX ACC81232;

XX 28-JUL-2003 (first entry)

XX Human secreted polypeptide PRO11411-encoding cDNA, SEQ ID NO:201.

XX Human; PRO; secreted protein; transmembrane protein;

KW extracellular domain; tumour necrosis factor-alpha; TNF-alpha;

KW

KW chondrocyte; proliferation; differentiation; cartilage disorder;  
 KW bone disorder; arthritis; sports injury; cancer; tumour; diagnosis;  
 KW adrenal tumour; lung; colon; breast; prostate; kidney; rectum; cervix;  
 KW liver; drug screening; transgenic animal; genetic analysis;  
 KW antiarthritic; vulnary; gene therapy; gene; ss.

OS Homo sapiens.

XX US2003032120-A1.

XX 13-FEB-2003.

XX 25-JUN-2002; 2002US-00180546.

XX 18-SEP-1997; 97US-0059263P.

PR 18-SEP-1997; 97US-0059266P.

PR 17-OCT-1997; 97US-0062250P.

PR 21-OCT-1997; 97US-0063486P.

PR 24-OCT-1997; 97US-0063120P.

PR 24-OCT-1997; 97US-0063121P.

PR 28-OCT-1997; 97US-0063540P.

PR 28-OCT-1997; 97US-0063541P.

PR 28-OCT-1997; 97US-0063544P.

PR 28-OCT-1997; 97US-0063564P.

PR 29-OCT-1997; 97US-0063734P.

PR 31-OCT-1997; 97US-0063970P.

PR 31-OCT-1997; 97US-0064103P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066120P.

PR 24-NOV-1997; 97US-0066466P.

PR 11-DEC-1997; 97US-0066772P.

PR 11-DEC-1997; 97US-0069335P.

PR 12-DEC-1997; 97US-0069425P.

PR 17-DEC-1997; 97US-0069870P.

PR 18-DEC-1997; 97US-0068017P.

PR 11-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077649P.

PR 20-MAR-1998; 98US-0078866P.

PR 20-MAR-1998; 98US-0078939P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079786P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080194P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080333P.

PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.

PR 09-APR-1998; 98US-0081195P.

PR 15-APR-1998; 98US-0081838P.

PR 21-APR-1998; 98US-0082569P.

PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.

PR 28-APR-1998; 98US-0083322P.

PR 29-APR-1998; 98US-0083495P.

PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083499P.

PR 29-APR-1998; 98US-0083559P.

PR 05-MAY-1998; 98US-0084366P.

PR 06-MAY-1998; 98US-0084414P.

PR 07-MAY-1998; 98US-0084639P.

PR 07-MAY-1998; 98US-0084640P.

PR 07-MAY-1998; 98US-0084643P.

PR 15-MAY-1998; 98US-0085579P.

PR 15-MAY-1998; 98US-0085580P.

PR 15-MAY-1998; 98US-0085582P.

PR 18-MAY-1998; 98US-0085700P.

PR 22-MAY-1998; 98US-0086023P.

PR 22-MAY-1998; 98US-0086392P.

PR 28-MAY-1998; 98US-0086486P.

PR 28-MAY-1998; 98US-0087098P.

PR 28-MAY-1998; 98US-0087208P.

```
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088653P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089103P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 24-JUN-1998; 98US-0090423P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090679P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090699P.
PR 26-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090698P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091632P.
PR 24-JUL-1998; 98US-0094006P.
PR 04-AUG-1998; 98US-0095282P.
PR 10-AUG-1998; 98US-0095998P.
PR 10-AUG-1998; 98US-0096012P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0097022P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0098014P.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 02-SEP-1998; 98US-0098801P.
PR 02-SEP-1998; 98US-0098821P.
PR 09-SEP-1998; 98US-0098960P.
PR 10-SEP-1998; 98US-0098974P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 15-SEP-1998; 98US-0099812P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0101751P.
PR 16-SEP-1998; 98US-0101751P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101739P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101922P.
PR 25-SEP-1998; 98US-0101786P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
Query Match 2.9%; Score 65.2; DB 8; Length 1734;
Best Local Similarity 67.4%; Pred. No. 0.0004;
Matches 91; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
Qy 2108 CATCAATGATCGCTTGTGCTTTTACCACTCTTTCTTTTATCTTATTAATAAATGTTG 2167
Db 1555 CCTTAAACACCACCTCTCATCACTATCTCAGCCCTTGCCCTTGAATTAACCTTAGC 1614
Qy 2168 GTCTCCACCACTGCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2227
Db 1615 TGCCCCACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1674
Qy 2228 AAAAAAAAAAAAAA 2242
Db 1675 AAAAAAAAAAAAAA 1689
Search completed: February 13, 2005, 23:37:55
Job time : 1044 secs
```

**THIS PAGE BLANK (USPTO)**